

PCT COOPERATION TREATY

09/00/582

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

MERCK & CO., INC.
126 East Lincoln Avenue
Rahway, NJ 07065
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 21 July 2000 (21.07.00)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference PCT 20052Y	
International application No. PCT/US99/02361	International filing date (day/month/year) 03 February 1999 (03.02.99)

1. The following indications appeared on record concerning:

☒ the applicant
 ☐ the inventor
 ☐ the agent
 ☐ the common representative

Name and Address	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☒ the person
 ☒ the name
 ☒ the address
 ☐ the nationality
 ☐ the residence

Name and Address MERCK SHARPE & DOHME, LTD. Heartfordshire Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	State of Nationality GB	State of Residence GB
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	

3. Further observations, if necessary:

The person identified in Box 2 has been added as applicant for the purposes of all designated States except US. A power from the new applicant is required.

4. A copy of this notification has been sent to:

<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input type="checkbox"/> other:

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Christine Carrié Telephone No.: (41-22) 338.83.38
---	--

INTERNATIONAL COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 04 January 2000 (04.01.00)	Applicant's or agent's file reference PCT 20052Y
International application No. PCT/US99/02361	Priority date (day/month/year) 05 February 1998 (05.02.98)
International filing date (day/month/year) 03 February 1999 (03.02.99)	
Applicant LIU, Quingyun et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
01 September 1999 (01.09.99)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer V. Gross
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 20 JUL 2000

WIPO

PCT

Applicant's or agent's file reference PCT 20052Y	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US99/02361	International filing date (day/month/year) 03 FEBRUARY 1999	Priority date (day/month/year) 05 FEBRUARY 1998
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant MERCK & CO., INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 7 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 01 SEPTEMBER 1999	Date of completion of this report 15 JUNE 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer CLAIRE M. KAUFMAN
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/02361

I. Basis of the report

1. With regard to the **elements** of the international application:*☒ the international application as originally filed☒ the description:pages 1-90 , as originally filedpages NONE , filed with the demandpages NONE , filed with the letter of _____☒ the claims:pages 91-96 , as originally filedpages NONE , as amended (together with any statement) under Article 19pages NONE , filed with the demandpages NONE , filed with the letter of _____☒ the drawings:pages 1-35 , as originally filedpages NONE , filed with the demandpages NONE , filed with the letter of _____☒ the sequence listing part of the description:pages 1-28 , as originally filedpages NONE , filed with the demandpages NONE , filed with the letter of _____2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application (under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:☐ contained in the international application in printed form.☐ filed together with the international application in computer readable form.☒ furnished subsequently to this Authority in written form.☒ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4. ☒ The amendments have resulted in the cancellation of:☒ the description, pages NONE☒ the claims, Nos. NONE☒ the drawings, sheets/fig NONE5. ☒ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

**Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US99/02361

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been and will not be examined in respect of:

☐ the entire international application.

☒ claims Nos. 6, 10-13, 15, 17

because:

☐ the said international application, or the said claim Nos. _ relate to the following subject matter which does not require international preliminary examination (*specify*).

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _ are so unclear that no meaningful opinion could be formed (*specify*).

☐ the claims, or said claims Nos. _ are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for said claims Nos. 6, 10-13, 15, 17.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/02361

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. statement

Novelty (N)	Claims	<u>(Please See supplemental sheet)</u>	YES
	Claims	<u>(Please See supplemental sheet)</u>	NO
Inventive Step (IS)	Claims	<u>(Please See supplemental sheet)</u>	YES
	Claims	<u>(Please See supplemental sheet)</u>	NO
Industrial Applicability (IA)	Claims	<u>(Please See supplemental sheet)</u>	YES
	Claims	<u>(Please See supplemental sheet)</u>	NO

2. citations and explanations (Rule 70.7)

Claims 1, 2, 4, 5, 7-9, 14, 16, 18 and 19 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the HG20 polypeptide, encoding nucleic acid or specifically recited fragments thereof. The invention has industrial applicability.

Claim 3 lacks novelty under PCT Article 33(2) as being anticipated by GenBank Database Accession Numbers H14151, Z43654 or T07621.

GenBank Database Accession Numbers H14151, Z43654 and T07621 each teach isolated DNA molecules that would hybridize under stringent conditions to the DNA described in claim 2 because there is about 95% identity over at least 341 consecutive nucleotides between the DNA of claim 2 and each of the GenBank DNAs.

-----NEW CITATIONS-----

NONE

----- NEW CITATIONS -----

NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/02361

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

Claim 14 is objected to under PCT Rule 66.2(a)(iii) as containing the following defect(s) in the form or contents thereof: In line 4 of the claim "c1'omprising" should be "comprising".

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 3, 6, 16 and 18 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because claims are indefinite for the following reason(s): Claim 3 is indefinite because it is not clear what conditions are intended by "stringent" hybridization conditions, since the description gives examples of high stringency (pages 15-16), but it is unclear if moderate and low stringency conditions are also intended to be included. Claim 6 is indefinite because no group is listed. Claim 16 is indefinite because it is unclear the polypeptides of the heterodimers are those expressed from the vectors or are endogenous (see claim 14(b) for example of clear expression language). Claim 18 is indefinite because it is unclear what the truncation is--that is, is it the first amino terminal amino acid or can it be a larger fragment, and if it can be a fragment--how big a fragment.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/02361

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(7): C07K 14/705; C12N 5/10, 15/09, 15/11, 15/12, 15/62; G01N 33/566 and US Cl.: 536/23.1, 23.5; 530/350; 435/6, 7.1, 7.2, 69.1, 320.1, 325, 252.3, 254.11

I. BASIS OF REPORT:

5. (Some) amendments are considered to go beyond the disclosure as filed:

NONE

V. 1. REASONED STATEMENTS:

The report as to Novelty was positive (YES) with respect to claims 1, 2, 4, 5, 7-9, 14, 16, 18, 19.

The report as to Novelty was negative (NO) with respect to claims 3.

The report as to Inventive Step was positive (YES) with respect to claims 1, 2, 4, 5, 7-9, 14, 16, 18, 19.

The report as to Inventive Step was negative (NO) with respect to claims 3.

The report as to Industrial Applicability was positive (YES) with respect to claims 1-5, 7-9, 14, 16, 18, 19.

The report as to Industrial Applicability was negative (NO) with respect to claims NONE.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : C07K 14/705, C12N 5/10, 15/09, 15/11, 15/12, 15/62, G01N 33/566		A1	(11) International Publication Number: WO 99/40114
			(43) International Publication Date: 12 August 1999 (12.08.99)
(21) International Application Number: PCT/US99/02361		(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	
(22) International Filing Date: 3 February 1999 (03.02.99)		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/073,767 5 February 1998 (05.02.98) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicants (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO [US/US]; 7703 Floyd Curl Drive, San Antonio, TX 78284 (US). NATIONAL INSTITUTES OF HEALTH [US/US]; 36 Convent Drive, Bethesda, MD 20892-4094 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): LIU, Quingyun [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). McDONALD, Terrence [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BONNERT, Timothy, P. [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). NG, Gordon, Yiu, Kon [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). KOLAKOWSKI, Lee, F., Jr. [US/US]; 7703 Floyd			
(54) Title: NOVEL GABA _B RECEPTOR DNA SEQUENCES			
(57) Abstract DNA encoding a novel human GABA _B receptor subunit, HG20, as well as the protein encoded by the DNA, is provided. Also provided is DNA encoding a novel murine GABA _B receptor subunit, GABA _B R1a, as well as the protein encoded by the DNA. Heterodimers of HG20 protein and GABA _B R1a protein that form a functional GABA _B receptor are disclosed. Methods of identifying agonists and antagonists of the GABA _B receptor are also provided.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

TITLE OF THE INVENTION
NOVEL GABA_B RECEPTOR DNA SEQUENCES

CROSS-REFERENCE TO RELATED APPLICATIONS

5 Not applicable.

STATEMENT REGARDING FEDERALLY-SPONSORED R&D

Not applicable.

10 REFERENCE TO MICROFICHE APPENDIX

Not applicable.

FIELD OF THE INVENTION

15 The present invention is directed to a novel human DNA sequence encoding HG20, a subunit of the GABA_B receptor, the protein encoded by the DNA, and uses thereof. The present invention also is directed to the murine GABA_BR1a subunit of the GABA_B receptor as well as to methods of combining an HG20 subunit with a GABA_BR1a subunit to form a GABA_B receptor having functional activity.

20

BACKGROUND OF THE INVENTION

Amino acids such as glutamic acid, γ -amino-butyric acid (GABA), and glycine are neurotransmitters that bind to specific receptors in the vertebrate nervous system and mediate synaptic transmission. Of these amino acids, GABA is the most widely distributed amino acid inhibitory neurotransmitter in the vertebrate central nervous system. The biological activities of GABA are mediated by three types of GABA receptors: ionotropic GABA_A receptors, metabotropic GABA_B receptors, and ionotropic GABA_C receptors. Each type of receptor has its own characteristic molecular structure, pattern of gene expression, agonist and antagonist mediated pharmacological effects, and spectrum of physiological activities.

30 GABA_A receptors mediate fast synaptic inhibition. They are heterooligomeric proteins (most likely pentamers) containing α , β , γ , and perhaps δ , subunits that function as ligand-gated Cl⁻ channels and have binding sites for benzodiazepines, barbiturates, and neuroactive steroids. Bicuculline is a widely used antagonist of GABA_A receptors.

35

Bicuculline is selective for GABA_A receptors in that it has no effect on GABA_B or GABA_C receptors. The expression of GABA_A receptors has been observed in a variety of brain structures (see. *e.g.*, McKernan & Whiting, 1996, Trends Neurosci. 16:139-143; Sequier et al., 1988, Proc. Natl. Acad. Sci. USA 85:7815-7819).

GABA_C receptors are ligand-gated Cl⁻ channels found in the vertebrate retina. They can be distinguished from GABA_A and GABA_B receptors in that they are insensitive to the GABA_A receptor antagonist bicuculline and the GABA_B receptor agonist (-)baclofen but are selectively activated by *cis*-4-aminocrotonic acid. GABA_C receptors are composed of homooligomers of a category of GABA receptor subunits known as "ρ" subunits, the best-studied of which are ρ1 and ρ2. ρ1 and ρ2 share 74% amino acid sequence identity but are only about 30-38% identical in amino acid sequence when compared to GABA_A receptor subunits. For a review of GABA_C receptors, see Bormann & Feigenspan, 1995, Trends Neurosci. 18:515-518.

GABA_B receptors play a role in the mediation of late inhibitory postsynaptic potentials (IPSPs). GABA_B receptors belong to the superfamily of seven transmembrane-spanning G-protein coupled receptors that are coupled through G-proteins to neuronal K⁺ or Ca⁺⁺ channels. GABA_B receptors are coupled through G-proteins to neuronal K⁺ or Ca⁺⁺ channels, and receptor activation increases K⁺ or decreases Ca⁺⁺ conductance and also inhibits or potentiates stimulated adenylyl cyclase activity. The expression of GABA_B receptors is widely distributed in the mammalian brain (*e.g.*, frontal cortex, cerebellar molecular layer, interpeduncular nucleus) and has been observed in many peripheral organs as well.

A large number of pharmacological activities have been attributed to GABA_B receptor activation, *e.g.*, analgesia; hypothermia; catatonia; hypotension; reduction of memory consolidation and retention; and stimulation of insulin, growth hormone, and glucagon release (see Bowery, 1989, Trends Pharmacol. Sci. 10:401-407, for a review.) It is well accepted that GABA_B receptor agonists and antagonists are pharmacologically useful. For example, the GABA_B receptor agonist (-)baclofen, a structural analog of GABA, is a clinically effective muscle relaxant (Bowery & Pratt, 1992, Arzneim.-Forsch./Drug

Res. 42:215-223). (-)baclofen, as part of a racemic mixture with (+)baclofen, has been sold in the United States as a muscle relaxant under the name LIORESAL® since 1972.

GABA_B receptors represent a large family of related proteins, new family members of which are still being discovered. For example, Kaupmann et al., 1997, Nature 386:239-246 (Kaupmann) reported the cloning and expression of two members of the rat GABA_B receptor family, GABA_BR1a and GABA_BR1b. A variety of experiments using known agonists and antagonists of GABA_B receptors seemed to indicate that GABA_BR1a and GABA_BR1b represented rat GABA_B receptors. This conclusion was based primarily on the ability of GABA_BR1a and GABA_BR1b to bind agonists and antagonist of GABA_B receptors with the expected rank order, based upon studies of rat cerebral cortex GABA_B receptors. However, there were data that did not fit the theory that Kaupmann had cloned the pharmacologically and functionally active GABA_B receptor. For example, Kaupmann noted that agonists had significantly lower binding affinity to recombinant GABA_BR1a and GABA_BR1b as opposed to native GABA_B receptors. Also, Couve et al., 1998, J. Biol. Chem. 273:26361-26367 showed that recombinantly expressed GABA_BR1a and GABA_BR1b failed to target correctly to the plasma membrane and failed to give rise to functional GABA_B receptors when expressed in a variety of cell types.

Examination of the amino acid and gene sequence of GABA_BR1a led Kaupmann to propose a structure for GABA_BR1a similar to that of the metabotropic glutamate receptor gene family. The metabotropic glutamate receptor family comprises eight glutamate binding receptors and five calcium sensing receptors which exhibit a signal peptide sequence followed by a large N-terminal domain believed to represent the ligand binding pocket that precedes seven transmembrane spanning domains. The hallmark seven transmembrane spanning domains are typical of G-protein coupled receptors (GPCRs), although metabotropic glutamate receptors and GABA_BR1a are considerably larger than most GPCRs and contain a signal peptide sequence. No significant amino acid sequence similarities were found between GABA_BR1a and GABA_A receptors, GABA_C receptors, or other typical GPCRs.

Despite work such as that of Kaupmann, pharmacological and physiological evidence indicates that a large number of amino acid binding GABA_B receptors remain to be cloned and expressed in recombinant systems where agonists and antagonists can be efficiently identified. In particular, it would be extremely valuable to be able to recombinantly express GABA_B receptors in such a manner that not only pharmacologically relevant ligand binding properties would be exhibited by the recombinant receptors, but also such that the recombinant receptors would show proper functional activity.

SUMMARY OF THE INVENTION

The present invention is directed to a novel human DNA that encodes a GABA_B receptor subunit, HG20. The DNA encoding HG20 is substantially free from other nucleic acids and has the nucleotide sequence shown in SEQ.ID.NO.:1. Also provided is an HG20 protein encoded by the novel DNA sequence. The HG20 protein is substantially free from other proteins and has the amino acid sequence shown in SEQ.ID.NO.:2. Methods of expressing HG20 in recombinant systems and of identifying agonists and antagonists of HG20 are provided.

The present invention is also directed to a novel murine DNA that encodes a GABA_B receptor subunit, GABA_BR1a. The DNA encoding GABA_BR1a is substantially free from other nucleic acids and has the nucleotide sequence shown in SEQ.ID.NO.:19. Also provided is a GABA_BR1a protein encoded by the novel DNA sequence. The GABA_BR1a protein is substantially free from other proteins and has the amino acid sequence shown in SEQ.ID.NO.:20. Methods of expressing GABA_BR1a in recombinant systems and of identifying agonists and antagonists of HG20 are provided.

Also provided by the present invention are methods of co-expressing HG20 and GABA_BR1a in the same cells. Such co-expression results in the production of a GABA_B receptor that exhibits expected functional properties of GABA_B receptors as well as expected ligand binding properties. Recombinant cells co-expressing HG20 and GABA_BR1a are provided as well as methods of utilizing such recombinant cells to identify agonists and antagonists of GABA_B receptors.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A-B shows the complete cDNA sequence of HG20 (SEQ.ID.NO.:1).

5 Figure 2 shows the complete amino acid sequence of HG20 (SEQ.ID.NO.:2).

Figure 3A-B shows predicted signal peptide cleavage sites of HG20. All sequences shown are portions of SEQ.ID.NO.:2.

10 Figure 4 shows *in situ* analysis of the expression of HG20 RNA in squirrel monkey brain.

Figure 5A shows *in vitro* coupled transcription/translation of a chimeric FLAG epitope-HG20 (amino acids 52-941) protein.

15 Figure 5B shows the expression in COS-7 cells and melanophores of a chimeric FLAG epitope-HG20 (amino acids 52-941) protein.

Figure 6 shows a comparison of the amino acid sequences of a portion of the N-terminus of HG20 protein and the ligand binding domain of the *Pseudomonas aeruginosa* amino acid binding protein LIVAT-BP (Swiss Protein database accession number P21175). The
20 upper sequence shown is from HG20 and corresponds to amino acids 63-259 of SEQ.ID.NO.:2. The lower sequence shown is from *Pseudomonas aeruginosa* LIVAT-BP and is SEQ.ID.NO.:16.

Figure 7 shows expression in mammalian cells of a chimeric HG20 protein.

25 Figure 8 shows a comparison of the amino acid sequences of HG20 and GABABR1b. The HG20 sequence is SEQ.ID.NO.:2. The GABABR1b sequence is SEQ.ID.NO.:17.

Figure 9 shows the expression of recombinant GABABR1a and HG20 in COS-7 cells. Lanes 1 and 2 show [¹²⁵I]CGP71872
30 photolabeling of recombinant murine GABABR1a monomer and dimer in the presence (+) and absence (-) of 1 μ M unlabeled CGP71872. Lanes 3 and 4 show that GABABR1a antibodies 1713.1-1713.2 confirmed (+) expression of recombinantly expressed murine GABABR1a (referred to as mgb1a here) and absence (-) in pcDNA3.1 mock transfected cells.
35 Lanes 5 and 6 show [¹²⁵I]CGP71872 photolabeling of human FLAG-HG20 in the presence (+) and absence (-) of 1 μ M unlabeled CGP71872. Lanes 7 and 8 show that an anti-FLAG antibody confirmed (+) the

expression of FLAG-HG20 (referred to as FLAG-gb2 here) and its absence (-) in pcDNA3.1 mock transfected cells. Experimental details were as in Examples 7-9 and 20 except that COS-7 rather than COS-1 cells were used.

5 Figure 10 shows co-localization of mRNA for HG20 and GABA_BR1a by *in situ* hybridization histochemistry in rat parietal cortex. Adjacent coronal sections of rat brain showing parietal cortex hybridized with radiolabelled GABA_BR1a (A) and HG20 (B) probes. Rat GABA_BR1a and HG20 probes were labelled using ³⁵S-UTP (A, B, and
10 D), and autoradiograms were developed after 4 weeks. For co-localization studies, the rat GABA_BR1a probe was digoxigenin labelled and developed using anti-digoxigenin HRP, the TSA amplification method and biotinyl tyramide followed by streptavidin-conjugated CY3 (C). (D) shows autoradiography of the same field as in (C), denoting
15 hybridization to HG20 mRNA. (E) is an overlay of images (C) and (D). Arrows denote some of the double-labelled cells. Scale bar = 0.5 mm in (A) and (B); scale bar = 50 μ m in (C-E).

 Figure 11 shows functional complementation following co-expression of GABA_BR1a and HG20 in *Xenopus* melanophores. GABA
20 mediated a dose-dependent aggregation response in melanophores co-expressing murine GABA_BR1a and FLAG-HG20 (■) that could be blocked with 100 nM (▼) and 1 μ M CGP71872 (▲). The response of GABA on mock-transfected cells is shown (●) as well as a control cannabinoid receptor subtype 2 response to HU210 ligand (inset). This experiment is
25 representative of n=4.

 Figure 12 shows GABA_B receptor modulation of forskolin-stimulated cAMP synthesis in HEK293 cells. HEK293 cells stably expressing HG20 (hgb2-42) or GABA_BR1a (rgb1a-50) were transiently transfected with GABA_BR1a and HG20 expression plasmids to examine
30 the effect of receptor co-expression on modulation of cAMP synthesis. All transfected cells were tested with 300 μ M baclofen or GABA (with 100 μ M AOAA and 100 μ M nipecotic acid) in the absence of forskolin and 30 μ M baclofen or GABA in the presence of 10 μ M forskolin. Wild-type HEK293 cells were tested with 250 μ M baclofen or 250 μ M GABA in the
35 presence of 10 μ M forskolin. Data are presented as the percent of total cAMP synthesized in the presence of forskolin only. The data presented are from single representative experiments that have been replicated

twice. Fsk, forskolin; B, baclofen; G, GABA with AOAA and nipecotic acid. The two right-most set of bar graphs (labeled "B + Fsk" and "G + Fsk") show that in cells expressing both GABA_BR1a and HG20 (rgb1a-50/hgb2 cells (□) and hgb2-42/rgb1a cells (■)), baclofen and GABA were able to mediate significant reductions in cAMP levels.

Figure 13 shows that co-expression of GABA_BR1a and HG20 permits inwardly rectifying potassium channel (GIRK or Kir) activation in *Xenopus* oocytes. (A) Representative current families of Kir 3.1/3.2. Currents were evoked by 500 msec voltage commands from a holding potential of -10 mV, delivered in 20 mV increments from -140 to 60 mV. (B) In a protocol designed to measure the effects of various receptors on Kir currents, oocytes were held at -80 mV (a potential where significant inward current is measured). Expression of GABA_BR1a or HG20 alone (with or without Gi α 1) resulted in no modulation of current after GABA treatment. Co-expression of GABA_BR1a and FLAG-HG20 receptors followed by treatment with 100 μ M GABA resulted in stimulation of Kir 3.1/3.2. Shown are representative traces from at least three independent experiments under each condition.

Figure 14 shows immunoblotting of murine GABA_BR1a and FLAG-HG20 transiently expressed in COS-7 cells. Digitonin-solubilized and anti-FLAG antibody immunoprecipitated membrane proteins were immunoblotted following SDS-PAGE with GABA_BR1a antibodies 1713.1-1713.2. The conditions are as follows: mock pcDNA3.1 vector transfected cells (lane 1), FLAG-HG20 expressing cells (lane 2), murine GABA_BR1a expressing cells (lane 3), and cells coexpressing murine GABA_BR1a and FLAG-HG20 (lane 4). The immunoreactive band corresponding to the GABA_BR1a /HG20 heterodimer as well as a band corresponding to the predicted GABA_BR1a monomer are denoted by arrows.

Figure 15 shows the complete cDNA sequence of murine GABA_BR1a (SEQ.ID.NO.:19). The sequence shown has been deposited in GenBank (accession number AF114168).

Figure 16 shows the complete amino acid sequence of murine GABA_BR1a (SEQ.ID.NO.:20). The sequence shown has been deposited in GenBank (accession number AF114168).

Figure 17A-B shows the results of experiments with N- and C-terminal fragments of murine GABA_BR1a. Figure 17A shows the results of coupled *in vitro* transcription/translation reactions; lane 1 = blank; lane 2 = full-length GABA_BR1a; lane 3 = N-terminal fragment of GABA_BR1a; lane 4 = C-terminal fragment of GABA_BR1a. Figure 17B shows the results of [¹²⁵I]CGP71872 photoaffinity labeling; lane 1 = N-terminal fragment of GABA_BR1a; lane 2 = N-terminal fragment of GABA_BR1a in the presence of GABA; lane 3 = C-terminal fragment of GABA_BR1a; lane 4 = C-terminal fragment of GABA_BR1a in the presence of GABA.

Figure 18A-B shows the amino acid sequence (Figure 18A) (SEQ.ID.NO.:21) and nucleotide sequence (Figure 18B) (SEQ.ID.NO.:22) (GenBank accession number AJ012185) of a human GABA_BR1a.

Figure 19A-B shows the nucleotide sequence (SEQ.ID.NO.:23) (GenBank accession number Y11044) of a human GABA_BR1a.

Figure 20 shows a framework map of chromosome 9. The locations of the HG20 gene (referred to as "GPR 51"), markers, and the HSN-1 locus are indicated.

Figure 21 shows a hydropathy plot for murine GABA_BR1a.

Figure 22 shows a family tree of genes related to HG20. Abbreviations are as follows: hGB1a = human GABA_BR1a; mGB1a = mouse GABA_BR1a; rGB1a = rat GABA_BR1a; hGB1b = human GABA_BR1b; rGB1b = rat GABA_BR1b; ceGB1b = a *C. elegans* gene related to mammalian GABA_BR1a and GABA_BR1b; hGB2 = human HG20; ceGB2 = a *C. elegans* gene related to human HG20; MGRDROME = a metabotropic glutamate receptor from *Drosophila melanogaster*; MGR2 HUMAN = human metabotropic glutamate receptor 2; MGR3 HUMAN = human metabotropic glutamate receptor 3; MGR6 HUMAN = human metabotropic glutamate receptor 6; MGR4 HUMAN = human metabotropic glutamate receptor 4; MGR7 HUMAN = human metabotropic glutamate receptor 7; MGR8 HUMAN = human metabotropic glutamate receptor 8; MGR1 HUMAN = human metabotropic glutamate receptor 1; MGR5 HUMAN = human metabotropic glutamate receptor 5.

Figure 23 shows the coiled-coil domains in the C-termini of human GABA_BR1a and HG20. The upper sequence is from human

GABA β R1a and is positions 886-949 of SEQ.ID.NO.:21. The lower sequence is from HG20 and is positions 756-829 of SEQ.ID.NO.:2.

Figure 24 shows a comparison of the amino acid sequences of human GABA β R1a (referred to as "Human GABA-B1aR,"

5 SEQ.ID.NO.:21); the proteins encoded by two genes from *C. elegans* (*C. elegans* GABA-B1 = SEQ.ID.NO.:42 and *C. elegans* GABA-B2 = SEQ.ID.NO.:43); and HG20) (referred to as "Human GABA-B2," (SEQ.ID.NO.:2). The *C. elegans* genes have been predicted from *C.elegans* DNA sequence alone. ZK180 accession number: U58748 is
10 predicted to be GABA-B2 and Y41G9. Contig99 and Y76F7.Contig73 were obtained from the Sanger *C. elegans* genomic sequence database and are predicted to be GABA-B1.

Figure 25A-D shows co-immunoprecipitation of the murine GABA β R1a and FLAG-HG20 receptor subunits and immunoblotting
15 using reciprocal receptor subunit antibodies. Murine GABA β R1a and FLAG-HG20 receptors were expressed individually or co-expressed in COS-7 cells. Figure 25A shows the results of immunoblotting using an anti-murine GABA β R1a antibody. Immunoblot of the solubilized membranes using murine GABA β R1a antibodies 1713.1-1713.2 shows
20 selective expression of murine GABA β R1a in murine GABA β R1a alone expressing cells (lane 3) and murine GABA β R1a /FLAG-HG20 co-expressing cells (lane 4), but not in mock transfected and FLAG-HG20 alone expressing cells (lanes 1 and 2). Staining of GABA β R1a subunits in co-expressing cells is more intense compared to cells expressing the
25 GABA β R1a subunit alone, suggesting that HG20 subunits facilitate GABA β R1a expression. Figure 25B shows the results of immunoblotting using an anti-FLAG-HG20 antibody. Immunoblotting of the solubilized membranes using the anti-FLAG-HG20 antibody shows selective expression of FLAG-HG20 subunits in FLAG-HG20
30 alone expressing cells (lane 6) and murine GABA β R1a /FLAG-HG20 co-expressing cells (lane 8), but not in mock transfected and murine GABA β R1a alone expressing cells (lanes 5 and 7). Staining of HG20 subunits in co-expressing cells is more intense compared to cells expressing the HG20 subunit alone, suggesting that GABA β R1a
35 subunits facilitate HG20 expression. Figure 25C shows the results of immunoprecipitation with an anti-FLAG-HG20 antibody followed by

immunoblotting with an anti-murine GABA β R1a antibody. GABA β R1a /HG20 heterodimers are observed only in murine GABA β R1a /FLAG-HG20 co-expressing cells due to the fact that the GABA β R1a subunit was co-immunoprecipitated with the FLAG-HG20 subunit using the FLAG antibody and detected with GABA β R1a antibodies (lane 12). GABA β R1a subunits are not detected in mock-transfected cells and cells expressing GABA β R1a alone or FLAG-HG20 (lanes 9-11). Figure 25D shows the results of immunoprecipitation with an anti-murine GABA β R1a antibody followed by immunoblotting with an anti-FLAG-HG20 antibody. GABA β R1a /HG20 heterodimers are observed only in murine GABA β R1a /FLAG-HG20 co-expressing cells due to the fact that the FLAG-HG20 subunit was co-immunoprecipitated using the GABA β R1a antibodies and detected with FLAG antibody (lane 16). No FLAG-HG20 subunits are detected in mock-transfected cells or cells expressing murine GABA β R1a alone or FLAG-HG20 (lanes 13-15). The immunoblots shown are from 1-3 independent experiments.

Figure 26A-B shows some of the motifs in the N-termini of GABA β receptor subunits and related genes. Figure 26A shows an alignment of murine GABA β R1a (mGABA β 1a; a portion of SEQ.ID.NO.:20), human GABA β R1a (hGABA β 1a; a portion of SEQ.ID.NO.:21), HG20 (hGABA β 2; a portion of SEQ.ID.NO.:2), metabotropic glutamate receptor 1 (mGluR1; SEQ.ID.NO.:44), and two *E. coli* proteins (LivK (SEQ.ID.NO.:45) and LivBP (SEQ.ID.NO.:46)). Figure 26B is a schematic drawing showing the location of the various motifs in murine GABA β R1a that are expected to be involved in heterodimer formation of GABA β R1a with HG20.

Figure 27 shows an expanded view of the coiled-coil region of homology between HG20 (hGABA β 2; shown is a portion of SEQ.ID.NO.:2) and murine GABA β R1a (mGABA β 1a; a portion of SEQ.ID.NO.:20). Also shown is the corresponding region of human GABA β R1a (hGABA β 1a; a portion of SEQ.ID.NO.:21).

DETAILED DESCRIPTION OF THE INVENTION

For the purposes of this invention:

"Substantially free from other proteins" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%,

free of other proteins. Thus, for example, an HG20 protein preparation that is substantially free from other proteins will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-HG20 proteins. Whether a given HG20 protein preparation is substantially free from other proteins can be determined by such conventional techniques of assessing protein purity as, *e.g.*, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with appropriate detection methods, *e.g.*, silver staining or immunoblotting.

"Substantially free from other nucleic acids" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other nucleic acids. Thus, for example, an HG20 DNA preparation that is substantially free from other nucleic acids will contain, as a percent of its total nucleic acid, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-HG20 nucleic acids. Whether a given HG20 DNA preparation is substantially free from other nucleic acids can be determined by such conventional techniques of assessing nucleic acid purity as, *e.g.*, agarose gel electrophoresis combined with appropriate staining methods, *e.g.*, ethidium bromide staining, or by sequencing.

An HG20 polypeptide has "substantially the same biological activity" as native HG20 (*i.e.*, SEQ.ID.NO.:2) if that polypeptide has a K_d for a ligand that is no more than 5-fold greater than the K_d of native HG20 for the same ligand. An HG20 polypeptide also has "substantially the same biological activity" as HG20 if that polypeptide can form heterodimers with either a GABABR1a or GABABR1b polypeptide, thus forming a functional GABAB receptor.

"Functional GABAB receptor" refers to a heterodimer of HG20 and either GABABR1a or GABABR1b where the heterodimer displays a functional response when exposed to GABA agonists. Examples of functional responses are: pigment aggregation in *Xenopus* melanophores, modulation of cAMP levels, coupling to inwardly rectifying potassium channels, mediation of late inhibitory postsynaptic potentials in neurons, increase in potassium conductance, and decrease in calcium conductance. One skilled in the art would be familiar with a

variety of methods of measuring the functional responses of G-protein coupled receptors such as the GABA_B receptor (see, e.g., Lerner, 1994, Trends Neurosci. 17:142-146 [changes in pigment distribution in melanophore cells]; Yokomizo et al., 1997, Nature 387:620-624 [changes in cAMP or calcium concentration; chemotaxis]; Howard et al., 1996, Science 273:974-977 [changes in membrane currents in *Xenopus* oocytes]; McKee et al., 1997, Mol. Endocrinol. 11:415-423 [changes in calcium concentration measured using the aequorin assay]; Offermanns & Simon, 1995, J. Biol. Chem. 270:15175, 15180 [changes in inositol phosphate levels]). Depending upon the cells in which heterodimers of HG20 and either GABA_BR1a or GABA_BR1b are expressed, and thus the G-proteins with which the heterodimers are coupled, certain of such methods may be appropriate for measuring the functional responses of such heterodimers. It is well with the competence of one skilled in the art to select the appropriate method of measuring functional responses for a given experimental system.

A GABA_BR1a or GABA_BR1b polypeptide has "substantially the same biological activity" as a native GABA_BR1a or GABA_BR1b polypeptide if that polypeptide has a K_d for an amino acid, amino acid analogue, GABA_B receptor agonist, or GABA_B receptor antagonist such as CGP71872, GABA, saclofen, (-)baclofen, or (L)-glutamic acid that is no more than 5-fold greater than the K_d of a native GABA_BR1a or GABA_BR1b polypeptide for the same amino acid, amino acid analogue, GABA_B receptor agonist, or GABA_B receptor antagonist. A GABA_BR1a or GABA_BR1b polypeptide also has "substantially the same biological activity" as a native GABA_BR1a or GABA_BR1b polypeptide if that polypeptide can form heterodimers with an HG20 polypeptide, thus forming a functional GABA_B receptor. Native GABA_BR1a or GABA_BR1b polypeptides include the murine GABA_BR1a sequence shown as SEQ.ID.NO.:20; the rat GABA_BR1a or GABA_BR1b polypeptides disclosed in Kaupmann et al., 1997, Nature 386:239-246; the human GABA_BR1a sequence disclosed in GenBank accession number AJ012185 (SEQ.ID.NO.:21); and the protein encoded by the DNA sequence disclosed in GenBank accession number Y11044 (SEQ.ID.NO.:23).

A "conservative amino acid substitution" refers to the replacement of one amino acid residue by another, chemically similar,

amino acid residue. Examples of such conservative substitutions are: substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (*e.g.*, arginine for lysine; glutamic acid
5 for aspartic acid).

The present invention relates to the identification and cloning of HG20, a novel G-protein coupled receptor-like protein that represents a subunit for the GABA_B receptor. The present invention provides DNA encoding HG20 that is substantially free from other
10 nucleic acids. The present invention also provides recombinant DNA molecules encoding HG20 as well as isolated DNA molecules encoding HG20. Following the cloning of HG20 by the present inventors, a sequence highly similar to the sequence of HG20 was deposited in GenBank by Clark et al. (GenBank accession number AF056085), by
15 White et al. (GenBank accession number AJ012188), and by Borowsky et al. (GenBank accession number AF074483). Two ESTs (GenBank accession number T07621, deposited June 30, 1993, and GenBank accession number Z43654, deposited September 21, 1995) each contain partial sequences of HG20 cDNA.

The present invention provides a DNA molecule substantially free from other nucleic acids comprising the nucleotide sequence shown in Figure 1 as SEQ.ID.NO.:1. Analysis of
20 SEQ.ID.NO.:1 revealed that it contains a long open reading frame at positions 293-3,115. Thus, the present invention also provides a DNA molecule substantially free from other nucleic acids comprising the
25 nucleotide sequence of positions 293-3,115 of SEQ.ID.NO.:1. The present invention also provides an isolated DNA molecule comprising the nucleotide sequence of positions 293-3,115 of SEQ.ID.NO.:1.

Sequence analysis of the open reading frame of the HG20
30 DNA revealed that it encodes a protein of 941 amino acids with a calculated molecular weight of 104 kd and a predicted signal peptide. The predicted amino acid sequence of HG20 is 36% identical to the metabotropic GABA receptor-like sequence GABA_BR1a described in Kaupmann (see above) throughout the entire sequence, and thus HG20
35 most likely represents a novel metabotropic GABA receptor or receptor subunit. *In situ* hybridization showed that HG20 RNA is highly expressed in the cortex, thalamus, hippocampus, and cerebellum of the

brain, showing overlapping distribution with GABA_BR1a RNA as judged by *in situ* hybridization as well as with the expression of GABA_B receptors as judged by pharmacological studies. HG20 RNA exhibits restricted distribution in the periphery, with low abundance of the 6.5 kb
5 RNA in the heart, spleen, and pancreas and high levels in the adrenal gland. HG20 recombinantly expressed in COS-1 cells showed no specific binding for [³H](+)-baclofen, and when expressed in *Xenopus* oocyte and *Xenopus* melanophore functional assays, showed no activity to GABA, (-)-baclofen, and glutamic acid.

10 The novel DNA sequences of the present invention encoding HG20, in whole or in part, can be linked with other DNA sequences, *i.e.*, DNA sequences to which HG20 is not naturally linked, to form "recombinant DNA molecules" containing HG20. Such other sequences can include DNA sequences that control transcription or translation
15 such as, *e.g.*, translation initiation sequences, promoters for RNA polymerase II, transcription or translation termination sequences, enhancer sequences, sequences that control replication in microorganisms, or that confer antibiotic resistance. The novel DNA sequences of the present invention can be inserted into vectors such as
20 plasmids, cosmids, viral vectors, or yeast artificial chromosomes.

The present invention also includes isolated forms of DNA encoding HG20. By "isolated DNA encoding HG20" is meant DNA encoding HG20 that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that DNA
25 encoding HG20 is not present in its normal cellular environment. Thus, an isolated DNA encoding HG20 may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that isolated DNA encoding HG20 is the only DNA present. but instead means that isolated DNA
30 encoding HG20 is at least 95% free of non-nucleic acid material (*e.g.*, proteins, lipids, carbohydrates) naturally associated with the DNA encoding HG20. Thus, DNA encoding HG20 that is expressed in bacteria or even in eukaryotic cells which do not naturally (*i.e.*, without human intervention) contain it through recombinant means is "isolated
35 DNA encoding HG20."

Included in the present invention are DNA sequences that hybridize to SEQ.ID.NO.:1 under stringent conditions. By way of example, and not limitation, a procedure using conditions of high stringency is as follows: Prehybridization of filters containing DNA is carried out for 2 hr. to overnight at 65°C in buffer composed of 6X SSC, 5X Denhardt's solution, and 100 µg/ml denatured salmon sperm DNA. Filters are hybridized for 12 to 48 hrs at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 hr in a solution containing 2X SSC, 0.1% SDS. This is followed by a wash in 0.1X SSC, 0.1% SDS at 50°C for 45 min. before autoradiography.

Other procedures using conditions of high stringency would include either a hybridization carried out in 5XSSC, 5X Denhardt's solution, 50% formamide at 42°C for 12 to 48 hours or a washing step carried out in 0.2X SSPE, 0.2% SDS at 65°C for 30 to 60 minutes.

Reagents mentioned in the foregoing procedures for carrying out high stringency hybridization are well known in the art. Details of the composition of these reagents can be found in, *e.g.*, Sambrook, Fritsch, and Maniatis, 1989, Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press. In addition to the foregoing, other conditions of high stringency which may be used are well known in the art.

Another aspect of the present invention includes host cells that have been engineered to contain and/or express DNA sequences encoding HG20. Such recombinant host cells can be cultured under suitable conditions to produce HG20. An expression vector containing DNA encoding HG20 can be used for expression of HG20 in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Cell lines derived from mammalian species which are suitable for recombinant expression of HG20 and which are commercially available, include but are not limited to, L cells L-M(TK-) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL 1573), Raji

(ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, and *Xenopus* oocytes. In particular embodiments, the recombinant cells expressing HG20 protein co-express a GABA β R1a or GABA β R1b protein, thus forming a functional GABA β receptor comprising a heterodimer of HG20 and either GABA β R1a or GABA β R1b. In particular embodiments, the recombinant cells have been transfected with expression vectors that direct the expression of HG20 and GABA β R1a or GABA β R1b.

Cells that are particularly suitable for expression of the HG20 protein are melanophore pigment cells from *Xenopus laevis*. Such melanophore pigment cells can be used for functional assays that employ recombinant expression of HG20 in a manner similar to the use of such melanophore pigment cells for the functional assay of other recombinant GPCRs (Graminski et al., 1993, J. Biol. Chem. 268:5957-5964; Lerner, 1994, Trends Neurosci. 17:142-146; Potenza & Lerner, 1992, Pigment Cell Res. 5:372-378; Potenza et al., 1992, Anal. Biochem. 206:315-322). Especially preferred are *Xenopus* melanophore pigment cells co-expressing HG20 and GABA β R1a or GABA β R1b, in which HG20 has formed a heterodimer with GABA β R1a or GABA β R1b, thus forming a functional GABA β receptor. The presence of functional GABA β receptors in such cells can be determined by the use of assays such as the pigment aggregation assay described herein. Other assays that reflect a decrease in cAMP levels mediated by exposure to GABA or other agonists of GABA β receptors would also be suitable.

Also preferred are stably or transiently transfected HEK293 cells co-expressing HG20 and GABA β R1a or GABA β R1b, in which HG20 has formed a heterodimer with GABA β R1a or GABA β R1b, thus forming a functional GABA β receptor. The presence of functional GABA β receptors in such cells can be determined by the use of assays such as those that measure cAMP levels as described herein.

Also preferred are *Xenopus* oocytes co-expressing HG20 and GABA β R1a or GABA β R1b, in which HG20 has formed a heterodimer with GABA β R1a or GABA β R1b, thus forming a functional GABA β receptor. The presence of functional GABA β receptors in such

cells can be determined by the use of assays that measure coupling of functional GABA_B receptors comprising heterodimers of HG20 and GABA_BR1a or GABA_BR1b to inwardly rectifying potassium channels (especially the Kir3 family).

5 In order to produce the above-described cells co-expressing HG20 and GABA_BR1a or GABA_BR1b, expression vectors comprising DNA encoding HG20 and GABA_BR1a or GABA_BR1b can be transfected into the cells. HG20 and GABA_BR1a or GABA_BR1b can be transfected separately, each on its own expression vector, or, alternatively, a single
10 expression vector encoding both HG20 and GABA_BR1a or GABA_BR1b can be used.

A variety of mammalian expression vectors can be used to express recombinant HG20, GABA_BR1a, or GABA_BR1b in mammalian cells. Commercially available mammalian expression vectors which
15 are suitable include, but are not limited to, pMC1neo (Stratagene), pSG5 (Stratagene), pcDNA1 and pcDNA1amp, pcDNA3, pcDNA3.1, pCR3.1 (Invitrogen), EBO-pSV2-neo (ATCC 37593), pBPV-1(8-2) (ATCC 37110), pDBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), and the PT7TS oocyte
20 expression vector (or similar expression vectors containing the globin 5' UTR and the globin 3' UTR). The choice of vector will depend upon cell type used, level of expression desired, and the like. Following expression in recombinant cells, HG20, GABA_BR1a, GABA_BR1b, or heterodimers of HG20 and either GABA_BR1a or GABA_BR1b can be
25 purified to a level that is substantially free from other proteins by conventional techniques, *e.g.*, salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography, hydrophobic interaction chromatography, and preparative gel electrophoresis. Also, membrane preparations
30 comprising HG20, GABA_BR1a, GABA_BR1b, or heterodimers of HG20 and either GABA_BR1a or GABA_BR1b can be prepared. Especially preferred are membrane preparations that comprise heterodimers of HG20 and either GABA_BR1a or GABA_BR1b in which the heterodimers represent functional GABA_B receptors.

35 The present invention includes a method of producing HG20 protein comprising:

(a) transfecting a host cell with an expression vector comprising DNA that encodes an HG20 protein;

(b) growing the host cells under conditions such that HG20 protein is produced; and

5 (c) recovering HG20 protein from the host cells.

In particular embodiments, the method of recovering HG20 protein involves obtaining membrane preparations that contain HG20 protein from the host cells. In particular embodiments, such membrane preparations contain heterodimers of HG20 protein and GABABR1a or
10 GABABR1b protein that form functional GABAB receptors.

The present invention includes a method of expressing a truncated HG20 protein comprising:

(a) transfecting a host cell with an expression vector comprising DNA that encodes an HG20 protein that has been truncated
15 at the amino or carboxyl terminus;

(b) culturing the transfected cells of step (a) under conditions such that the truncated HG20 protein is expressed.

Truncated HG20 proteins are those HG20 proteins in which contiguous portions of the N terminus or C terminus have been
20 removed. For example, positions 52-941 of SEQ.ID.NO.:2 represents a truncated HG20 protein. Truncated HG20 proteins may be fused in frame to non-HG20 amino acid sequences, as, *e.g.*, in the FLAG-HG20 construct described herein.

The present invention includes a method of producing
25 functional GABAB receptors in cells comprising:

(a) transfecting cells with:

(1) an expression vector that directs the expression of HG20 in the cells; and

(2) an expression vector that directs the
30 expression of GABABR1a or GABABR1b in the cells;

(b) culturing the cells under conditions such that heterodimers of HG20 and GABABR1a or GABABR1b are formed where the heterodimers constitute functional GABAB receptors.

In particular embodiments of the above methods, the cells
35 are eukaryotic cells. In other embodiments, the cells are mammalian cells. In still other embodiments, the cells are COS cells, *e.g.*, COS-7

cells (ATCC CRL 1651) or COS-1 cells (ATCC CRL 1650); HEK293 cells (ATCC CRL 1573); or *Xenopus* melanophores.

In particular embodiments, the HG20 protein comprises the amino acid sequence shown in SEQ.ID.NO.:2. In particular
5 embodiments, the HG20 protein is a truncated HG20 protein. In particular embodiments, the truncated HG20 protein comprises amino acids 52-941 of SEQ.ID.NO.:2. In particular embodiments, the truncated HG20 protein is a chimeric HG20 protein.

The present invention includes HG20 protein substantially
10 free from other proteins. The amino acid sequence of the full-length HG20 protein is shown in Figure 2 as SEQ.ID.NO.:2. Thus, the present invention includes polypeptides comprising HG20 protein substantially free from other proteins where the polypeptides comprise the amino acid sequence SEQ.ID.NO.:2. The present invention also includes
15 polypeptides comprising HG20 proteins lacking a signal sequence. Examples of amino acid sequences of HG20 proteins lacking a signal sequence are:

Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
20 Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
25 Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

The present invention also includes DNA encoding the above-described HG20 proteins lacking a signal sequence. Thus, *e.g.*,
30 the present invention includes a DNA molecule comprising a nucleotide sequence selected from the group consisting of:

Positions 293-3,115 of SEQ.ID.NO.:1;
Positions 317-3,115 of SEQ.ID.NO.:1;
Positions 395-3,115 of SEQ.ID.NO.:1;
35 Positions 398-3,115 of SEQ.ID.NO.:1;
Positions 404-3,115 of SEQ.ID.NO.:1;
Positions 407-3,115 of SEQ.ID.NO.:1;

Positions 416-3,115 of SEQ.ID.NO.:1;
Positions 422-3,115 of SEQ.ID.NO.:1;
Positions 428-3,115 of SEQ.ID.NO.:1;
Positions 446-3,115 of SEQ.ID.NO.:1; and
Positions 461-3,115 of SEQ.ID.NO.:1.

5 As with many receptor proteins, it is possible to modify many of the amino acids of HG20, particularly those which are not found in the ligand binding domain, and still retain substantially the same biological activity as the original protein. Thus this invention includes modified HG20 polypeptides which have amino acid deletions, additions, or substitutions but that still retain substantially the same biological activity as native HG20. It is generally accepted that single amino acid substitutions do not usually alter the biological activity of a protein (see, *e.g.*, Molecular Biology of the Gene, Watson et al., 1987, 10 Fourth Ed., The Benjamin/Cummings Publishing Co., Inc., page 226; and Cunningham & Wells, 1989, Science 244:1081-1085). Accordingly, the present invention includes polypeptides where one amino acid substitution has been made in SEQ.ID.NO.:2 or in one of the HG20 polypeptides lacking a signal sequence listed above, wherein the polypeptides still retain substantially the same biological activity as native HG20. The present invention also includes polypeptides where two or more amino acid substitutions have been made in SEQ.ID.NO.:2 or in one of the HG20 polypeptides lacking a signal sequence listed above, wherein the polypeptides still retain substantially the same biological 20 activity as native HG20. In particular, the present invention includes embodiments where the above-described substitutions are conservative substitutions. In particular, the present invention includes embodiments where the above-described substitutions do not occur in the ligand-binding domain of HG20. In particular, the present invention includes embodiments where amino acid changes have been made in the positions of HG20 where the amino acid sequence of HG20 differs from the amino acid sequence of GABAR1b (see Figure 8).

The present invention also includes C-terminal truncated forms of HG20, particularly those which encompass the extracellular 35 portion of the receptor, but lack the intracellular signaling portion of the receptor. Such truncated receptors are useful in various binding assays described herein, for crystallization studies, and for structure-activity-

relationship studies. Accordingly, the present invention includes an HG20 protein substantially free from other proteins having the amino acid sequence of positions 1-480 of SEQ.ID.NO.:2.

O'Hara et al., 1993, Neuron 11:41-52 (O'Hara) reported that
5 the amino terminal domains of several metabotropic glutamate
receptors showed amino acid sequence similarities to the amino termini
of several bacterial periplasmic binding proteins. O'Hara used this
similarity to predict, and then experimentally confirm, that these amino
terminal domains correspond to the location of the ligand binding
10 domains of these metabotropic glutamate receptors.

The present inventors have discovered a region of amino
acid sequence in the N-terminal domain of HG20 that is similar to the
amino acid sequence of the bacterial periplasmic binding protein
Leucine, Isoleucine, Valine (Alanine and Threonine) Binding Protein
15 (LIVAT-BP) of *Pseudomonas aeruginosa*. See Figure 6. The region
shown is about 25% identical between the two proteins. This is above the
maximum identity of 17% reported by O'Hara between any one
metabotropic glutamate receptor and any one periplasmic binding
protein and indicates that the region of HG20 depicted is highly likely to
20 contain the ligand binding domain.

Accordingly, the present invention includes a polypeptide
representing the ligand binding domain of HG20 that includes amino
acids 63-259 of SEQ.ID.NO.:2. Also provided are chimeric proteins
comprising amino acids 63-259 of SEQ.ID.NO.:2.

25 Romano et al., 1996, J. Biol. Chem. 271:28612-28616
demonstrated that metabotropic glutamate receptors are often found as
homodimers formed by an intermolecular disulfide bond. The location
of the cysteines responsible for the disulfide bond was found to be in the
amino terminal 17kD of the receptors. Transmembrane interactions
30 may also contribute to functional GABAB receptor dimer formation, as
previously reported for the dopamine D2 receptor and β 2-adrenergic
receptor (Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204;
Hebert et al., 1996, J. Biol. Chem. 271, 16384-16392). Accordingly, the
present invention includes dimers of HG20 proteins. In particular
35 embodiments, the HG20 protein has an amino acid selected from the
group consisting of:

SEQ.ID.NO.:2;

Positions 9-941 of SEQ.ID.NO.:2;

Positions 35-941 of SEQ.ID.NO.:2;

Positions 36-941 of SEQ.ID.NO.:2;

5 Positions 38-941 of SEQ.ID.NO.:2;

Positions 39-941 of SEQ.ID.NO.:2;

Positions 42-941 of SEQ.ID.NO.:2;

Positions 44-941 of SEQ.ID.NO.:2;

Positions 46-941 of SEQ.ID.NO.:2;

10 Positions 52-941 of SEQ.ID.NO.:2;

Positions 57-941 of SEQ.ID.NO.:2; and

Positions 1-480 of SEQ.ID.NO.:2.

It has been found that, in some cases, membrane spanning regions of receptor proteins can be used to inhibit receptor function (Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204; Hebert et al., 1996, J. Biol. Chem. 271, 16384-16392; Lofts et al., Oncogene 8:2813-2820). Accordingly, the present invention provides peptides derived from the seven membrane spanning regions of HG20 and their use to inhibit HG20 or GABAB receptor function. Such peptides can include the whole or parts of the membrane spanning domains.

The present invention also includes isolated forms of HG20 proteins. By "isolated HG20 protein" is meant HG20 protein that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that HG20 protein is not present in its normal cellular environment. Thus, an isolated HG20 protein may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that an isolated HG20 protein is the only protein present, but instead means that an isolated HG20 protein is at least 95% free of non-amino acid material (e.g., nucleic acids, lipids, carbohydrates) naturally associated with the HG20 protein. Thus, an HG20 protein that is expressed through recombinant means in bacteria or even in eukaryotic cells which do not naturally (i.e., without human intervention) express it is an "isolated HG20 protein."

35 The present invention also includes chimeric HG20 proteins. By chimeric HG20 protein is meant a contiguous polypeptide sequence of HG20 fused in frame to a polypeptide sequence of a non-

HG20 protein. For example, the N-terminal domain and seven transmembrane spanning domains of HG20 fused at the C-terminus in frame to a G protein would be a chimeric HG20 protein. Another example of a chimeric HG20 protein would be a polypeptide comprising the FLAG epitope fused in frame at the amino terminus of amino acids 52-941 of SEQ.ID.NO.:2.

The present invention also includes HG20 proteins that are in the form of multimeric structures, *e.g.*, dimers. Such multimers of other metabotropic G-protein coupled receptors are known (Hebert et al., 1996, J. Biol. Chem. 271, 16384-16392; Ng et al., 1996, Biochem. Biophys. Res. Comm. 227, 200-204; Romano et al., 1996, J. Biol. Chem. 271, 28612-28616).

Preferred forms of dimers of HG20 are heterodimers comprising HG20 and other G-protein coupled receptors (GPCRs). Such GPCRs could be, *e.g.*, other subunits of GABA_B receptors, proteins from *C. elegans* showing homology to HG20 (see Figure 24), or human GPCRs that are homologs of the *C. elegans* proteins. Particularly preferred forms of heterodimers are heterodimers of HG20 and either GABA_BR1a or GABA_BR1b. It has been found by the present inventors that such heterodimers exhibit functional properties of GABA_B receptors while monomers or homodimers of HG20, GABA_BR1a, or GABA_BR1b do not exhibit functional properties. Another likely heterodimer partner for HG20 is the protein corresponding to the sequence deposited in GenBank at accession number 3776096.

The strongest evidence that functional GABA_B receptors require both HG20 and GABA_BR1a or GABA_BR1b comes from studies demonstrating that co-transfection and co-expression of both HG20 and either GABA_BR1a or GABA_BR1b is necessary in order for the detection of GABA_B receptor functional responses. Transfection and expression of HG20, GABA_BR1a, or GABA_BR1b alone does not lead to the production of functional GABA_B receptors.

For example, in *Xenopus* melanophores co-expressing HG20 and GABA_BR1a, but not in melanophores expressing HG20 or GABA_BR1a alone, or in mock transfected melanophores, GABA mediated a dose-dependent pigment aggregation response that could be inhibited with the GABA_B receptor specific CGP71872 antagonist. This pigment aggregation response is associated with a decrease in

intracellular cAMP levels. Such a decrease has been confirmed in HEK293 cells. Also, co-expression of HG20 and GABA_BR1a in *Xenopus* oocytes resulted in the stimulation of inwardly rectifying potassium currents (Kirs). Native functional GABA_B receptors have been reported to couple to Kirs (Misgeld et al., 1995, Prog. Neurobiol. 46:423-462).

Consistent with the need for both HG20 and GABA_BR1a for detection of functional GABA_B receptors in transfected cells, the present inventors have demonstrated that HG20 and GABA_BR1a form heterodimers by immunoprecipitation of HG20 followed by immunoblotting with a GABA_BR1a antibody.

That a functional GABA_B receptor requires both HG20 and either GABA_BR1a or GABA_BR1b is also suggested by the observation that GABA_BR1a or GABA_BR1b, recombinantly expressed in the absence of HG20, binds ligand with much reduced affinity compared to the affinity of native GABA_B receptors. Also, characterization of the tissue distribution of each of the receptors by *in situ* hybridization histochemistry in rat brain revealed co-localization of HG20 and GABA_BR1a transcripts in many brain regions, including cortex, at both the regional and cellular levels.

The *Xenopus* melanophore pigment aggregation/dispersion assay has been shown to be highly suitable for monitoring agonist activation of Gi-, Gq-, and Gs-coupled receptors (Potenza et al., 1992, Anal. Biochem. 206:315-322; Lerner, 1994, Trends Neurosci. 17:142-146). Agonist activation of Gi-coupled receptors expressed in melanophores results in pigment aggregation via a reduction in intracellular cAMP levels, whereas activation of Gs- and Gq-coupled receptors results in pigment dispersion via elevations in intracellular cAMP and calcium levels, respectively. Melanophores transfected separately with either GABA_BR1a or HG20 showed no pigment aggregation or dispersion response following treatment with up to 1 mM concentrations of (L)-glutamic acid, GABA, or prototypic GABAergic agonists: (-)baclofen, 3-aminopropyl-(methyl)phosphonic acid, cis-4-aminocrotonic acid, piperidine-4-sulfonic acid (data not shown). Similarly, both receptors failed to couple to K⁺ channels in *Xenopus* oocytes under patch-clamp conditions when transfected separately (data not shown). However, in melanophores transiently co-transfected with GABA_BR1a and HG20, GABA mediated a dose-dependent aggregation response with an IC₅₀

value of 3-7 μ M (n=3). This aggregation was absent in mock-transfected cells and in cells transfected with GABA_BR1a or HG20 alone (Figure 11). The GABA-mediated activity represented 42-56% (n=3) of a control cannabinoid receptor subtype 2 response (Figure 11, inset), and could be inhibited by the CGP71872 antagonist (n=3), indicating it was GABA_B receptor specific (Figure 11). GABA_BR1a was expressed by subcloning full-length GABA_BR1a into the *NheI*-*NotI* site of pcDNA3.1 or pCIneo; HG20 was expressed as a FLAG-HG20 chimeric protein. See Examples 11 and 20 for further experimental details of expression vectors used, transfection conditions, assay conditions, *etc.* for the above-described co-expression studies.

The functional data arising from co-expression of GABA_BR1a and HG20 receptors were confirmed in HEK293 cells. HEK293 cells transfected with and stably expressing GABA_BR1a and HG20 were selected based on expression of receptor message as determined by dot blot analyses. In cell lines stably expressing the individual receptors, we observed small and inconsistent responses in assays to examine agonist-mediated modulation of cAMP synthesis. However, transient transfection of HEK293 cells stably expressing GABA_BR1a (rgb1a-50) with an HG20 expression plasmid and transient transfection of HEK293 cells stably expressing HG20 (hgb2-42) with a GABA_BR1a expression plasmid significantly enhanced the ability of baclofen and GABA to inhibit forskolin-stimulated cAMP synthesis. Rgb1a-50 cells transfected with HG20 exhibited a 28% reduction in forskolin-stimulated cAMP synthesis with 30 μ M baclofen and a 40% decrease with 30 μ M GABA plus 100 μ M aminooxyacetic acid (AOAA; a GABA transaminase inhibitor) and 100 μ M nipecotic acid (a GABA uptake inhibitor) (Figure 12B). A 34% reduction in forskolin-stimulated cAMP synthesis was observed for hgb2-42 cells transfected with GABA_BR1a treated with baclofen and a 43% decrease was observed for GABA plus AOAA and nipecotic acid (Figure 12B). While inhibition of cAMP synthesis was sometimes observed with rgb1a-50 cells transfected with GABA_BR1a and hgb2-42 cells transfected with HG20, these effects were small and inconsistent (0-20% inhibition; Figure 12B). Neither baclofen nor GABA plus AOAA and nipecotic acid in the absence of forskolin had any affect on cAMP synthesis (Figure 12B). In addition,

wild-type HEK293 cells did not exhibit baclofen- or GABA-mediated inhibition of forskolin-stimulated cAMP synthesis (Figure 12B). These data demonstrate that the functional GABA_B receptor requires both GABA_BR1a and HG20. For experimental details of these studies in

5 HEK293 cells, see Example 12.

Co-expression of the GABA_BR1a and HG20 with the inwardly rectifying potassium channels Kir 3.1/3.2 in *Xenopus* oocytes resulted in a significant stimulation of inwardly rectifying potassium current (Kir) in response to GABA [301 +/- 20.6 %, (n=3) increase over
10 control current] measured at -80 mV which could subsequently be washed out with control solution (Figure 13). Modulation of Kir 3.1/3.2 was not seen in oocytes expressing GABA_BR1a or HG20 individually, even in the presence of Gi α 1 (Figure 13). See Example 21 for details.

To determine whether receptor intermolecular interactions
15 accounted for the functional activity that was observed following the co-expression of recombinant GABA_BR1a and HG20, membranes from cells co-expressing GABA_BR1a and HG20 or the individual proteins were first immunoprecipitated using anti-FLAG antibodies (to detect the recombinant FLAG-HG20 chimeric proteins) followed by
20 immunoblotting with a GABA_BR1a-specific antibody. As seen in Figure 14, lanes 1-3, no GABA_BR1a immunoreactivity was detected in samples prepared from mock vector transfected cells, FLAG-HG20 alone expressing cells, and GABA_BR1a alone expressing cells
immunoprecipitated with the FLAG-antibody. Since immunoreactive
25 species were detected only in cells co-expressing HG20 and GABA_BR1a, this experiment demonstrates that HG20 and GABA_BR1a can only be co-immunoprecipitated as part of a complex (Figure 14, lane 4). Based on the predicted molecular mass of a heterodimer of HG20 and GABA_BR1a, the ~250+ and ~130 kDa species may represent a
30 heterodimer and GABA_BR1a monomers, respectively. The stability of the HG20/GABA_BR1a heterodimer in denaturing and reducing conditions suggests that SDS-stable transmembrane interactions form the heterodimer, as reported previously for β 2 adrenergic and dopamine D2 receptors (Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204; Hebert et al., 1996, J. Biol. Chem. 271, 16384-16392). The monomer might
35 result from partial disruption, subsequent to immunoprecipitation, of N-terminal Sushi repeats, C-terminal alpha-helical interacting domains

(*e.g.*, coiled-coils) present in HG20 and GABA_BR1a subunits, transmembrane interactions, or disulfide bonds that contribute to forming the heterodimer.

Particular examples of such regions likely to be involved in forming the heterodimer are shown in Figure 23. Regions such as those shown in Figure 23, as well as polypeptides comprising such regions are expected to be useful for the purpose of modulating the formation of heterodimers involving HG20 and thus controlling GABA_B receptor activity. Accordingly, the present invention includes polypeptides comprising the coiled-coil domains of HG20, GABA_BR1a, and GABA_BR1b. In particular, the present invention includes polypeptides comprising an amino acid sequence selected from the group consisting of: positions 756-829 of SEQ.ID.NO.:2; positions 779-814 of SEQ.ID.NO.:2; positions 886-949 of SEQ.ID.NO.:21; and positions 889-934 of SEQ.ID.NO.:21; where the polypeptides do not contain other contiguous amino acid sequences longer than 5 amino acids from a GABA_B receptor subunit. The present invention also includes heterodimers of such polypeptides. In more general terms, the present invention includes comprising a coiled-coil domain from a first GABA_B receptor subunit and no other contiguous amino acid sequences longer than 5 amino acids from the first GABA_B receptor subunit where the coiled-coil domain is present in the C-terminus of the first GABA_B receptor subunit and mediates heterodimerization of the first GABA_B receptor subunit with a second GABA_B receptor subunit.

In addition to the coiled-coil domains discussed above, a variety of regions of HG20 and GABA_BR1a are expected to be important for heterodimer formation. Motif analysis of the N-terminus of murine GABA_BR1a revealed seven consensus N-linked glycosylation sites and three putative short consensus repeats (SCRs) of ~60 amino acids each: amino acids 27-96 and amino acids 102-157 (GABA_BR1a specific), and amino acids 183-245 (common to GABA_BR1b (Kaupmann et al., 1997, Nature 386:239-246) and HG20 (Jones et al., 1998, Nature 396:674-679; White et al., 1998, Nature 396:679-682; Kaupmann et al., 1998, Nature 396:683-687; Kuner et al., 1999, Science 283:74-77) not described previously (Figure 26A-B). Since SCRs are known to play important roles in protein-protein interactions in a wide variety of complement

proteins, adhesion proteins, and selectins (Chou and Heinrikson, 1997, J. Protein Chem. 16:765-773; Perkins et al., 1998, Biochemistry 27:4004-4012), of which the latter shows weak amino acid identity to murine GABA_BR1a, these SCRs, together with the coiled-coil domains
5 discussed above in the carboxyl tails of GABA_BR1a and HG20 (Figure 23), are expected to be involved in the heterodimerization of GABA_BR1a and HG20.

Therefore, the present invention includes a polypeptide comprising an SCR domain from a first GABA_B receptor subunit and
10 no other contiguous amino acid sequences longer than 5 amino acids from the first GABA_B receptor subunit where the SCR domain is present in the N-terminus of the first GABA_B receptor subunit and mediates heterodimerization of the first GABA_B receptor subunit with a second GABA_B receptor subunit. In particular embodiments, the SCR
15 is selected from the group consisting of: positions 27-96 of SEQ.ID.NO.:20; positions 102-157 of SEQ.ID.NO.:20; positions 183-245 of SEQ.ID.NO.:20; positions 28-97 of SEQ.ID.NO.:21; positions 103-158 of SEQ.ID.NO.:21; positions 184-246 of SEQ.ID.NO.:21; positions 4-22 of SEQ.ID.NO.:2; positions 23-49 of SEQ.ID.NO.:2; and positions 72-135 of
20 SEQ.ID.NO.:2.

As in the metabotropic glutamate receptors (mGLURs), the second intracellular loop of murine GABA_BR1a is rich in basic amino acids which may play a role in G-protein-interactions (reviewed by Pin and Duvoisin, 1995, Neuropharmacology 34:1-26), and, as in the
25 mGLURs, the carboxyl tail of murine GABA_BR1a contains a PDZ protein-interacting module (serine-arginine-valine, amino acids 953-955) which has been shown for mGLURs to play an important role in the interactions among the signaling components of synaptic junctions (Brakeman et al.1997, Nature 386:284-288). The murine GABA_BR1a
30 receptor also contains potential protein kinase C and casein kinase II recognition sites predicted using ProSearch (Kolakowski et al., 1992, Biotechniques 13:919-921).

The present invention also relates to the identification and cloning of the murine GABA_BR1a receptor, the murine ortholog of the
35 rat GABA_BR1a receptor described in Kaupmann et al., 1997, Nature 386:239-246 (Kaupmann). The present invention provides DNA encoding murine GABA_BR1a that is substantially free from other nucleic acids.

The present invention also provides recombinant DNA molecules encoding murine GABA_BR1a.

The present invention provides a DNA molecule encoding murine GABA_BR1a that is substantially free from other nucleic acids and comprises the nucleotide sequence shown in Figure 15 as SEQ.ID.NO.:19. The open reading frame of SEQ.ID.NO.:19, encoding mouse GABA_BR1a protein, is positions 1-2,880, with positions 2,881-2,883 representing a stop codon. Thus, the present invention also provides a DNA molecule substantially free from other nucleic acids comprising the nucleotide sequence of positions 1-2,880 of SEQ.ID.NO.:19.

Sequence analysis of the open reading frame of the murine GABA_BR1a DNA revealed that it encodes a mature protein (*i.e.*, lacking a signal sequence) of 942 amino acids with a predicted molecular weight of 106.5 kDa that is 99% identical to rat GABA_BR1a (described in Kaupmann), with only six amino acid changes overall. Murine GABA_BR1a protein shares 31% overall amino acid identity to HG20.

CGP71872 is a photoaffinity ligand specific for GABA_BR1a receptors ($K_d = 1.0 \pm 0.2$ nM) that can be cross-linked to rat GABA_BR1a (Kaupmann et al., 1997, Nature 386:239-246). In crude membranes prepared from COS-7 cells transiently transfected with murine GABA_BR1a, [¹²⁵I]CGP71872 photolabelled a major band at ~130 kDa representing the mature (presumably glycosylated) protein and an additional band at approximately twice that molecular weight, possibly representing dimers (Figure 9). Ligand-binding species could also be detected with affinity purified GABA_BR1a antibodies 1713.1 (raised against the peptide acetyl-DVNSRRDILPDYELKLC-amide; a portion of SEQ.ID.NO.:20) and 1713.2 (raised against the peptide acetyl-CATLHNPTRVKLF EK-amide; a portion of SEQ.ID.NO.:20) (Figure 9). In contrast, FLAG-tagged HG20 protein did not bind the high-affinity CGP71872 ligand, although expression of the protein was confirmed by immunoblot analysis (Figure 9).

Displacement of [¹²⁵I]CGP71872 binding to recombinant murine GABA_BR1a was in the appropriate rank order of potency for GABAergic ligands: CGP71872 > SKF-97541 (3-aminopropyl(methyl)-phosphinic acid) > GABA > (-)baclofen > saclofen > (L)-glutamic acid.. Interestingly, recombinant rat GABA_BR1a exhibits 10-25 fold lower affinity for agonists than native GABA_B receptors in brain (Kaupmann

et al., 1997, *Nature* 386:239). Although the reason for this discrepancy remains unclear, a recent report indicated that recombinant GABA β R1a may require additional cellular components for functional targeting to the plasma membrane (Couve et al., 1998, *J. Biol. Chem.* 273:26361-26367). Thus, GABA β R1a alone, without such additional components, might be expected to exhibit somewhat altered ligand binding characteristics.

In the binding experiments discussed above using GABA β R1a alone, surprisingly, dose-dependent displacement was not detected for (+)baclofen, and the affinities of agonists (GABA, SKF-97541, and (-)baclofen) and partial agonists ((+)baclofen, saclofen, (L)-glutamic acid) but not the affinity of antagonist (CGP71872) for the recombinant GABA β R1a were markedly lower compared to native receptors in rat brain (Table 1). Agonist affinities of co-expressed HG20 and GABA β R1a were examined in membranes prepared from cells co-expressing GABA β R1a and FLAG-tagged HG20. Competition of [¹²⁵I]CGP71872 binding in these membranes showed recovery of high-affinity ligand binding comparable to native receptors in rat brain (Table 1). The simplest explanation for these results is that the high-affinity agonist binding pocket may comprise interactions between the N-terminal domains of HG20 and GABA β R1a that form the heterodimer.

Table 1

Ligand	rat cortex*	gb1a	gb1a/gb2
CGP71872	0.5 nM	0.52 - 0.67 nM	0.15 - 0.27 nM
GABA	2.5 μ M	42.55 - 68.38 μ M	1.77 - 2.55 μ M
SKF-97541**	not determined	11.09 - 11.47 μ M	0.80 - 0.96 μ M
(-)Baclofen	0.5 μ M	31.46 - 53.70 μ M	3.92 - 7.78 μ M
(+)Baclofen	not determined	no fit	1.25 - 3.94 mM
Saclofen	156 μ M	280.5 - 365.0 μ M	119.4 - 131.4 μ M
L-Glutamate	not determined	119.4 - 285.0 mM	116.2 - 201.6 mM

* reported by Kaupmann et al., (1997) *Nature* 386, 239-246

** 3-aminopropyl(methyl)phosphinic acid

In Table 1, gb1a refers to GABA β R1a and gb1a/gb2 refers to HG20/ GABA β R1a heterodimers.

Co-localization studies were performed to determine if mRNAs for GABA β R1a and HG20 co-exist in the same cells in the brain. Figure 10A-B shows equivalent levels of GABA β R1a and HG20

hybridization in adjacent coronal sections of rat parietal cortex, indicating that messages for both receptors are expressed in this brain region. Radiolabelled and fluorescent probes for the two receptors were used to look at the cellular level where it was observed that message for both receptors is expressed in the same cells (Example 13 and Figure 10C-E). In the parietal cortex and all other major brain regions studied, including the hippocampus, thalamus, cerebellum, and vestibular ganglion, GABA_BR1a and HG20 mRNAs are co-localized in the same cells. These results suggest that the functional native GABA_B receptors found in these cells involve both GABA_BR1a and HG20. Co-immunoprecipitation, functional, and anatomical data described herein converge to strongly support the argument that the native, functional GABA_B receptor is a heterodimer of GABA_BR1a and HG20. This work is particularly exciting because it represents the first example of a heteromeric G protein-coupled receptor.

The novel murine GABA_BR1a DNA sequences of the present, in whole or in part, can be linked with other DNA sequences, *i.e.*, DNA sequences to which GABA_BR1a DNA is not naturally linked, to form "recombinant DNA molecules" encoding murine GABA_BR1a. Such other sequences can include DNA sequences that control transcription or translation such as, *e.g.*, translation initiation sequences, promoters for RNA polymerase II, transcription or translation termination sequences, enhancer sequences, sequences that control replication in microorganisms, or that confer antibiotic resistance. The novel DNA sequences of the present invention can be inserted into vectors such as plasmids, cosmids, viral vectors, or yeast artificial chromosomes.

The present invention also includes isolated forms of DNA encoding GABA_BR1a. By "isolated DNA encoding GABA_BR1a" is meant DNA encoding GABA_BR1a that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that DNA encoding GABA_BR1a is not present in its normal cellular environment. Thus, an isolated DNA encoding GABA_BR1a may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that isolated DNA encoding GABA_BR1a is the only DNA present, but instead means that isolated DNA encoding GABA_BR1a is at

least 95% free of non-nucleic acid material (e.g., proteins, lipids, carbohydrates) naturally associated with the DNA encoding GABABR1a. Thus, DNA encoding GABABR1a that is expressed in bacteria or even in eukaryotic cells which do not naturally (i.e., without human intervention) contain it through recombinant means is "isolated DNA encoding GABABR1a."

Another aspect of the present invention includes host cells that have been engineered to contain and/or express DNA sequences encoding murine GABABR1a. Such recombinant host cells can be cultured under suitable conditions to produce murine GABABR1a protein. An expression vector containing DNA encoding the murine GABABR1a protein can be used for expression of the murine GABABR1a protein in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Cell lines derived from mammalian species which are suitable for recombinant expression of the murine GABABR1a protein and which are commercially available, include but are not limited to, L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus melanophores*, and *Xenopus oocytes*.

A variety of mammalian expression vectors can be used to express recombinant murine GABABR1a in mammalian cells. Commercially available mammalian expression vectors which are suitable include, but are not limited to, pMC1neo (Stratagene), pSG5 (Stratagene), pcDNAI and pcDNAIamp, pcDNA3, pcDNA3.1, pCR3.1 (Invitrogen), EBO-pSV2-neo (ATCC 37593), pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), and the PT7TS oocyte expression vector (or similar expression vectors containing the globin 5' UTR and the globin 3' UTR). Following expression in recombinant cells,

the murine GABA β R1a protein can be purified by conventional techniques to a level that is substantially free from other proteins.

Other cells that are particularly suitable for expression of the murine GABA β R1a protein are immortalized melanophore pigment cells from *Xenopus laevis*. Such melanophore pigment cells can be used for functional assays using recombinant expression of murine GABA β R1a in a manner similar to the use of such melanophore pigment cells for the functional assay of other recombinant GPCRs (Graminski et al., 1993, J. Biol. Chem. 268:5957-5964; Lerner, 1994, Trends Neurosci. 17:142-146; Potenza & Lerner, 1992, Pigment Cell Res. 5:372-378; Potenza et al., 1992, Anal. Biochem. 206:315-322).

The present invention includes a method of producing the murine GABA β R1a protein comprising:

- (a) transfecting a host cell with a expression vector comprising DNA that encodes the murine GABA β R1a protein;
- (b) growing the host cells under conditions such that the murine GABA β R1a protein is produced; and
- (c) recovering the murine GABA β R1a protein from the host cells.

In particular embodiments, the method of recovering the murine GABA β R1a protein may involve obtaining membrane preparations from the host cells that contain the murine GABA β R1a protein. Such membrane preparations may contain heterodimers of GABA β R1a protein and HG20 protein that form functional GABA β receptors.

In particular embodiments, the cells are eukaryotic cells. In other embodiments, the cells are mammalian cells. In still other embodiments, the cells are COS cells, in particular COS-7 cells (ATCC CRL 1651), COS-1 cells (ATCC CRL 1650), HEK293 cells (ATCC CRL 1573), or *Xenopus* melanophores.

The present inventors have discovered that, when either HG20 or GABA β R1a subunits are recombinantly expressed separately, *i.e.*, in different cells, very little or no expression is observed. It is only when HG20 and GABA β R1a subunits are recombinantly co-expressed, *i.e.*, expressed in the same cells at the same time, that high level expression of HG20 and GABA β R1a is observed (see Figure 25). Given

the close relationship among GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20 (see Figure 24), and the close relationship that is expected to be found between other isoforms of GABA_BR1a and GABA_BR1b, it is believed that co-expression of HG20 and either GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b will also result in increased expression of HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b as compared to expression of these proteins separately.

Accordingly, the present invention includes a method of co-expressing HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b so as to result in an increase in expression of HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b as compared to expression when HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b are expressed separately. In particular embodiments, the level of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b is measured in the co-expressing cells. In particular embodiments, the level of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b is measured by immunoblot or by immunoprecipitation/immunoblotting methods.

Thus, the present invention includes a method of increasing expression of HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b comprising:

- (a) recombinantly expressing HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the same cells;
- (b) measuring the expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b, where a measurement of

detectable expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b indicates that increased expression has been achieved.

5 In particular embodiments, the measurement of expression is carried out by immunoblotting with or without immunoprecipitation.

In other embodiments, the method also comprises the steps of recombinantly expressing HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b separately, measuring the level of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the separately expressing cells, and comparing the amount of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the separately expressing cells to the amount of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the co-expressing cells.

20 Accordingly, the present invention includes a a method of increasing expression of HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b comprising:

- (a) recombinantly expressing HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the same cells to form co-expressing cells;
- (b) recombinantly expressing HG20 and GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in different cells to form separately expressing cells;
- (c) measuring the expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other isoforms of GABA_BR1a and GABA_BR1b in the co-expressing cells;
- (d) measuring the expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other

isoforms of GABA_BR1a and GABA_BR1b in the separately expressing cells;

where if the amount of expression of HG20, GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20, or other
5 isoforms of GABA_BR1a and GABA_BR1b is greater in the co-expressing cells as compared to the separately expressing cells, this indicates that increased expression has been achieved.

In particular embodiments, the measurement of expression is carried out by immunoblotting with or without
10 immunoprecipitation.

The present invention includes murine GABA_BR1a protein substantially free from other proteins. The amino acid sequence of the full-length murine GABA_BR1a protein is shown in Figure 16 as SEQ.ID.NO.:20. Thus, the present invention includes polypeptides
15 comprising the murine GABA_BR1a protein substantially free from other proteins having the amino acid sequence SEQ.ID.NO.:20. The present invention also includes murine GABA_BR1a protein lacking a signal sequence as well as DNA encoding such a protein. Such a murine GABA_BR1a protein lacking a signal sequence is represented by
20 amino acids 18-960 of SEQ.ID.NO.:20.

The present invention includes modified murine GABA_BR1a polypeptides which have amino acid deletions, additions, or substitutions but that still retain substantially the same biological activity as native murine GABA_BR1a protein. The present invention
25 includes polypeptides where one amino acid substitution has been made in SEQ.ID.NO.:20 or in a polypeptide represented by SEQ.ID.NO.:20 lacking a signal sequence, wherein the polypeptides still retain substantially the same biological activity as native murine GABA_BR1a protein. The present invention also includes polypeptides where two or
30 more amino acid substitutions have been made in SEQ.ID.NO.:20 or in a polypeptide represented by SEQ.ID.NO.:20 lacking a signal sequence, wherein the polypeptides still retain substantially the same biological activity as native murine GABA_BR1a protein. In particular, the present invention includes embodiments where the above-described
35 substitutions are conservative substitutions. In particular, the present invention includes embodiments where the above-described

substitutions do not occur in the ligand-binding domain of native murine GABA_BR1a protein. In particular, the present invention includes embodiments where amino acid changes have been made in positions of native murine GABA_BR1a protein where the amino acid sequence of native murine GABA_BR1a protein differs from the amino acid sequence of HG20 when the amino acid sequences of native murine GABA_BR1a protein and HG20 are aligned in a manner similar to the alignment of the amino acid sequences of GABA_BR1b protein and HG20 shown in Figure 8.

10 The present invention also includes isolated forms of murine GABA_BR1a proteins. By "isolated murine GABA_BR1a protein" is meant murine GABA_BR1a protein that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that murine GABA_BR1a protein is not present in its normal cellular environment. Thus, an isolated murine GABA_BR1a protein may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that an isolated murine GABA_BR1a protein is the only protein present, but instead means that an isolated murine GABA_BR1a protein is at least 95% free of non-amino acid material (e.g., nucleic acids, lipids, carbohydrates) naturally associated with the murine GABA_BR1a protein. Thus, an murine GABA_BR1a protein that is expressed in bacteria or even in eukaryotic cells which do not naturally (i.e., without human intervention) express it through recombinant means is an "isolated murine GABA_BR1a protein."

 The present invention also provides ligand-binding domains of murine GABA_BR1a protein. A FASTA search of the database GenBank (bacterial division) using the N-terminal domain of murine GABA_BR1a (amino acid positions 147-551 of SEQ.ID.NO.:20) as the probe reveals a match with the *E.coli* leucine-specific binding protein (livK) (22% identity over 339 amino acids), whereas no match to any bacterial amino acid binding protein is found using the receptor sequence inclusive of the region that includes the seven transmembrane domains (TM 1-7; amino acid positions 552-960) as a probe. The ligand-binding domain(s) of GABA_BR1a was also experimentally determined. Photoaffinity [¹²⁵I]CGP71872 labeling experiments provided direct physical evidence that the N-terminal extracellular domain but not a C-

terminal fragment of GABA_BR1a (comprising TM1-7 and inclusive to the carboxyl tail) is responsible for ligand-binding (see Examples 14-19 and Figure 17B).

Accordingly, the present invention includes a polypeptide
5 comprising the ligand binding domain of murine GABA_BR1a. In preferred embodiments, the polypeptide comprises amino acids 147-551 of SEQ.ID.NO.:20.

The present invention includes methods of identifying compounds that specifically bind to the GABA_B receptor, as well as
10 compounds identified by such methods. The specificity of binding of compounds showing affinity for the GABA_B receptor is shown by measuring the affinity of the compounds for recombinant cells expressing HG20 and either GABA_BR1a or GABA_BR1b, or for membranes from such cells. Expression of the GABA_B receptor and
15 screening for compounds that bind to the GABA_B receptor or that inhibit the binding of a known, radiolabeled ligand of the GABA_B receptor, *e.g.*, an amino acid or a GABA analogue such as (-)baclofen, to these cells, or membranes prepared from these cells, provides an effective method for the rapid selection of compounds with high affinity for the GABA_B
20 receptor. Other radiolabeled ligands that might be used are ibotenic acid, the amino acids glutamate and glycine, other amino acids, decarboxylated amino acids, or any of the other GABA_B receptor ligands disclosed herein or known in the art. Such ligands need not necessarily be radiolabeled but can also be nonisotopic compounds that can be used
25 to displace bound radiolabeled compounds or that can be used as activators in functional assays. Compounds identified by the methods disclosed herein are likely to be agonists or antagonists of the GABA_B receptor and may be peptides, proteins, or non-proteinaceous organic molecules.

Therefore, the present invention includes assays by which
30 GABA_B receptor agonists and antagonists can be identified. Methods for identifying agonists and antagonists of other receptors are well known in the art and can often be adapted to identify agonists and antagonists of the GABA_B receptor. Accordingly, the present invention includes a
35 method for determining whether a substance binds GABA_B receptors

and is thus a potential agonist or antagonist of the GABA_B receptor that comprises:

- (a) providing cells comprising an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b;
 - (b) culturing the cells under conditions such that HG20 and GABA_BR1a or GABA_BR1b are expressed and heterodimers of HG20 and GABA_BR1a or GABA_BR1b are formed;
 - (c) exposing the cells to a labeled ligand of GABA_B receptors in the presence and in the absence of the substance;
 - (d) measuring the binding of the labeled ligand to the heterodimers of HG20 and GABA_BR1a or GABA_BR1b in the presence and in the absence of the substance;
- where if the amount of binding of the labeled ligand is less in the presence of the substance than in the absence of the substance, then the substance is a potential agonist or antagonist of GABA_B receptors.

Examples of ligands of GABA_B receptors are: CGP71872, GABA, saclofen, (-)baclofen, glycine, and (L)-glutamic acid.

The present invention also includes a method for determining whether a substance is capable of binding to GABA_B receptors, *i.e.*, whether the substance is a potential agonist or an antagonist of GABA_B receptors, where the method comprises:

- (a) providing test cells comprising an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b;
- (b) culturing the test cells under conditions such that HG20 and GABA_BR1a or GABA_BR1b are expressed and heterodimers of HG20 and GABA_BR1a or GABA_BR1b are formed;
- (c) exposing the test cells to the substance;
- (d) measuring the amount of binding of the substance to the test cells;
- (e) measuring the amount of binding of the substance to control cells;
- (f) comparing the amount of binding of the substance to the test cells with the amount of binding of the substance to control cells;

where if the amount of binding of the substance to the test cells is greater than the amount of binding of the substance to control cells, then the substance is capable of binding to GABA_B receptors;

5 where the control cells are essentially the same as the test cells except that the control cells do not comprise an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b.

Once a substance has been identified by the above-described methods, determining whether the substance is an agonist or
10 antagonist can then be accomplished by the use of functional assays such as those described herein.

In particular embodiments, the cells are transfected with an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b.

15 In particular embodiments, the binding affinity of the substance for the test cells is determined. In particular embodiments, such binding affinity is between 1nM and 200 mM; preferably between 5 nM and 1 mM; more preferably between 10 nM and 100 μM; and even more preferably between 10 nM and 100 nM.

20 The conditions under which step (c) of the above-described methods is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

25 In a particular embodiment of the above-described methods, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), or *Xenopus* melanophores.

35 The assays described above can be carried out with cells that have been transiently or stably transfected with an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b. Transfection is meant to include any method known in the

art for introducing HG20 and GABA_BR1a or GABA_BR1b into the test cells. For example, transfection includes calcium phosphate or calcium chloride mediated transfection, lipofection, infection with a retroviral construct, and electroporation. In particular embodiments, a single
5 expression vector encodes HG20 and GABA_BR1a or GABA_BR1b.

Where binding of the substance or ligand is measured, such binding can be measured by employing a labeled substance or ligand. The substance or ligand can be labeled in any convenient manner known to the art, *e.g.*, radioactively, fluorescently,
10 enzymatically.

In particular embodiments of the above-described methods, the substance or ligand is an amino acid or an amino acid analogue such as CGP71872, GABA, saclofen, (-)baclofen, glycine, and (L)-glutamic acid.

15 In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

In particular embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group consisting of:

20 SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
25 Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
30 Positions 57-941 of SEQ.ID.NO.:2.

In particular embodiments, GABA_BR1a is murine GABA_BR1a and has the amino acid sequence SEQ.ID.NO.:20. In particular embodiments, GABA_BR1a is rat GABA_BR1a and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-
35 246. In particular embodiments, GABA_BR1b is rat GABA_BR1b and has the amino acid sequence reported in Kaupmann et al., 1997, Nature

386:239-246. In particular embodiments, GABA_BR1a is human GABA_BR1a and has an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

The above-described methods can be modified in that,
5 rather than exposing cells to the substance, membranes can be prepared from the cells and those membranes can be exposed to the substance. Such a modification utilizing membranes rather than cells is well known in the art with respect to other receptors and is described in, *e.g.*, Hess et al., 1992, Biochem. Biophys. Res. Comm. 184:260-268.

10 As a further modification of the above-described method, RNA encoding HG20 and GABA_BR1a or GABA_BR1b can be prepared as, *e.g.*, by *in vitro* transcription using a plasmid containing HG20 and a plasmid containing GABA_BR1a or GABA_BR1b under the control of a bacteriophage T7 promoter, and the RNA can be microinjected into
15 *Xenopus* oocytes in order to cause the expression of HG20 and GABA_BR1a or GABA_BR1b in the oocytes. Substances are then tested for binding to the heterodimer of HG20 and GABA_BR1a or GABA_BR1b expressed in the oocytes. Alternatively, rather than detecting binding, the effect of the substances on the electrophysiological properties of the
20 oocytes can be determined.

The present invention includes assays by which GABA_B receptor agonists and antagonists may be identified by their ability to stimulate or antagonize a functional response mediated by the GABA_B receptor in cells that have been co-transfected with and that co-express
25 HG20 and GABA_BR1a or GABA_BR1b.

Accordingly, the present invention provides a method of identifying agonists and antagonists of HG20 comprising:

- (a) providing test cells by transfecting cells with:
 - (1) an expression vector that directs the
30 expression of HG20 in the cells; and
 - (2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;
- (b) exposing the test cells to a substance that is suspected of being an agonist of the GABA_B receptor;
- 35 (c) measuring the amount of a functional response of the test cells that have been exposed to the substance;

(d) comparing the amount of the functional response exhibited by the test cells with the amount of the functional response exhibited by control cells;

5 wherein if the amount of the functional response exhibited by the test cells differs from the amount of the functional response exhibited by the control cells, the substance is an agonist or antagonist of the GABA_B receptor;

where the control cells are cells that have not been transfected with HG20 and GABA_BR1a or GABA_BR1b but have been
10 exposed to the substance or are test cells that have not been exposed to the substance.

In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

In particular embodiments of the above-described methods,
15 HG20 comprises an amino acid sequence selected from the group consisting of:

SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
20 Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
25 Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

In particular embodiments, GABA_BR1a is murine GABA_BR1a and has the amino acid sequence SEQ.ID.NO.:20. In
30 particular embodiments, GABA_BR1a is rat GABA_BR1a and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In particular embodiments, GABA_BR1b is rat GABA_BR1b and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In particular embodiments, GABA_BR1a is human
35 GABA_BR1a and has an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

In particular embodiments, the functional response is selected from the group consisting of: changes in pigment distribution in melanophore cells; changes in cAMP or calcium concentration; and changes in membrane currents in *Xenopus* oocytes. In particular
5 embodiments, the change in pigment distribution is pigment aggregation; the change in cAMP concentration is a decrease in cAMP concentration; the change in membrane current is the modulation of an inwardly rectifying potassium current.

In a particular embodiment of the above-described method,
10 the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK-) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92),
15 NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, or *Xenopus* oocytes.

In a particular embodiment of the above-described method, the cells are transfected with separate expression vectors that direct the
20 expression of HG20 and either GABA_BR1a or GABA_BR1b in the cells. In other embodiments, the cells are transfected with a single expression vector that direct the expression of both HG20 and GABA_BR1a or GABA_BR1b in the cells.

In a particular embodiment, the cells are *Xenopus*
25 melanophores and the functional response is pigment aggregation. In another embodiment, the cells are HEK293 cells and the functional response is a decrease in cAMP level. In another embodiment, the cells are *Xenopus* oocytes and the functional response is the production of an inwardly rectifying potassium current.

30 The conditions under which step (b) of the method is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: e.g., physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

35 The above-described assay can be easily modified to form a method to identify antagonists of the GABA_B receptor. Such a method comprises:

- (a) providing cells by transfecting cells with:
- (1) an expression vector that directs the expression of HG20 in the cells; and
- (2) an expression vector that directs the expression of GABABR1a or GABABR1b in the cells;
- (b) exposing the cells to a substance that is a known agonist of the GABAB receptor;
- (c) measuring the amount of a functional response of the cells that have been exposed to the known agonist;
- (d) exposing the cells concurrently to the known agonist and to a substance that is suspected of being an antagonist of the GABAB receptor;
- (e) measuring the amount of a functional response of the cells that have been exposed to the substance and the known agonist;
- (f) comparing the amount of the functional response measured in step (c) with the amount of the functional response measured in step (e);
- wherein if the amount of the functional response measured in step (c) is greater than the amount of the functional response measured in step (e), the substance is an antagonist of the GABAB receptor.

Additional types of functional assays that can be used to identify agonists and antagonists of GABAB receptors include transcription-based assays. Transcription-based assays involve the use of a reporter gene whose transcription is driven by an inducible promoter whose activity is regulated by a particular intracellular event such as, *e.g.*, changes in intracellular calcium levels that are caused by the interaction of a receptor with a ligand. Transcription-based assays are reviewed in Rutter et al., 1998, *Chemistry & Biology* 5:R285-R290.

The transcription-based assays of the present invention rely on the expression of reporter genes whose transcription is activated or repressed as a result of intracellular events that are caused by the interaction of an agonist with a heterodimer of HG20 and either GABABR1a or GABABR1b where the heterodimer forms a functional GABAB receptor.

An extremely sensitive transcription based assay is disclosed in Zlokarnik et al., 1998, *Science* 279:84-88 (Zlokarnik) and also

in U.S. Patent No. 5,741,657. The assay disclosed in Zlokarnik and U.S. Patent No. 5,741,657 employs a plasmid encoding β -lactamase under the control of an inducible promoter. This plasmid is transfected into cells together with a plasmid encoding a receptor for which it is desired to
5 identify agonists. The inducible promoter on the β -lactamase is chosen so that it responds to at least one intracellular signal that is generated when an agonist binds to the receptor. Thus, following such binding of agonist to receptor, the level of β -lactamase in the transfected cells increases. This increase in β -lactamase is made measurable by treating
10 the cells with a cell-permeable dye that is a substrate for β -lactamase. The dye contains two fluorescent moieties. In the intact dye, the two fluorescent moieties are close enough to one another that fluorescent resonance energy transfer (FRET) can take place between them. Following cleavage of the dye into two parts by β -lactamase, the two
15 fluorescent moieties are located on different parts, and thus can drift apart. This increases the distance between the fluorescent moieties, thus decreasing the amount of FRET that can occur between them. It is this decrease in FRET that is measured in the assay.

One skilled in the art can modify the assay described in
20 Zlokarnik and U.S. Patent No. 5,741,657 to form an assay for identifying agonists of GABA_B receptors by using an inducible promoter to drive β -lactamase that is activated by an intracellular signal generated by the interaction of agonists and the GABA_B receptor. To produce the GABA_B receptor, a plasmid encoding HG20 and a plasmid encoding
25 GABA_BR1a or GABA_BR1b would be transfected into the cells. The cells would be exposed to the cell-permeable dye and then exposed to substances suspected of being agonists of the GABA_B receptor. Those substances that cause a decrease in FRET are likely to actually be agonists of the GABA_B receptor.

30 Accordingly, the present invention includes a method for identifying agonists of the GABA_B receptor comprising:

- (a) transfecting cells with:
 - (1) an expression vector that directs the
expression of HG20 in the cells;
 - 35 (2) an expression vector that directs the
expression of GABA_BR1a or GABA_BR1b in the cells;

(3) an expression vector that directs the expression of β -lactamase under the control of an inducible promoter that is activated by an intracellular signal generated by the interaction of agonists and the GABAB receptor;

5 (b) exposing the cells to a substrate of β -lactamase that is a cell-permeable dye that contains two fluorescent moieties where the two fluorescent moieties are on different parts of the dye and cleavage of the dye by β -lactamase allows the two fluorescent moieties to drift apart;

10 (c) measuring the amount of fluorescent resonance energy transfer (FRET) in the cells in the absence of the substance of step (d);

(d) exposing the cells to a substance that is suspected of being an agonist of the GABAB receptor;

15 (e) measuring the amount of FRET in the cells after exposure of the cells to the substance;

wherein if the amount of FRET in the cells measured in step (e) is less than the amount of FRET measured in the cells in step (c), then the substance is an agonist of the GABAB receptor.

20 Substeps (1)-(3) of step (a) can be practiced in any order.

The assay described above can be modified to an assay for identifying antagonists of the GABAB receptor. Such modification would involve the use of β -lactamase under the control of a promoter that is repressed by at least one intracellular signal generated by
25 interaction of an agonist with the GABAB receptor and would also involve running the assay in the presence of a known agonist. When the cells are exposed to substances suspected of being antagonists of the GABAB receptor, β -lactamase will be induced, and FRET will decrease, only if the substance tested is able to counteract the effect of the agonist,
30 *i.e.*, only if the substance tested is actually an antagonist.

Accordingly, the present invention includes a method for identifying antagonists of the GABAB receptor comprising:

(a) transfecting cells with:

35 (1) an expression vector that directs the expression of HG20 in the cells;

(2) an expression vector that directs the expression of GABABR1a or GABABR1b in the cells;

- (3) an expression vector that directs the expression of β -lactamase under the control of an inducible promoter that is repressed by at least one intracellular signal generated by interaction of an agonist with the GABA_B receptor;
- 5 (b) exposing the cells to a known agonist of the GABA_B receptor;
- (c) exposing the cells to a substrate of β -lactamase that is a cell-permeable dye that contains two fluorescent moieties where the two fluorescent moieties are on different parts of the dye and cleavage of the dye by β -lactamase allows the two fluorescent moieties to drift
- 10 apart;
- (d) measuring the amount of fluorescent resonance energy transfer (FRET) in the cells in the absence of the substance of step (e);
- 15 (e) exposing the cells to a substance that is suspected of being an antagonist of the GABA_B receptor;
- (f) measuring the amount of FRET in the cells after exposure of the cells to the substance;
- wherein if the amount of FRET in the cells measured in
- 20 step (f) is less than the amount of FRET measured in the cells in step (d), then the substance is an antagonist of the GABA_B receptor.
- Substeps (1)-(3) of step (a) can be practiced in any order.
- In particular embodiments of the assays employing β -lactamase described above, the cells are eukaryotic cells. In particular
- 25 embodiments, the cells are mammalian cells. In particular embodiments, the cells are selected from the group consisting of: L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC
- 30 CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, and *Xenopus* oocytes.
- In other embodiments, the inducible promoter that is repressed by at least one intracellular signal generated by interaction of
- 35 an agonist with the GABA_B receptor is a promoter that is repressed by decreases in cAMP levels or changes in potassium currents.

In other embodiments, the inducible promoter that is activated by at least one intracellular signal generated by interaction of an agonist with the GABA_B receptor is a promoter that is activated by decreases in cAMP levels or changes in potassium currents.

5 In other embodiments, the known agonist is selected from the group consisting of: GABA, saclofen, (-)baclofen, glycine, and (L)-glutamic acid.

In other embodiments, β -lactamase is TEM-1 β -lactamase from *Escherichia coli*.

10 In other embodiments, the substrate of β -lactamase is CCF2/AM (Zlokarnik et al., 1998, Science 279:84-88).

In other embodiments, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

15 In other embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group consisting of:

SEQ.ID.NO.:2;

Positions 9-941 of SEQ.ID.NO.:2;

Positions 35-941 of SEQ.ID.NO.:2;

20 Positions 36-941 of SEQ.ID.NO.:2;

Positions 38-941 of SEQ.ID.NO.:2;

Positions 39-941 of SEQ.ID.NO.:2;

Positions 42-941 of SEQ.ID.NO.:2;

Positions 44-941 of SEQ.ID.NO.:2;

25 Positions 46-941 of SEQ.ID.NO.:2;

Positions 52-941 of SEQ.ID.NO.:2; and

Positions 57-941 of SEQ.ID.NO.:2.

In other embodiments, GABA_BR1a is murine GABA_BR1a and has the amino acid sequence SEQ.ID.NO.:20. In other
30 embodiments, GABA_BR1a is rat GABA_BR1a and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In other embodiments, GABA_BR1b is rat GABA_BR1b and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In other embodiments, GABA_BR1a is human GABA_BR1a and has an
35 amino acid sequence selected from the group consisting of: SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

In particular embodiments, the cells express a promiscuous G-protein, *e.g.*, G α 15 or G α 16.

In particular embodiments, the inducible promoter is a promoter that is activated or repressed by NF- κ B or NFAT.

5 The assays described above could be modified to identify inverse agonists. In such assays, one would expect a decrease in β -lactamase activity. Similarly, inverse agonists can be identified by modifying the functional assays that were described previously where those functional assays monitored decreases in cAMP levels. In the
10 case of assays for inverse agonists, increases in cAMP levels would be observed.

Other transcription-based assays that can be used to identify agonists and antagonists of the GABA β receptor rely on the use of green fluorescent proteins or luciferase as reported genes. An
15 example of such an assay comprises:

- (a) transfecting cells with:
 - (1) an expression vector that directs the expression of HG20 in the cells;
 - (2) an expression vector that directs the
20 expression of GABA β R1a or GABA β R1b in the cells;
 - (3) an expression vector that directs the expression of green fluorescent protein (GFP) under the control of an inducible promoter that is activated by an intracellular signal generated by the interaction of agonists and the GABA β receptor;
- 25 (b) measuring the amount of fluorescence from GFP in the cells;
- (c) exposing the cells to a substance that is suspected of being an agonist of the GABA β receptor;
- (d) measuring the amount of fluorescence from GFP in
30 the cells that have been exposed to the substance;
- wherein if the amount of fluorescence from GFP in the cells measured in step (b) is less than the amount of fluorescence from GFP measured in the cells in step (d), then the substance is an agonist of the GABA β receptor.

35 The present invention also includes assays for the identification of agonists or antagonists of GABA β receptors that are based upon FRET between a first and a second fluorescent dye where the

first dye is bound to one side of the plasma membrane of a cell expressing a heterodimer of HG20 and GABA_BR1a or GABA_BR1b and the second dye is free to shuttle from one face of the membrane to the other face in response to changes in membrane potential. In certain
5 embodiments, the first dye is impenetrable to the plasma membrane of the cells and is bound predominately to the extracellular surface of the plasma membrane. The second dye is trapped within the plasma membrane but is free to diffuse within the membrane. At normal (*i.e.*,
10 negative) resting potentials of the membrane, the second dye is bound predominately to the inner surface of the extracellular face of the plasma membrane, thus placing the second dye in close proximity to the first dye. This close proximity allows for the generation of a large amount of FRET between the two dyes. Following membrane
15 depolarization, the second dye moves from the extracellular face of the membrane to the intracellular face, thus increasing the distance between the dyes. This increased distance results in a decrease in FRET, with a corresponding increase in fluorescent emission derived from the first dye and a corresponding decrease in the fluorescent emission from the second dye. See figure 1 of González & Tsien, 1997,
20 Chemistry & Biology 4:269-277. See also González & Tsien, 1995, Biophys. J. 69:1272-1280 and U.S. Patent No. 5,661,035.

 In certain embodiments, the first dye is a fluorescent lectin or a fluorescent phospholipid that acts as the fluorescent donor. Examples of such a first dye are: a coumarin-labeled
25 phosphatidylethanolamine (*e.g.*, N-(6-chloro-7-hydroxy-2-oxo-2H--1-benzopyran-3-carboxamidoacetyl)-dimyristoylphosphatidyl-ethanolamine) or N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-dipalmitoylphosphatidylethanolamine); a fluorescently-labeled lectin (*e.g.*, fluorescein-labeled wheat germ agglutinin). In certain
30 embodiments, the second dye is an oxonol that acts as the fluorescent acceptor. Examples of such a second dye are: bis(1,3-dialkyl-2-thiobarbiturate)trimethineoxonols (*e.g.*, bis(1,3-dihexyl-2-thiobarbiturate)trimethineoxonol) or pentamethineoxonol analogues (*e.g.*, bis(1,3-dihexyl-2-thiobarbiturate)pentamethineoxonol; or bis(1,3-
35 dibutyl-2-thiobarbiturate)pentamethineoxonol). See González & Tsien, 1997, Chemistry & Biology 4:269-277 for methods of synthesizing various dyes suitable for use in the present invention. In certain embodiments,

the assay may comprise a natural carotenoid, *e.g.*, astaxanthin, in order to reduce photodynamic damage due to singlet oxygen.

Accordingly, the present invention provides a method of identifying agonists of GABA_B receptors comprising:

- 5 (a) providing test cells comprising:
 - (1) an expression vector that directs the expression of HG20 in the cells;
 - (2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;
 - 10 (3) an expression vector that directs the expression of an inwardly rectifying potassium channel;
 - (4) a first fluorescent dye, where the first dye is bound to one side of the plasma membrane; and
 - (5) a second fluorescent dye, where the second
 - 15 fluorescent dye is free to shuttle from one face of the plasma membrane to the other face in response to changes in membrane potential;
 - (b) exposing the test cells to a substance that is suspected of being an agonist of the GABA_B receptor;
 - (c) measuring the amount of fluorescence resonance
 - 20 energy transfer (FRET) in the test cells that have been exposed to the substance;
 - (d) comparing the amount of FRET exhibited by the test cells that have been exposed to the substance with the amount of FRET exhibited by control cells;
 - 25 wherein if the amount of FRET exhibited by the test cells is less than the amount of FRET exhibited by the control cells, the substance is an agonist of the GABA_B receptor;
 - where the control cells are either (1) cells that are essentially the same as the test cells except that they do not comprise at
 - 30 least one of the items listed at (a) (1)-(5) but have been exposed to the substance; or (2) test cells that have not been exposed to the substance.
- The above-described assay can be easily modified to form a method to identify antagonists of the GABA_B receptor. Such a method comprises:
- 35 (a) providing test cells comprising:
 - (1) an expression vector that directs the expression of HG20 in the cells;

(2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;

(3) an expression vector that directs the expression of an inwardly rectifying potassium channel;

5 (4) a first fluorescent dye, where the first dye is bound to one side of the plasma membrane; and

(5) a second fluorescent dye, where the second fluorescent dye is free to shuttle from one face of the plasma membrane to the other face in response to changes in membrane potential;

10 (b) exposing the test cells to a known agonist of the GABA_B receptor in the presence of a substance that is suspected of being an antagonist of the GABA_B receptor;

(c) exposing the test cells to the known agonist of the GABA_B receptor in the absence of the substance that is suspected of being
15 an antagonist of the GABA_B receptor;

(d) measuring the amount of fluorescence resonance energy transfer (FRET) in the test cells of steps (b) and (c);

(e) comparing the amount of FRET exhibited by the test cells of steps (b) and (c);

20 where if the amount of FRET exhibited by the test cells of step (b) is greater than the amount of FRET exhibited by the test cells of step (c), the substance is an antagonist of the GABA_B receptor.

In particular embodiments of the above-described methods, the expression vectors are transfected into the test cells.

25 In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

In particular embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group consisting of:

30 SEQ.ID.NO.:2;

Positions 9-941 of SEQ.ID.NO.:2;

Positions 35-941 of SEQ.ID.NO.:2;

Positions 36-941 of SEQ.ID.NO.:2;

Positions 38-941 of SEQ.ID.NO.:2;

35 Positions 39-941 of SEQ.ID.NO.:2;

Positions 42-941 of SEQ.ID.NO.:2;

Positions 44-941 of SEQ.ID.NO.:2;

Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

In particular embodiments of the above-described methods,
5 GABABR1a is murine GABABR1a and has the amino acid sequence
SEQ.ID.NO.:20. In particular embodiments, GABABR1a is rat
GABABR1a and has the amino acid sequence reported in Kaupmann et
al., 1997, Nature 386:239-246. In particular embodiments, GABABR1b is
10 rat GABABR1b and has the amino acid sequence reported in Kaupmann
et al., 1997, Nature 386:239-246. In particular embodiments, GABABR1a
is human GABABR1a and has an amino acid sequence selected from
the group consisting of: SEQ.ID.NO.:21 and the protein encoded by
SEQ.ID.NO.:23.

Inwardly rectifying potassium channels that are suitable
15 for use in the methods of the present invention are disclosed in, *e.g.*,
Misgeld et al., 1995, Prog. Neurobiol. 46:423-462; North, 1989, Br. J.
Pharmacol. 98:13-23; Gahwiler et al., 1985, Proc. Natl. Acad. Sci USA
82:1558-1562; Andrade et al., 1986, Science 234:1261.

In particular embodiments of the above-described methods,
20 the first fluorescent dye is selected from the group consisting of: a
fluorescent lectin; a fluorescent phospholipid; a coumarin-labeled
phosphatidylethanolamine; N-(6-chloro-7-hydroxy-2-oxo-2H--1-
benzopyran-3-carboxamidoacetyl)-dimyristoylphosphatidyl-
ethanolamine); N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-
25 dipalmitoylphosphatidylethanolamine); and fluorescein-labeled wheat
germ agglutinin.

In particular embodiments of the above-described methods,
the second fluorescent dye is selected from the group consisting of: an
oxonol that acts as the fluorescent acceptor; bis(1,3-dialkyl-2-
30 thiobarbiturate)trimethineoxonols; bis(1,3-dihexyl-2-
thiobarbiturate)trimethineoxonol; bis(1,3-dialkyl-2-
thiobarbiturate)quatramethineoxonols; bis(1,3-dialkyl-2-
thiobarbiturate)pentamethineoxonols; bis(1,3-dihexyl-2-
thiobarbiturate)pentamethineoxonol; bis(1,3-dibutyl-2-
35 thiobarbiturate)pentamethineoxonol); and bis(1,3-dialkyl-2-
thiobarbiturate)hexamethineoxonols.

In a particular embodiment of the above-described methods, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573),
5 Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, or *Xenopus* oocytes.

10 In a particular embodiment of the above-described methods, the cells are transfected with separate expression vectors that direct the expression of HG20 and either GABABR1a or GABABR1b in the cells. In other embodiments, the cells are transfected with a single expression vector that direct the expression of both HG20 and GABABR1a or
15 GABABR1b in the cells.

The conditions under which step (b) of the first method described above and steps (b) and (c) of the second method described above are practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt
20 conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

The GABAB receptor belongs to the class of proteins known as G-protein coupled receptors (GPCRs). GPCRs transmit signals across cell membranes upon the binding of ligand. The ligand-bound
25 GPCR interacts with a heterotrimeric G-protein, causing the G α subunit of the G-protein to disassociate from the G β and G γ subunits. The G α subunit can then go on to activate a variety of second messenger systems.

Generally, a particular GPCR is only coupled to a
30 particular type of G-protein. Thus, to observe a functional response from the GPCR, it is necessary to ensure that the proper G-protein is present in the system containing the GPCR. It has been found, however, that there are certain G-proteins that are "promiscuous." These promiscuous G-proteins will couple to, and thus transduce a
35 functional signal from, virtually any GPCR. See Offermanns & Simon, 1995, J. Biol. Chem. 270:15175, 15180 (Offermanns). Offermanns described a system in which cells are transfected with expression

vectors that result in the expression of one of a large number of GPCRs as well as the expression of one of the promiscuous G-proteins $G\alpha 15$ or $G\alpha 16$. Upon the addition of an agonist of the GPCR to the transfected cells, the GPCR was activated and was able, via $G\alpha 15$ or $G\alpha 16$, to
5 activate the β isoform of phospholipase C, leading to an increase in inositol phosphate levels in the cells.

Therefore, by making use of these promiscuous G-proteins as in Offermanns, it is possible to set up functional assays for the GABA β receptor, even in the absence of knowledge of the G-protein with which
10 the GABA β receptor is coupled *in vivo*. One possibility for utilizing promiscuous G-proteins in connection with the GABA β receptor includes a method of identifying agonists of the GABA β receptor comprising:

(a) providing cells that express HG20, GABA β R1a or
15 GABA β R1b, and a promiscuous G-protein, where HG20 and either GABA β R1a or GABA β R1b form a heterodimer representing a functional GABA β receptor;

(b) exposing the cells to a substance that is a suspected agonist of the GABA β receptor;

20 (c) measuring the level of inositol phosphates in the cells;

where an increase in the level of inositol phosphates in the cells as compared to the level of inositol phosphates in the cells in the absence of the suspected agonist indicates that the substance is an
25 agonist of the GABA β receptor.

Levels of inositol phosphates can be measured by monitoring calcium mobilization. Intracellular calcium mobilization is typically assayed in whole cells under a microscope using fluorescent dyes or in cell suspensions via luminescence using the aequorin assay.

30 In methods related to those described above, rather than using changes in inositol phosphate levels as an indication of GABA β receptor function, potassium currents are measured. This is feasible since the GABA β receptor, like other metabotropic receptors, is expected to be coupled to potassium channels. Thus, one could measure GABA β
35 receptor coupling to GIRK2 channels or to other potassium channels in oocytes.

In a particular embodiment of the above-described method, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573),
5 Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), or *Xenopus* oocytes.

10 In a particular embodiment of the above-described method, the cells are transfected with expression vectors that direct the expression of HG20, GABA_BR1a or GABA_BR1b, and the promiscuous G-protein in the cells.

The conditions under which step (b) of the method is
15 practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

In a particular embodiment of the above-described method,
20 the promiscuous G-protein is selected from the group consisting of Gα15 or Gα16. Expression vectors containing Gα15 or Gα16 are known in the art. See, *e.g.*, Offermanns; Buhl et al., 1993, FEBS Lett. 323:132-134; Amatruda et al., 1993, J. Biol. Chem. 268:10139-10144.

The above-described assay can be easily modified to form a
25 method to identify antagonists of the GABA_B receptor. Such a method is also part of the present invention and comprises:

- (a) providing cells that express HG20, GABA_BR1a or GABA_BR1b, and a promiscuous G-protein;
- (b) exposing the cells to a substance that is an agonist of
30 the GABA_B receptor;
- (c) subsequently or concurrently to step (b), exposing the cells to a substance that is a suspected antagonist of the GABA_B receptor;
- (d) measuring the level of inositol phosphates in the
cells;

35 where a decrease in the level of inositol phosphates in the cells in the presence of the suspected antagonist as compared to the level of inositol phosphates in the cells in the absence of the suspected

antagonist indicates that the substance is an antagonist of the GABA_B receptor.

In a particular embodiment of the above-described method, the agonist is an amino acid such as GABA, glutamate, glycine, or
5 amino acid analogues such as (-)baclofen.

In a particular embodiment of the above-described method, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL
10 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), or Xenopus oocytes.

15 The conditions under which steps (b) and (c) of the method are practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

20 In a particular embodiment of the above-described method, the cells are transfected with expression vectors that direct the expression of HG20, GABA_BR1a or GABA_BR1b, and the promiscuous G-protein in the cells.

In a particular embodiment of the above-described method,
25 the promiscuous G-protein is selected from the group consisting of Gα15 or Gα16.

In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

In other embodiments of the above-described methods,
30 HG20 comprises an amino acid sequence selected from the group consisting of:

SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
35 Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;

Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
5 Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

In other embodiments, GABA_BR1a is murine GABA_BR1a and has the amino acid sequence SEQ.ID.NO.:20. In other
embodiments, GABA_BR1a is rat GABA_BR1a and has the amino acid
10 sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In
other embodiments, GABA_BR1b is rat GABA_BR1b and has the amino
acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In
other embodiments, GABA_BR1a is human GABA_BR1a and has an
amino acid sequence selected from the group consisting of:
15 SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

While the above-described methods are explicitly directed to
testing whether "a" substance is an agonist or antagonist of the GABA_B
receptor, it will be clear to one skilled in the art that such methods can
be adapted to test collections of substances, *e.g.*, combinatorial libraries,
20 to determine whether any members of such collections are activators or
inhibitors of the GABA_B receptor. Accordingly, the use of collections of
substances, or individual members of such collections, as the substance
in the above-described methods is within the scope of the present
invention.

25 The present invention includes pharmaceutical
compositions comprising agonists and antagonists of GABA_B receptors
that have been identified by the above-described methods. The agonists
and antagonists are generally combined with pharmaceutically
acceptable carriers to form pharmaceutical compositions. Examples of
30 such carriers and methods of formulation of pharmaceutical
compositions containing agonists and antagonists and carriers can be
found in Remington's Pharmaceutical Sciences. To form a
pharmaceutically acceptable composition suitable for effective
administration, such compositions will contain a therapeutically
35 effective amount of the agonists and antagonists.

Therapeutic or prophylactic compositions are administered
to an individual in amounts sufficient to treat or prevent conditions

where GABA_B receptor activity is abnormal. The effective amount can vary according to a variety of factors such as the individual's condition, weight, gender, and age. Other factors include the mode of administration. The appropriate amount can be determined by a skilled
5 physician.

Compositions can be used alone at appropriate dosages. Alternatively, co-administration or sequential administration of other agents can be desirable.

The compositions can be administered in a wide variety of
10 therapeutic dosage forms in conventional vehicles for administration. For example, the compositions can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection.
15 Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

Advantageously, compositions can be administered in a
20 single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. Furthermore, compositions can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be
25 administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

The dosage regimen utilizing the compositions is selected in accordance with a variety of factors including type, species, age,
30 weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal, hepatic and cardiovascular function of the patient; and the particular composition thereof employed. A physician of ordinary skill can readily determine and prescribe the effective amount of the composition
35 required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of composition within

the range that yields efficacy without toxicity requires a regimen based on the kinetics of the composition's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a composition.

5 Agonists and antagonists identified by the above-described methods are useful in the same manner as well-known agonists and antagonists of other GABA_B receptors. For example, (-) baclofen is a known agonist of GABA_B receptors and, in racemic form, is a clinically useful muscle relaxant known as LIORESAL® (Bowery & Pratt, 1992, 10 *Arzneim.-Forsch./Drug Res.* 42:215-223 [Bowery & Pratt]). Similarly, the agonists and antagonists of GABA_B receptors identified by the methods of the present invention are expected to be useful as muscle relaxants. Bowery & Pratt, at Table 1, page 219, list the therapeutic potential of GABA_B receptor agonists and antagonists. For agonists, the 15 therapeutic potential is said to include use as muscle relaxants and anti-asthmatics. For antagonists, the therapeutic potential is said to include use as antidepressants, anticonvulsants, nootropics, and anxiolytics. Additionally, at page 220, left column, Bowery & Pratt list some additional therapeutic uses for the GABA_B receptor agonist (-) 20 baclofen: treatment of trigeminal neuralgia and reversal of ethanol withdrawal symptoms. Given the wide range of utility displayed by known agonists and antagonists of GABA_B receptors, it is clear that those skilled in the art would consider the agonists and antagonists identified by the methods of the present invention to be 25 pharmacologically useful. In addition, it is believed that such agonists and antagonists will also be useful in the treatment of epilepsy, neuropsychiatric disorders, and dementias.

When screening compounds in order to identify potential pharmaceuticals that specifically interact with a target receptor, it is 30 necessary to ensure that the compounds identified are as specific as possible for the target receptor. To do this, it is necessary to screen the compounds against as wide an array as possible of receptors that are similar to the target receptor. Thus, in order to find compounds that are potential pharmaceuticals that interact with receptor A, it is necessary 35 not only to ensure that the compounds interact with receptor A (the "plus target") and produce the desired pharmacological effect through receptor A, it is also necessary to determine that the compounds do not

interact with receptors B, C, D, etc (the "minus targets"). In general, as part of a screening program, it is important to have as many minus targets as possible (see Hodgson, 1992, Bio/Technology 10:973-980, at 980). HG20 protein, DNA encoding HG20 protein, GABABR1a protein, DNA
5 encoding GABABR1a protein, and recombinant cells that have been engineered to express HG20 protein and GABABR1a protein have utility in that they can be used as "minus targets" in screens design to identify compounds that specifically interact with other G-protein coupled receptors, *i.e.*, non-GABAB receptors.

10 The present invention also includes antibodies to the HG20 protein. Such antibodies may be polyclonal antibodies or monoclonal antibodies. The antibodies of the present invention are raised against the entire HG20 protein or against suitable antigenic fragments of the protein that are coupled to suitable carriers, *e.g.*, serum albumin or
15 keyhole limpet hemocyanin, by methods well known in the art. Methods of identifying suitable antigenic fragments of a protein are known in the art. See, *e.g.*, Hopp & Woods, 1981, Proc. Natl. Acad. Sci. USA 78:3824-3828; and Jameson & Wolf, 1988, CABIOS (Computer Applications in the Biosciences) 4:181-186. Particularly suitable peptides are: amino acids
20 357-371 of SEQ.ID.NO.:2 and amino acids 495-511 of SEQ.ID.NO.:2. Also, anti-peptide antisera can be generated by immunization of New Zealand White rabbits with a KLH-conjugation of a 20 amino acid synthetic peptide corresponding to residues 283-302 of HG20
(GWYEPSWWEQVHTEANSSRC) (a portion of SEQ.ID.NO.:2).

25 For the production of polyclonal antibodies, HG20 protein or an antigenic fragment, coupled to a suitable carrier, is injected on a periodic basis into an appropriate non-human host animal such as, *e.g.*, rabbits, sheep, goats, rats, mice. The animals are bled periodically and sera obtained are tested for the presence of antibodies to the injected
30 antigen. The injections can be intramuscular, intraperitoneal, subcutaneous, and the like, and can be accompanied with adjuvant.

For the production of monoclonal antibodies, HG20 protein or an antigenic fragment, coupled to a suitable carrier, is injected into an appropriate non-human host animal as above for the production of
35 polyclonal antibodies. In the case of monoclonal antibodies, the animal is generally a mouse. The animal's spleen cells are then immortalized, often by fusion with a myeloma cell, as described in Kohler & Milstein,

1975, Nature 256:495-497. For a fuller description of the production of monoclonal antibodies, see Antibodies: A Laboratory Manual, Harlow & Lane, eds., Cold Spring Harbor Laboratory Press, 1988.

Gene therapy may be used to introduce HG20 polypeptides into the cells of target organs. Nucleotides encoding HG20 polypeptides can be ligated into viral vectors which mediate transfer of the nucleotides by infection of recipient cells. Suitable viral vectors include retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, and polio virus based vectors. Alternatively, nucleotides encoding HG20 polypeptides can be transferred into cells for gene therapy by non-viral techniques including receptor-mediated targeted transfer using ligand-nucleotide conjugates, lipofection, membrane fusion, or direct microinjection. These procedures and variations thereof are suitable for *ex vivo* as well as *in vivo* gene therapy. Gene therapy with HG20 polypeptides will be particularly useful for the treatment of diseases where it is beneficial to elevate HG20 activity.

The following non-limiting examples are presented to better illustrate the invention.

20

EXAMPLE 1

Cloning and sequencing of HG20

A cDNA fragment encoding full-length HG20 can be isolated from a human fetal brain cDNA library by using the polymerase chain reaction (PCR) employing the following primer pair:

25

HG20.F139 5'-CCGTTCTGAGCCGAGCCG -3' (SEQ.ID.NO.:3)
HG20.R3195 5'-TCCGCAGCCAGAGCCGACAG-3' (SEQ.ID.NO.:4)

30

The above primer pair is meant to be illustrative only. Those skilled in the art would recognize that a large number of primer pairs, based upon SEQ.ID.NO.:1, could also be used.

PCR reactions can be carried out with a variety of thermostable enzymes including but not limited to AmpliTaq, AmpliTaq Gold, Vent polymerase. For AmpliTaq, reactions can be carried out in 10 mM Tris-Cl, pH 8.3, 2.0 mM MgCl₂, 200 μM for each dNTP, 50 mM

35

KCl, 0.2 μ M for each primer, 10 ng of DNA template, 0.05 units/ μ l of AmpliTaq. The reactions are heated at 95°C for 3 minutes and then cycled 35 times using the cycling parameters of 95°C, 20 seconds, 62°C, 20 seconds, 72°C, 3 minutes. In addition to these conditions, a variety of
5 suitable PCR protocols can be found in PCR Primer, A Laboratory Manual, edited by C.W. Dieffenbach and G.S. Dveksler, 1995, Cold Spring Harbor Laboratory Press.

A suitable cDNA library from which a clone encoding HG20 can be isolated would be a random primed fetal brain cDNA library
10 consisting of approximately 4.0 million primary clones constructed in the plasmid vector pBluescript (Stratagene, LaJolla, CA). The primary clones of such a library can be subdivided into pools with each pool containing approximately 20,000 clones and each pool can be amplified separately.

By this method, a cDNA fragment (SEQ.ID.NO.:1) encoding an open reading frame of 941 amino acids (SEQ.ID.NO.:2) is obtained. This cDNA fragment can be cloned into a suitable cloning vector or expression vector. For example, the fragment can be cloned into the mammalian expression vector pcDNA3.1 (Invitrogen, San Diego, CA).
20 HG20 protein can then be produced by transferring an expression vector containing SEQ.ID.NO.:1 or portions thereof into a suitable host cell and growing the host cell under appropriate conditions. HG20 protein can then be isolated by methods well known in the art.

Alternatively, other cDNA libraries made from human
25 tissues that express HG20 RNA can be used with PCR primers HG20.F139 and HG20.R3195 in order to amplify a cDNA fragment encoding full-length HG20. Suitable cDNA libraries would be those prepared from cortex, cerebellum, testis, ovary, adrenal gland, thyroid, or spinal cord.

As an alternative to the above-described PCR method, a
30 cDNA clone encoding HG20 can be isolated from a cDNA library using as a probe oligonucleotides specific for HG20 and methods well known in the art for screening cDNA libraries with oligonucleotide probes. Such methods are described in, e.g., Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold
35 Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K., Vol. I, II.

Oligonucleotides that are specific for HG20 and that can be used to screen cDNA libraries are:

	HG20.F46	5'-GGGATGATCATGGCCAGTGC-3' (SEQ.ID.NO.:5)
5	HG20.R179	5'-GGATCCATCAAGGCCAAAGA-3' (SEQ.ID.NO.:6)
	HG21.F43	5'-GCCGCTGTCTCCTTCCTGA-3' (SEQ.ID.NO.:7)
	HG21.R251	5'-TTGGTTCACACTGGTGACCGA-3' (SEQ.ID.NO.:8)
	HG20.R123	5'-TTCACCTCCCTGCTGTCTTG-3' (SEQ.ID.NO.:9)
	HG20.F1100	5'-CAGGCGATTCCAGTTCCTCA-5' (SEQ.ID.NO.:10)
10	HG20.F1747	5'-GAACCAAGCCAGCACATCCC-3' (SEQ.ID.NO.:11)
	HG20.R54	5'-CCTCGCCATACAGAACTCC-3' (SEQ.ID.NO.:12)
	HG20.R75	5'-GTGTCATAGAGCCGCAGGTC-3' (SEQ.ID.NO.:13)
	HG20.F139	5'-CCGTTCTGAGCCGAGCCG-3' (SEQ.ID.NO.:3)
	HG20.R3195	5'-TCCGCAGCCAGAGCCGACAG-3' (SEQ.ID.NO.:4)

15

Membrane-spanning proteins, such as GABAB receptors, when first translated generally possess an approximately 16 to 40 amino acid segment known as a signal sequence. Signal sequences direct the nascent protein to be transported through the endoplasmic reticulum

20 membrane, following which signal sequences are cleaved from the protein. Signal sequences generally contain from 4 to 12 hydrophobic residues but otherwise possess little sequence homology. The Protein Analysis tool of the GCG program (Genetics Computer Group, Madison, Wisconsin), a computer program capable of identifying likely signal

25 sequences, was used to examine the N terminus of HG20. Several likely candidates for cleavage sites which would generate mature HG20 protein, *i.e.*, protein lacking the signal sequence, were identified. The results are shown in Figure 3.

30

EXAMPLE 2

Expression of HG20 in normal and diseased adrenal tissue

Northern blots were performed to measure the amount of HG20 RNA in normal and diseased adrenal tissue. The results are shown in Table 2 below. The amount of the approximately 6.5 kb HG20

35 transcript is shown normalized to the amount of β -actin transcript.

Table 2

<u>Pathology</u>	<u>Profile</u>	<u>HG20</u> <u>RNA</u>	<u>Actin</u> <u>RNA</u>	<u>HG20</u> <u>/actin</u>
Pheochromocytoma	M, 30 yr	0.47	0.74	0.64
Adrenal carcinoma cortex	M, 69 yr	0.61	0.80	0.76
Adrenal adenoma cortex	M, 69 yr	0.62	1.15	0.54
Normal Adrenal	M, 26 yr	1.00	1.00	1.00

5 The results shown in Table 2 indicate that HG20 expression is decreased in diseased states of the adrenal gland. Thus, increasing the concentration of HG20 in such diseased states is likely to be pharmacologically useful. Accordingly, one skilled in the art would expect agonists of HG20 to be pharmacologically useful.

10

EXAMPLE 3

Tissue distribution of various HG20 RNA transcripts

15 Table 3, below, shows the results of experiments to measure the amount of HG20 RNA transcripts of various lengths in various tissues. The results shown were derived from a multiple tissue Northern blot that was hybridized overnight in expressHyb solution (Clontech). Washing conditions were: 0.1X SSC, 0.1% SDS, at 60°C. A ³²P-random primer labelled Eco RI fragment containing the full-length native HG20 DNA was used as a hybridization probe. The greater
20 the number of plus signs in a particular tissue, the greater was the amount of HG20 RNA detected in that tissue.

Table 3

Tissue	6.5 kb	4.5 kb	4.0 kb	1.8 kb
cerebellum	++	+		
cerebral cortex	++++	+		
medulla	+	+		
occipital pole	+	+		
frontal lobe	+++	+		
temporal lobe	+++	+		
putamen	++	+		
spinal cord n=2	++	+		
amygdala	+++			
caudate nucleus	+	+		
corpus callosum	+	+		
hippocampus	++	+		
whole brain	+++	+		
substantia nigra	+	+		
subthalamic nucleus	+	+		
thalamus	++	+		
spleen		+		
thymus n=2		++		
prostate		++		
testis n=2	++	+	+++	
ovary		++	+	+
small intestine n=2		++		
colon (mucosal lining)		++		
peripheral blood leucocytes		++		
stomach n=2	+	+		
thyroid n=2	++	++++		
lymph node		+		
trachea		++		
adrenal gland	+++	+++	+	++++
bone marrow		++		
heart	+	++		
brain	+++++			
placenta		+		
lung		+		
liver		+		
skeletal muscle	+	++		
kidney		+		
pancreas	+	+		
adrenal medulla	+++			+
adrenal cortex	+++++		++	++

The distribution of HG20 RNA shown in Table 3 suggests that HG20 mediates activities of the central and peripheral nervous system.

5

EXAMPLE 4

Distribution of HG20 mRNA in brain

Using in situ hybridisation, the distribution of HG20 mRNA in squirrel monkey brain was studied. Antisense oligonucleotide probes to HG20 were generated on an Applied Biosystems Model 394 DNA
10 synthesiser and purified by preparative polyacrylamide electrophoresis. Probe 1: 5'ATC-TGG-GTT-TGT-TCT-CAG-GGT-GAT-GAG-CTT-CGG-CAC-GAA-TAC-CAG 3' (SEQ.ID.NO.:14); Probe2: 5' GCT-CTG-TGA-TCT-TCA-TTC-GCA-GGC-GAT-GGT-TTT-CTG-ACT-GTA-GGC 3' (SEQ.ID.NO.:15).
15 Each oligonucleotide was 3'-end labelled with [³⁵S] deoxyadenosine 5'-(thiotriphosphate) in a 30:1 molar ratio of ³⁵S-isotope:oligonucleotide using terminal deoxynucleotidyl transferase for 15 min at 37°C in the reaction buffer supplied (Boehringer). Radiolabelled oligonucleotide was separated from unincorporated nucleotides using Sephadex G50 spin
20 columns. The specific activities of the labelled probes in several labelling reactions varied from 1.2-2.3 x 10⁹ cpm/mg. Squirrel monkey brains were removed and fresh frozen in 1 cm blocks. 12 mm sections were taken and fixed for *in situ* hybridisation. Hybridisation of the sections was carried out according to the method of Sirinathsinghji et
25 al., 1993, Neuroreports 4:175-178. Briefly, sections were removed from alcohol, air dried and 5 x10⁵ cpm of each ³⁵S-labelled probe (both oligonucleotides) in 100 ml of hybridisation buffer was applied to each slide. Labelled "antisense" probe was also used in the presence of an excess (100x) concentration of unlabelled antisense probe to define non-
30 specific hybridisation. Parafilm coverslips were placed over the sections which were incubated overnight (about 16 hr) at 37°C. Following hybridisation the sections were washed for 1 hr at 57°C in 1xSSC, then rinsed briefly in 0.1xSSC, dehydrated in a series of alcohols, air dried, and exposed to Amersham Hyperfilm bmax X-ray film.

Autoradiographs were analysed using a MCID computerised image analysis system (Image Research Inc., Ontario, Canada).

Highest levels of mRNA for HG20 were found in the hippocampus (dentate gyrus, CA3, CA2, and CA1). High levels were also seen in cortical regions (frontal, cingulate, temporal parietal, entorhinal, and visual) and the cerebellum, although medial septum, thalamic nuclei (medial-dorsal and lateral posterior), lateral geniculates, red nucleus, reticular formation, and griseum pontis all show expression of message. While there are many similarities with the distribution reported for the GABA_B receptor mRNA in rat, one marked difference is that expression of HG20 mRNA in the monkey caudate and putamen is below the level of detection while cortical levels are high. In the rat, the GABA_B receptor mRNA appears equally expressed in striatum as in cortex. Figure 4 illustrates these results.

EXAMPLE 5

Attempted recombinant expression of full-length HG20 protein

Following the cloning of HG20 DNA, attempts were made to express full-length HG20 protein (941 amino acids) using various eukaryotic cell lines and expression vectors. The cell lines that were used were: COS-7 cells, HEK293 cells, and frog melanophores. The expression vectors that were used to attempt to express the full-length HG20 protein were: pCR3.1 and pcDNA3.1 (Invitrogen, San Diego, CA) and pciNEO (promega)

All of the attempts to express full-length HG20 described above were unsuccessful. See, *e.g.*, Figure 7, second bar from the left, marked "HG20." See also Figure 5A, lane 1. Although the reason for these failures is not known, it is possible that the highly GC rich nature of the region of the HG20 mRNA that encodes amino acids 1-51 results in the formation of secondary structure in the mRNA that impedes translation. It was only after the construction of an expression vector that encodes a truncated HG20 protein, lacking the first 51 amino acids, that HG20 was successfully expressed. Figure 5A-B shows the results of the successful expression of an HG20 protein having amino acids 52-941. It is expected that expression of HG20 proteins having amino acids 53-

941, 54-941, 55-941, *etc.*, could be accomplished in a similar manner. It is also expected that expression of HG20 proteins having the above-described amino termini but having different carboxyl termini could be accomplished in a similar manner as well. Thus, the expression of an
5 HG20 protein having an amino terminus as listed above and having a truncated carboxyl terminus could be accomplished. Alternatively, the carboxyl terminus could be fused to non-HG20 amino acid sequences, forming a chimeric HG20 protein. It is also possible to express HG20 having an amino terminus listed above as a chimeric protein with non-
10 HG20 sequences fused to the amino terminus.

Figure 5A shows the expression of amino acids 52-941 of HG20 as part of a chimeric or fusion protein with the FLAG epitope fused to the amino terminus of the HG20 sequences in a coupled *in vitro* transcription/translation experiment. Figure 5B shows the expression
15 of amino acids 52-941 of HG20 as part of a chimeric or fusion protein with the FLAG epitope fused to the amino terminus of the HG20 sequences in COS-7 cells and melanophores. The expression vector used in this experiment was pcDNA3.1. The expression constructs used in
20 Figure 5A-B also encoded a cleavable signal sequence from the influenza hemagglutinin gene that has been shown to facilitate the membrane insertion of G-protein coupled receptors (Guan et al., 1992, J. Biol. Chem. 267:21995-21998) and the fusion proteins were detected with anti-FLAG antibody. The expression constructs had also been engineered to
25 contain a Kozak consensus sequence prior to the initiating ATG. The amino acid sequences of the hemagglutinin signal sequence and the FLAG epitope were:

[MKTIIALSYIFCLVFA] [DYKDDDDDK] SEQ.ID.NO:17

HA signal peptide FLAG epitope

30

Amino acids 57-941 have been expressed in mammalian cells as part of a chimeric protein. A chimeric construct of HG20 was made that consisted of bases -224 to 99 of the bovine GABA_A α 1 gene, a sequence encoding the c-myc epitope tag (amino acid residues 410-419 of the
35 human oncogene product c-myc), a cloning site encoding the amino acid asparagine, and DNA encoding residues 57-941 of HG20. The resultant

chimeric protein has the amino acid sequence shown below, with the construct cloned into pcDNA1.1Amp (Invitrogen, San Diego, CA).

5 ____Bovine alpha 1 signal seq____ c-myc____
 MKKSPGLSDYLWAWTLFLSTLTGRSYGQPSLQD EQKLISEEDL N
 res. 57-941 HG20
 SIMGLMPLT... (SEQ.ID.NO.:18)

10 The three periods "..." indicate that the chimeric protein sequence extends until amino acid 941 of HG20.

 The cell surface expression of this construct was verified using a cell surface ELISA technique. Briefly, HEK293 cells were seeded at ~1x10⁵ cells per well in a 24 well tissue culture plate and allowed to adhere for 24 hours. Each well was transfected with a total of 1 µg of
 15 DNA. In addition to tagged and un-tagged HG20 constructs, c-myc tagged GABA_A α1 was transfected with GABA_A β1 as a positive control for cell surface expression. Two days after transfection, the cells were assayed for surface expression of the c-myc epitope using the 9E10 monoclonal antibody raised to the c-myc epitope, followed by HRP (horse
 20 radish peroxidase) conjugated anti-mouse antibody (Promega) and colormetric development using K-Blue (Bionostics). The results are shown in Figure 7. Figure 7 demonstrates that when HG20 is part of a chimeric protein, it can be expressed well in mammalian cells but that when attempts are made to express full-length HG20 (amino acids 1-941)
 25 directly, *i.e.*, not as part of a chimeric protein, essentially no expression is observed.

EXAMPLE 6

Construction of Full Length Murine GABABR1a Coding Region

30 Using a combination of TFASTX (Pearson et al., 1997, Genomics 46:24-36) and TBLASTX (Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402) searching programs against dbEST: Database of Expressed Sequence Tags (URL <http://www.ncbi.nlm.nih.gov/dbEST/index.html>), we identified partial cDNA clones in the EST collection
 35 which encoded murine GABABR1a using the rat GABA_B receptor

subunit cDNAs (GenBank Accession Numbers Y10369 and Y10370) as probe sequences (Kaupmann et al., 1997, Nature 386:239-246). Two of these ESTs (IMAGE Consortium clone identification numbers 472408 and 319196) were obtained (Research Genetics, Birmingham, Ala). The
5 DNA sequences of both cDNA clones were determined using standard methods on an ABI 373a automated sequencer (Perkin-Elmer-Applied Biosystems, Foster City, CA).

The partial cDNAs were assembled by long accurate PCR using the following oligonucleotides: 472408 sense: 5' - GC GAATTC
10 GGTACC ATG CTG CTG CTG CTG CTG GTG CCT - 3'
(SEQ.ID.NO.:24), 472408 antisense: 5' - GG GAATTC TGG ATA TAA CGA GCG TGG GAG TTG TAG ATG TTA AA - 3' (SEQ.ID.NO.:25), 319196 sense: 5' - CCA GAATTC CCA GCC CAA CCT GAA CAA TC - 3' (SEQ.ID.NO.:26), 319196 antisense: 5' - CG GCGGCCGC TCA CTT GTA
15 AAG CAA ATG TA - 3' (SEQ.ID.NO.:27) which amplified two fragments corresponding to the 5' 2,100 basepairs and 3' 1,000 basepairs of the murine GABABR1a coding region. The PCR conditions were 200 ng of cDNA template, 2.5 units of Takara LA Taq (PanVera, Madison, WI), 25 mM TAPS (pH 9.3), 50 mM KCl, 2.5 mM MgCl₂, 1 mM 2-
20 mercaptoethanol, 100 mM each dNTP and 1 mM each primer with cycling as follows 94°C 1 min, 9 cycles of 98°C for 20 seconds, 72°C-56°C (decreases 2°C per cycle), 72°C for 30 seconds, followed by 30 cycles of 98°C for 20 seconds, 60°C for 3 minutes. A final extension at 72°C for 10 minutes was performed. PCR products were cloned into the TA-Cloning
25 vector pCRII-TOPO (Invitrogen, San Diego, CA) following the manufacturers directions. Cloned PCR products were confirmed by DNA sequencing. To form full-length cDNA, the pCINeo mammalian expression vector was digested with EcoRI and NotI. The EcoRI fragment from PCR cloning of 472408 and the EcoRI/NotI product from
30 PCR cloning of 319196 were ligated in a three part ligation with digested pCINeo vector. The resulting clones were screened by restriction digestion with SstI which cuts once in the vector and once in the 472408 derived fragment. The resulting expression clone is 2,903 basepairs in length. The overall cDNA length, including untranslated sequences,
35 inferred from the full length of the two ESTs is 4,460 basepairs.

EXAMPLE 7

Preparation of membrane fractions

P2 membrane fractions were prepared at 4°C as follows. Tissues or cells were washed twice with cold PBS, collected by centrifugation at 100xg for 7 min, and resuspended in 10 ml of buffer A: 5 mM Tris-HCl, 2 mM EDTA containing (1X) protease inhibitor cocktail Complete® tablets (Boehringer Mannheim), pH 7.4 at 4°C. Tissues or cells were disrupted by polytron homogenization, centrifuged at 100xg for 7 min to pellet unbroken cells and nuclei, and the supernatant collected. The resulting pellet was homogenized a second time in 10 ml of buffer A, centrifuged as described above and supernatant fractions saved. The pooled S1 supernatant was centrifuged at high speed (27 000xg for 20 min) and the pellet was washed once with buffer A, centrifuged (27 000xg for 20 min) and resuspended in buffer A to make the P2 membrane fraction, and stored at -80°C. Protein content was determined using the Bio-Rad Protein Assay Kit according to manufacturer instructions.

EXAMPLE 8

20 Receptor filter-binding assays

Competition of [¹²⁵I]CGP71872 binding experiments were performed with ~7 µg P2 membrane protein and increasing concentrations of cold ligand (10⁻¹²-10⁻³ M). The concentration of radioligand used in the competition assays was 1 nM (final). Each concentration was examined in duplicate and incubated for 2 hours at 22°C in the dark in a total volume of 250 µL binding buffer: 50 mM Tris-HCl, 2.5 mM CaCl₂ (pH 7.4) with (1X) protease inhibitor cocktail Complete® tablets. Bound ligand was isolated by rapid filtration through a Brandel 96 well cell harvester using Whatman GF/B filters. Data were analysed by nonlinear least-squares regression using the computer-fitting program GraphPad Prism version 2.01 (San Diego).

EXAMPLE 9

Photoaffinity labelling

P2 membranes were resuspended in binding buffer and incubated in the dark with 1 nM final concentration [¹²⁵I]CGP71872 (2200 Ci/mmol) in a final volume of 1 ml for 2 h at 22°C. The membranes were centrifuged at 27,000xg for 10 min and the pellet was washed in ice-cold binding buffer, centrifuged at 27,000xg for 20 min, resuspended in 1 ml of ice-cold binding buffer, and exposed on ice 2 inches from 360 nm ultraviolet light for 10 min. Photolabelled membranes were washed, pelleted by centrifugation, and solubilized in sample buffer (50 mM Tris-HCl pH 6.5, 10% SDS, 10% glycerol, and 0.003% bromophenol blue with 10% 2-mercaptoethanol). Samples were electrophoresed on precast NOVEX 10% Tris-glycine gels, fixed, dried, and exposed to Kodak XAR film with an intensifying screen at -70°C.

15

EXAMPLE 10

Immunoprecipitation and immunoblotting of GABA_B receptors

Digitonin solubilized FLAG-tagged HG20 receptors were immunoprecipitated with a mouse anti-FLAG M2 antibody affinity resin (Kodak IBI) and immunoblot analysis conducted as previously described (Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204). Following washing of the immunoprecipitate, the pellet was resuspended in SDS sample buffer and subjected to SDS-PAGE and immunoblotted with affinity purified GABA_BR1a-specific antibodies 1713.1 (raised against the peptide acetyl-DVNSRRDILPDYELKLC-amide (a portion of SEQ.ID.NO.:20)) and 1713.2 (raised against the peptide acetyl-CATLHNPTRVKLF EK-amide (a portion of SEQ.ID.NO.:20)).

25

EXAMPLE 11

Melanophore functional assay

Growth of *Xenopus laevis* melanophores and fibroblasts was performed as described previously (Potenza et al., 1992, Anal. Biochem. 206:315-322). The cells (obtained from Dr. M.R. Lerner, Yale University) were collected by centrifugation at 200xg for 5 min at 4°C, and resuspended at 5 x 10⁶ cells per ml in ice cold 70% PBS, pH 7.0. DNA encoding the relevant GPCR was transiently transfected into melanophores by electroporation using a BTX ECM600 electroporator (Genetronics, Inc., San Diego, CA). To monitor the efficiency of transfection, two internal control GPCRs were used independently (pcDNA1amp-cannabinoid 2 and pcDNA3-thromboxane A2; (Lerner, 1994, Trends Neurosci. 17:142-146)). Cells were electroporated using the following settings: capacitance of 325 microfarad, voltage of 450 volts, and resistance of 720 ohms. Following electroporation, cells were mixed with fibroblast-conditioned growth medium and plated onto flat bottom 96 well microtiter plates (NUNC). 24 hrs after the transfection, the media was replaced with fresh fibroblast-conditioned growth media and incubated for an additional day at 27°C prior to assaying for receptor expression. For Gs/Gq-coupling responses (resulting in pigment dispersion), cells were incubated in 100 µl of 70% L-15 media containing 15 mM HEPES, pH 7.3, and melatonin (0.8 nM final concentration) for 1 hr in the dark at room temperature, and then incubated in the presence of melatonin (0.8 nM final concentration) for 1 h in the dark at room temperature to induce pigment aggregation. For Gi-coupled responses (resulting in pigment aggregation), cells were incubated in the presence of 100 µl/well of 70% L-15 media containing 2.5% fibroblast-conditioned growth medium, 2 mM glutamine, 100 µg /ml streptomycin, 100 units/ml penicillin and 15 mM HEPES, pH 7.3, for 30 min in the dark at room temperature to induce pigment dispersion. Absorbance readings at 600 nm were measured using a Bio-Tek Elx800 Microplate reader (ESBE Scientific) before (Ai) and after (Af) incubation with ligand (GABA; 1.5 hr in the dark at room temperature).

EXAMPLE 12

Stable and transient transfections and determination of cAMP response in HEK293 cells

5 HG20 and murine GABA_BR1a cDNAs were subcloned into pcDNA3.1 (Invitrogen, San Diego, CA) and used to transfect HEK293 cells. Stably expressing cells were identified after selection in geneticin (0.375 mg/ml) by dot blot analysis. For co-expression experiments, the stable cell lines hgb2-42 (expressing HG20) and rglb1a-50 (expressing murine GABA_BR1a) were transiently transfected with murine
10 GABA_BR1a and HG20, respectively, in pcDNA3.1 and cells were assayed for cAMP responses.

Wild-type HEK293 cells, or HEK293 cells stably and transiently expressing HG20 and murine GABA_BR1a receptors were lifted in 1X PBS, 2.5 mM EDTA, counted, pelleted and resuspended at 1.5
15 x 10⁵ cells per 100 µl in Krebs-Ringer-Hepes medium (Blakely et al., 1991, Anal. Biochem. 194:302-308), 100 mM Ro 20-1724 (RBI) and incubated at 37°C for 20 min. 100 µl of cells was added to 100 µl of prewarmed (37°C, 10 min) Krebs-Ringer-Hepes medium, 100 mM Ro 20-1724 without or with agonist and/or 10 µM forskolin. Incubations with GABA included
20 100 µM aminooxyacetic acid (a GABA transaminase inhibitor) to prevent breakdown of GABA and 100 µM nipecotic acid to block GABA uptake. Following a 20 min incubation at 37°C, the assay was terminated by setting the cells on ice and centrifuging at 2,000 rpm for 5 min at 4°C. 175 ml of assay solution was removed and replaced with 175 ml of 0.1 N
25 hydrochloric acid, 0.1 mM calcium chloride and cells were set on ice for 30 min and then stored at -20°C. cAMP determinations were made using a solid phase modification (Maidment et al., 1989, Neurosci. 33:549-557) of the cAMP radioimmunoassay described by Brooker et al. 1979, Adv. Cyclic Nucl. Res. 10:1-33) and previously reported in Clark et al., 1998, Mol. Endocrinol. 12:193-206). Immulon II removable wells
30 (Dynatech; Chantilly, VA) were coated overnight with 100 µl of protein G (1mg/ml in 0.1M NaHCO₃, pH 9.0) at 4°C. Prior to use, protein G-coated plates were rinsed with PBS-gelatin-Tween (phosphate buffered saline containing 0.1% gelatin, 0.2% Tween-20) 3 times quickly, and then once
35 for 30 minutes. Following the rinse with PBS-gelatin-Tween, the RIA

was set up by adding 100 μ l 50 mM sodium acetate, pH 4.75, cAMP standards or aliquots from treated cells, 5,000-7,000 cpm 125 I-succinyl cAMP, and 25 μ l of a sheep antibody to cAMP diluted in 50 mM sodium acetate, pH 4.75 (Atto instruments; dilution of stock to 2.5×10^{-5} ,
 5 determined empirically) to the plates in a final volume of 175 μ l. Plates were incubated 2 hr at 37°C or overnight at 4°C, rinsed 3 times with sodium acetate buffer, blotted dry, and then individual wells were broken off and bound radioactivity was determined in a gamma counter.

10

EXAMPLE 13

In situ hybridization for co-localization experiments

Preparation of rat brain sections, prehybridization and hybridization of rat brain slices was performed as described previously (Bradley et al., 1992, J. Neurosci. 12:2288-2302;
 15 <http://intramural.nimh.nih.gov/lcmr/snge/Protocol.html>). Adjacent coronal rat brain sections were hybridized with labeled antisense and sense riboprobes directed against HG20 (GenBank accession number AF058795) or murine GABABR1a.

HG20 probes were generated by amplification of HG20 with
 20 JC216 (T3 promotor/primer and bases 1172-1191) paired with JC217 (T7 promotor/primer and bases 1609-1626) or with JC218 (T3 promotor/primer and bases 2386-2405) paired with JC219 (T7 promotor/primer and bases 2776-2793):
 (JC216: cgcgcaattaaccctcactaaaggACAACAGCAAACGTTTCAGGC
 25 (SEQ.ID.NO.:28);
 JC217: gcgcgtaatacg actcactatagggCATGCCTATGATGGTGAG
 (SEQ.ID.NO.:29);
 JC218: cgcgcaattaaccctcactaaagg CTGAGGACAAACCCTGACGC
 (SEQ.ID.NO.:30);
 30 JC219: gcgcgtaatacgactcactatagggGATGTC TTCTATGGGGTC;
 (SEQ.ID.NO.:31)).

Murine GABABR1a probes were generated by amplification of murine GABABR1a with JC160 (T3 promotor/primer and bases 631-648) paired with JC161 (T7 promotor/primer and bases 1024-1041):

(JC160: cgcgcaattaaccctcactaaaggAAGCTTATCCACCACGAC
(SEQ.ID.NO.:32);

JC161:gcgcgtaa tacgactcactatagggAGCTGGATCCGAGAAGAA
(SEQ.ID.NO.:33)).

- 5 For colocalization experiments, murine GABABR1a probes were labeled with digoxigenin-UTP and detected using a peroxidase-conjugated antibody to digoxigenin and TSA amplification involving biotinyl tyramide and subsequent detection with streptavidin-conjugated fluorescein. HG20 probes were radiolabelled
- 10 (<http://intramural.nimh.nih.gov/lcmr/snge/Protocol.html>). For individual hybridizations, murine GABABR1a and HG20 riboprobes were radiolabeled with ³⁵S-UTP and detected as described previously (Bradley et al., 1992, J. Neurosci. 12:2288-2302; <http://intramural.nimh.nih.gov/lcmr/snge/Protocol.html>). Brain slices
- 15 were either hybridized with individual radiolabelled probes or, for colocalization studies, simultaneously with probes to both murine GABABR1a and HG20 receptors. Detection of the radiolabeled HG20 probe was performed after detection of the digoxigenin-labeled rgl1 probe on the same brain slices.

20

EXAMPLE 14

Construction of N-terminal and C-terminal fragments of murine GABABR1a

- The N-terminal fragment of murine GABABR1a,
- 25 comprising amino acid positions 1-625, was generated by PCR. The coding sequence of the N-terminal fragment was amplified by using primer pairs: NFP-CJ7843F139 (5'- ACC ACT GCT AGC ACC GCC ATG CTG CTG CTG CTG CTT CTG C -3'; SEQ.IS.NO.:34) and NRP-CJ7844 (3'- GG GTG CGA GCA ATA TAG GTC TTA AGG GTC GGC CGC
- 30 CGG CGT CAC CA -5'; ; SEQ.IS.NO.:35). Similarly, the C-terminal fragment, amino acid positions 588-942, was generated by PCR using primer pairs: CFP-CJ7845 (5'- ACC ACT GCT AGC ACC GCC ATG CAG AAA CTC TTT ATC TCC GTC TCA GTT CTC TCC AGC-3'; ; SEQ.IS.NO.:36) and CRP-CJ7846 (3'- CAG CTC ATG TAA ACG AAA
- 35 TGT TCA CTC GCC GGC CGC CGG CGT CAC CA-5'; ; SEQ.IS.NO.:37).

PCR reactions were carried out using the Advantage-HF PCR kit (Clontech, Palo Alto, CA) with 0.2 ng of murine GABABR1a DNA as the template, and 10 μ M of each primer according to manufacturer instructions. The PCR conditions were as follows: precycle
5 denaturation at 94°C for 1 min, and then 35 cycles at 94°C (15 s), annealing and extension at 72°C (3 min), followed by a final extension for 3 min at 72°C. The PCR products, N-gb 1a and C-gb 1a DNA, flanked by Nhe1 and Not1 sites, were digested and subcloned into the Nhe1/Not1 site of pcDNA3.1 (Invitrogen, San Diego, Ca).

10

EXAMPLE 15

Cell culture and preparation of membrane fractions for binding experiments using N-terminal and C-terminal GABABR1a fragments

COS-7 cells (ATCC) were cultured in DMEM, 10% bovine
15 serum, 25 mM HEPES, and antibiotics and transiently transfected with murine gb1a/pcDNA3.1 (encoding full-length GABABR1a), N-gb 1a/pcDNA3.1 (encoding the N-terminal fragment of GABABR1a; see Example 14) or C-gb 1a/pcDNA3.1 (encoding the C-terminal fragment of GABABR1a; see Example 14) using Lipofectamine reagent (Gibco BRL)
20 following the conditions recommended by the manufacturer. At 48 h post-transfection, P2 membrane fractions were prepared at 4°C as follows: Cells were washed twice with cold PBS, collected by centrifugation at 100xg for 7 min, and resuspended in 10 ml of buffer A: 5 mM Tris-HCl, 2 mM EDTA containing (1X) protease inhibitor cocktail
25 Complete® tablets (Boehringer Mannheim), pH 7.4 at 4°C. Cells were disrupted by polytron homogenization, centrifuged at 100xg for 7 min to pellet unbroken cells and nuclei, and the supernatant collected. The resulting pellet was homogenized a second time in 10 ml of buffer A, centrifuged as described above and supernatant fractions saved. The
30 pooled S1 supernatant was centrifuged at high speed (27,000xg for 20 min) and the pellet was washed once with buffer A, centrifuged (27,000xg for 20 min), resuspended in buffer A to make the P2 membrane fraction, and stored at -80°C. Protein content was determined using the Bio-Rad Protein Assay Kit according to manufacturer instructions.

EXAMPLE 16

In vitro transcription/translation of GABABR1a and N-terminal and C-terminal fragments

- 5 *In vitro* transcription coupled translation reactions were performed in the presence of [³⁵S]-methionine in the TNT Coupled Reticulocyte Lysate system (Promega, WI) using the pcDNA3.1 plasmid containing the full-length GABABR1a, N-gb1a, and C-gb1a DNAs. Translation products were analysed by electrophoresis on 8-16% Tris-
10 Glycine gradient gels (Novex pre-cast gel system) under denaturing and reducing conditions. Gels were fixed, treated with enlightening fluid (NEN), dried and exposed to Kodak X-AR film at -70°C for 4 to 24 h. Analysis of the results of these *in vitro* transcription coupled translation reactions confirmed that the constructs whose production is described in
15 Example 14 directed the expression of the appropriate GABABR1a fragments (see Figure 17A).

EXAMPLE 17

Immunoblot analysis for experiments with N-terminal and C-terminal fragments of GABABR1a

- 20 The expression of full-length and N-terminal and C-terminal GABABR1a fragments *in vivo* was confirmed by immunoblot analysis. Membranes were solubilized in SDS sample buffer consisting of 50 mM Tris-HCl pH 6.5, 10% SDS, 10% glycerol, and 0.003%
25 bromophenol blue with 10% 2-mercaptoethanol and separated on SDS-PAGE. The full-length receptor and N-terminal fragment were detected using affinity purified rabbit GABABR1a polyclonal antibody 1713.1 (acetyl-DVNSRRDILPDYELKLC-amide; a portion of SEQ.ID.NO.:20) and 1713.2 (acetyl-CATLHNPTRVKLF EK-amide; a portion of
30 SEQ.ID.NO.:20) (Quality Control Biochemicals (Hopkinton, MA). The C-terminal fragment was detected using a GABABR1a antibody raised against the C-terminal tail of the receptor (acetyl-PSEPPDRLSCDGSRVHLLYK-amide; SEQ.ID.NO.:20) (Chemicon Int.,

Inc., Canada).

EXAMPLE 18

5 Receptor filter-binding assays for experiments with N-terminal and C-terminal fragments of GABA_BR1a

Competition of [¹²⁵I] CGP71872 binding experiments were performed with ~7 µg P2 membrane protein and increasing concentrations of cold ligand (10⁻¹²-10⁻³ M). The concentration of radioligand used in the competition assays was 1 nM (final). Each
10 concentration was examined in duplicate and incubated for 2 hr at 22°C in the dark in a total volume of 250 µL binding buffer: 50 mM Tris-HCl, 2.5 mM CaCl₂ (pH 7.4) with (1X) protease inhibitor cocktail Complete® tablets. Bound ligand was isolated by rapid filtration through a Brandel 96 well cell harvester using Whatman GF/B filters. Data were analysed
15 by nonlinear least-squares regression using the computer-fitting program GraphPad Prism version 2.01 (San Diego).

EXAMPLE 19

20 Photoaffinity labeling for experiments with N-terminal and C-terminal fragments of GABA_BR1a

P2 membranes were resuspended in binding buffer, and incubated in the dark with 1 nM final concentration [¹²⁵I]CGP71872 (2200 Ci/mmol) in a final volume of 1 ml for 2 h at 22°C. The membranes were centrifuged at 27, 000xg for 10 min and the pellet was washed in
25 ice-cold binding buffer, centrifuged at 27, 000xg for 20 min and resuspended in 1 ml of ice-cold binding buffer and exposed on ice 2 inches from 360 nm ultraviolet light for 10 min. Photolabeled membranes were washed and membranes pelleted by centrifugation and solubilized in sample buffer (50 mM Tris-HCl pH 6.5, 10% SDS, 10% glycerol, and 0.003% bromophenol blue with 10% 2-mercaptoethanol).
30 Samples were electrophoresed on precast NOVEX 10% Tris-glycine gels,

fixed, dried, and exposed to Kodak XAR film with an intensifying screen at -70°C .

EXAMPLE 20

5

Construction of the FLAG epitope-tagged HG20 and detection of expression in vitro and in COS-1 cells

The FLAG epitope-tagged HG20 receptor subunit was constructed by PCR using a sense primer encoding a modified influenza hemagglutinin signal sequence (MKTHIALSYIFCLVFA; a portion of SEQ.ID.NO.:17) (Jou et al., 1980, Cell 19:683-696) followed by an antigenic FLAG epitope (DYKDDDDK; a portion of SEQ.ID.NO.:17) and DNA encoding amino acids 52-63 of HG20 and an antisense primer encoding amino acids 930-941 of the HG20 in a high-fidelity PCR reaction with HG20/pCR 3.1 as a template. HG20/pCR 3.1 is a plasmid that contains full-length HG20 (SEQ.ID.NO.:2) cloned into pCR3.1. The nucleotide sequences of the sense and antisense primers are: sense: 5'-GCC GCT AGC GCC ACC ATG AAG ACG ATC ATC GCC CTG AGC TAC ATC TTC TGC CTG GTA TTC GCC GAC TAC AAG GAC GAT GAT GAC AAG AGC AGC CCG CCG CTC TCC ATC ATG GGC CTC ATG CCG CTC-3', (SEQ.ID.NO.:38); antisense: 5'-GCC TCT AGA TTA CAG GCC CGA GAC CAT GAC TCG GAA GGA GGG TGG CAC-3' (SEQ.ID.NO.:39). The PCR conditions were: precycle denaturation at 94°C for 1 min, 94°C for 30 sec, annealing and extension at 72°C for 4 min for 25 cycles, followed by a 7 min extension at 72°C . The PCR product, SF-HG20 DNA, flanked by NheI and XbaI sites was subcloned into the NheI/XbaI site of pcDNA3.1 (Invitrogen, San Diego, Ca) to give rise to the expression construct SF-HG20/pcDNA3.1. The sequence of this construct was verified on both strands.

The SF-HG20 receptor was expressed in an *in vitro* coupled transcription/translation reaction using the TNT Coupled Reticulocyte Lysate system (Promega, WI) in the presence of [^{35}S]methionine according to the manufacturer instructions. Radiolabeled proteins were analyzed by electrophoresis on 8-16% Tris-Glycine gradient gels (Novex pre-cast gel system) under denaturing and reducing conditions.

Gels were fixed and treated with Enlightening fluid (NEN), dried and exposed to Kodak X-AR film at -70°C.

COS-1 cells (ATCC, CRL 1650) were cultured in DMEM, 10% bovine serum, 25 mM HEPES, pH 7.4, and 10 units/mL penicillin- 10
5 µg/mL streptomycin. Transient transfection of COS-1 cells with SF-HG20/pcDNA 3.1 was carried out using Lipofectamine reagent (Gibco BRL) following the conditions recommended by the manufacturer. At 48 h post-transfection, crude membranes were prepared and receptors were solubilized with digitonin and immunoprecipitated with anti-
10 FLAG M2 affinity gel resin (IBI) under previously described conditions (Ng et al., 1993). The immunoprecipitate was washed and solubilized in SDS sample buffer, sonicated, electrophoresed, and blotted on to nitrocellulose membrane as described (Ng et al., 1993). The FLAG-tagged HG20 receptor was detected using an anti-FLAG antibody (Santa
15 Cruz Biotech., Inc.) by following a chemilumescence protocol of the manufacturer (NEN).

EXAMPLE 21

Kir channel activity in *Xenopus* oocytes

20 With the following modifications, *Xenopus* oocytes were isolated as described (Hébert et al., 1994, Proc. R. Soc. Lond. B 256:253-261) from live frogs supplied by Boreal, Inc. After a brief (10 min) hypertonic shock with 125 mM potassium phosphate pH 6.5, oocytes were allowed to recover in Barth's solution for 1-2 hr. cDNA constructs
25 for human Kir 3.1, Kir 3.2 channel isoforms (generous gifts from Dr. Hubert Van Tol, University of Toronto), and $G\alpha 1$ (a generous gift of Dr. Maureen Linder, Washington University) were linearized by restriction enzymes and purified using GeneClean (Bio 101). Murine GABA β R1a or FLAG-HG20 clones were subcloned into pT7TS (a generous gift of Dr.
30 Paul Krieg, University of Texas) before linearization and transcription. Capped cRNA was made using T7 RNA polymerase and the mMessage mMachine (Ambion). Individual oocytes were injected with 5-10 ng (in 25-50 nL) of Kir3.1 and Kir3.2 constructs with mRNAs for murine GABA β R1a or FLAG-HG20 and in combination with $G\alpha 1$ as well. Kir
35 currents were also evaluated in oocytes co-injected with Kir3.1, Kir3.2,

murine GABA_BR1a and FLAG-HG20 mRNAs. Currents were recorded after 48 hr. Standard recording solution was KD-98, 98 mM KCl, 1 mM MgCl₂, 5 mM K-HEPES, pH 7.5, unless otherwise stated.

Microelectrodes were filled with 3 M KCl and had resistances of 1-3 MW and 0.1-0.5 MW for voltage and current electrodes, respectively. In addition, current electrodes were backfilled with 1% agarose (in 3M KCl) to prevent leakage as described (Hébert et al., 1994, Proc. R. Soc. Lond. B 256:253-261). Recordings were made at room temperature using a Geneclamp 500 amplifier (Axon Instruments). Oocytes were voltage clamped and perfused continuously with different recording solutions. Currents were evoked by 500 msec voltage commands from a holding potential of -10 mV, delivered in 20 mV increments from -140 to 60 mV to test for inward rectifying potassium currents. Data were recorded at a holding potential of -80 mV and drugs were added to the bath with a fast perfusion system. Data collection and analysis were performed using pCLAMP v6.0 (Axon Instruments) and Origin v4.0 (MicroCal) software. For subtraction of endogenous and leak currents, records were obtained in ND-96, 96 mM NaCl, 2 mM KCl, 1 mM MgCl₂, 5 mM Na-HEPES and these were subtracted from recordings in KD-98 before further analysis.

EXAMPLE 22

Radiation Hybrid mapping of HG20

Radiation hybrid analysis assigned the HG20 gene to chromosome 9, placing it 4.81 cR from the WI-8684 marker on the GeneBridge 4 panel of 93 RH clones of the whole human genome. Searching of the OMIM database with D9S176 and D9S287 markers proximal to the HG20 gene revealed it to map proximal to the hereditary sensory neuropathy type 1 (HSN-1) locus, a ~8 cM region flanked by D9S176 and 9S318 (Nicholson et al., 1996, Nature Genetics 13, 101-104) (Figure 20). HSN-1 is the most common form of a group of degenerative disorders of sensory neurons characterized by a progressive degeneration of dorsal root ganglion and motor neurons that lead to distal sensory loss, distal muscle wasting and weakness, and neural deafness, among a number of other neuronally related deficits

(Nicholson et al., 1996, Nature Genetics 13, 101-104). FCMD (Fukuyama congenital muscular dystrophy) and DYS (dysautonomia, another type of HSN) also map to this area. Candidate gene(s) in these disorders are likely critical to the development, survival, and differentiation of
5 neurons.

A human BAC library was screened using the EcoRI fragment containing the full-length HG20 DNA, and end-sequencing was performed on BAC clones designated 6D18, 168K19, 486B24, and 764N4. The primer pair: ngf1t7+ (5'-AAC AGT CAA AAC CCA CCC
10 AG-3'; SEQ.ID.NO.:40) and ngf1t7- (5'-AAC AGT TTC CAG CTG TGC CT-3'; SEQ.ID.NO.:41) were identified for radiation hybrid mapping of the HG20 gene on the GENEBRIDGE 4 panel. BAC library screening and radiation hybrid mapping were performed by Research Genetics (Huntsville, AL).

15

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such
20 modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

WHAT IS CLAIMED:

1. An isolated DNA molecule encoding an HG20 polypeptide comprising an amino acid sequence selected from the group consisting of:
- 5
- SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
10 Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
15 Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.
2. The isolated DNA molecule of claim 1 comprising a nucleotide sequence selected from the group consisting of:
- 20
- SEQ.ID.NO.:1;
Positions 293-3,115 of SEQ.ID.NO.:1;
Positions 317-3,115 of SEQ.ID.NO.:1;
Positions 395-3,115 of SEQ.ID.NO.:1;
Positions 398-3,115 of SEQ.ID.NO.:1;
25 Positions 404-3,115 of SEQ.ID.NO.:1;
Positions 407-3,115 of SEQ.ID.NO.:1;
Positions 416-3,115 of SEQ.ID.NO.:1;
Positions 422-3,115 of SEQ.ID.NO.:1;
Positions 428-3,115 of SEQ.ID.NO.:1;
30 Positions 446-3,115 of SEQ.ID.NO.:1; and
Positions 461-3,115 of SEQ.ID.NO.:1.
3. An isolated DNA molecule that hybridizes under stringent conditions to the DNA molecule of claim 2.
- 35
4. An expression vector comprising the DNA of claim 1.

5. A recombinant host cell comprising the expression vector of claim 4.
- 5 6. The recombinant cell of claim 5 further comprising an expression vector comprising DNA encoding a protein selected from the group consisting of:
- 10 7. A protein, substantially free from other proteins, comprising an HG20 protein having an amino acid sequence selected from the group consisting of:
- SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
15 Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
20 Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.
- 25 8. A heterodimer comprising the protein of claim 7 and a G-protein coupled receptor protein where the heterodimer is substantially free from other proteins.
9. The heterodimer of claim 8 where the heterodimer is
30 held together by N-terminal Sushi repeats, C-terminal alpha-helical interacting domains, coiled-coil domains, transmembrane interactions, or disulfide bonds.
- 35 10. A polypeptide comprising a coiled-coil domain from a first GABA_B receptor subunit and no other contiguous amino acid sequences longer than 5 amino acids from the first GABA_B receptor subunit where the coiled-coil domain is present in the C-terminus of the

GABA_B receptor subunit and mediates heterodimerization of the first GABA_B receptor subunit with a second GABA_B receptor subunit.

11. The polypeptide of claim 10 where the coiled-coil
5 domain is selected from the group consisting of: positions 756-829 of SEQ.ID.NO.:2; positions 779-814 of SEQ.ID.NO.:2; positions 886-949 of SEQ.ID.NO.:21; and positions 889-934 of SEQ.ID.NO.:21.

12. An isolated DNA molecule encoding a GABA_BR1a
10 polypeptide comprising the amino acid sequence SEQ.ID.NO.:20.

13. A protein, substantially free from other proteins,
comprising a GABA_BR1a protein having the amino acid sequence
SEQ.ID.NO.:20.
15

14. A method for determining whether a substance binds
GABA_B receptors and is thus a potential agonist or antagonist of the
GABA_B receptor that comprises:

(a) providing cells comprising an expression vector
20 encoding HG20 and an expression vector encoding GABA_BR1a or
GABA_BR1b;

(b) culturing the cells under conditions such that HG20
and GABA_BR1a or GABA_BR1b are expressed and heterodimers of HG20
and GABA_BR1a or GABA_BR1b are formed;

(c) exposing the cells to a labeled ligand of GABA_B
25 receptors in the presence and in the absence of the substance;

(d) measuring the binding of the labeled ligand to the
heterodimers of HG20 and GABA_BR1a or GABA_BR1b;

where if the amount of binding of the labeled ligand is less
30 in the presence of the substance than in the absence of the substance,
then the substance is a potential agonist or antagonist of GABA_B
receptors.

15. A method of identifying agonists and antagonists of
35 HG20 comprising:

(a) providing test cells by transfecting cells with:

(1) an expression vector that directs the expression of HG20 in the cells; and

(2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;

5 (b) exposing the test cells to a substance that is suspected of being an agonist of the GABA_B receptor;

(c) measuring the amount of a functional response of the test cells that have been exposed to the substance;

(d) comparing the amount of the functional response
10 exhibited by the test cells with the amount of the functional response exhibited by control cells;

wherein if the amount of the functional response exhibited by the test cells differs from the amount of the functional response exhibited by the control cells, the substance is an agonist or antagonist of
15 the GABA_B receptor;

where the control cells are cells that have not been transfected with HG20 and GABA_BR1a or GABA_BR1b but have been exposed to the substance or are test cells that have not been exposed to the substance.

20

16. A method of producing functional GABA_B receptors in cells comprising:

(a) transfecting cells with:

(1) an expression vector that directs the
25 expression of HG20 in the cells; and

(2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;

(b) culturing the cells under conditions such that heterodimers of HG20 and GABA_BR1a or GABA_BR1b are formed where
30 the heterodimers constitute functional GABA_B receptors.

17. An antibody that binds specifically to HG20 where HG20 has an amino acid sequence selected from the group consisting of:
SEQ.ID.NO.:2;

35 Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;

5 Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

10 18. A method of expressing a truncated version of HG20 protein comprising:

- (a) transfecting a host cell with a expression vector that encodes an HG20 protein that has been truncated at the amino terminus;
- 15 (b) culturing the transfected cells of step (a) under conditions such that the truncated HG20 protein is expressed.

19. A chimeric HG20 protein having an amino acid sequence of HG20 selected from the group consisting of:

- 20 Positions 51-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2;
Positions 53-941 of SEQ.ID.NO.:2;
Positions 54-941 of SEQ.ID.NO.:2;
Positions 55-941 of SEQ.ID.NO.:2;
Positions 56-941 of SEQ.ID.NO.:2;
25 Positions 57-941 of SEQ.ID.NO.:2; and
Positions 58-941 of SEQ.ID.NO.:2;

covalently linked at the N-terminus with a non-HG20 amino acid sequence.

1/32
FIGURE 1A

1 CCGCCCTCCC CCGGCCGAGC TCCAGGGCTG CCGCCTAGCA GCTCCCGGCG
51 GGAGAGCGGT TCAGAGCTCG CTCCCACCCC TTCCCGGCGT GATTGATCCG
101 TCACGGGCGC CTCCGCTGCC GCCGCCGCGG CCGCGGCCGT TCTGAGCCGA
151 GCCGGAACCC TAGCCCGAGA CGGAGCCGGG GCCCGGGCCG GCGCCATTGC
201 GCGGGCGCCG CGGGAAGACC TTGGCGCGGG GCGGCGGGCC GGGCCAGGCC
251 ATGCGGGCCG AGTGAGCCGG CGCCCGCAGC CCGCGGCGCG GCATGGCTTC
301 CCCGCGGAGC TCCGGGCAGC CCGGGCCGCC GCCGCCGCCG CCACCGCCCG
351 CCGCGCGCCT GCTACTGCTA CTGCTGCTGC CGCTGCTGCT GCCTCTGGCG
401 CCCGGGGCCT GGGGCTGGGC GCGGGGCGCC CCCC GGCCGCGC CGCCAGCAG
451 CCCGCCGCTC TCCATCATGG GCCTCATGCC GCTACCAAG GAGGTGGCCA
501 AGGGCAGCAT CCGGGCGCGT GTGCTCCCCG CCGTGGAAGT GGCCATCGAG
551 CAGATCCGCA ACGAGTCACT CTTGCGCCCC TACTTCCTCG ACCTGCGGCT
601 CTATGACACG GAGTGCAGCA ACGCAAAAGG GTTGAAAGCC TTCTACGATG
651 CAATAAAATA CGGGCCGAAC CACTTGATGG TGTGTTGGAG CGTCTGTCCA
701 TCCGTCACAT CCATCATTGC AGAGTCCCTC CAAGGCTGGA ATCTGGTGCA
751 GCTTTCTTTT GCTGCAACCA CGCCTGTTCT AGCCGATAAG AAAAAATACC
801 CTTATTTCTT TCGGACCGTC CCATCAGACA ATGCGGTGAA TCCAGCCATT
851 CTGAAGTTGC TCAAGCACTA CCAGTGGAAG CGCGTGGGCA CGTGACGCA
901 AGACCTTCAG AGGTTCTCTG AGGTGCGGAA TGACCTGACT GGAGTTCTGT
951 ATGGCGAGGA CATTGAGATT TCAGACACCG AGAGCTTCTC CAACGATCCC
1001 TGTACCAGTG TCAAAAAGCT GAAGGGGAAT GATGTGCGGA TCATCCTTGG
1051 CCAGTTTGAC CAGAATATGG CAGCAAAAGT GTTCTGTTGT GCATACGAGG
1101 AGAACATGTA TGGTAGTAAA TATCAGTGGA TCATTCCGGG CTGGTACGAG
1151 CCTTCTTGGT GGGAGCAGGT GCACACGGAA GCCAACTCAT CCCGCTGCCT
1201 CCGGAAGAAT CTGCTTGCTG CCATGGAGGG CTACATTGGC GTGGATTTCG
1251 AGCCCTGAG CTCCAAGCAG ATCAAGACCA TCTCAGGAAA GACTCCACAG
1301 CAGTATGAGA GAGAGTACAA CAACAAGCGG TCAGGCGTGG GGCCAGCAA
1351 GTTCCACGGG TACGCCTACG ATGGCATCTG GGTCATCGCC AAGACACTGC
1401 AGAGGGCCAT GGAGACACTG CATGCCAGCA GCCGGCACCA GCGGATCCAG
1451 GACTTCAACT ACACGGACCA CACGCTGGG AGGATCATCC TCAATGCCAT
1501 GAACGAGACC AACTTCTTCG GGGTCACGGG TCAAGTTGTA TTCCGGAATG
1551 GGGAGAGAAT GGGGACCATT AAATTTACTC AATTTCAAGA CAGCAGGGAG
1601 TGGAAGGTGG GAGAGTACAA CGCTGTGGCC GACACACTGG AGATCATCAA
1651 TGACACCATC AGGTTCCAAG GATCCGAACC ACCAAAAGAC AAGACCATCA
1701 TCCTGGAGCA GCTGCGGAAG ATCTCCCTAC CTCTCTACAG CATCCTCTCT
1751 GCCCTACCA TCCTCGGGAT GATCATGGCC AGTGCTTTTC TCTTCTTCAA
1801 CATCAAGAAC CGGAATCAGA AGTCATAAA GATGTCGAGT CCATACATGA
1851 ACAACCTTAT CATCCTTGGA GGGATGCTCT CCTATGCTTC CATATTTCTC
1901 TTTGGCCTTG ATGGATCCTT TGTCTCTGAA AAGACCTTG AACACTTTG
1951 CACCGTCAGG ACCTGGATTG TCACCGTGGG CTACACGACC GCTTTTGGGG
2001 CCATGTTTGC AAAGACCTGG AGAGTCCACG CCATCTTCAA AAATGTGAAA
2051 ATGAAGAAGA AGATCATCAA GGACCAGAAA CTGCTTGTGA TCGTGGGGGG
2101 CATGCTGCTG ATCGACCTGT GTATCCTGAT CTGCTGGCAG GCTGTGGACC
2151 CCCTGCGAAG GACAGTGGAG AAGTACAGCA TGGAGCCGGA CCCAGCAGGA
2201 CGGGATATCT CCATCCGCCC TCTCTGGAG CACTGTGAGA ACACCCATAT
2251 GACCATCTGG CTTGGCATCG TCTATGCCTA CAAGGGACTT CTCATGTTGT
2301 TCGGTTGTTT CTTAGCTTGG GAGACCCGCA ACGTCAGCAT CCCC GACTC
2351 AACGACAGCA AGTACATCGG GATGAGTGTG TACAACGTGG GGATCATGTG
2401 CATCATCGGG GCCGCTGTCT CTTCTGAC CCGGGACCAG CCAATGTGC
2451 AGTTCTGCAT CGTGGCTCTG GTCATCATCT TCTGCAGCAC CATCACCTC
2501 TGCCTGGTAT TCGTGCCGAA GTCATCACC CTGAGAACAA ACCCAGATGC
2551 AGCAACGCAG AACAGGCGAT TCCAGTTCAC TCAGAATCAG AAGAAAGAAG
2601 ATTCTAAAAC GTCCACCTCG GTCACCAAGT TGAACCAAGC CAGCACATCC
2651 CGCCTGGAGG GCCTACAGTC AGAAAACCAT CGCCTGCGAA TGAAGATCAC
2701 AGAGCTGGAT AAAGACTTGG AAGAGGTCAC CATGCAGCTG CAGGACACAC

2751 CAGAAAAGAC CACCTACATT AAACAGAACC ACTACCAAGA GCTCAATGAC
2801 ATCCTCAACC TGGGAAACTT CACTGAGAGC ACAGATGGAG GAAAGGCCAT
2851 TTTAAAAAAT CACCTCGATC AAAATCCCCA GCTACAGTGG AACACAACAG
2901 AGCCCTCTCG AACATGCAAA GATCCTATAG AAGATATAAA CTCTCCAGAA
2951 CACATCCAGC GTCGGCTGTC CCTCCAGCTC CCCATCCTCC ACCACGCCTA
3001 CCTCCCATCC ATCGGAGGCG TGGACGCCAG CTGTGTCAGC CCCTGCGTCA
3051 GCCCCACCGC CAGCCCCCGC CACAGACATG TGCCACCCTC CTTCCGAGTC
3101 ATGGTCTCGG GCCTGTAAGG GTGGGGGGCC TGGGCCCGGG GCCTCCCCCG
3151 TGACAGAACC AACTGGGCA GAGGGGTCTG CTGCAGAAAC ACTGTGCGCT
3201 CTGGCTGCGG AGAAGCTGGG CACCATGGCT GGCCTCTCAG GACCACTCGG
3251 ATGGCACTCA GGTGGACAGG ACGGGGCAGG GGGAGACTTG GCACCTGACC
3301 TCGAGCCTTA TTGTGAAGT CCTATTCT TCACAAAGAA GAGGAACGGA
3351 AATGGGACGT CTTCTTAAC ATCTGCAAAC AAGGAGGCGC TGGGATATCR
3401 AATTCCACCA CACTGGCGGC CCGCGCTTGS TCSTAATCAT GGTCATAACT
3451 GTTTCCTGTG TTGAAATTGT TATCCGCTCC

FIGURE 2

1 MASPRSSGQP GPPPPPPPP ARLLLLLLLP LLLPLAPGAW GWARGAPRPP
51 PSSPPLSIMG LMPLTKEVAK GSIGRGLVPA VELAIEQIRN ESLLRPYFLD
101 LRLYDTECDN AKGLKAFYDA IKYGNHLMV FGGVCPSVTS IIAESLQGWN
151 LVQLSFAATT PVLADKKKYP YFFRTVPSDN AVNPAILKLL KHYQWKRVT
201 LTQDVQRFSE VRNDLTGVLY GEDIEISDTE SFSNDPCTSV KKLKGNVRI
251 ILQFDQNMA AKVFCCAYEE NMYGSKYQWI IPGWYEPSWW EQVHTEANSS
301 RCLRKNLLAA MEGYIGVDFE PLSSKQIKTI SGKTPQQYER EYNNKRSGVG
351 PSKFHGYAYD GIWVIAKTLQ RAMETLHASS RHQRIQDFNY TDHTLGRIL
401 NAMNETNFFG VTGQVVRNG ERMGTIKFTQ FQDSREVKVG EYNAVADTLE
451 IINDTIRFQG SEPPKDKTII LEQLRKISLP LYSILSALTI LGMIMASAFI
501 FFNKRNQK LIKMSSPYMN NLILGGMLS YASIFLGLD GSFVSEKTFE
551 TLCTVRTWIL TVGYTTAFGA MFAKTWRVHA IFKNVKMKKK IKDQKLLVI
601 VGGMLLDLC ILICWQAVDP LRRTVEKYSM EPDPAGRDIS IRPLLEHCEN
651 THMTTWLGIV YAYKGLMLF GCFLAWETRN VSIPALNSK YIGMSVYNVG
701 IMCIIGAAVS FLTRDQPNVQ FCIVALVIF CSTITLCLVF VPKLITLRTN
751 PDAATQNRRF QFTQNQKKED SKTSTSVTSV NQASTSRLEG LQSENHRLRM
801 KITELDKDLE EVTMQLQDTP EKTTYIKQNH YQELNDILNL GNFTSTDDG
851 KAILKNHLDQ NPQLQWNTTE PSRTCKDPIE DINSPEHIQR RLSLQLPILH
901 HAYLPSIGGV DASCVSPCVS PTASPRHRHV PPSFRVMVSG L

Sequence: LPLLLPLAPGAWG-WARGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQIRNE
| (signal) | (mature peptide)
29 42

Other entries above 3.50

Score 11.1 at residue 39

Sequence: LLLLPLLLPLAPG-AWGWARGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQI
| (signal) | (mature peptide)
26 39

Score 8.6 at residue 38

Sequence: LLLLPLLLPLAP-GAWGWARGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQ
| (signal) | (mature peptide)
25 38

Score 8.1 at residue 35

Sequence: RLILLLLPLLLP-LAPGAWGWARGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELA
| (signal) | (mature peptide)
22 35

Score 7.9 at residue 36

Sequence: LILLLLPLLLPL-APGAWGWARGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAI
| (signal) | (mature peptide)
23 36

Score 6.2 at residue 9

Sequence: -QGRPPPPPPPARLILLLLPLLLPLAPGAWGWARGAPRPPSSPPLSI
| (signal) | (mature peptide)
-4 9

Score 5.7 at residue 46

Sequence: LPLAPGAWGWARG-APRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQIRNESLLR
| (signal) | (mature peptide)
33 46

Score 5.6 at residue 747

Sequence: ITLCLVFVKLIT-LRTNPDAATQNRRFQFTQNQKKEDSKTSTSVTSVNQASTSRLEGLQSENH
| (signal) | (mature peptide)
734 747

Score 5.0 at residue 44

Sequence: LLLPLAPGAWGWA-RGAPRPPSSPPLSIMGLMPLTKEVAKGSIGRGVLPAVELAIEQIRNESL
| (signal) | (mature peptide)
31 44

Score 4.9 at residue 497

Sequence: ILSALTILGMIMA-SAFFNIKNRNQKLIKMSPPYMNLIILGGMLSYASIFLFGLDGSFVSE
| (signal) | (mature peptide)
484 497

Score 4.5 at residue 141

Sequence: LMVFGGVCPSVTS-IIAESLQGWNLVQLSFAATTPVLADKKKYPYFFRTVPSDNAVNPAILKLL³
| (signal) | (mature peptide)
128 141

Score 4.4 at residue 734

FIGURE 3B

Sequence: FCIVALVIFCST-ITLCLVFVPKLITLRTNPDAATQNRRFQFTQNQKKEDSKTSTSVTSVNQA
| (signal) | (mature peptide)

721 734

Score 4.1 at residue 165

Sequence: VQLSFAATTPVLA-DKKKYPYFFRTVPSDNAVNPAILKLLKHYQWKRVGTLTQDVQRFSEVRND
| (signal) | (mature peptide)

152 165

Score 3.6 at residue 158

Sequence: SLQGWNLVQLSFA-ATTPVLADKKKYPYFFRTVPSDNAVNPAILKLLKHYQWKRVGTLTQDVQR
| (signal) | (mature peptide)

145 158

FIGURE 4




FIGURE 5




FIGURE 7




FIGURE 8

GABA-BR1b	MGPGGPCTPVGWPLPLLVMAGVAPVWASHSPHL---PRPHPRVPPHPSSERRAVYIGALFPMSSGGWP-G--GQ	69
HG20	MASPRSSGQGRPPPPPPPARLILLLLLPPLLAPGAWGARGAPRPPSSPPLSIMGLMPLTKEVAGSISGR	75
Consensus	M.....G.P.P.....A.....L.....R..P.P.....I..L.P.....G...I	75
GABA-BR1b	ACQPAVEMAEDEVNSRRDILPDVELKLIHHSKCDPGQATKYLYELLVNDPIKIIILMPG-CSSVSTLVAEAARMW	143
HG20	GVLPAVELAIEQIRN-ESLLRPYFLDLRLYTECDNAKGLKAFYDAIKYGNHLMVFGVCPSVTSIIAESLQGW	149
Consensus	...PAVE..A..E.....L..Y..L..L...D...CD.....K..Y.....P.....G.C.SV....AE....W	150
GABA-BR1b	NLIVLSYGCSSSPALSNRQRFPTTFRTHPSATLHNPTRVKLFKWKWKIATIIQQTTEVFTSTLDDLEERVKEAGI	218
HG20	NLVQLSFAATTTPVLADKKKYPYFFRTVPSDNVNPAILKLLKHVQWKRVGTLTQDVQRFSEVRNDLTGVLYGEDI	224
Consensus	NL..LS.....P..L.....P.FFRT..PS....NP...KL.....WK...T..Q...F....DL.....I	225
GABA-BR1b	EITFRQSFSDPAVPVKNLKRQDARIIVGLFYETEARKVFCEVYKERLFGKKYVWFLIGWYADNWF---KTYDPS	290
HG20	EISDTESFNDPCTSVKLLKGNQVRIILGQFDQNAKAVFCCAYEENMYGSKYQWLIIPGWYEPSWWEQVHTAENS	299
Consensus	EI....SF..DP...VK.LK...D.RII.G.F....A.KVFC..Y.E...G.KY.W...GWY...W....T...S	300
GABA-BR1b	INCTVEEMTEAVECHITTEIVMLNPANTRISINMSTQEFVEKLTKRLKRHPPEETGGFOEAPLAYDAIWALALAN	365
HG20	SRCLRNLNLLAAMEGYIGVDFEPLSSKQIKTISGKTPQQY-EREYNN-KRSGVGPSKFGHYAYDGIWVIKTLQRA	372
Consensus	..C.....A..EG..I.....L.....IS...T.Q...E.....KR.....F.....A..L...	375
GABA-BR1b	KTSGGGGRSGVRLDFNYNNQTTDQIYRAMNSSFEGVSGHVVFDSGSRMAWTLIEQLQGGYSKKIGYDSTK	440
HG20	METLHASSRHQRIQDFNYTDHTLGRILNAMNETNFFGVTVQGVVFR-NGERMGTIKFTQFQDSREVKVGEYNAVA	446
ConsensusR...DFNY...T.....I...AMN...F.GV.G.VVF...G.RM.....Q.Q....K.G.Y....	450
GABA-BR1b	DDLWSKTDKWIGGSPPADQTLVIKTRFLSOKLFISVSVLSSLGIVLAVVC---LSFNIYNSHVRYIQNSQPNL	512
HG20	DTLEIINDTIRFQGSPPKDKTII--LEQLRKISLPLYSILSALTILGMIMASAFLEFFIKNRNQKLIKMSPPYM	519
Consensus	D..L.....GS.P.....I.....L.....S.LS.L.I.....L.FNI.N....I..S.P..	525
GABA-BR1b	NNLTAVGCSLALAAVFPGLDGYHIGRSQFPFVCQARLWLLGLGFSLGYSMFTKIWWVHTVFTKKEKKEWKRT	587
HG20	NNLIILGMLSYASIFLFGLDGSEFVSEKTFETLCTVTRTWLTGVTTFAGAMFAKTWRVHAIF--KNVKMK-KKI	591
Consensus	NNL...G...L..A..F..GLDG.....F...C..R.W..L..G.....G.MF.K.W.VH...F..K..K...K.	600
GABA-BR1b	LEPWKLYATVGLLVGMDVLTALWQIVDPLHRTIETFAKEEPKEDIDVSIPLQLEHCSSKKMNTWLGIFYCYKGL	662
HG20	IKDQKLLVIVGMLLIDLCILICWQAVDPLRRTVEKYSMEPDAGRDISIRPLLEHCENTHMTIWLGIYVAYKGL	666
Consensus	...KL...VG.....D...L..WQ.VDPL.RT.E....E.....D.SI.P.LEHC...M..WLGI.Y.YRGL	675
GABA-BR1b	LLLLGIFLAYETKSVSTEKINDHRAVGMAIYNVAVLCLITAPVTMILSSQDAAAFASLAIVFSSYITLVVLFV	737
HG20	LMLFGCFLAWETRNVSIPALNDSKYIGMSVYVGMCIIGAAVSFLTRDQPNVQFCIVALVIIFCSTITLCLVFLV	741
Consensus	L..L.G.FLA.ET..VS....ND....GM..YVNV...C.I.A.V.....Q.....F.....L.I..F.S..ITL...FV	750
GABA-BR1b	PKMRLITRGE-----W-----QSETODTMKTGSS-TNNNEEEKSRL--LEKE-----NRELEKI----	784
HG20	PKLITLRINPDAAATQNRRFQFTQNKKEDESKTSTSVTSVQASTSRLEGLQSENHRLRMKITELDKDLEEVTMQL	816
Consensus	PK...L.T.....Q.....KT...S.T..N...SRL...L..E.....LE.....	825
GABA-BR1b	--IAEKE-----ERVSE-----LRHQLQSRQQLRSRRHPPTPP--DPSGG-----	820
HG20	QDTPEKTTYIKONHYQELNDILNLGNFTSTGGKAILKNHLDQNPQLQWNTEPSRTCKDPIEDINSPEHIQRR	891
Consensus	...EK.....L...L...QL.....P.....DP.....	900
GABA-BR1b	-----LPR-GPSEPPDRLSC-----DGSRVHLL---YK-----	844
HG20	LSLQLPILHHAYLPSIGGVDAACVSPCVSPASPRHRHVPSPFRVMVSGL	941
ConsensusLP..G.....C.....R.....	950

FIGURE 9




FIGURE 10




FIGURE 11




FIGURE 12





FIGURE 13

A



B




FIGURE 14




FIGURE 15

1 atgctgctgc tgctgcttct gcttctcttc ctccgcccc tgggcgctgg cggggctcag
61 acccccaacg tcacctcgga aggttgccag attatacatc cgccctggga aggtggcatc
121 aggtaccgtg gcttgattcg cgaccaggtg aaggccatca atttctgcc tgtggactat
181 gagattgaat atgtgtgccg gggcgaaacg gaggtgggtg ggcccaaggt gcgcaagtgc
241 ctggccaacg gctcctggac ggatatggac acaccagtc gctgtgtccg aatctgctcc
301 aagtcttatt tgacctgga aaatgggaag gtttctctga cgggtgggga cctcccagct
361 ctggatggag cccgggtgga ttccgatgt gacctgact tccatctggt gggcagctcc
421 cggagcatct gtagtcaggg ccagtggagc accccaagc cccactgcca ggtgaatcga
481 acgccacct cagaacggcg tgcagtatac atcggggcgc tgttcccat gagcgggggc
541 tggccggggg gccaggcctg ccagcctgcg gtggagatgg cgctggagga cgttaacagc
601 cgagagaca tctgcccga ctacgagtc aagcttatcc accacgacag caagtgcgac
661 ccagggcaag ccaccaagta cttgtatgaa ctactctaca acgacccat caagatcatc
721 ctcagccccg gctgcagetc tgtgtccaca ctggtagccg aggtgcgccg gatgtggaac
781 cttattgtgc tctcatatgg ctccagctca ccagcctgt caaacgaca cgggtttcca
841 acgttctttc ggacacatcc atccgccaca ctccacaate ccaccgggt gaaactctc
901 gaaaagtggg gctggaagaa gattgccacc atccagcaga ctaccgaggt cttcacctca
961 aactggatg acctggagga gcgagtgaag gaggtgggga ttgagatcac ttttcgacag
1021 agtttcttct cagatccagc tgtgctgtt aaaaacctga agcgtcaaga tgcctgaatc
1081 atcgtgggac ttttctatga gaccgaagcc cggaaagttt tttgtagggt ctataaggaa
1141 cggctctttg ggaagaagta tgtctggtt ctcacgggt ggtatgtga caactgttc
1201 aaaacctatg accgctcaat caattgtaca gtagaagaga tgaactaggc ggtggagggc
1261 catatcacca cggagattgt catgtgaac cctgccaaca cccgaagcat ttccaacatg
1321 acatcacagg aatttgtgga gaaactaacc aagcggctga aaagacacc tgaggagact
1381 ggaggcttc aggaggcacc actggcctat gatgtatatt ggccttggc ttggccttg
1441 aacaagacct ctggaggagg tggcgttca ggagtgcgc tggaggactt taactacaac
1501 aaccagacca ttacagacca aatctaccg gccatgaact cctctctct tggagggtgt
1561 tctggccacg tggcttttga tgccagcgc tcccggatgg catggacgt tatcgagcag
1621 ctacaggcgc gcagctacaa gaagatcgc tactacgaca gcaccaagga tgaatcttc
1681 tggtecaaaa cagacaagt gatcgagggt tctccccag ccgaccagac ctgtgtcatc
1741 aagacattcc gtttctgtc acagaaactc ttatctcgc tctcagttct cccagcctg
1801 ggcattgtc ttgctgtgt ctgtctgtc ttaacatct acaactccca cgctcgtat
1861 atccagaatt cccagccaa cctgaacaat ctgactgtg tgggtgtct actggcactg
1921 gctgtgtct tccctctcg gctggatgt taccacatag ggagaagcca gttcccgtt
1981 gtctgccagg ccgcctttg gctctgggc ttgggcttta gtctgggcta tggctctatg
2041 ttaccaaga tctggtgggt ccacacagtc ttacgaaga aggaggagaa gaaggagtgg
2101 aggaagacc tagagccctg gaaactctat gccactgtg gctgtgtgt gggcatggat
2161 gtctgactc ttgccatctg gcagattgtg gacctgtg accgaacct tgagacttt
2221 gccaggagg aaccaaagga agacatcat gtctccattc tgccccagt ggagcactgc
2281 agtccaaga agatgaatac gtggcttgc attttctatg gttacaagg gctgtgtctg
2341 ctgtgggaa tcttcttgc ttacgaaacc aagagcgtgt ccactgaaaa gatcaatgac
2401 cacaggcgc tgggcatggt tatctacaat gtcgcggtcc tgtgtctcat cactgtctc
2461 gtgacctga tctttccag tcagcaggac gcagccttg ctttgcctc tctggccatc
2521 gtgttctct cctacatcac tctggtgtg ctcttctgc ccaagatgc caggctgac
2581 acccgagggg aatggcagtc tgaacgcag gacacatga aaacaggatc atccaccaac
2641 aacaacagg aagagaagtc cgcactgtg gagaaggaaa accgagaact ggaaaagatc
2701 atcgtgaga aagaggagcg cgtctctgaa ctgcgccatc agtccagtc tcggcagcaa
2761 ctccgtcac ggcgccacc ccaacacc ccagatccct ctgggggctc tcccaggga
2821 cctctgagc ccctgaccg gcttagctgt gatggagtc gactacattt gtttacaag
2881 tga

FIGURE 16

MLLLLLLLFLRPLGAGGAQTPNVTSEGCQIIHPPWEGGIRYRGLIRDQVKAINFLPVDY
EIEYVCRGEREVVGPKVRKCLANGSWTDMDTPSRCVRICSKSYLTLENGKVFLTGGDLPA
LDGARVDFRCDPDFHLVGSSRSICSQGWSTPKPHCQVNRTPHSERRAVYIGALFPMSGG
WPGGQACQPAVEMALEDVNSRRDILPDYELKLIHHDSKCDPGQATKLYELLYNDPIKII
LMPGCSSVSTLVAEAARMWNLI VLSYGSSSPALSNRQRFPTFFRTHPSATLHNPTRVKLF
EKWGWKKIATIQQTTEVFTSTLDDLEERVKEAGIEITFRQSFFSDPAVPVKNLKRQDARI
IVGLFYETEARKVFCEVYKERLFGKKYVWFLGWYADNWFKTYDPSINCTVEEMTEAVEG
HITTEIVMLNPANTRISISNMTSQEFVEKLTkRLKRHPEETGGFQEAPLAYDAIWALALAL
NKTSGGGGRSGVRLEDNFYNNQTTTDQIYRAMNSSSFEGVSGHVFDASGSRMAWTJEQ
LQGGSYKKIGYYDSTKDDLSWSKTDKWIGGSPPADQTLVIKTRFLSQKLFISVSVLSSL
GIVLAVVCLSFNIYN SHARYIQNSQPNLNNLTAVGCSLALAVVFLGLDGYHIGRSQFPF
VCOARLWLLGLGFSLGYGSMFTKIWWWVHTVFTKKEEKKEWRKTLEPWKLYATVGLLVGMD
VLT LAIWQIVDPLHRTIETFAKEEPKEDIDVSILPQLEHCSSKKMNTWLGIFYGYKGLLL
LLGIFLAYETKSVSTEKINDHRAVGMAIYNVAVLCLITAPVTMILSSQQDAAFASLAI
VFSSYITLVVLFVPKMRRLLITRGEWQSETQDTMKTGSSTNNNEEEKSRILLEKENRELEKI
IAEKEERVSELRHQLQSRQQLRSRRHPPTPPDPSSGGLPRGPSEPPDRLSCDGSRVHLLYK

FIGURE 17

[¹²⁵I]CGP71872 labeling of the GABA_B receptor
N-terminal domain




FIGURE 18A

MLLLLLLAPLFLRPPGAGGAHTPNATSEGCQIIHPPWEGGIRYRGLTRDQV
KAINFLPVDYIEIYVCRGEREVVGPKVRKCLANGSWTDMTPSRCVRICS
KSYLTLENGKVFLTGGDLPALD GARADFRCDPDFHLVGSSRSICSQQQWST
PKPHCQVNRTPHSERRAVYIGALFPMSGGWPGGQACQPAVEMALEDVNS
RRDILPDYELKLIHHSKCDPGQATKYLYELLYNDPIKIILMPGCSSVSTLV
AEAARMWNLIVLSYGSSSPALSNRQRFPTFFRTHPSATLHNPTRVKLFEKW
GWKKIATIQQTTEVFTSTLDDLEERVKEAGIEITFRQSFFSDPAVPVKNLKRQ
DARIIVGLFYETEARKVFCEVYKERLFGKKYVWFLIGWYADNWFKIYDPS
INCTVDEMTEAVEGHITTEIVMLNPANTRISISNMTSQEFVEKLTKRLKRHPE
ETGGFQEAPLAYDAIWALALALNKTSGGGGRSGVRLEDFNYNNTITDQI
YRAMNSSSFEGVSGHVVF DASGSRMAWTLIEQLQGGSYKKIGYYDSTKDD
LSWSKTDKWIGGSPPADQTLVIKTRFLSQKLFISVSVLSSLGIVLAVVCLSF
NIYN SHVRYIQNSQPNLNNLTAVGCSLALAAVFPGLDGYHIGRNQFPFV
CQARLWLLGLGFS LGYGSMTFKIWWVHTVFTKKEEKEWRKTLEPWKLY
ATVGLLVGMDVLT LAIWQIVDPLHRTIETFAKEEPKEDIDVSILPQLEHCSS
RKMNTWLGIFYGYKGLLLLLGIFLAYETKSVSTEKINDHRAVGMAIYNVA
VLCLITAPVTMILSSQQDAAFASFASLAIVFSSYITLVVLFVPKMRRLITRGE
WQSEAQDTMKTGSSTNNNEEEKSRLLKENRELEKIAEKEERVSELRHQLQ
SRQQLRSRRHPPTPPEPSGGLPRGPPEPPDRLSCDGSRVHLLYK

FIGURE 18B

1 atgttgctgc tgcgtctact ggccgacctc ttctccgcc ccccgggcgc gggcggggcg
61 cataccccca acgccacctc agaagggtgc cagatcatac acccgccctg ggaagggggc
121 atcaggtacc ggggacctgac tggggaccag gtaaggcta tcaacttctt gccagtggac
181 tatgagartg agtatgtgtg ccggggggag cgcgaggtgg tggggcccaa ggtccgcaag
241 tgcctggcca acggctcctg gacagatatg gacacacca gccgctgtgt ccgaatctgc
301 tccaagtctt attgacctt ggaaaatggg aagggtttcc tgacgggtgg ggaacctcca
361 gctctggacg gagcccgggc ggatttccgg tgtgaccccg acttccatct ggtgggcagc
421 tcccgagaca tctgtagica gggccagtgg agcaccacca agccccactg ccagggtgaat
481 cgaacgccac actcagaacg gcgcgcagtg tacatcgggg cactgtttcc catgagcggg
541 ggctggccag gggggccaggc ctgccagccc gcggtggaga tggcgctgga ggacgtgaat
601 agccgcaggg acatcctgcc ggactatgag ctcaagctca tccaccacga cagcaagtgt
661 gatccaggcc aagccacca gtaacctata gagctgctct acaacgaccc tatcaagatc
721 atccttatgc ctggctgcag ctctgtctcc acgctgtggg ctgaggctgc taggaatggg
781 aacctcattg tgccttcta tggctccagc tcaccagccc tgtcaaaccc gcagcgtttc
841 cccactttct tccgaacga cccatcagcc acactccaca accctaccgg cgtgaaactc
901 ttgaaaagt ggggctgga gaagattgct accatccagc agaccactga ggttttact
961 tgcactctgg acgacctgga ggaacgagtg aaggaggctg gaattgagat tactttccgc
1021 cagagtttct tctcagatcc agctgtgccc gtcaaaaacc tgaagcgcca ggaatcccca
1081 atcatctggg gacttttcta tgagactgaa gcccggaaag tttttgtga ggtgtacaag
1141 gagcgtctct tggggaagaa gtacgtctgg ttctcattg ggtggtatgc tgacaattgg
1201 ttcaagatct acgaccttc tatcaactgc acagtggatg agatgactga ggcggtggag
1261 ggccacatca caactgagat tgcattgctg aatcctgcca ataccgcag catttccaac
1321 atgacatccc aggaattgt ggagaaacta accaagcgac tgaagagaca cctgaggag
1381 acaggaggct tccaggaggc accgctggcc tatgatgcca tctgggccc ggcactggcc
1441 ctgaacaaga catctggagg aggcggccgt tctggtgtgc gcctggagga cttaactac
1501 aacaaccaga ccattaccga ccaatctac cgggcaatga actttctgic cttgagggg
1561 gtctctggcc atgtggtgtg tgatgccagc ggctctcgga tggcatggac gcttatcgag
1621 cagcttcagg gtggcagcta caagaagat ggctactatg acagcacca ggaratctt
1681 tcttggtcca aaacagataa atggattgga ggggtcccc cagctgacca gacctgtgc
1741 atcaagacat tccgttctt gtcacagaaa ctctttatct cgtctcagt tcttccagc
1801 ctgggcattg tctagctgtg tctgtctg tctttaaca tctacaactc acatgtccgt
1861 tataccaga actcacagcc caacctgaac aacctgactg ctgtgggctg ctacttggct
1921 ttactgtctg tcttccccct ggggctcgat ggttaccaca ttggaggaa ccagtttct
1981 ttctgtgcc aggcccgct ctggctctg ggctgggct ttactgtgg ctacggttcc
2041 atgttccca agatttggg ggtccacag gtcttcaaa agaaggaa aaagaaggag
2101 tggaggaa ga ctctggaacc ctggaagctg tatgccacag tgggctgct ggtgggcatg
2161 gatgtctca ctctgccat ctggcagatc gtggacctc tgcaccggac cattgagaca
2221 ttgccaagg aggaacctaa ggaagatatt gacgtctcta ttctgcccc gctggagcat
2281 tgcagctcca ggaagatgaa tacatggctt ggcattttct atggttaca ggggctgctg
2341 ctgctgtgg gaatttctt tgcattatg accaagagtg tgtccactga gaagatcaat
2401 gatcaccggg ctgtggcat ggctatctac aatgtggcag tctgtgctt catcactgt
2461 cctgtacca tgattctgic cagccagcag gatgcagcct ttgccttgc ctcttggc
2521 atagttttct cctctatat cactctgtt gtgctcttg tgcccaagat gcgcaggctg
2581 atcaccgag gggaaatggca gtcggaggcg caggacacca tgaagacagg gtcacgacc
2641 aacaacaacg aggaggagaa gtcccggctg ttggagaagg agaaccgtga actgaaaag
2701 atcattgctg agaaagagga gcgtgtctct gaactgcgc atcaactcca gtctggcag
2761 cagctccgct cccggcgcca cccaccgaca ccccagaac cctctggggg cctgcccagg
2821 ggacccctg agcccccca cggccttagc tgtgatggga gtcgagtga ttgcttat
2881 aagtga

FIGURE 19A

1 atgtctgtgc tgcgtctggc gccactcttc ctccgcccc cgggcgcggg cggggcgag
 61 acccccaacg ccactcaga aggttgcag atcatacacc gcacctggga agggggcacc
 121 aggtaccggg gcctgactcg ggaccagggt aaggctatca acttctgcc agtggactat
 181 gagattgagt atgtgtccg gggggagcgc gaggtgttg ggcccaaggt ccgcaagtgc
 241 ctggccaacg gctcctggac agatatggac acaccagcc gctgtgtcc aatctgtcc
 301 aagtcctatt tgaccttga aaatgggaag gtttctga cgggtggga cctccagct
 361 ctggacggag cccgggttga ttccgtgt gacccgact tccatctgt gggcagctcc
 421 cggagcatct gtagtcagg ccagtggagc accccaagc cccactgcca ggtgaatga
 481 acgccacat cagaacggcg cgcagtgtac atcggggcac ttttccat gagcgggggc
 541 tggccagggg gccaggcctg ccagcccgcg gtggagatgg cgttgggga cgtgaatagc
 601 cgcagggaca tcttccgga ctatgagctc aagctcacc accacgacag caagtgtgat
 661 ccaggccaag ccaccaagta cctatatgag ctgctctaca acgacctat caagaratc
 721 ctatgcttg gctgcagctc tgtctccag ctggtggctg aggtcttag gatgtgaac
 781 ctatgtgc tttctatgg ctccagctca ccagccctgt caaacggga gcgttcccc
 841 actttctcc gaacgcacc atcagccaca ctccacaacc ctaccgcgt gaaactctt
 901 gaaaagtggg gctggaagaa gattgtacc atccagcaga ccactgaggt ctacactcg
 961 actctggacg acctgggga acgagtgaag gaggtggaa ttgagattc tttccgtag
 1021 agttctctc cagatccagc tgtgccgctc aaaaacctga agcggcagga tgcggaac
 1081 atcgtgggac tttctatga gactgaagcc cggaaagttt ttgtgaggt gtacaaggag
 1141 cgtctcttg ggaagaagta cgtctgttc ctattgggt ggtatctga caattgttc
 1201 aagatctacg acctcttat caactgcaca gtggatgaga tgaactgagc ggtggaggc
 1261 cacatcaca ctgagattgt catgctgaat cctgccaata cccgcagcat ttccaatg
 1321 acatccagg aattgttga gaaactaacc aagcgactga aaagacacc tgaggagaca
 1381 ggaggtctcc aggagggacc gctggcctat gatgccatct gggcctggc actggcctg
 1441 aacaagacat ctggaggagg cggccgttct ggtgtgcgcc tggaggactt caactacaac
 1501 aaccagacca ttaccgacca aatctaccgg gcaatgaact ctctctctt tgagggttc
 1561 tctggccatg tgggtttga tggcagggc tctggatgg catggacgt tatcgagcag
 1621 cctcagggtg gcagctacaa gaagattggc tactatgaca gcaccaagga tgatcttcc
 1681 tggccaaaa cagataaatg gatggaggg tccccccag ctgaccagac cctgtctac
 1741 aagacattcc gcttctgtc acagaaactc ttatctccg tctcagttc ctccagcctg
 1801 ggcatgtcc tagctgtgt ctgtgttcc tttaacatc acaactaca tgtccgtat
 1861 atccagaact cacagccaa cctgaacaac ctgactgtg tgggtgtc actggctta
 1921 gctgtgtct tccccctgg gctcgtggt taccacatg ggaggaaaca gtttcttc
 1981 gtctgccagg cncgctctg gctcctggg ctgggctta gtctgggcta cgttccatg
 2041 ttaccaaga ttgtgtgggt ccacacggc ttacaaaga aggaagaaa gaaggagtgg
 2101 aggaagactc tggaaacctg gaagctgtat gccacagtgg cctgtgtgt gggcatggat
 2161 gtctcactc tgcctatctg gcagatctg gacctctgc accggacct tgagacatt
 2221 gccaaaggag aacctaaagg agatatggc gtctctatc tggccagct ggagcattc
 2281 agctccagga agatgaatc atggcttggc atttctatg gttacaagg gctgtgtctg
 2341 ctgtgggaa tcttcttgc ttatgagacc aagagtgtgt ccactgagaa gatcaatgat
 2401 caccgggctg tgggcatggc tatctacaat gtggcagtc tgtgctcat cactgtctct
 2461 gtcacatga ttctgtccag ccagcaggat gcagccttg ctttgcctc tcttccata
 2521 gtttctctt cctatacac tctgtgtg ctctgtg ccaagatgc caggctgatc
 2581 acccgagggg aatggcagtc ggaggcgag gacaccatga agacagggtc atcgaccaac
 2641 aacaacgagg aggagaagtc ccggctgtt gagaaggaga accgtgaact ggaagaatc
 2701 attgtgaga aagaggagcg tgtcttga ctgcgccatc aactccagtc tggcagcag
 2761 ctccgtccc ggcgccacc accgacacc ccagaacct ctgggggct cccagggga
 2821 cccctgagc ccccgaccg gcttagctgt gatgggagtc gattgcatg gttataag
 2881 tgagggtagg gtaggagg acaggccagt agggggagg aaaggagag gggaaggga
 2941 ggggactcag gaagcagggt gtccccatcc ccagctggga agaacatgt atccaatc
 3001 atcttcta aatacatgt cccctgtgag ttctgggctg attgggtct ctatactc
 3061 tgggaacag acctttct ctctactc ttatgtaatt ttgtatcac ctctcaca

FIGURE 19B

3121 ttatgttcgt acctggcttg aagctgctca ctgctcacac gctgctcct cagcagcctc
3181 actgcatctt tctcttccca tgcaacaccc tcttctagtt accacggcaa cccctgcagc
3241 tctctgcct ttgtgctctg ttctgtcca gcaggggtct cccaacaagt gctcttcca
3301 ccccaaagg gectctectt ttctccactg tcataatctc ttccatctt acttgccct
3361 ctatacttc tcacatgttg ctcacctga atttgctc ctttgggagc tcattcttt
3421 cgccaaggt cacatgtcc ttgctctgc tctgtgact cagctcagc acacatgcat
3481 cctccccct cctgcgttg cccactgaac atgctcatgt gtacacacgc ttccccgta
3541 tgctttctc atgttcagtc acatgtgctc tcgggtgccc tgcattcaca gctacgtgtg
3601 cccctctcat ggtcatgggt ctgccctga gcgtgtttgg gtaggcagt gcaattgtc
3661 tagcatgctg agtcatgtct ttctattg cacacgtcca tgttatcca tgtacttcc
3721 ctgtgtacc tccatgtacc ttgtgtact tcttccctta aatcatggtt ttctctgac
3781 agagccatat gtacctacc ctgcacatg ttatgcact ttcccaatt catgtttgt
3841 ggggccatcc acacctctc ctgtcacag aatctccatt tctgtcaga ttcccccat
3901 ctccattgca ttcatgtact acctcagtc tacactaca atcatctct cccaagactg
3961 ctccttttg ttgtgttt ttgtagggg aattaaggaa aaataagtgg gggcagggt
4021 ggagagctgc ttccagtga tagttgatga gaatcctgac caaggaagg caccctgac
4081 tgttgggata gacagatgga cctatgggt gggaggtggt gtcccttca cactgtggtg
4141 tcttggggg aaggatctcc ccgaatctca ataaaccagt gaacagtgtg actcggaaaa
4201 aaaaaaaaa aaaaaaaaa

FIGURE 20

| proximal to HSN-1, FCMD, DYS loci on chromosome 9




FIGURE 21




FIGURE 22




FIGURE 23

Coiled-coil domain in C-terminus of gb1a and HG20 mediating
heterodimerization

94ACSEA. QDTHKTCGSTNNHEEK...SRLEK..ESRELEKI LAEKEERVSSELRLHQLQSRQQLASRRHPP
102 QNRRFCTQNKKEQSKTSTSVTSTNQASTSRLEGLQSENHRLRMKITELEKDLLEVTHQLQDTPKTTYIDN

FIGURE 24

..CVSPCVSP.TAS.PAHRAHVPPSF.RV.MV.SGL

FIGURE 25




FIGURE 26B




FIGURE 27

mGABAb1a .KMR...RLITRGEW...QSETQDTMKTGSS.TNNNEEEKSRL...LEKE: 39
 hGABAb1a PKMR...RLITRGEW...QSEAQDTMKTGSS.TNNNEEEKSRL...LEKE: 40
 hGABAb2 ITLRTPDAAATQNRRFQFTQNKKEDESKTSTVTSVNQASTSRLEGLQSE: 50
 mGABAb1a NR...ELEKIIAE...KEERVSE...: 56
 hGABAb1a NR...ELEKIIAE...KEERVSE...: 57
 hGABAb2 NHRLRMKITELEDKDLEEVMTMQLQDTPEKTTYIKQNHYYQELNDILNLGNFT:100
 mGABAb1a .LRHQLOSRQQL.RSRRHPP.TPPDPHSGGLPRGPEPPDRLS: 95
 hGABAb1a .LRHQLOSRQQL.RSRRHPP.TPPEPSGGLPRGPEPPDRLS: 96
 hGABAb2 ESTDGGKAILKNHLQDNPQLQWNTTEPSRTCKDPIEDI.NSPEHIQRRLS:149
 PDZ
 mGABAb1a .CDGSRV...HLL...YK...:106
 hGABAb1a .CDGSRV...HLL...YK...:107
 hGABAb2 LQLPILHHAYLPSIGGVDAFCVSPCVSPTASPRHRHVPPSFRVMVSGL:197

→ coiled-coil domain

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/02361

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/705; C12N 5/10, 15/09, 15/11, 15/12, 15/62; G01N 33/566

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5; 530/350; 435/6, 7.1, 7.2, 69.1, 320.1, 325, 252.3, 254.11

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

GenBank, APS, Medline, Biosis, Caplus

search terms: HG20, gaba? receptor, t mcdonald, t bonnert, gaba?, gamma?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GenBank Database, National Library of Medicine, Bethesda, Maryland USA, HILLIER et al., Accession Number H14151, ym62d04.rl Homo sapiens cDNA clone 163495 5', 10 July 1995.	3
X	GenBank Database, Bethesda, National Library of Medicine, Maryland USA, GENEXPRESS, Accession Number Z43654, H. Sapiens partial cDNA sequence; clone c-1hh04, 21 September 1995.	3
X	GenBank Database, National Library of Medicine, Bethesda, Maryland USA, ADAMS et al., Accession Number T07621, EST05511 Homo sapiens cDNA clone HFBEL81, 30 June 1993.	3



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 JUNE 1999

Date of mailing of the international search report

02 JUL 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CLAIRE KAUFMAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/02361

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P ----- A,P	WO 97/46675 A1 (NOVARTIS) 11 December 1997, especially claims 1 and 3.	3 ----- 1, 2, 4, 5, 7-9, 14, 16, 18, 19

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/02361

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 6
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

THERE IS NO RECITATION OF WHAT IS INCLUDED IN THE GROUP FROM WHICH THE ENCODED PROTEIN IS SELECTED.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-5, 7-9, 14, 16, 18, 19

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/02361

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

536/23.1, 23.5; 530/350; 435/6, 7.1, 7.2, 69.1, 320.1, 325, 252.3, 254.11

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-5, 7-9, 14, 16, 18, 19, drawn to HG20 DNA, vector, host cell, protein, heterodimer comprising the protein, method of detecting binding to GABAB receptors, method of producing functional GABAB receptors, and method of expression an amino-terminal truncated HG20.

Group II, claim(s) 10-11, drawn to a polypeptide consisting of a coiled-coil domain.

Group III, claim(s) 12-13, drawn to DNA encoding a GABABR1a polypeptide and GABABR1a protein.

Group IV, claim(s) 15, drawn to method of identifying agonists and antagonists of HG20.

Group V, claim(s) 17, drawn to antibody that binds HG20.

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Pursuant to 37 C.F.R. 1.475(d), this Authority considers that the main invention in the instant application comprises the first-recited product, DNA encoding HG20, and the first-recited method of using that product, namely the method of detecting binding to GABAB receptors. Note that there is no method of making the polynucleotide. Also included in the first group is the encoded protein and the process of producing the encoded protein, in addition to a heterodimer, vector and host cell. Further, pursuant to 37 C.F.R. 1.475(b)-(d), the ISA/US considers that the materially and functionally dissimilar product of groups II and V and the additional methods of groups III-IV do not correspond to the main invention. This Authority therefore considers that the several inventions do not share a special technical feature within the meaning of PCT Rule 13.2 and thus do not relate to a single general inventive concept within the meaning of PCT Rule 13.1.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : C07K 14/705, C12N 5/10, 15/09, 15/11, 15/12, 15/62, G01N 33/566	A1	(11) International Publication Number: WO 99/40114
		(43) International Publication Date: 12 August 1999 (12.08.99)
(21) International Application Number: PCT/US99/02361 (22) International Filing Date: 3 February 1999 (03.02.99) (30) Priority Data: 60/073,767 5 February 1998 (05.02.98) US (71) Applicants (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO [US/US]; 7703 Floyd Curl Drive, San Antonio, TX 78284 (US). NATIONAL INSTITUTES OF HEALTH [US/US]; 36 Convent Drive, Bethesda, MD 20892-4094 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LIU, Quingyun [CN/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). McDONALD, Terrence [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BONNERT, Timothy, P. [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). NG, Gordon, Yiu, Kon [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). KOLAKOWSKI, Lee, F., Jr. [US/US]; 7703 Floyd		(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NOVEL GABA _B RECEPTOR DNA SEQUENCES		
(57) Abstract DNA encoding a novel human GABA _B receptor subunit, HG20, as well as the protein encoded by the DNA, is provided. Also provided is DNA encoding a novel murine GABA _B receptor subunit, GABA _B R1a, as well as the protein encoded by the DNA. Heterodimers of HG20 protein and GABA _B R1a protein that form a functional GABA _B receptor are disclosed. Methods of identifying agonists and antagonists of the GABA _B receptor are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION
NOVEL GABA_B RECEPTOR DNA SEQUENCES

CROSS-REFERENCE TO RELATED APPLICATIONS

5 Not applicable.

STATEMENT REGARDING FEDERALLY-SPONSORED R&D

Not applicable.

10 REFERENCE TO MICROFICHE APPENDIX

Not applicable.

FIELD OF THE INVENTION

15 The present invention is directed to a novel human DNA sequence encoding HG20, a subunit of the GABA_B receptor, the protein encoded by the DNA, and uses thereof. The present invention also is directed to the murine GABA_B1a subunit of the GABA_B receptor as well as to methods of combining an HG20 subunit with a GABA_B1a subunit to form a GABA_B receptor having functional activity.

20

BACKGROUND OF THE INVENTION

Amino acids such as glutamic acid, γ -amino-butyric acid (GABA), and glycine are neurotransmitters that bind to specific receptors in the vertebrate nervous system and mediate synaptic transmission. Of
25 these amino acids, GABA is the most widely distributed amino acid inhibitory neurotransmitter in the vertebrate central nervous system. The biological activities of GABA are mediated by three types of GABA receptors: ionotropic GABA_A receptors, metabotropic GABA_B receptors, and ionotropic GABA_C receptors. Each type of receptor has its own
30 characteristic molecular structure, pattern of gene expression, agonist and antagonist mediated pharmacological effects, and spectrum of physiological activities.

GABA_A receptors mediate fast synaptic inhibition. They are heterooligomeric proteins (most likely pentamers) containing α , β , γ , and

perhaps δ , subunits that function as ligand-gated Cl^- channels and have binding sites for benzodiazepines, barbiturates, and neuroactive steroids. Bicuculline is a widely used antagonist of GABA_A receptors. Bicuculline is selective for GABA_A receptors in that it has no effect on GABA_B or
5 GABA_C receptors. The expression of GABA_A receptors has been observed in a variety of brain structures (see, e.g., McKernan & Whiting, 1996, Trends Neurosci. 16:139-143; Sequier et al., 1988, Proc. Natl. Acad. Sci. USA 85:7815-7819).

GABA_C receptors are ligand-gated Cl^- channels found in the
10 vertebrate retina. They can be distinguished from GABA_A and GABA_B receptors in that they are insensitive to the GABA_A receptor antagonist bicuculline and the GABA_B receptor agonist (-)baclofen but are selectively activated by *cis*-4-aminocrotonic acid. GABA_C receptors are composed of homooligomers of a category of GABA receptor subunits known as " ρ "
15 subunits, the best-studied of which are $\rho 1$ and $\rho 2$. $\rho 1$ and $\rho 2$ share 74% amino acid sequence identity but are only about 30-38% identical in amino acid sequence when compared to GABA_A receptor subunits. For a review of GABA_C receptors, see Bormann & Feigenspan, 1995, Trends Neurosci. 18:515-518.

GABA_B receptors play a role in the mediation of late
20 inhibitory postsynaptic potentials (IPSPs). GABA_B receptors belong to the superfamily of seven transmembrane-spanning G-protein coupled receptors that are coupled through G-proteins to neuronal K^+ or Ca^{++} channels. GABA_B receptors are coupled through G-proteins to neuronal
25 K^+ or Ca^{++} channels, and receptor activation increases K^+ or decreases Ca^{++} conductance and also inhibits or potentiates stimulated adenylyl cyclase activity. The expression of GABA_B receptors is widely distributed in the mammalian brain (e.g., frontal cortex, cerebellar molecular layer, interpeduncular nucleus) and has been observed in many peripheral
30 organs as well.

A large number of pharmacological activities have been attributed to GABA_B receptor activation, e.g., analgesia; hypothermia; catatonia; hypotension; reduction of memory consolidation and retention; and stimulation of insulin, growth hormone, and glucagon release (see

Bowery, 1989, Trends Pharmacol. Sci. 10:401-407, for a review.) It is well accepted that GABA_B receptor agonists and antagonists are pharmacologically useful. For example, the GABA_B receptor agonist (-)baclofen, a structural analog of GABA, is a clinically effective muscle relaxant (Bowery & Pratt, 1992, *Arzneim.-Forsch./Drug Res.* 42:215-223). (-)baclofen, as part of a racemic mixture with (+)baclofen, has been sold in the United States as a muscle relaxant under the name LIORESAL® since 1972.

GABA_B receptors represent a large family of related proteins, new family members of which are still being discovered. For example, Kaupmann et al., 1997, *Nature* 386:239-246 (Kaupmann) reported the cloning and expression of two members of the rat GABA_B receptor family, GABA_BR1a and GABA_BR1b. A variety of experiments using known agonists and antagonists of GABA_B receptors seemed to indicate that GABA_BR1a and GABA_BR1b represented rat GABA_B receptors. This conclusion was based primarily on the ability of GABA_BR1a and GABA_BR1b to bind agonists and antagonist of GABA_B receptors with the expected rank order, based upon studies of rat cerebral cortex GABA_B receptors. However, there were data that did not fit the theory that Kaupmann had cloned the pharmacologically and functionally active GABA_B receptor. For example, Kaupmann noted that agonists had significantly lower binding affinity to recombinant GABA_BR1a and GABA_BR1b as opposed to native GABA_B receptors. Also, Couve et al., 1998, *J. Biol. Chem.* 273:26361-26367 showed that recombinantly expressed GABA_BR1a and GABA_BR1b failed to target correctly to the plasma membrane and failed to give rise to functional GABA_B receptors when expressed in a variety of cell types.

Examination of the amino acid and gene sequence of GABA_BR1a led Kaupmann to propose a structure for GABA_BR1a similar to that of the metabotropic glutamate receptor gene family. The metabotropic glutamate receptor family comprises eight glutamate binding receptors and five calcium sensing receptors which exhibit a signal peptide sequence followed by a large N-terminal domain believed to represent the ligand binding pocket that precedes seven transmembrane

spanning domains. The hallmark seven transmembrane spanning domains are typical of G-protein coupled receptors (GPCRs), although metabotropic glutamate receptors and GABA_BR1a are considerably larger than most GPCRs and contain a signal peptide sequence. No significant amino acid sequence similarities were found between GABA_BR1a and GABA_A receptors, GABA_C receptors, or other typical GPCRs.

Despite work such as that of Kaupmann, pharmacological and physiological evidence indicates that a large number of amino acid binding GABA_B receptors remain to be cloned and expressed in recombinant systems where agonists and antagonists can be efficiently identified. In particular, it would be extremely valuable to be able to recombinantly express GABA_B receptors in such a manner that not only pharmacologically relevant ligand binding properties would be exhibited by the recombinant receptors, but also such that the recombinant receptors would show proper functional activity.

SUMMARY OF THE INVENTION

The present invention is directed to a novel human DNA that encodes a GABA_B receptor subunit, HG20. The DNA encoding HG20 is substantially free from other nucleic acids and has the nucleotide sequence shown in SEQ.ID.NO.:1. Also provided is an HG20 protein encoded by the novel DNA sequence. The HG20 protein is substantially free from other proteins and has the amino acid sequence shown in SEQ.ID.NO.:2. Methods of expressing HG20 in recombinant systems and of identifying agonists and antagonists of HG20 are provided.

The present invention is also directed to a novel murine DNA that encodes a GABA_B receptor subunit, GABA_BR1a. The DNA encoding GABA_BR1a is substantially free from other nucleic acids and has the nucleotide sequence shown in SEQ.ID.NO.:19. Also provided is a GABA_BR1a protein encoded by the novel DNA sequence. The GABA_BR1a protein is substantially free from other proteins and has the amino acid sequence shown in SEQ.ID.NO.:20. Methods of expressing GABA_BR1a in recombinant systems and of identifying agonists and antagonists of HG20 are provided.

Also provided by the present invention are methods of co-expressing HG20 and GABA_BR1a in the same cells. Such co-expression results in the production of a GABA_B receptor that exhibits expected functional properties of GABA_B receptors as well as expected ligand binding properties. Recombinant cells co-expressing HG20 and GABA_BR1a are provided as well as methods of utilizing such recombinant cells to identify agonists and antagonists of GABA_B receptors.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A-B shows the complete cDNA sequence of HG20 (SEQ.ID.NO.:1).

Figure 2 shows the complete amino acid sequence of HG20 (SEQ.ID.NO.:2).

Figure 3A-B shows predicted signal peptide cleavage sites of HG20. All sequences shown are portions of SEQ.ID.NO.:2.

Figure 4 shows *in situ* analysis of the expression of HG20 RNA in squirrel monkey brain.

Figure 5A shows *in vitro* coupled transcription/translation of a chimeric FLAG epitope-HG20 (amino acids 52-941) protein.

Figure 5B shows the expression in COS-7 cells and melanophores of a chimeric FLAG epitope-HG20 (amino acids 52-941) protein.

Figure 6 shows a comparison of the amino acid sequences of a portion of the N-terminus of HG20 protein and the ligand binding domain of the *Pseudomonas aeruginosa* amino acid binding protein LIVAT-BP (Swiss Protein database accession number P21175). The upper sequence shown is from HG20 and corresponds to amino acids 63-259 of SEQ.ID.NO.:2. The lower sequence shown is from *Pseudomonas aeruginosa* LIVAT-BP and is SEQ.ID.NO.:16.

Figure 7 shows expression in mammalian cells of a chimeric HG20 protein.

Figure 8 shows a comparison of the amino acid sequences of HG20 and GABA_BR1b. The HG20 sequence is SEQ.ID.NO.:2. The GABA_BR1b sequence is SEQ.ID.NO.:17.

Figure 9 shows the expression of recombinant GABA_BR1a and HG20 in COS-7 cells. Lanes 1 and 2 show [¹²⁵I]CGP71872 photolabeling of recombinant murine GABA_BR1a monomer and dimer in the presence (+) and absence (-) of 1 μ M unlabeled CGP71872. Lanes 3 and 4 show that GABA_BR1a antibodies 1713.1-1713.2 confirmed (+) expression of recombinantly expressed murine GABA_BR1a (referred to as mgb1a here) and absence (-) in pcDNA3.1 mock transfected cells. Lanes 5 and 6 show [¹²⁵I]CGP71872 photolabeling of human FLAG-HG20 in the presence (+) and absence (-) of 1 μ M unlabeled CGP71872. Lanes 7 and 8 show that an anti-FLAG antibody confirmed (+) the expression of FLAG-HG20 (referred to as FLAG-gb2 here) and its absence (-) in pcDNA3.1 mock transfected cells. Experimental details were as in Examples 7-9 and 20 except that COS-7 rather than COS-1 cells were used.

Figure 10 shows co-localization of mRNA for HG20 and GABA_BR1a by *in situ* hybridization histochemistry in rat parietal cortex. Adjacent coronal sections of rat brain showing parietal cortex hybridized with radiolabelled GABA_BR1a (A) and HG20 (B) probes. Rat GABA_BR1a and HG20 probes were labelled using ³⁵S-UTP (A, B, and D), and autoradiograms were developed after 4 weeks. For co-localization studies, the rat GABA_BR1a probe was digoxigenin labelled and developed using anti-digoxigenin HRP, the TSA amplification method and biotinyl tyramide followed by streptavidin-conjugated CY3 (C). (D) shows autoradiography of the same field as in (C), denoting hybridization to HG20 mRNA. (E) is an overlay of images (C) and (D). Arrows denote some of the double-labelled cells. Scale bar = 0.5 mm in (A) and (B); scale bar = 50 μ m in (C-E).

Figure 11 shows functional complementation following co-expression of GABA_BR1a and HG20 in *Xenopus* melanophores. GABA mediated a dose-dependent aggregation response in melanophores co-expressing murine GABA_BR1a and FLAG-HG20 (■) that could be blocked with 100 nM (▼) and 1 μ M CGP71872 (▲). The response of GABA on mock-transfected cells is shown (●) as well as a control cannabinoid receptor subtype 2 response to HU210 ligand (inset). This experiment is representative of n=4.

Figure 12 shows GABA_B receptor modulation of forskolin-stimulated cAMP synthesis in HEK293 cells. HEK293 cells stably expressing HG20 (hgb2-42) or GABA_BR1a (rgb1a-50) were transiently transfected with GABA_BR1a and HG20 expression plasmids to examine the effect of receptor co-expression on modulation of cAMP synthesis. All transfected cells were tested with 300 μ M baclofen or GABA (with 100 μ M AOAA and 100 μ M nipecotic acid) in the absence of forskolin and 30 μ M baclofen or GABA in the presence of 10 μ M forskolin. Wild-type HEK293 cells were tested with 250 μ M baclofen or 250 μ M GABA in the presence of 10 μ M forskolin. Data are presented as the percent of total cAMP synthesized in the presence of forskolin only. The data presented are from single representative experiments that have been replicated twice. Fsk, forskolin; B, baclofen; G, GABA with AOAA and nipecotic acid. The two right-most set of bar graphs (labeled "B + Fsk" and "G + Fsk") show that in cells expressing both GABA_BR1a and HG20 (rgb1a-50/hgb2 cells (\square)) and hgb2-42/rgb1a cells (\blacksquare)), baclofen and GABA were able to mediate significant reductions in cAMP levels.

Figure 13 shows that co-expression of GABA_BR1a and HG20 permits inwardly rectifying potassium channel (GIRK or Kir) activation in *Xenopus* oocytes. (A) Representative current families of Kir 3.1/3.2. Currents were evoked by 500 msec voltage commands from a holding potential of -10 mV, delivered in 20 mV increments from -140 to 60 mV. (B) In a protocol designed to measure the effects of various receptors on Kir currents, oocytes were held at -80 mV (a potential where significant inward current is measured). Expression of GABA_BR1a or HG20 alone (with or without G α 1) resulted in no modulation of current after GABA treatment. Co-expression of GABA_BR1a and FLAG-HG20 receptors followed by treatment with 100 μ M GABA resulted in stimulation of Kir 3.1/3.2. Shown are representative traces from at least three independent experiments under each condition.

Figure 14 shows immunoblotting of murine GABA_BR1a and FLAG-HG20 transiently expressed in COS-7 cells. Digitonin-solubilized and anti-FLAG antibody immunoprecipitated membrane proteins were immunoblotted following SDS-PAGE with GABA_BR1a antibodies 1713.1-

1713.2. The conditions are as follows: mock pcDNA3.1 vector transfected cells (lane 1), FLAG-HG20 expressing cells (lane 2), murine GABABR1a expressing cells (lane 3), and cells coexpressing murine GABABR1a and FLAG-HG20 (lane 4). The immunoreactive band corresponding to the GABABR1a /HG20 heterodimer as well as a band corresponding to the predicted GABABR1a monomer are denoted by arrows.

Figure 15 shows the complete cDNA sequence of murine GABABR1a (SEQ.ID.NO.:19). The sequence shown has been deposited in GenBank (accession number AF114168).

Figure 16 shows the complete amino acid sequence of murine GABABR1a (SEQ.ID.NO.:20). The sequence shown has been deposited in GenBank (accession number AF114168).

Figure 17A-B shows the results of experiments with N- and C-terminal fragments of murine GABABR1a. Figure 17A shows the results of coupled *in vitro* transcription/translation reactions; lane 1 = blank; lane 2 = full-length GABABR1a; lane 3 = N-terminal fragment of GABABR1a; lane 4 = C-terminal fragment of GABABR1a. Figure 17B shows the results of [¹²⁵I]CGP71872 photoaffinity labeling; lane 1 = N-terminal fragment of GABABR1a; lane 2 = N-terminal fragment of GABABR1a in the presence of GABA; lane 3 = C-terminal fragment of GABABR1a; lane 4 = C-terminal fragment of GABABR1a in the presence of GABA.

Figure 18A-B shows the amino acid sequence (Figure 18A) (SEQ.ID.NO.:21) and nucleotide sequence (Figure 18B) (SEQ.ID.NO.:22) (GenBank accession number AJ012185) of a human GABABR1a.

Figure 19A-B shows the nucleotide sequence (SEQ.ID.NO.:23) (GenBank accession number Y11044) of a human GABABR1a.

Figure 20 shows a framework map of chromosome 9. The locations of the HG20 gene (referred to as "GPR 51"), markers, and the HSN-1 locus are indicated.

Figure 21 shows a hydropathy plot for murine GABABR1a.

Figure 22 shows a family tree of genes related to HG20. Abbreviations are as follows: hGB1a = human GABABR1a; mGB1a =

mouse GABA_BR1a; rGB1a = rat GABA_BR1a; hGB1b = human
 GABA_BR1b; rGB1b = rat GABA_BR1b; ceGB1b = a *C. elegans* gene related
 to mammalian GABA_BR1a and GABA_BR1b; hGB2 = human HG20;
 ceGB2 = a *C. elegans* gene related to human HG20; MGRDROME = a
 5 metabotropic glutamate receptor from *Drosophila melanogaster*; MGR2
 HUMAN = human metabotropic glutamate receptor 2; MGR3 HUMAN =
 human metabotropic glutamate receptor 3; MGR6 HUMAN = human
 metabotropic glutamate receptor 6; MGR4 HUMAN = human
 metabotropic glutamate receptor 4; MGR7 HUMAN = human
 10 metabotropic glutamate receptor 7; MGR8 HUMAN = human
 metabotropic glutamate receptor 8; MGR1 HUMAN = human
 metabotropic glutamate receptor 1; MGR5 HUMAN = human
 metabotropic glutamate receptor 5.

Figure 23 shows the coiled-coil domains in the C-termini of
 15 human GABA_BR1a and HG20. The upper sequence is from human
 GABA_BR1a and is positions 886-949 of SEQ.ID.NO.:21. The lower
 sequence is from HG20 and is positions 756-829 of SEQ.ID.NO.:2.

Figure 24 shows a comparison of the amino acid sequences of
 human GABA_BR1a (referred to as "Human GABA-B1aR,"
 20 SEQ.ID.NO.:21); the proteins encoded by two genes from *C. elegans* (*C.*
elegans GABA-B1 = SEQ.ID.NO.:42 and *C. elegans* GABA-B2 =
 SEQ.ID.NO.:43); and HG20) (referred to as "Human GABA-B2,"
 (SEQ.ID.NO.:2). The *C. elegans* genes have been predicted from *C. elegans*
 DNA sequence alone. ZK180 accession number: U58748 is predicted to be
 25 GABA-B2 and Y41G9. Contig99 and Y76F7.Contig73 were obtained from
 the Sanger *C. elegans* genomic sequence database and are predicted to be
 GABA-B1.

Figure 25A-D shows co-immunoprecipitation of the murine
 GABA_BR1a and FLAG-HG20 receptor subunits and immunoblotting
 30 using reciprocal receptor subunit antibodies. Murine GABA_BR1a and
 FLAG-HG20 receptors were expressed individually or co-expressed in
 COS-7 cells. Figure 25A shows the results of immunoblotting using an
 anti-murine GABA_BR1a antibody. Immunoblot of the solubilized
 membranes using murine GABA_BR1a antibodies 1713.1-1713.2 shows

selective expression of murine GABA_BR1a in murine GABA_BR1a alone expressing cells (lane 3) and murine GABA_BR1a /FLAG-HG20 co-expressing cells (lane 4), but not in mock transfected and FLAG-HG20 alone expressing cells (lanes 1 and 2). Staining of GABA_BR1a subunits in

5 co-expressing cells is more intense compared to cells expressing the GABA_BR1a subunit alone, suggesting that HG20 subunits facilitate GABA_BR1a expression. Figure 25B shows the results of immunoblotting using an anti-FLAG-HG20 antibody. Immunoblotting of the solubilized

10 membranes using the anti-FLAG-HG20 antibody shows selective expression of FLAG-HG20 subunits in FLAG-HG20 alone expressing cells (lane 6) and murine GABA_BR1a /FLAG-HG20 co-expressing cells (lane 8), but not in mock transfected and murine GABA_BR1a alone expressing cells (lanes 5 and 7). Staining of HG20 subunits in co-expressing cells is more

15 intense compared to cells expressing the HG20 subunit alone, suggesting that GABA_BR1a subunits facilitate HG20 expression. Figure 25C shows the results of immunoprecipitation with an anti-FLAG-HG20 antibody followed by immunoblotting with an anti-murine GABA_BR1a antibody. GABA_BR1a /HG20 heterodimers are observed only in murine GABA_BR1a /FLAG-HG20 co-expressing cells due to the fact that the GABA_BR1a

20 subunit was co-immunoprecipitated with the FLAG-HG20 subunit using the FLAG antibody and detected with GABA_BR1a antibodies (lane 12). GABA_BR1a subunits are not detected in mock-transfected cells and cells expressing GABA_BR1a alone or FLAG-HG20 (lanes 9-11). Figure 25D

25 shows the results of immunoprecipitation with an anti-murine GABA_BR1a antibody followed by immunoblotting with an anti-FLAG-HG20 antibody. GABA_BR1a /HG20 heterodimers are observed only in murine GABA_BR1a /FLAG-HG20 co-expressing cells due to the fact that the FLAG-HG20 subunit was co-immunoprecipitated using the

30 GABA_BR1a antibodies and detected with FLAG antibody (lane 16). No FLAG-HG20 subunits are detected in mock-transfected cells or cells expressing murine GABA_BR1a alone or FLAG-HG20 (lanes 13-15). The immunoblots shown are from 1-3 independent experiments.

Figure 26A-B shows some of the motifs in the N-termini of GABA_B receptor subunits and related genes. Figure 26A shows an

alignment of murine GABA_BR1a (mGABA_B1a; a portion of SEQ.ID.NO.:20), human GABA_BR1a (hGABA_B1a; a portion of SEQ.ID.NO.:21), HG20 (hGABA_B2; a portion of SEQ.ID.NO.:2), metabotropic glutamate receptor 1 (mGluR1; SEQ.ID.NO.:44), and two *E. coli* proteins (LivK (SEQ.ID.NO.:45) and LivBP (SEQ.ID.NO.:46)).
5 Figure 26B is a schematic drawing showing the location of the various motifs in murine GABA_BR1a that are expected to be involved in heterodimer formation of GABA_BR1a with HG20.

Figure 27 shows an expanded view of the coiled-coil region of
10 homology between HG20 (hGABA_B2; shown is a portion of SEQ.ID.NO.:2) and murine GABA_BR1a (mGABA_B1a; a portion of SEQ.ID.NO.:20). Also shown is the corresponding region of human GABA_BR1a (hGABA_B1a; a portion of SEQ.ID.NO.:21).

15 DETAILED DESCRIPTION OF THE INVENTION

For the purposes of this invention:

"Substantially free from other proteins" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other proteins. Thus, for example, an HG20 protein preparation
20 that is substantially free from other proteins will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-HG20 proteins. Whether a given HG20 protein preparation is substantially free from other proteins can be determined by such
25 conventional techniques of assessing protein purity as, *e.g.*, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with appropriate detection methods, *e.g.*, silver staining or immunoblotting.

"Substantially free from other nucleic acids" means at least
30 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other nucleic acids. Thus, for example, an HG20 DNA preparation that is substantially free from other nucleic acids will contain, as a percent of its total nucleic acid, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more

preferably no more than 0.1%, of non-HG20 nucleic acids. Whether a given HG20 DNA preparation is substantially free from other nucleic acids can be determined by such conventional techniques of assessing nucleic acid purity as, *e.g.*, agarose gel electrophoresis combined with appropriate staining methods, *e.g.*, ethidium bromide staining, or by sequencing.

An HG20 polypeptide has "substantially the same biological activity" as native HG20 (*i.e.*, SEQ.ID.NO.:2) if that polypeptide has a K_d for a ligand that is no more than 5-fold greater than the K_d of native HG20 for the same ligand. An HG20 polypeptide also has "substantially the same biological activity" as HG20 if that polypeptide can form heterodimers with either a GABA β R1a or GABA β R1b polypeptide, thus forming a functional GABA β receptor.

"Functional GABA β receptor" refers to a heterodimer of HG20 and either GABA β R1a or GABA β R1b where the heterodimer displays a functional response when exposed to GABA agonists. Examples of functional responses are: pigment aggregation in *Xenopus* melanophores, modulation of cAMP levels, coupling to inwardly rectifying potassium channels, mediation of late inhibitory postsynaptic potentials in neurons, increase in potassium conductance, and decrease in calcium conductance. One skilled in the art would be familiar with a variety of methods of measuring the functional responses of G-protein coupled receptors such as the GABA β receptor (see, *e.g.*, Lerner, 1994, Trends Neurosci. 17:142-146 [changes in pigment distribution in melanophore cells]; Yokomizo et al., 1997, Nature 387:620-624 [changes in cAMP or calcium concentration; chemotaxis]; Howard et al., 1996, Science 273:974-977 [changes in membrane currents in *Xenopus* oocytes]; McKee et al., 1997, Mol. Endocrinol. 11:415-423 [changes in calcium concentration measured using the aequorin assay]; Offermanns & Simon, 1995, J. Biol. Chem. 270:15175, 15180 [changes in inositol phosphate levels]). Depending upon the cells in which heterodimers of HG20 and either GABA β R1a or GABA β R1b are expressed, and thus the G-proteins with which the heterodimers are coupled, certain of such methods may be appropriate for measuring the functional responses of such heterodimers.

It is well with the competence of one skilled in the art to select the appropriate method of measuring functional responses for a given experimental system.

5 A GABA_BR1a or GABA_BR1b polypeptide has "substantially the same biological activity" as a native GABA_BR1a or GABA_BR1b polypeptide if that polypeptide has a K_d for an amino acid, amino acid analogue, GABA_B receptor agonist, or GABA_B receptor antagonist such as CGP71872, GABA, saclofen, (-)-baclofen, or (L)-glutamic acid that is no more than 5-fold greater than the K_d of a native GABA_BR1a or
10 GABA_BR1b polypeptide for the same amino acid, amino acid analogue, GABA_B receptor agonist, or GABA_B receptor antagonist. A GABA_BR1a or GABA_BR1b polypeptide also has "substantially the same biological activity" as a native GABA_BR1a or GABA_BR1b polypeptide if that polypeptide can form heterodimers with an HG20 polypeptide, thus
15 forming a functional GABA_B receptor. Native GABA_BR1a or GABA_BR1b polypeptides include the murine GABA_BR1a sequence shown as SEQ.ID.NO.:20; the rat GABA_BR1a or GABA_BR1b polypeptides disclosed in Kaupmann et al., 1997, Nature 386:239-246; the human GABA_BR1a sequence disclosed in GenBank accession number AJ012185
20 (SEQ.ID.NO.:21); and the protein encoded by the DNA sequence disclosed in GenBank accession number Y11044 (SEQ.ID.NO.:23).

A "conservative amino acid substitution" refers to the replacement of one amino acid residue by another, chemically similar, amino acid residue. Examples of such conservative substitutions are:
25 substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (e.g., arginine for lysine; glutamic acid for aspartic acid).

The present invention relates to the identification and
30 cloning of HG20, a novel G-protein coupled receptor-like protein that represents a subunit for the GABA_B receptor. The present invention provides DNA encoding HG20 that is substantially free from other nucleic acids. The present invention also provides recombinant DNA molecules encoding HG20 as well as isolated DNA molecules encoding HG20.

Following the cloning of HG20 by the present inventors, a sequence highly similar to the sequence of HG20 was deposited in GenBank by Clark et al. (GenBank accession number AF056085), by White et al. (GenBank accession number AJ012188), and by Borowsky et al. (GenBank accession number AF074483). Two ESTs (GenBank accession number T07621, deposited June 30, 1993, and GenBank accession number Z43654, deposited September 21, 1995) each contain partial sequences of HG20 cDNA.

The present invention provides a DNA molecule substantially free from other nucleic acids comprising the nucleotide sequence shown in Figure 1 as SEQ.ID.NO.:1. Analysis of SEQ.ID.NO.:1 revealed that it contains a long open reading frame at positions 293-3,115. Thus, the present invention also provides a DNA molecule substantially free from other nucleic acids comprising the nucleotide sequence of positions 293-3,115 of SEQ.ID.NO.:1. The present invention also provides an isolated DNA molecule comprising the nucleotide sequence of positions 293-3,115 of SEQ.ID.NO.:1.

Sequence analysis of the open reading frame of the HG20 DNA revealed that it encodes a protein of 941 amino acids with a calculated molecular weight of 104 kd and a predicted signal peptide. The predicted amino acid sequence of HG20 is 36% identical to the metabotropic GABA receptor-like sequence GABABR1a described in Kaupmann (see above) throughout the entire sequence, and thus HG20 most likely represents a novel metabotropic GABA receptor or receptor subunit. *In situ* hybridization showed that HG20 RNA is highly expressed in the cortex, thalamus, hippocampus, and cerebellum of the brain, showing overlapping distribution with GABABR1a RNA as judged by *in situ* hybridization as well as with the expression of GABAB receptors as judged by pharmacological studies. HG20 RNA exhibits restricted distribution in the periphery, with low abundance of the 6.5 kb RNA in the heart, spleen, and pancreas and high levels in the adrenal gland. HG20 recombinantly expressed in COS-1 cells showed no specific binding for [³H](+)-baclofen, and when expressed in *Xenopus* oocyte and *Xenopus* melanophore functional assays, showed no activity to GABA,

(-)-baclofen, and glutamic acid.

The novel DNA sequences of the present invention encoding HG20, in whole or in part, can be linked with other DNA sequences, *i.e.*, DNA sequences to which HG20 is not naturally linked, to form
5 "recombinant DNA molecules" containing HG20. Such other sequences can include DNA sequences that control transcription or translation such as, *e.g.*, translation initiation sequences, promoters for RNA polymerase II, transcription or translation termination sequences, enhancer
10 sequences, sequences that control replication in microorganisms, or that confer antibiotic resistance. The novel DNA sequences of the present invention can be inserted into vectors such as plasmids, cosmids, viral vectors, or yeast artificial chromosomes.

The present invention also includes isolated forms of DNA encoding HG20. By "isolated DNA encoding HG20" is meant DNA
15 encoding HG20 that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that DNA encoding HG20 is not present in its normal cellular environment. Thus, an isolated DNA encoding HG20 may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally.
20 The term isolated does not imply that isolated DNA encoding HG20 is the only DNA present, but instead means that isolated DNA encoding HG20 is at least 95% free of non-nucleic acid material (*e.g.*, proteins, lipids, carbohydrates) naturally associated with the DNA encoding HG20. Thus, DNA encoding HG20 that is expressed in bacteria or even in eukaryotic
25 cells which do not naturally (*i.e.*, without human intervention) contain it through recombinant means is "isolated DNA encoding HG20."

Included in the present invention are DNA sequences that hybridize to SEQ.ID.NO.:1 under stringent conditions. By way of
example, and not limitation, a procedure using conditions of high
30 stringency is as follows: Prehybridization of filters containing DNA is carried out for 2 hr. to overnight at 65°C in buffer composed of 6X SSC, 5X Denhardt's solution, and 100 µg/ml denatured salmon sperm DNA. Filters are hybridized for 12 to 48 hrs at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm

of ^{32}P -labeled probe. Washing of filters is done at 37°C for 1 hr in a solution containing 2X SSC, 0.1% SDS. This is followed by a wash in 0.1X SSC, 0.1% SDS at 50°C for 45 min. before autoradiography.

Other procedures using conditions of high stringency would
5 include either a hybridization carried out in 5XSSC, 5X Denhardt's solution, 50% formamide at 42°C for 12 to 48 hours or a washing step carried out in 0.2X SSPE, 0.2% SDS at 65°C for 30 to 60 minutes.

Reagents mentioned in the foregoing procedures for carrying
out high stringency hybridization are well known in the art. Details of
10 the composition of these reagents can be found in, e.g., Sambrook, Fritsch, and Maniatis, 1989, Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory Press. In addition to the foregoing, other conditions of high stringency which may be used are well known in the art.

15 Another aspect of the present invention includes host cells that have been engineered to contain and/or express DNA sequences encoding HG20. Such recombinant host cells can be cultured under suitable conditions to produce HG20. An expression vector containing DNA encoding HG20 can be used for expression of HG20 in a recombinant
20 host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Cell lines
25 derived from mammalian species which are suitable for recombinant expression of HG20 and which are commercially available, include but are not limited to, L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC
30 CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, and *Xenopus* oocytes. In particular embodiments, the recombinant cells expressing HG20 protein co-express a GABABR1a or GABABR1b protein, thus forming a functional GABAB

receptor comprising a heterodimer of HG20 and either GABA β R1a or GABA β R1b. In particular embodiments, the recombinant cells have been transfected with expression vectors that direct the expression of HG20 and GABA β R1a or GABA β R1b.

5 Cells that are particularly suitable for expression of the HG20 protein are melanophore pigment cells from *Xenopus laevis*. Such melanophore pigment cells can be used for functional assays that employ recombinant expression of HG20 in a manner similar to the use of such melanophore pigment cells for the functional assay of other recombinant
10 GPCRs (Graminski et al., 1993, J. Biol. Chem. 268:5957-5964; Lerner, 1994, Trends Neurosci. 17:142-146; Potenza & Lerner, 1992, Pigment Cell Res. 5:372-378; Potenza et al., 1992, Anal. Biochem. 206:315-322). Especially preferred are *Xenopus* melanophore pigment cells co-expressing HG20 and GABA β R1a or GABA β R1b, in which HG20 has formed a
15 heterodimer with GABA β R1a or GABA β R1b, thus forming a functional GABA β receptor. The presence of functional GABA β receptors in such cells can be determined by the use of assays such as the pigment aggregation assay described herein. Other assays that reflect a decrease in cAMP levels mediated by exposure to GABA or other agonists of
20 GABA β receptors would also be suitable.

 Also preferred are stably or transiently transfected HEK293 cells co-expressing HG20 and GABA β R1a or GABA β R1b, in which HG20 has formed a heterodimer with GABA β R1a or GABA β R1b, thus forming a functional GABA β receptor. The presence of functional GABA β receptors
25 in such cells can be determined by the use of assays such as those that measure cAMP levels as described herein.

 Also preferred are *Xenopus* oocytes co-expressing HG20 and GABA β R1a or GABA β R1b, in which HG20 has formed a heterodimer with GABA β R1a or GABA β R1b, thus forming a functional GABA β
30 receptor. The presence of functional GABA β receptors in such cells can be determined by the use of assays that measure coupling of functional GABA β receptors comprising heterodimers of HG20 and GABA β R1a or GABA β R1b to inwardly rectifying potassium channels (especially the Kir3 family).

In order to produce the above-described cells co-expressing HG20 and GABA_BR1a or GABA_BR1b, expression vectors comprising DNA encoding HG20 and GABA_BR1a or GABA_BR1b can be transfected into the cells. HG20 and GABA_BR1a or GABA_BR1b can be transfected
5 separately, each on its own expression vector, or, alternatively, a single expression vector encoding both HG20 and GABA_BR1a or GABA_BR1b can be used.

A variety of mammalian expression vectors can be used to express recombinant HG20, GABA_BR1a, or GABA_BR1b in mammalian
10 cells. Commercially available mammalian expression vectors which are suitable include, but are not limited to, pMC1neo (Stratagene), pSG5 (Stratagene), pcDNA1 and pcDNA1amp, pcDNA3, pcDNA3.1, pCR3.1 (Invitrogen), EBO-pSV2-neo (ATCC 37593), pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199),
15 pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), and the PT7TS oocyte expression vector (or similar expression vectors containing the globin 5' UTR and the globin 3' UTR). The choice of vector will depend upon cell type used, level of expression desired, and the like. Following expression in recombinant cells, HG20, GABA_BR1a, GABA_BR1b, or heterodimers of
20 HG20 and either GABA_BR1a or GABA_BR1b can be purified to a level that is substantially free from other proteins by conventional techniques, e.g., salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography, hydrophobic interaction chromatography, and preparative gel
25 electrophoresis. Also, membrane preparations comprising HG20, GABA_BR1a, GABA_BR1b, or heterodimers of HG20 and either GABA_BR1a or GABA_BR1b can be prepared. Especially preferred are membrane preparations that comprise heterodimers of HG20 and either GABA_BR1a or GABA_BR1b in which the heterodimers represent functional GABA_B
30 receptors.

The present invention includes a method of producing HG20 protein comprising:

(a) transfecting a host cell with an expression vector comprising DNA that encodes an HG20 protein;

(b) growing the host cells under conditions such that HG20 protein is produced; and

(c) recovering HG20 protein from the host cells.

In particular embodiments, the method of recovering HG20 protein involves obtaining membrane preparations that contain HG20 protein from the host cells. In particular embodiments, such membrane preparations contain heterodimers of HG20 protein and GABABR1a or GABABR1b protein that form functional GABAB receptors.

The present invention includes a method of expressing a truncated HG20 protein comprising:

(a) transfecting a host cell with an expression vector comprising DNA that encodes an HG20 protein that has been truncated at the amino or carboxyl terminus;

(b) culturing the transfected cells of step (a) under conditions such that the truncated HG20 protein is expressed.

Truncated HG20 proteins are those HG20 proteins in which contiguous portions of the N terminus or C terminus have been removed. For example, positions 52-941 of SEQ.ID.NO.:2 represents a truncated HG20 protein. Truncated HG20 proteins may be fused in frame to non-HG20 amino acid sequences, as, *e.g.*, in the FLAG-HG20 construct described herein.

The present invention includes a method of producing functional GABAB receptors in cells comprising:

(a) transfecting cells with:

(1) an expression vector that directs the expression of HG20 in the cells; and

(2) an expression vector that directs the expression of GABABR1a or GABABR1b in the cells;

(b) culturing the cells under conditions such that heterodimers of HG20 and GABABR1a or GABABR1b are formed where the heterodimers constitute functional GABAB receptors.

In particular embodiments of the above methods, the cells are eukaryotic cells. In other embodiments, the cells are mammalian cells. In still other embodiments, the cells are COS cells, *e.g.*, COS-7 cells

(ATCC CRL 1651) or COS-1 cells (ATCC CRL 1650); HEK293 cells (ATCC CRL 1573); or *Xenopus* melanophores.

In particular embodiments, the HG20 protein comprises the amino acid sequence shown in SEQ.ID.NO.:2. In particular embodiments, the HG20 protein is a truncated HG20 protein. In particular
5 embodiments, the truncated HG20 protein comprises amino acids 52-941 of SEQ.ID.NO.:2. In particular embodiments, the truncated HG20 protein is a chimeric HG20 protein.

The present invention includes HG20 protein substantially
10 free from other proteins. The amino acid sequence of the full-length HG20 protein is shown in Figure 2 as SEQ.ID.NO.:2. Thus, the present invention includes polypeptides comprising HG20 protein substantially free from other proteins where the polypeptides comprise the amino acid sequence SEQ.ID.NO.:2. The present invention also includes polypeptides
15 comprising HG20 proteins lacking a signal sequence. Examples of amino acid sequences of HG20 proteins lacking a signal sequence are:

Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
20 Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
25 Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

The present invention also includes DNA encoding the above-described HG20 proteins lacking a signal sequence. Thus, *e.g.*, the present invention includes a DNA molecule comprising a nucleotide
30 sequence selected from the group consisting of:

Positions 293-3,115 of SEQ.ID.NO.:1;
Positions 317-3,115 of SEQ.ID.NO.:1;
Positions 395-3,115 of SEQ.ID.NO.:1;
Positions 398-3,115 of SEQ.ID.NO.:1;

Positions 404-3,115 of SEQ.ID.NO.:1;
Positions 407-3,115 of SEQ.ID.NO.:1;
Positions 416-3,115 of SEQ.ID.NO.:1;
Positions 422-3,115 of SEQ.ID.NO.:1;
5 Positions 428-3,115 of SEQ.ID.NO.:1;
Positions 446-3,115 of SEQ.ID.NO.:1; and
Positions 461-3,115 of SEQ.ID.NO.:1.

As with many receptor proteins, it is possible to modify many
of the amino acids of HG20, particularly those which are not found in the
10 ligand binding domain, and still retain substantially the same biological
activity as the original protein. Thus this invention includes modified
HG20 polypeptides which have amino acid deletions, additions, or
substitutions but that still retain substantially the same biological
activity as native HG20. It is generally accepted that single amino acid
15 substitutions do not usually alter the biological activity of a protein (see,
e.g., Molecular Biology of the Gene, Watson et al., 1987, Fourth Ed., The
Benjamin/Cummings Publishing Co., Inc., page 226; and Cunningham &
Wells, 1989, Science 244:1081-1085). Accordingly, the present invention
includes polypeptides where one amino acid substitution has been made
20 in SEQ.ID.NO.:2 or in one of the HG20 polypeptides lacking a signal
sequence listed above, wherein the polypeptides still retain substantially
the same biological activity as native HG20. The present invention also
includes polypeptides where two or more amino acid substitutions have
been made in SEQ.ID.NO.:2 or in one of the HG20 polypeptides lacking a
25 signal sequence listed above, wherein the polypeptides still retain
substantially the same biological activity as native HG20. In particular,
the present invention includes embodiments where the above-described
substitutions are conservative substitutions. In particular, the present
invention includes embodiments where the above-described substitutions
30 do not occur in the ligand-binding domain of HG20. In particular, the
present invention includes embodiments where amino acid changes have
been made in the positions of HG20 where the amino acid sequence of
HG20 differs from the amino acid sequence of GABA_BBR1b (see Figure 8).

The present invention also includes C-terminal truncated forms of HG20, particularly those which encompass the extracellular portion of the receptor, but lack the intracellular signaling portion of the receptor. Such truncated receptors are useful in various binding assays
5 described herein, for crystallization studies, and for structure-activity-relationship studies. Accordingly, the present invention includes an HG20 protein substantially free from other proteins having the amino acid sequence of positions 1-480 of SEQ.ID.NO.:2.

O'Hara et al., 1993, Neuron 11:41-52 (O'Hara) reported that
10 the amino terminal domains of several metabotropic glutamate receptors showed amino acid sequence similarities to the amino termini of several bacterial periplasmic binding proteins. O'Hara used this similarity to predict, and then experimentally confirm, that these amino terminal domains correspond to the location of the ligand binding domains of these
15 metabotropic glutamate receptors.

The present inventors have discovered a region of amino acid sequence in the N-terminal domain of HG20 that is similar to the amino acid sequence of the bacterial periplasmic binding protein Leucine, Isoleucine, Valine (Alanine and Threonine) Binding Protein (LIVAT-BP)
20 of *Pseudomonas aeruginosa*. See Figure 6. The region shown is about 25% identical between the two proteins. This is above the maximum identity of 17% reported by O'Hara between any one metabotropic glutamate receptor and any one periplasmic binding protein and indicates that the region of HG20 depicted is highly likely to contain the ligand
25 binding domain.

Accordingly, the present invention includes a polypeptide representing the ligand binding domain of HG20 that includes amino acids 63-259 of SEQ.ID.NO.:2. Also provided are chimeric proteins comprising amino acids 63-259 of SEQ.ID.NO.:2.

30 Romano et al., 1996, J. Biol. Chem. 271:28612-28616 demonstrated that metabotropic glutamate receptors are often found as homodimers formed by an intermolecular disulfide bond. The location of the cysteines responsible for the disulfide bond was found to be in the amino terminal 17kD of the receptors. Transmembrane interactions may

also contribute to functional GABA_B receptor dimer formation, as previously reported for the dopamine D2 receptor and β 2-adrenergic receptor (Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204; Hebert et al., 1996, J. Biol. Chem. 271, 16384-16392). Accordingly, the present invention includes dimers of HG20 proteins. In particular
5 embodiments, the HG20 protein has an amino acid selected from the group consisting of:

SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
10 Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
15 Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2;
Positions 57-941 of SEQ.ID.NO.:2; and
Positions 1-480 of SEQ.ID.NO.:2.

20 It has been found that, in some cases, membrane spanning regions of receptor proteins can be used to inhibit receptor function (Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204; Hebert et al., 1996, J. Biol. Chem. 271, 16384-16392; Lofts et al., Oncogene 8:2813-2820). Accordingly, the present invention provides peptides derived from the
25 seven membrane spanning regions of HG20 and their use to inhibit HG20 or GABA_B receptor function. Such peptides can include the whole or parts of the membrane spanning domains.

30 The present invention also includes isolated forms of HG20 proteins. By "isolated HG20 protein" is meant HG20 protein that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that HG20 protein is not present in its normal cellular environment. Thus, an isolated HG20 protein may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that an

isolated HG20 protein is the only protein present. but instead means that an isolated HG20 protein is at least 95% free of non-amino acid material (e.g., nucleic acids, lipids, carbohydrates) naturally associated with the HG20 protein. Thus, an HG20 protein that is expressed through
5 recombinant means in bacteria or even in eukaryotic cells which do not naturally (i.e., without human intervention) express it is an "isolated HG20 protein."

The present invention also includes chimeric HG20 proteins. By chimeric HG20 protein is meant a contiguous polypeptide sequence of
10 HG20 fused in frame to a polypeptide sequence of a non-HG20 protein. For example, the N-terminal domain and seven transmembrane spanning domains of HG20 fused at the C-terminus in frame to a G protein would be a chimeric HG20 protein. Another example of a chimeric HG20 protein would be a polypeptide comprising the FLAG epitope fused in frame at the
15 amino terminus of amino acids 52-941 of SEQ.ID.NO.:2.

The present invention also includes HG20 proteins that are in the form of multimeric structures, e.g., dimers. Such multimers of other metabotropic G-protein coupled receptors are known (Hebert et al., 1996, J. Biol. Chem. 271, 16384-16392; Ng et al., 1996, Biochem. Biophys.
20 Res. Comm. 227, 200-204; Romano et al., 1996, J. Biol. Chem. 271, 28612-28616).

Preferred forms of dimers of HG20 are heterodimers comprising HG20 and other G-protein coupled receptors (GPCRs). Such GPCRs could be, e.g., other subunits of GABA_B receptors, proteins from *C. elegans* showing homology to HG20 (see Figure 24), or human GPCRs that
25 are homologs of the *C. elegans* proteins. Particularly preferred forms of heterodimers are heterodimers of HG20 and either GABA_BR1a or GABA_BR1b. It has been found by the present inventors that such heterodimers exhibit functional properties of GABA_B receptors while
30 monomers or homodimers of HG20, GABA_BR1a, or GABA_BR1b do not exhibit functional properties. Another likely heterodimer partner for HG20 is the protein corresponding to the sequence deposited in GenBank at accession number 3776096.

The strongest evidence that functional GABA_B receptors require both HG20 and GABA_BR1a or GABA_BR1b comes from studies demonstrating that co-transfection and co-expression of both HG20 and either GABA_BR1a or GABA_BR1b is necessary in order for the detection of
5 GABA_B receptor functional responses. Transfection and expression of HG20, GABA_BR1a, or GABA_BR1b alone does not lead to the production of functional GABA_B receptors.

For example, in *Xenopus* melanophores co-expressing HG20 and GABA_BR1a, but not in melanophores expressing HG20 or
10 GABA_BR1a alone, or in mock transfected melanophores, GABA mediated a dose-dependent pigment aggregation response that could be inhibited with the GABA_B receptor specific CGP71872 antagonist. This pigment aggregation response is associated with a decrease in intracellular cAMP levels. Such a decrease has been confirmed in HEK293 cells. Also, co-
15 expression of HG20 and GABA_BR1a in *Xenopus* oocytes resulted in the stimulation of inwardly rectifying potassium currents (Kirs). Native functional GABA_B receptors have been reported to couple to Kirs (Misgeld et al., 1995, Prog. Neurobiol. 46:423-462).

Consistent with the need for both HG20 and GABA_BR1a for
20 detection of functional GABA_B receptors in transfected cells, the present inventors have demonstrated that HG20 and GABA_BR1a form heterodimers by immunoprecipitation of HG20 followed by immunoblotting with a GABA_BR1a antibody.

That a functional GABA_B receptor requires both HG20 and
25 either GABA_BR1a or GABA_BR1b is also suggested by the observation that GABA_BR1a or GABA_BR1b, recombinantly expressed in the absence of HG20, binds ligand with much reduced affinity compared to the affinity of native GABA_B receptors. Also, characterization of the tissue distribution of each of the receptors by *in situ* hybridization
30 histochemistry in rat brain revealed co-localization of HG20 and GABA_BR1a transcripts in many brain regions, including cortex, at both the regional and cellular levels.

The *Xenopus* melanophore pigment aggregation/dispersion assay has been shown to be highly suitable for monitoring agonist

activation of Gi-, Gq-, and Gs-coupled receptors (Potenza et al., 1992, Anal. Biochem. 206:315-322; Lerner, 1994, Trends Neurosci. 17:142-146). Agonist activation of Gi-coupled receptors expressed in melanophores results in pigment aggregation via a reduction in intracellular cAMP levels, whereas
5 activation of Gs- and Gq-coupled receptors results in pigment dispersion via elevations in intracellular cAMP and calcium levels, respectively. Melanophores transfected separately with either GABA_BR1a or HG20 showed no pigment aggregation or dispersion response following treatment with up to 1 mM concentrations of (L)-glutamic acid, GABA, or
10 prototypic GABAergic agonists: (-)baclofen, 3-aminopropyl-(methyl)phosphonic acid, cis-4-aminocrotonic acid, piperidine-4-sulfonic acid (data not shown). Similarly, both receptors failed to couple to K⁺ channels in *Xenopus* oocytes under patch-clamp conditions when transfected separately (data not shown). However, in melanophores
15 transiently co-transfected with GABA_BR1a and HG20, GABA mediated a dose-dependent aggregation response with an IC₅₀ value of 3-7 μ M (n=3). This aggregation was absent in mock-transfected cells and in cells transfected with GABA_BR1a or HG20 alone (Figure 11). The GABA-mediated activity represented 42-56% (n=3) of a control cannabinoid
20 receptor subtype 2 response (Figure 11, inset), and could be inhibited by the CGP71872 antagonist (n=3), indicating it was GABA_B receptor specific (Figure 11). GABA_BR1a was expressed by subcloning full-length GABA_BR1a into the NheI-NotI site of pcDNA3.1 or pCIneo; HG20 was expressed as a FLAG-HG20 chimeric protein. See Examples 11 and 20 for
25 further experimental details of expression vectors used, transfection conditions, assay conditions, etc. for the above-described co-expression studies.

The functional data arising from co-expression of GABA_BR1a and HG20 receptors were confirmed in HEK293 cells. HEK293 cells
30 transfected with and stably expressing GABA_BR1a and HG20 were selected based on expression of receptor message as determined by dot blot analyses. In cell lines stably expressing the individual receptors, we observed small and inconsistent responses in assays to examine agonist-mediated modulation of cAMP synthesis. However, transient transfection

of HEK293 cells stably expressing GABA_BR1a (rgb1a-50) with an HG20 expression plasmid and transient transfection of HEK293 cells stably expressing HG20 (hgb2-42) with a GABA_BR1a expression plasmid significantly enhanced the ability of baclofen and GABA to inhibit forskolin-stimulated cAMP synthesis. Rgb1a-50 cells transfected with HG20 exhibited a 28% reduction in forskolin-stimulated cAMP synthesis with 30 μ M baclofen and a 40% decrease with 30 μ M GABA plus 100 μ M aminooxyacetic acid (AOAA; a GABA transaminase inhibitor) and 100 μ M nipecotic acid (a GABA uptake inhibitor) (Figure 12B). A 34% reduction in forskolin-stimulated cAMP synthesis was observed for hgb2-42 cells transfected with GABA_BR1a treated with baclofen and a 43% decrease was observed for GABA plus AOAA and nipecotic acid (Figure 12B). While inhibition of cAMP synthesis was sometimes observed with rgb1a-50 cells transfected with GABA_BR1a and hgb2-42 cells transfected with HG20, these effects were small and inconsistent (0-20% inhibition; Figure 12B). Neither baclofen nor GABA plus AOAA and nipecotic acid in the absence of forskolin had any affect on cAMP synthesis (Figure 12B). In addition, wild-type HEK293 cells did not exhibit baclofen- or GABA-mediated inhibition of forskolin-stimulated cAMP synthesis (Figure 12B). These data demonstrate that the functional GABA_B receptor requires both GABA_BR1a and HG20. For experimental details of these studies in HEK293 cells, see Example 12.

Co-expression of the GABA_BR1a and HG20 with the inwardly rectifying potassium channels Kir 3.1/3.2 in *Xenopus* oocytes resulted in a significant stimulation of inwardly rectifying potassium current (Kir) in response to GABA [301 +/- 20.6 %, (n=3) increase over control current] measured at -80 mV which could subsequently be washed out with control solution (Figure 13). Modulation of Kir 3.1/3.2 was not seen in oocytes expressing GABA_BR1a or HG20 individually, even in the presence of Gi α 1 (Figure 13). See Example 21 for details.

To determine whether receptor intermolecular interactions accounted for the functional activity that was observed following the co-expression of recombinant GABA_BR1a and HG20, membranes from cells co-expressing GABA_BR1a and HG20 or the individual proteins were first

immunoprecipitated using anti-FLAG antibodies (to detect the recombinant FLAG-HG20 chimeric proteins) followed by immunoblotting with a GABABR1a-specific antibody. As seen in Figure 14, lanes 1-3, no GABABR1a immunoreactivity was detected in samples prepared from

5 mock vector transfected cells, FLAG-HG20 alone expressing cells, and GABABR1a alone expressing cells immunoprecipitated with the FLAG-antibody. Since immunoreactive species were detected only in cells co-expressing HG20 and GABABR1a, this experiment demonstrates that HG20 and GABABR1a can only be co-immunoprecipitated as part of a

10 complex (Figure 14, lane 4). Based on the predicted molecular mass of a heterodimer of HG20 and GABABR1a, the ~250+ and ~130 kDa species may represent a heterodimer and GABABR1a monomers, respectively. The stability of the HG20/GABABR1a heterodimer in denaturing and

15 reducing conditions suggests that SDS-stable transmembrane interactions form the heterodimer, as reported previously for β 2 adrenergic and dopamine D2 receptors (Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204; Hebert et al., 1996, J. Biol. Chem. 271, 16384-16392). The monomer might result from partial disruption, subsequent to

20 immunoprecipitation, of N-terminal Sushi repeats, C-terminal alpha-helical interacting domains (e.g., coiled-coils) present in HG20 and GABABR1a subunits, transmembrane interactions, or disulfide bonds that contribute to forming the heterodimer.

Particular examples of such regions likely to be involved in forming the heterodimer are shown in Figure 23. Regions such as those

25 shown in Figure 23, as well as polypeptides comprising such regions are expected to be useful for the purpose of modulating the formation of heterodimers involving HG20 and thus controlling GABAB receptor activity. Accordingly, the present invention includes polypeptides comprising the coiled-coil domains of HG20, GABABR1a, and GABABR1b.

30 In particular, the present invention includes polypeptides comprising an amino acid sequence selected from the group consisting of: positions 756-829 of SEQ.ID.NO.:2; positions 779-814 of SEQ.ID.NO.:2; positions 886-949 of SEQ.ID.NO.:21; and positions 889-934 of SEQ.ID.NO.:21; where the polypeptides do not contain other contiguous amino acid sequences

longer than 5 amino acids from a GABA_B receptor subunit. The present invention also includes heterodimers of such polypeptides. In more general terms, the present invention includes comprising a coiled-coil domain from a first GABA_B receptor subunit and no other contiguous amino acid sequences longer than 5 amino acids from the first GABA_B receptor subunit where the coiled-coil domain is present in the C-terminus of the first GABA_B receptor subunit and mediates heterodimerization of the first GABA_B receptor subunit with a second GABA_B receptor subunit.

In addition to the coiled-coil domains discussed above, a variety of regions of HG20 and GABA_BR1a are expected to be important for heterodimer formation. Motif analysis of the N-terminus of murine GABA_BR1a revealed seven consensus N-linked glycosylation sites and three putative short consensus repeats (SCRs) of ~60 amino acids each: amino acids 27-96 and amino acids 102-157 (GABA_BR1a specific), and amino acids 183-245 (common to GABA_BR1b (Kaupmann et al., 1997, Nature 386:239-246) and HG20 (Jones et al., 1998, Nature 396:674-679; White et al., 1998, Nature 396:679-682; Kaupmann et al., 1998, Nature 396:683-687; Kuner et al., 1999, Science 283:74-77) not described previously (Figure 26A-B). Since SCRs are known to play important roles in protein-protein interactions in a wide variety of complement proteins, adhesion proteins, and selectins (Chou and Heinrikson, 1997, J. Protein Chem. 16:765-773; Perkins et al., 1998, Biochemistry 27:4004-4012), of which the latter shows weak amino acid identity to murine GABA_BR1a, these SCRs, together with the coiled-coil domains discussed above in the carboxyl tails of GABA_BR1a and HG20 (Figure 23), are expected to be involved in the heterodimerization of GABA_BR1a and HG20.

Therefore, the present invention includes a polypeptide comprising an SCR domain from a first GABA_B receptor subunit and no other contiguous amino acid sequences longer than 5 amino acids from the first GABA_B receptor subunit where the SCR domain is present in the N-terminus of the first GABA_B receptor subunit and mediates heterodimerization of the first GABA_B receptor subunit with a second GABA_B receptor subunit. In particular embodiments, the SCR is selected from the group consisting of: positions 27-96 of SEQ.ID.NO.:20; positions

102-157 of SEQ.ID.NO.:20; positions 183-245 of SEQ.ID.NO.:20; positions 28-97 of SEQ.ID.NO.:21; positions 103-158 of SEQ.ID.NO.:21; positions 184-246 of SEQ.ID.NO.:21; positions 4-22 of SEQ.ID.NO.:2; positions 23-49 of SEQ.ID.NO.:2; and positions 72-135 of SEQ.ID.NO.:2.

5 As in the metabotropic glutamate receptors (mGLURs), the second intracellular loop of murine GABABR1a is rich in basic amino acids which may play a role in G-protein-interactions (reviewed by Pin and Duvoisin, 1995, Neuropharmacology 34:1-26), and, as in the mGLURs, the carboxyl tail of murine GABABR1a contains a PDZ protein-
10 interacting module (serine-arginine-valine, amino acids 953-955) which has been shown for mGLURs to play an important role in the interactions among the signaling components of synaptic junctions (Brakeman et al.1997, Nature 386:284-288). The murine GABABR1a receptor also
15 contains potential protein kinase C and casein kinase II recognition sites predicted using ProSearch (Kolakowski et al., 1992, Biotechniques 13:919-921).

 The present invention also relates to the identification and cloning of the murine GABABR1a receptor, the murine ortholog of the rat GABABR1a receptor described in Kaupmann et al., 1997, Nature 386:239-
20 246 (Kaupmann). The present invention provides DNA encoding murine GABABR1a that is substantially free from other nucleic acids. The present invention also provides recombinant DNA molecules encoding murine GABABR1a.

 The present invention provides a DNA molecule encoding
25 murine GABABR1a that is substantially free from other nucleic acids and comprises the nucleotide sequence shown in Figure 15 as SEQ.ID.NO.:19. The open reading frame of SEQ.ID.NO.:19, encoding mouse GABABR1a protein, is positions 1-2,880, with positions 2,881-2,883 representing a stop codon. Thus, the present invention also provides a DNA molecule
30 substantially free from other nucleic acids comprising the nucleotide sequence of positions 1-2,880 of SEQ.ID.NO.:19.

 Sequence analysis of the open reading frame of the murine GABABR1a DNA revealed that it encodes a mature protein (*i.e.*, lacking a signal sequence) of 942 amino acids with a predicted molecular weight of

106.5 kDa that is 99% identical to rat GABA_BR1a (described in Kaupmann), with only six amino acid changes overall. Murine GABA_BR1a protein shares 31% overall amino acid identity to HG20.

CGP71872 is a photoaffinity ligand specific for GABA_BR1a receptors ($K_d = 1.0 \pm 0.2$ nM) that can be cross-linked to rat GABA_BR1a (Kaupmann et al., 1997, Nature 386:239-246). In crude membranes prepared from COS-7 cells transiently transfected with murine GABA_BR1a, [¹²⁵I]CGP71872 photolabelled a major band at ~130 kDa representing the mature (presumably glycosylated) protein and an additional band at approximately twice that molecular weight, possibly representing dimers (Figure 9). Ligand-binding species could also be detected with affinity purified GABA_BR1a antibodies 1713.1 (raised against the peptide acetyl-DVNSRRDILPDYELKLC-amide; a portion of SEQ.ID.NO.:20) and 1713.2 (raised against the peptide acetyl-CATLHNPTRVKLF EK-amide; a portion of SEQ.ID.NO.:20) (Figure 9). In contrast, FLAG-tagged HG20 protein did not bind the high-affinity CGP71872 ligand, although expression of the protein was confirmed by immunoblot analysis (Figure 9).

Displacement of [¹²⁵I]CGP71872 binding to recombinant murine GABA_BR1a was in the appropriate rank order of potency for GABAergic ligands: CGP71872 > SKF-97541 (3-aminopropyl(methyl)-phosphinic acid) > GABA > (-)baclofen > saclofen > (L)-glutamic acid.. Interestingly, recombinant rat GABA_BR1a exhibits 10-25 fold lower affinity for agonists than native GABA_B receptors in brain (Kaupmann et al., 1997, Nature 386:239). Although the reason for this discrepancy remains unclear, a recent report indicated that recombinant GABA_BR1a may require additional cellular components for functional targeting to the plasma membrane (Couve et al., 1998, J. Biol. Chem. 273:26361-26367). Thus, GABA_BR1a alone, without such additional components, might be expected to exhibit somewhat altered ligand binding characteristics.

In the binding experiments discussed above using GABA_BR1a alone, surprisingly, dose-dependent displacement was not detected for (+)baclofen, and the affinities of agonists (GABA, SKF-97541, and (-)baclofen) and partial agonists ((+)baclofen, saclofen, (L)-glutamic

acid) but not the affinity of antagonist (CGP71872) for the recombinant GABA_BR1a were markedly lower compared to native receptors in rat brain (Table 1). Agonist affinities of co-expressed HG20 and GABA_BR1a were examined in membranes prepared from cells co-expressing GABA_BR1a and FLAG-tagged HG20. Competition of [¹²⁵I]CGP71872 binding in these membranes showed recovery of high-affinity ligand binding comparable to native receptors in rat brain (Table 1). The simplest explanation for these results is that the high-affinity agonist binding pocket may comprise interactions between the N-terminal domains of HG20 and GABA_BR1a that form the heterodimer.

Table 1

Ligand	rat cortex*	gb1a	gb1a/gb2
CGP71872	0.5 nM	0.52 - 0.67 nM	0.15 - 0.27 nM
GABA	2.5 uM	42.55 - 68.38 uM	1.77 - 2.55 uM
SKF-97541**	not determined	11.09 - 11.47 uM	0.80 - 0.96 uM
(-)Baclofen	0.5 uM	31.46 - 53.70 uM	3.92 - 7.78 uM
(+)Baclofen	not determined	no fit	1.25 - 3.94 mM
Saclofen	156 uM	280.5 - 365.0 uM	119.4 - 131.4 uM
L-Glutamate	not determined	119.4 - 285.0 mM	116.2 - 201.6 mM

* reported by Kaupmann et al., (1997) *Nature* 386, 239-246
 ** 3-aminopropyl(methyl)phosphinic acid

In Table 1, gb1a refers to GABA_BR1a and gb1a/gb2 refers to HG20/ GABA_BR1a heterodimers.

Co-localization studies were performed to determine if mRNAs for GABA_BR1a and HG20 co-exist in the same cells in the brain.

Figure 10A-B shows equivalent levels of GABA_BR1a and HG20 hybridization in adjacent coronal sections of rat parietal cortex, indicating that messages for both receptors are expressed in this brain region. Radiolabelled and fluorescent probes for the two receptors were used to look at the cellular level where it was observed that message for both receptors is expressed in the same cells (Example 13 and Figure 10C-E). In the parietal cortex and all other major brain regions studied, including the hippocampus, thalamus, cerebellum, and vestibular ganglion, GABA_BR1a and HG20 mRNAs are co-localized in the same cells. These results suggest that the functional native GABA_B receptors found in these

cells involve both GABA_BR1a and HG20. Co-immunoprecipitation, functional, and anatomical data described herein converge to strongly support the argument that the native, functional GABA_B receptor is a heterodimer of GABA_BR1a and HG20. This work is particularly exciting
5 because it represents the first example of a heteromeric G protein-coupled receptor.

The novel murine GABA_BR1a DNA sequences of the present, in whole or in part, can be linked with other DNA sequences, *i.e.*, DNA sequences to which GABA_BR1a DNA is not naturally linked, to form
10 "recombinant DNA molecules" encoding murine GABA_BR1a. Such other sequences can include DNA sequences that control transcription or translation such as, *e.g.*, translation initiation sequences, promoters for RNA polymerase II, transcription or translation termination sequences, enhancer sequences, sequences that control replication in microorganisms,
15 or that confer antibiotic resistance. The novel DNA sequences of the present invention can be inserted into vectors such as plasmids, cosmids, viral vectors, or yeast artificial chromosomes.

The present invention also includes isolated forms of DNA encoding GABA_BR1a. By "isolated DNA encoding GABA_BR1a" is meant
20 DNA encoding GABA_BR1a that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that DNA encoding GABA_BR1a is not present in its normal cellular environment. Thus, an isolated DNA encoding GABA_BR1a may be in a cell-free solution or placed in a different cellular environment from that in
25 which it occurs naturally. The term isolated does not imply that isolated DNA encoding GABA_BR1a is the only DNA present, but instead means that isolated DNA encoding GABA_BR1a is at least 95% free of non-nucleic acid material (*e.g.*, proteins, lipids, carbohydrates) naturally associated with the DNA encoding GABA_BR1a. Thus, DNA encoding GABA_BR1a
30 that is expressed in bacteria or even in eukaryotic cells which do not naturally (*i.e.*, without human intervention) contain it through recombinant means is "isolated DNA encoding GABA_BR1a."

Another aspect of the present invention includes host cells that have been engineered to contain and/or express DNA sequences

encoding murine GABA_BR1a. Such recombinant host cells can be cultured under suitable conditions to produce murine GABA_BR1a protein. An expression vector containing DNA encoding the murine GABA_BR1a protein can be used for expression of the murine GABA_BR1a protein in a recombinant host cell. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Cell lines derived from mammalian species which are suitable for recombinant expression of the murine GABA_BR1a protein and which are commercially available, include but are not limited to, L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, and *Xenopus* oocytes.

A variety of mammalian expression vectors can be used to express recombinant murine GABA_BR1a in mammalian cells. Commercially available mammalian expression vectors which are suitable include, but are not limited to, pMC1neo (Stratagene), pSG5 (Stratagene), pcDNA1 and pcDNA1amp, pcDNA3, pcDNA3.1, pCR3.1 (Invitrogen), EBO-pSV2-neo (ATCC 37593), pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), and the PT7TS oocyte expression vector (or similar expression vectors containing the globin 5' UTR and the globin 3' UTR). Following expression in recombinant cells, the murine GABA_BR1a protein can be purified by conventional techniques to a level that is substantially free from other proteins.

Other cells that are particularly suitable for expression of the murine GABA_BR1a protein are immortalized melanophore pigment cells from *Xenopus laevis*. Such melanophore pigment cells can be used for functional assays using recombinant expression of murine GABA_BR1a in

a manner similar to the use of such melanophore pigment cells for the functional assay of other recombinant GPCRs (Graminski et al., 1993, J. Biol. Chem. 268:5957-5964; Lerner, 1994, Trends Neurosci. 17:142-146; Potenza & Lerner, 1992, Pigment Cell Res. 5:372-378; Potenza et al.,
5 1992, Anal. Biochem. 206:315-322).

The present invention includes a method of producing the murine GABA_BR1a protein comprising:

- (a) transfecting a host cell with a expression vector comprising DNA that encodes the murine GABA_BR1a protein;
- 10 (b) growing the host cells under conditions such that the murine GABA_BR1a protein is produced; and
- (c) recovering the murine GABA_BR1a protein from the host cells.

In particular embodiments, the method of recovering the
15 murine GABA_BR1a protein may involve obtaining membrane preparations from the host cells that contain the murine GABA_BR1a protein. Such membrane preparations may contain heterodimers of GABA_BR1a protein and HG20 protein that form functional GABA_B receptors.

20 In particular embodiments, the cells are eukaryotic cells. In other embodiments, the cells are mammalian cells. In still other embodiments, the cells are COS cells, in particular COS-7 cells (ATCC CRL 1651), COS-1 cells (ATCC CRL 1650), HEK293 cells (ATCC CRL 1573), or *Xenopus* melanophores.

25 The present inventors have discovered that, when either HG20 or GABA_BR1a subunits are recombinantly expressed separately, *i.e.*, in different cells, very little or no expression is observed. It is only when HG20 and GABA_BR1a subunits are recombinantly co-expressed, *i.e.*, expressed in the same cells at the same time, that high level
30 expression of HG20 and GABA_BR1a is observed (see Figure 25). Given the close relationship among GABA_BR1a, GABA_BR1b, *C. elegans* genes related to GABA_BR1a and HG20 (see Figure 24), and the close relationship that is expected to be found between other isoforms of GABA_BR1a and GABA_BR1b, it is believed that co-expression of HG20

and either GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b will also result in increased expression of HG20 and GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b as compared to expression of these proteins separately.

Accordingly, the present invention includes a method of co-expressing HG20 and GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b so as to result in an increase in expression of HG20 and GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b as compared to expression when HG20 and GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b are expressed separately. In particular embodiments, the level of expression of HG20, GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b is measured in the co-expressing cells. In particular embodiments, the level of expression of HG20, GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b is measured by immunoblot or by immunoprecipitation/immunoblotting methods.

Thus, the present invention includes a method of increasing expression of HG20 and GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b comprising:

- (a) recombinantly expressing HG20 and GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b in the same cells;
- (b) measuring the expression of HG20, GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b, where a measurement of detectable expression of HG20, GABA β R1a, GABA β R1b, *C. elegans* genes

related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b indicates that increased expression has been achieved.

In particular embodiments, the measurement of expression is carried out by immunoblotting with or without immunoprecipitation.

5 In other embodiments, the method also comprises the steps of recombinantly expressing HG20 and GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b separately, measuring the level of expression of HG20, GABA β R1a, GABA β R1b, *C. elegans* genes related to
10 GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b in the separately expressing cells, and comparing the amount of expression of HG20, GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b in the separately expressing cells to the amount of expression of HG20,
15 GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b in the co-expressing cells.

Accordingly, the present invention includes a a method of increasing expression of HG20 and GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b comprising:

20 (a) recombinantly expressing HG20 and GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b in the same cells to form co-expressing cells;

25 (b) recombinantly expressing HG20 and GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b in different cells to form separately expressing cells;

30 (c) measuring the expression of HG20, GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other isoforms of GABA β R1a and GABA β R1b in the co-expressing cells;

(d) measuring the expression of HG20, GABA β R1a, GABA β R1b, *C. elegans* genes related to GABA β R1a and HG20, or other

isoforms of GABABR1a and GABABR1b in the separately expressing cells;

where if the amount of expression of HG20, GABABR1a, GABABR1b, *C. elegans* genes related to GABABR1a and HG20, or other isoforms of GABABR1a and GABABR1b is greater in the co-expressing cells as compared to the separately expressing cells, this indicates that increased expression has been achieved.

In particular embodiments, the measurement of expression is carried out by immunoblotting with or without immunoprecipitation.

The present invention includes murine GABABR1a protein substantially free from other proteins. The amino acid sequence of the full-length murine GABABR1a protein is shown in Figure 16 as SEQ.ID.NO.:20. Thus, the present invention includes polypeptides comprising the murine GABABR1a protein substantially free from other proteins having the amino acid sequence SEQ.ID.NO.:20. The present invention also includes murine GABABR1a protein lacking a signal sequence as well as DNA encoding such a protein. Such a murine GABABR1a protein lacking a signal sequence is represented by amino acids 18-960 of SEQ.ID.NO.:20.

The present invention includes modified murine GABABR1a polypeptides which have amino acid deletions, additions, or substitutions but that still retain substantially the same biological activity as native murine GABABR1a protein. The present invention includes polypeptides where one amino acid substitution has been made in SEQ.ID.NO.:20 or in a polypeptide represented by SEQ.ID.NO.:20 lacking a signal sequence, wherein the polypeptides still retain substantially the same biological activity as native murine GABABR1a protein. The present invention also includes polypeptides where two or more amino acid substitutions have been made in SEQ.ID.NO.:20 or in a polypeptide represented by SEQ.ID.NO.:20 lacking a signal sequence, wherein the polypeptides still retain substantially the same biological activity as native murine GABABR1a protein. In particular, the present invention includes embodiments where the above-described substitutions are conservative substitutions. In particular, the present invention includes embodiments

where the above-described substitutions do not occur in the ligand-binding domain of native murine GABABR1a protein. In particular, the present invention includes embodiments where amino acid changes have been made in positions of native murine GABABR1a protein where the amino acid sequence of native murine GABABR1a protein differs from the amino acid sequence of HG20 when the amino acid sequences of native murine GABABR1a protein and HG20 are aligned in a manner similar to the alignment of the amino acid sequences of GABABR1b protein and HG20 shown in Figure 8.

10 The present invention also includes isolated forms of murine GABABR1a proteins. By "isolated murine GABABR1a protein" is meant murine GABABR1a protein that has been isolated from a natural source or produced by recombinant means. Use of the term "isolated" indicates that murine GABABR1a protein is not present in its normal cellular
15 environment. Thus, an isolated murine GABABR1a protein may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that an isolated murine GABABR1a protein is the only protein present, but instead means that an isolated murine GABABR1a protein is at least 95%
20 free of non-amino acid material (*e.g.*, nucleic acids, lipids, carbohydrates) naturally associated with the murine GABABR1a protein. Thus, an murine GABABR1a protein that is expressed in bacteria or even in eukaryotic cells which do not naturally (*i.e.*, without human intervention) express it through recombinant means is an "isolated murine GABABR1a
25 protein."

 The present invention also provides ligand-binding domains of murine GABABR1a protein. A FASTA search of the database GenBank (bacterial division) using the N-terminal domain of murine GABABR1a (amino acid positions 147-551 of SEQ.ID.NO.:20) as the probe reveals a
30 match with the *E.coli* leucine-specific binding protein (livK) (22% identity over 339 amino acids), whereas no match to any bacterial amino acid binding protein is found using the receptor sequence inclusive of the region that includes the seven transmembrane domains (TM 1-7; amino acid positions 552-960) as a probe. The ligand-binding domain(s) of

GABA_BR1a was also experimentally determined. Photoaffinity [125I]CGP71872 labeling experiments provided direct physical evidence that the N-terminal extracellular domain but not a C-terminal fragment of GABA_BR1a (comprising TM1-7 and inclusive to the carboxyl tail) is responsible for ligand-binding (see Examples 14-19 and Figure 17B).

Accordingly, the present invention includes a polypeptide comprising the ligand binding domain of murine GABA_BR1a. In preferred embodiments, the polypeptide comprises amino acids 147-551 of SEQ.ID.NO.:20.

The present invention includes methods of identifying compounds that specifically bind to the GABA_B receptor, as well as compounds identified by such methods. The specificity of binding of compounds showing affinity for the GABA_B receptor is shown by measuring the affinity of the compounds for recombinant cells expressing HG20 and either GABA_BR1a or GABA_BR1b, or for membranes from such cells. Expression of the GABA_B receptor and screening for compounds that bind to the GABA_B receptor or that inhibit the binding of a known, radiolabeled ligand of the GABA_B receptor, *e.g.*, an amino acid or a GABA analogue such as (-)baclofen, to these cells, or membranes prepared from these cells, provides an effective method for the rapid selection of compounds with high affinity for the GABA_B receptor. Other radiolabeled ligands that might be used are ibotenic acid, the amino acids glutamate and glycine, other amino acids, decarboxylated amino acids, or any of the other GABA_B receptor ligands disclosed herein or known in the art. Such ligands need not necessarily be radiolabeled but can also be nonisotopic compounds that can be used to displace bound radiolabeled compounds or that can be used as activators in functional assays. Compounds identified by the methods disclosed herein are likely to be agonists or antagonists of the GABA_B receptor and may be peptides, proteins, or non-proteinaceous organic molecules.

Therefore, the present invention includes assays by which GABA_B receptor agonists and antagonists can be identified. Methods for identifying agonists and antagonists of other receptors are well known in the art and can often be adapted to identify agonists and antagonists of

the GABA_B receptor. Accordingly, the present invention includes a method for determining whether a substance binds GABA_B receptors and is thus a potential agonist or antagonist of the GABA_B receptor that comprises:

- 5 (a) providing cells comprising an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b;
- (b) culturing the cells under conditions such that HG20 and GABA_BR1a or GABA_BR1b are expressed and heterodimers of HG20
10 and GABA_BR1a or GABA_BR1b are formed;
- (c) exposing the cells to a labeled ligand of GABA_B receptors in the presence and in the absence of the substance;
- (d) measuring the binding of the labeled ligand to the heterodimers of HG20 and GABA_BR1a or GABA_BR1b in the presence and
15 in the absence of the substance;

where if the amount of binding of the labeled ligand is less in the presence of the substance than in the absence of the substance, then the substance is a potential agonist or antagonist of GABA_B receptors.

- Examples of ligands of GABA_B receptors are: CGP71872,
20 GABA, saclofen, (-)baclofen, glycine, and (L)-glutamic acid.

The present invention also includes a method for determining whether a substance is capable of binding to GABA_B receptors, *i.e.*, whether the substance is a potential agonist or an antagonist of GABA_B receptors, where the method comprises:

- 25 (a) providing test cells comprising an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b;
- (b) culturing the test cells under conditions such that HG20 and GABA_BR1a or GABA_BR1b are expressed and heterodimers of
30 HG20 and GABA_BR1a or GABA_BR1b are formed;
- (c) exposing the test cells to the substance;
- (d) measuring the amount of binding of the substance to the test cells;

(e) measuring the amount of binding of the substance to control cells;

(f) comparing the amount of binding of the substance to the test cells with the amount of binding of the substance to control cells;

5 where if the amount of binding of the substance to the test cells is greater than the amount of binding of the substance to control cells, then the substance is capable of binding to GABA_B receptors;

10 where the control cells are essentially the same as the test cells except that the control cells do not comprise an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b.

15 Once a substance has been identified by the above-described methods, determining whether the substance is an agonist or antagonist can then be accomplished by the use of functional assays such as those described herein.

In particular embodiments, the cells are transfected with an expression vector encoding HG20 and an expression vector encoding GABA_BR1a or GABA_BR1b.

20 In particular embodiments, the binding affinity of the substance for the test cells is determined. In particular embodiments, such binding affinity is between 1nM and 200 mM; preferably between 5 nM and 1 mM; more preferably between 10 nM and 100 μM; and even more preferably between 10 nM and 100 nM.

25 The conditions under which step (c) of the above-described methods is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

30 In a particular embodiment of the above-described methods, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC

CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), or *Xenopus* melanophores.

The assays described above can be carried out with cells that
5 have been transiently or stably transfected with an expression vector encoding HG20 and an expression vector encoding GABABR1a or GABABR1b. Transfection is meant to include any method known in the art for introducing HG20 and GABABR1a or GABABR1b into the test
10 cells. For example, transfection includes calcium phosphate or calcium chloride mediated transfection, lipofection, infection with a retroviral construct, and electroporation. In particular embodiments, a single expression vector encodes HG20 and GABABR1a or GABABR1b.

Where binding of the substance or ligand is measured, such
binding can be measured by employing a labeled substance or ligand. The
15 substance or ligand can be labeled in any convenient manner known to the art, e.g., radioactively, fluorescently, enzymatically.

In particular embodiments of the above-described methods,
the substance or ligand is an amino acid or an amino acid analogue such
as CGP71872, GABA, saclofen, (-)baclofen, glycine, and (L)-glutamic acid.

20 In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

In particular embodiments of the above-described methods,
HG20 comprises an amino acid sequence selected from the group
consisting of:

25 SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
30 Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and

Positions 57-941 of SEQ.ID.NO.:2.

In particular embodiments, GABABR1a is murine GABABR1a and has the amino acid sequence SEQ.ID.NO.:20. In particular embodiments, GABABR1a is rat GABABR1a and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In particular embodiments, GABABR1b is rat GABABR1b and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In particular embodiments, GABABR1a is human GABABR1a and has an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

The above-described methods can be modified in that, rather than exposing cells to the substance, membranes can be prepared from the cells and those membranes can be exposed to the substance. Such a modification utilizing membranes rather than cells is well known in the art with respect to other receptors and is described in, e.g., Hess et al., 1992, Biochem. Biophys. Res. Comm. 184:260-268.

As a further modification of the above-described method, RNA encoding HG20 and GABABR1a or GABABR1b can be prepared as, e.g., by *in vitro* transcription using a plasmid containing HG20 and a plasmid containing GABABR1a or GABABR1b under the control of a bacteriophage T7 promoter, and the RNA can be microinjected into *Xenopus* oocytes in order to cause the expression of HG20 and GABABR1a or GABABR1b in the oocytes. Substances are then tested for binding to the heterodimer of HG20 and GABABR1a or GABABR1b expressed in the oocytes. Alternatively, rather than detecting binding, the effect of the substances on the electrophysiological properties of the oocytes can be determined.

The present invention includes assays by which GABAB receptor agonists and antagonists may be identified by their ability to stimulate or antagonize a functional response mediated by the GABAB receptor in cells that have been co-transfected with and that co-express HG20 and GABABR1a or GABABR1b.

Accordingly, the present invention provides a method of identifying agonists and antagonists of HG20 comprising:

- (a) providing test cells by transfecting cells with:
- (1) an expression vector that directs the expression of HG20 in the cells; and
- (2) an expression vector that directs the expression of GABABR1a or GABABR1b in the cells;
- (b) exposing the test cells to a substance that is suspected of being an agonist of the GABAB receptor;
- (c) measuring the amount of a functional response of the test cells that have been exposed to the substance;
- (d) comparing the amount of the functional response exhibited by the test cells with the amount of the functional response exhibited by control cells;
- wherein if the amount of the functional response exhibited by the test cells differs from the amount of the functional response exhibited by the control cells, the substance is an agonist or antagonist of the GABAB receptor;
- where the control cells are cells that have not been transfected with HG20 and GABABR1a or GABABR1b but have been exposed to the substance or are test cells that have not been exposed to the substance.
- In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.
- In particular embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group consisting of:
- SEQ.ID.NO.:2;
- Positions 9-941 of SEQ.ID.NO.:2;
- Positions 35-941 of SEQ.ID.NO.:2;
- Positions 36-941 of SEQ.ID.NO.:2;
- Positions 38-941 of SEQ.ID.NO.:2;
- Positions 39-941 of SEQ.ID.NO.:2;
- Positions 42-941 of SEQ.ID.NO.:2;
- Positions 44-941 of SEQ.ID.NO.:2;
- Positions 46-941 of SEQ.ID.NO.:2;

Positions 52-941 of SEQ.ID.NO.:2; and

Positions 57-941 of SEQ.ID.NO.:2.

In particular embodiments, GABA_BR1a is murine GABA_BR1a and has the amino acid sequence SEQ.ID.NO.:20. In
5 particular embodiments, GABA_BR1a is rat GABA_BR1a and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In particular embodiments, GABA_BR1b is rat GABA_BR1b and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In particular embodiments, GABA_BR1a is human
10 GABA_BR1a and has an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

In particular embodiments, the functional response is selected from the group consisting of: changes in pigment distribution in melanophore cells; changes in cAMP or calcium concentration; and
15 changes in membrane currents in *Xenopus* oocytes. In particular embodiments, the change in pigment distribution is pigment aggregation; the change in cAMP concentration is a decrease in cAMP concentration; the change in membrane current is the modulation of an inwardly rectifying potassium current.

20 In a particular embodiment of the above-described method, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650),
25 COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, or *Xenopus* oocytes.

In a particular embodiment of the above-described method,
30 the cells are transfected with separate expression vectors that direct the expression of HG20 and either GABA_BR1a or GABA_BR1b in the cells. In other embodiments, the cells are transfected with a single expression vector that direct the expression of both HG20 and GABA_BR1a or GABA_BR1b in the cells.

In a particular embodiment, the cells are *Xenopus* melanophores and the functional response is pigment aggregation. In another embodiment, the cells are HEK293 cells and the functional response is a decrease in cAMP level. In another embodiment, the cells
5 are *Xenopus* oocytes and the functional response is the production of an inwardly rectifying potassium current.

The conditions under which step (b) of the method is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as
10 those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

The above-described assay can be easily modified to form a method to identify antagonists of the GABA_B receptor. Such a method
comprises:

- 15 (a) providing cells by transfecting cells with:
 - (1) an expression vector that directs the expression of HG20 in the cells; and
 - (2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;
- 20 (b) exposing the cells to a substance that is a known agonist of the GABA_B receptor;
- (c) measuring the amount of a functional response of the cells that have been exposed to the known agonist;
- (d) exposing the cells concurrently to the known agonist
25 and to a substance that is suspected of being an antagonist of the GABA_B receptor;
- (e) measuring the amount of a functional response of the cells that have been exposed to the substance and the known agonist;
- (f) comparing the amount of the functional response
30 measured in step (c) with the amount of the functional response measured in step (e);

wherein if the amount of the functional response measured in step (c) is greater than the amount of the functional response measured in step (e), the substance is an antagonist of the GABA_B receptor.

Additional types of functional assays that can be used to identify agonists and antagonists of GABA_B receptors include transcription-based assays. Transcription-based assays involve the use of a reporter gene whose transcription is driven by an inducible promoter whose activity is regulated by a particular intracellular event such as, *e.g.*, changes in intracellular calcium levels that are caused by the interaction of a receptor with a ligand. Transcription-based assays are reviewed in Rutter et al., 1998, *Chemistry & Biology* 5:R285-R290.

The transcription-based assays of the present invention rely on the expression of reporter genes whose transcription is activated or repressed as a result of intracellular events that are caused by the interaction of an agonist with a heterodimer of HG20 and either GABA_BR1a or GABA_BR1b where the heterodimer forms a functional GABA_B receptor.

An extremely sensitive transcription based assay is disclosed in Zlokarnik et al., 1998, *Science* 279:84-88 (Zlokarnik) and also in U.S. Patent No. 5,741,657. The assay disclosed in Zlokarnik and U.S. Patent No. 5,741,657 employs a plasmid encoding β -lactamase under the control of an inducible promoter. This plasmid is transfected into cells together with a plasmid encoding a receptor for which it is desired to identify agonists. The inducible promoter on the β -lactamase is chosen so that it responds to at least one intracellular signal that is generated when an agonist binds to the receptor. Thus, following such binding of agonist to receptor, the level of β -lactamase in the transfected cells increases. This increase in β -lactamase is made measurable by treating the cells with a cell-permeable dye that is a substrate for β -lactamase. The dye contains two fluorescent moieties. In the intact dye, the two fluorescent moieties are close enough to one another that fluorescent resonance energy transfer (FRET) can take place between them. Following cleavage of the dye into two parts by β -lactamase, the two fluorescent moieties are located on different parts, and thus can drift apart. This increases the distance between the fluorescent moieties, thus decreasing the amount of FRET that can occur between them. It is this decrease in FRET that is measured in the assay.

One skilled in the art can modify the assay described in Zlokarnik and U.S. Patent No. 5,741,657 to form an assay for identifying agonists of GABA_B receptors by using an inducible promoter to drive β -lactamase that is activated by an intracellular signal generated by the interaction of agonists and the GABA_B receptor. To produce the GABA_B receptor, a plasmid encoding HG20 and a plasmid encoding GABA_BR1a or GABA_BR1b would be transfected into the cells. The cells would be exposed to the cell-permeable dye and then exposed to substances suspected of being agonists of the GABA_B receptor. Those substances that cause a decrease in FRET are likely to actually be agonists of the GABA_B receptor.

Accordingly, the present invention includes a method for identifying agonists of the GABA_B receptor comprising:

- (a) transfecting cells with:
 - (1) an expression vector that directs the expression of HG20 in the cells;
 - (2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;
 - (3) an expression vector that directs the expression of β -lactamase under the control of an inducible promoter that is activated by an intracellular signal generated by the interaction of agonists and the GABA_B receptor;
- (b) exposing the cells to a substrate of β -lactamase that is a cell-permeable dye that contains two fluorescent moieties where the two fluorescent moieties are on different parts of the dye and cleavage of the dye by β -lactamase allows the two fluorescent moieties to drift apart;
- (c) measuring the amount of fluorescent resonance energy transfer (FRET) in the cells in the absence of the substance of step (d);
- (d) exposing the cells to a substance that is suspected of being an agonist of the GABA_B receptor;
- (e) measuring the amount of FRET in the cells after exposure of the cells to the substance;

wherein if the amount of FRET in the cells measured in step (e) is less than the amount of FRET measured in the cells in step (c), then the substance is an agonist of the GABA_B receptor.

Substeps (1)-(3) of step (a) can be practiced in any order.

5 The assay described above can be modified to an assay for identifying antagonists of the GABA_B receptor. Such modification would involve the use of β -lactamase under the control of a promoter that is repressed by at least one intracellular signal generated by interaction of an agonist with the GABA_B receptor and would also involve running the
10 assay in the presence of a known agonist. When the cells are exposed to substances suspected of being antagonists of the GABA_B receptor, β -lactamase will be induced, and FRET will decrease, only if the substance tested is able to counteract the effect of the agonist, *i.e.*, only if the substance tested is actually an antagonist.

15 Accordingly, the present invention includes a method for identifying antagonists of the GABA_B receptor comprising:

- (a) transfecting cells with:
 - (1) an expression vector that directs the expression of HG20 in the cells;
 - 20 (2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;
 - (3) an expression vector that directs the expression of β -lactamase under the control of an inducible promoter that is repressed by at least one intracellular signal generated by interaction of
25 an agonist with the GABA_B receptor;
- (b) exposing the cells to a known agonist of the GABA_B receptor;
- (c) exposing the cells to a substrate of β -lactamase that is a cell-permeable dye that contains two fluorescent moieties where the two
30 fluorescent moieties are on different parts of the dye and cleavage of the dye by β -lactamase allows the two fluorescent moieties to drift apart;
- (d) measuring the amount of fluorescent resonance energy transfer (FRET) in the cells in the absence of the substance of step (e);

(e) exposing the cells to a substance that is suspected of being an antagonist of the GABA_B receptor;

(f) measuring the amount of FRET in the cells after exposure of the cells to the substance;

5 wherein if the amount of FRET in the cells measured in step (f) is less than the amount of FRET measured in the cells in step (d), then the substance is an antagonist of the GABA_B receptor.

Substeps (1)-(3) of step (a) can be practiced in any order.

10 In particular embodiments of the assays employing β -lactamase described above, the cells are eukaryotic cells. In particular embodiments, the cells are mammalian cells. In particular embodiments, the cells are selected from the group consisting of: L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92),
15 NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, and *Xenopus* oocytes.

20 In other embodiments, the inducible promoter that is repressed by at least one intracellular signal generated by interaction of an agonist with the GABA_B receptor is a promoter that is repressed by decreases in cAMP levels or changes in potassium currents.

25 In other embodiments, the inducible promoter that is activated by at least one intracellular signal generated by interaction of an agonist with the GABA_B receptor is a promoter that is activated by decreases in cAMP levels or changes in potassium currents.

In other embodiments, the known agonist is selected from the group consisting of: GABA, saclofen, (-)baclofen, glycine, and (L)-glutamic acid.

30 In other embodiments, β -lactamase is TEM-1 β -lactamase from *Escherichia coli*.

In other embodiments, the substrate of β -lactamase is CCF2/AM (Zlokarnik et al., 1998, Science 279:84-88).

In other embodiments, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

In other embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group consisting of:

- 5 SEQ.ID.NO.:2;
 Positions 9-941 of SEQ.ID.NO.:2;
 Positions 35-941 of SEQ.ID.NO.:2;
 Positions 36-941 of SEQ.ID.NO.:2;
 Positions 38-941 of SEQ.ID.NO.:2;
10 Positions 39-941 of SEQ.ID.NO.:2;
 Positions 42-941 of SEQ.ID.NO.:2;
 Positions 44-941 of SEQ.ID.NO.:2;
 Positions 46-941 of SEQ.ID.NO.:2;
 Positions 52-941 of SEQ.ID.NO.:2; and
15 Positions 57-941 of SEQ.ID.NO.:2.

In other embodiments, GABABR1a is murine GABABR1a and has the amino acid sequence SEQ.ID.NO.:20. In other embodiments, GABABR1a is rat GABABR1a and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In other embodiments, 20 GABABR1b is rat GABABR1b and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In other embodiments, GABABR1a is human GABABR1a and has an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

25 In particular embodiments, the cells express a promiscuous G-protein, e.g., G α 15 or G α 16.

In particular embodiments, the inducible promoter is a promoter that is activated or repressed by NF- κ B or NFAT.

30 The assays described above could be modified to identify inverse agonists. In such assays, one would expect a decrease in β -lactamase activity. Similarly, inverse agonists can be identified by modifying the functional assays that were described previously where those functional assays monitored decreases in cAMP levels. In the case

of assays for inverse agonists, increases in cAMP levels would be observed.

Other transcription-based assays that can be used to identify agonists and antagonists of the GABA_B receptor rely on the use of green fluorescent proteins or luciferase as reported genes. An example of such an assay comprises:

- (a) transfecting cells with:
 - (1) an expression vector that directs the expression of HG20 in the cells;
 - (2) an expression vector that directs the expression of GABA_BR1a or GABA_BR1b in the cells;
 - (3) an expression vector that directs the expression of green fluorescent protein (GFP) under the control of an inducible promoter that is activated by an intracellular signal generated by the interaction of agonists and the GABA_B receptor;
 - (b) measuring the amount of fluorescence from GFP in the cells;
 - (c) exposing the cells to a substance that is suspected of being an agonist of the GABA_B receptor;
 - (d) measuring the amount of fluorescence from GFP in the cells that have been exposed to the substance;
- wherein if the amount of fluorescence from GFP in the cells measured in step (b) is less than the amount of fluorescence from GFP measured in the cells in step (d), then the substance is an agonist of the GABA_B receptor.

The present invention also includes assays for the identification of agonists or antagonists of GABA_B receptors that are based upon FRET between a first and a second fluorescent dye where the first dye is bound to one side of the plasma membrane of a cell expressing a heterodimer of HG20 and GABA_BR1a or GABA_BR1b and the second dye is free to shuttle from one face of the membrane to the other face in response to changes in membrane potential. In certain embodiments, the first dye is impenetrable to the plasma membrane of the cells and is bound predominately to the extracellular surface of the plasma

membrane. The second dye is trapped within the plasma membrane but is free to diffuse within the membrane. At normal (*i.e.*, negative) resting potentials of the membrane, the second dye is bound predominately to the inner surface of the extracellular face of the plasma membrane, thus placing the second dye in close proximity to the first dye. This close proximity allows for the generation of a large amount of FRET between the two dyes. Following membrane depolarization, the second dye moves from the extracellular face of the membrane to the intracellular face, thus increasing the distance between the dyes. This increased distance results in a decrease in FRET, with a corresponding increase in fluorescent emission derived from the first dye and a corresponding decrease in the fluorescent emission from the second dye. See figure 1 of González & Tsien, 1997, *Chemistry & Biology* 4:269-277. See also González & Tsien, 1995, *Biophys. J.* 69:1272-1280 and U.S. Patent No. 5,661,035.

In certain embodiments, the first dye is a fluorescent lectin or a fluorescent phospholipid that acts as the fluorescent donor. Examples of such a first dye are: a coumarin-labeled phosphatidylethanolamine (*e.g.*, N-(6-chloro-7-hydroxy-2-oxo-2H-1-benzopyran-3-carboxamidoacetyl)-dimyristoylphosphatidyl-ethanolamine) or N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-dipalmitoylphosphatidylethanolamine); a fluorescently-labeled lectin (*e.g.*, fluorescein-labeled wheat germ agglutinin). In certain embodiments, the second dye is an oxonol that acts as the fluorescent acceptor. Examples of such a second dye are: bis(1,3-dialkyl-2-thiobarbiturate)trimethineoxonols (*e.g.*, bis(1,3-dihexyl-2-thiobarbiturate)trimethineoxonol) or pentamethineoxonol analogues (*e.g.*, bis(1,3-dihexyl-2-thiobarbiturate)pentamethineoxonol; or bis(1,3-dibutyl-2-thiobarbiturate)pentamethineoxonol). See González & Tsien, 1997, *Chemistry & Biology* 4:269-277 for methods of synthesizing various dyes suitable for use in the present invention. In certain embodiments, the assay may comprise a natural carotenoid, *e.g.*, astaxanthin, in order to reduce photodynamic damage due to singlet oxygen.

Accordingly, the present invention provides a method of identifying agonists of GABA_B receptors comprising:

(a) providing test cells comprising:

- (1) an expression vector that directs the expression of HG20 in the cells;
- (2) an expression vector that directs the expression of GABABR1a or GABABR1b in the cells;
- 5 (3) an expression vector that directs the expression of an inwardly rectifying potassium channel;
- (4) a first fluorescent dye, where the first dye is bound to one side of the plasma membrane; and
- (5) a second fluorescent dye, where the second
10 fluorescent dye is free to shuttle from one face of the plasma membrane to the other face in response to changes in membrane potential;
- (b) exposing the test cells to a substance that is suspected of being an agonist of the GABAB receptor;
- (c) measuring the amount of fluorescence resonance
15 energy transfer (FRET) in the test cells that have been exposed to the substance;
- (d) comparing the amount of FRET exhibited by the test cells that have been exposed to the substance with the amount of FRET exhibited by control cells;
- 20 wherein if the amount of FRET exhibited by the test cells is less than the amount of FRET exhibited by the control cells, the substance is an agonist of the GABAB receptor;
- where the control cells are either (1) cells that are essentially the same as the test cells except that they do not comprise at least one of
25 the items listed at (a) (1)-(5) but have been exposed to the substance; or (2) test cells that have not been exposed to the substance.
- The above-described assay can be easily modified to form a method to identify antagonists of the GABAB receptor. Such a method comprises:
- 30 (a) providing test cells comprising:
- (1) an expression vector that directs the expression of HG20 in the cells;
- (2) an expression vector that directs the expression of GABABR1a or GABABR1b in the cells;

(3) an expression vector that directs the expression of an inwardly rectifying potassium channel;

(4) a first fluorescent dye, where the first dye is bound to one side of the plasma membrane; and

5 (5) a second fluorescent dye, where the second fluorescent dye is free to shuttle from one face of the plasma membrane to the other face in response to changes in membrane potential;

(b) exposing the test cells to a known agonist of the GABAB receptor in the presence of a substance that is suspected of being
10 an antagonist of the GABAB receptor;

(c) exposing the test cells to the known agonist of the GABAB receptor in the absence of the substance that is suspected of being an antagonist of the GABAB receptor;

(d) measuring the amount of fluorescence resonance
15 energy transfer (FRET) in the test cells of steps (b) and (c);

(e) comparing the amount of FRET exhibited by the test cells of steps (b) and (c);

where if the amount of FRET exhibited by the test cells of step (b) is greater than the amount of FRET exhibited by the test cells of
20 step (c), the substance is an antagonist of the GABAB receptor.

In particular embodiments of the above-described methods, the expression vectors are transfected into the test cells.

In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

25 In particular embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group consisting of:

SEQ.ID.NO.:2;

Positions 9-941 of SEQ.ID.NO.:2;

30 Positions 35-941 of SEQ.ID.NO.:2;

Positions 36-941 of SEQ.ID.NO.:2;

Positions 38-941 of SEQ.ID.NO.:2;

Positions 39-941 of SEQ.ID.NO.:2;

Positions 42-941 of SEQ.ID.NO.:2;

Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

5 In particular embodiments of the above-described methods,
GABA_BR1a is murine GABA_BR1a and has the amino acid sequence
SEQ.ID.NO.:20. In particular embodiments, GABA_BR1a is rat
GABA_BR1a and has the amino acid sequence reported in Kaupmann et
al., 1997, Nature 386:239-246. In particular embodiments, GABA_BR1b is
10 rat GABA_BR1b and has the amino acid sequence reported in Kaupmann
et al., 1997, Nature 386:239-246. In particular embodiments, GABA_BR1a
is human GABA_BR1a and has an amino acid sequence selected from the
group consisting of: SEQ.ID.NO.:21 and the protein encoded by
SEQ.ID.NO.:23.

15 Inwardly rectifying potassium channels that are suitable for
use in the methods of the present invention are disclosed in, *e.g.*, Misgeld
et al., 1995, Prog. Neurobiol. 46:423-462; North, 1989, Br. J. Pharmacol.
98:13-23; Gahwiler et al., 1985, Proc. Natl. Acad. Sci USA 82:1558-1562;
Andrade et al., 1986, Science 234:1261.

20 In particular embodiments of the above-described methods,
the first fluorescent dye is selected from the group consisting of: a
fluorescent lectin; a fluorescent phospholipid; a coumarin-labeled
phosphatidylethanolamine; N-(6-chloro-7-hydroxy-2-oxo-2H--1-
benzopyran-3-carboxamidoacetyl)-dimyristoylphosphatidyl-ethanolamine);
25 N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-
dipalmitoylphosphatidylethanolamine); and fluorescein-labeled wheat
germ agglutinin.

In particular embodiments of the above-described methods,
the second fluorescent dye is selected from the group consisting of: an
oxonol that acts as the fluorescent acceptor; bis(1,3-dialkyl-2-
30 thiobarbiturate)trimethineoxonols; bis(1,3-dihexyl-2-
thiobarbiturate)trimethineoxonol; bis(1,3-dialkyl-2-
thiobarbiturate)quatramethineoxonols; bis(1,3-dialkyl-2-
thiobarbiturate)pentamethineoxonols; bis(1,3-dihexyl-2-

thiobarbiturate)pentamethineoxonol; bis(1,3-dibutyl-2-thiobarbiturate)pentamethineoxonol; and bis(1,3-dialkyl-2-thiobarbiturate)hexamethineoxonols.

In a particular embodiment of the above-described methods, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), *Xenopus* melanophores, or *Xenopus* oocytes.

In a particular embodiment of the above-described methods, the cells are transfected with separate expression vectors that direct the expression of HG20 and either GABABR1a or GABABR1b in the cells. In other embodiments, the cells are transfected with a single expression vector that direct the expression of both HG20 and GABABR1a or GABABR1b in the cells.

The conditions under which step (b) of the first method described above and steps (b) and (c) of the second method described above are practiced are conditions that are typically used in the art for the study of protein-ligand interactions: e.g., physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

The GABAB receptor belongs to the class of proteins known as G-protein coupled receptors (GPCRs). GPCRs transmit signals across cell membranes upon the binding of ligand. The ligand-bound GPCR interacts with a heterotrimeric G-protein, causing the G α subunit of the G-protein to disassociate from the G β and G γ subunits. The G α subunit can then go on to activate a variety of second messenger systems.

Generally, a particular GPCR is only coupled to a particular type of G-protein. Thus, to observe a functional response from the GPCR, it is necessary to ensure that the proper G-protein is present in the system containing the GPCR. It has been found, however, that there are certain

G-proteins that are "promiscuous." These promiscuous G-proteins will couple to, and thus transduce a functional signal from, virtually any GPCR. See Offermanns & Simon, 1995, J. Biol. Chem. 270:15175, 15180 (Offermanns). Offermanns described a system in which cells are
5 transfected with expression vectors that result in the expression of one of a large number of GPCRs as well as the expression of one of the promiscuous G-proteins $G\alpha 15$ or $G\alpha 16$. Upon the addition of an agonist of the GPCR to the transfected cells, the GPCR was activated and was able, via $G\alpha 15$ or $G\alpha 16$, to activate the β isoform of phospholipase C, leading to
10 an increase in inositol phosphate levels in the cells.

Therefore, by making use of these promiscuous G-proteins as in Offermanns, it is possible to set up functional assays for the GABA_B receptor, even in the absence of knowledge of the G-protein with which the GABA_B receptor is coupled *in vivo*. One possibility for utilizing
15 promiscuous G-proteins in connection with the GABA_B receptor includes a method of identifying agonists of the GABA_B receptor comprising:

- (a) providing cells that express HG20, GABA_BR1a or GABA_BR1b, and a promiscuous G-protein, where HG20 and either GABA_BR1a or GABA_BR1b form a heterodimer representing a functional
20 GABA_B receptor;
- (b) exposing the cells to a substance that is a suspected agonist of the GABA_B receptor;
- (c) measuring the level of inositol phosphates in the cells; where an increase in the level of inositol phosphates in the
25 cells as compared to the level of inositol phosphates in the cells in the absence of the suspected agonist indicates that the substance is an agonist of the GABA_B receptor.

Levels of inositol phosphates can be measured by monitoring calcium mobilization. Intracellular calcium mobilization is typically
30 assayed in whole cells under a microscope using fluorescent dyes or in cell suspensions via luminescence using the aequorin assay.

In methods related to those described above, rather than using changes in inositol phosphate levels as an indication of GABA_B receptor function, potassium currents are measured. This is feasible since

the GABA_B receptor, like other metabotropic receptors, is expected to be coupled to potassium channels. Thus, one could measure GABA_B receptor coupling to GIRK2 channels or to other potassium channels in oocytes.

In a particular embodiment of the above-described method,
5 the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92),
10 NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), or *Xenopus* oocytes.

In a particular embodiment of the above-described method,
15 the cells are transfected with expression vectors that direct the expression of HG20, GABA_BR1a or GABA_BR1b, and the promiscuous G-protein in the cells.

The conditions under which step (b) of the method is practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as
20 those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

In a particular embodiment of the above-described method, the promiscuous G-protein is selected from the group consisting of Gα15 or Gα16. Expression vectors containing Gα15 or Gα16 are known in the
25 art. See, *e.g.*, Offermanns; Buhl et al., 1993, FEBS Lett. 323:132-134; Amatruda et al., 1993, J. Biol. Chem. 268:10139-10144.

The above-described assay can be easily modified to form a method to identify antagonists of the GABA_B receptor. Such a method is also part of the present invention and comprises:

- 30 (a) providing cells that express HG20, GABA_BR1a or GABA_BR1b, and a promiscuous G-protein;
(b) exposing the cells to a substance that is an agonist of the GABA_B receptor;

(c) subsequently or concurrently to step (b), exposing the cells to a substance that is a suspected antagonist of the GABA_B receptor;

(d) measuring the level of inositol phosphates in the cells; where a decrease in the level of inositol phosphates in the cells in the presence of the suspected antagonist as compared to the level of inositol phosphates in the cells in the absence of the suspected antagonist indicates that the substance is an antagonist of the GABA_B receptor.

In a particular embodiment of the above-described method, the agonist is an amino acid such as GABA, glutamate, glycine, or amino acid analogues such as (-)baclofen.

In a particular embodiment of the above-described method, the cells are eukaryotic cells. In another embodiment, the cells are mammalian cells. In other embodiments, the cells are L cells L-M(TK⁻) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), HEK293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26), MRC-5 (ATCC CCL 171), or Xenopus oocytes.

The conditions under which steps (b) and (c) of the method are practiced are conditions that are typically used in the art for the study of protein-ligand interactions: *e.g.*, physiological pH; salt conditions such as those represented by such commonly used buffers as PBS or in tissue culture media; a temperature of about 4°C to about 55°C.

In a particular embodiment of the above-described method, the cells are transfected with expression vectors that direct the expression of HG20, GABA_BR1a or GABA_BR1b, and the promiscuous G-protein in the cells.

In a particular embodiment of the above-described method, the promiscuous G-protein is selected from the group consisting of Gα15 or Gα16.

In particular embodiments of the above-described methods, HG20 has an amino acid sequence of SEQ.ID.NO.:2.

In other embodiments of the above-described methods, HG20 comprises an amino acid sequence selected from the group consisting of:

SEQ.ID.NO.:2;

Positions 9-941 of SEQ.ID.NO.:2;

5 Positions 35-941 of SEQ.ID.NO.:2;

Positions 36-941 of SEQ.ID.NO.:2;

Positions 38-941 of SEQ.ID.NO.:2;

Positions 39-941 of SEQ.ID.NO.:2;

Positions 42-941 of SEQ.ID.NO.:2;

10 Positions 44-941 of SEQ.ID.NO.:2;

Positions 46-941 of SEQ.ID.NO.:2;

Positions 52-941 of SEQ.ID.NO.:2; and

Positions 57-941 of SEQ.ID.NO.:2.

In other embodiments, GABA β R1a is murine GABA β R1a
15 and has the amino acid sequence SEQ.ID.NO.:20. In other embodiments, GABA β R1a is rat GABA β R1a and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In other embodiments, GABA β R1b is rat GABA β R1b and has the amino acid sequence reported in Kaupmann et al., 1997, Nature 386:239-246. In other embodiments,
20 GABA β R1a is human GABA β R1a and has an amino acid sequence selected from the group consisting of: SEQ.ID.NO.:21 and the protein encoded by SEQ.ID.NO.:23.

While the above-described methods are explicitly directed to testing whether "a" substance is an agonist or antagonist of the GABA β
25 receptor, it will be clear to one skilled in the art that such methods can be adapted to test collections of substances, *e.g.*, combinatorial libraries, to determine whether any members of such collections are activators or inhibitors of the GABA β receptor. Accordingly, the use of collections of substances, or individual members of such collections, as the substance in
30 the above-described methods is within the scope of the present invention.

The present invention includes pharmaceutical compositions comprising agonists and antagonists of GABA β receptors that have been identified by the above-described methods. The agonists and antagonists are generally combined with pharmaceutically acceptable carriers to form

pharmaceutical compositions. Examples of such carriers and methods of formulation of pharmaceutical compositions containing agonists and antagonists and carriers can be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain a therapeutically effective amount of the agonists and antagonists.

Therapeutic or prophylactic compositions are administered to an individual in amounts sufficient to treat or prevent conditions where GABAB receptor activity is abnormal. The effective amount can vary according to a variety of factors such as the individual's condition, weight, gender, and age. Other factors include the mode of administration. The appropriate amount can be determined by a skilled physician.

Compositions can be used alone at appropriate dosages. Alternatively, co-administration or sequential administration of other agents can be desirable.

The compositions can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the compositions can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

Advantageously, compositions can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. Furthermore, compositions can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

The dosage regimen utilizing the compositions is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal, hepatic and cardiovascular function of the patient; and the particular composition thereof employed. A physician of ordinary skill can readily determine and prescribe the effective amount of the composition required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentrations of composition within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the composition's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a composition.

Agonists and antagonists identified by the above-described methods are useful in the same manner as well-known agonists and antagonists of other GABA_B receptors. For example, (-) baclofen is a known agonist of GABA_B receptors and, in racemic form, is a clinically useful muscle relaxant known as LIORESAL® (Bowery & Pratt, 1992, *Arzneim.-Forsch./Drug Res.* 42:215-223 [Bowery & Pratt]). Similarly, the agonists and antagonists of GABA_B receptors identified by the methods of the present invention are expected to be useful as muscle relaxants. Bowery & Pratt, at Table 1, page 219, list the therapeutic potential of GABA_B receptor agonists and antagonists. For agonists, the therapeutic potential is said to include use as muscle relaxants and anti-asthmatics. For antagonists, the therapeutic potential is said to include use as antidepressants, anticonvulsants, nootropics, and anxiolytics. Additionally, at page 220, left column, Bowery & Pratt list some additional therapeutic uses for the GABA_B receptor agonist (-) baclofen: treatment of trigeminal neuralgia and reversal of ethanol withdrawal symptoms. Given the wide range of utility displayed by known agonists and antagonists of GABA_B receptors, it is clear that those skilled in the art would consider the agonists and antagonists identified by the methods of the present invention to be pharmacologically useful. In addition, it is believed that such agonists and antagonists will also be useful in the treatment of epilepsy, neuropsychiatric disorders, and dementias.

When screening compounds in order to identify potential pharmaceuticals that specifically interact with a target receptor, it is necessary to ensure that the compounds identified are as specific as possible for the target receptor. To do this, it is necessary to screen the compounds against as wide an array as possible of receptors that are similar to the target receptor. Thus, in order to find compounds that are potential pharmaceuticals that interact with receptor A, it is necessary not only to ensure that the compounds interact with receptor A (the "plus target") and produce the desired pharmacological effect through receptor A, it is also necessary to determine that the compounds do not interact with receptors B, C, D, etc (the "minus targets"). In general, as part of a screening program, it is important to have as many minus targets as possible (see Hodgson, 1992, Bio/Technology 10:973-980, at 980). HG20 protein, DNA encoding HG20 protein, GABABR1a protein, DNA encoding GABABR1a protein, and recombinant cells that have been engineered to express HG20 protein and GABABR1a protein have utility in that they can be used as "minus targets" in screens design to identify compounds that specifically interact with other G-protein coupled receptors, i.e., non-GABAB receptors.

The present invention also includes antibodies to the HG20 protein. Such antibodies may be polyclonal antibodies or monoclonal antibodies. The antibodies of the present invention are raised against the entire HG20 protein or against suitable antigenic fragments of the protein that are coupled to suitable carriers, e.g., serum albumin or keyhole limpet hemocyanin, by methods well known in the art. Methods of identifying suitable antigenic fragments of a protein are known in the art. See, e.g., Hopp & Woods, 1981, Proc. Natl. Acad. Sci. USA 78:3824-3828; and Jameson & Wolf, 1988, CABIOS (Computer Applications in the Biosciences) 4:181-186. Particularly suitable peptides are: amino acids 357-371 of SEQ.ID.NO.:2 and amino acids 495-511 of SEQ.ID.NO.:2. Also, anti-peptide antisera can be generated by immunization of New Zealand White rabbits with a KLH-conjugation of a 20 amino acid synthetic peptide corresponding to residues 283-302 of HG20 (GWYEPSWWEQVHTEANSSRC) (a portion of SEQ.ID.NO.:2).

For the production of polyclonal antibodies, HG20 protein or an antigenic fragment, coupled to a suitable carrier, is injected on a periodic basis into an appropriate non-human host animal such as, e.g., rabbits, sheep, goats, rats, mice. The animals are bled periodically and sera obtained are tested for the presence of antibodies to the injected antigen. The injections can be intramuscular, intraperitoneal, subcutaneous, and the like, and can be accompanied with adjuvant.

For the production of monoclonal antibodies, HG20 protein or an antigenic fragment, coupled to a suitable carrier, is injected into an appropriate non-human host animal as above for the production of polyclonal antibodies. In the case of monoclonal antibodies, the animal is generally a mouse. The animal's spleen cells are then immortalized, often by fusion with a myeloma cell, as described in Kohler & Milstein, 1975, Nature 256:495-497. For a fuller description of the production of monoclonal antibodies, see Antibodies: A Laboratory Manual, Harlow & Lane, eds., Cold Spring Harbor Laboratory Press, 1988.

Gene therapy may be used to introduce HG20 polypeptides into the cells of target organs. Nucleotides encoding HG20 polypeptides can be ligated into viral vectors which mediate transfer of the nucleotides by infection of recipient cells. Suitable viral vectors include retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, and polio virus based vectors. Alternatively, nucleotides encoding HG20 polypeptides can be transferred into cells for gene therapy by non-viral techniques including receptor-mediated targeted transfer using ligand-nucleotide conjugates, lipofection, membrane fusion, or direct microinjection. These procedures and variations thereof are suitable for *ex vivo* as well as *in vivo* gene therapy. Gene therapy with HG20 polypeptides will be particularly useful for the treatment of diseases where it is beneficial to elevate HG20 activity.

The following non-limiting examples are presented to better illustrate the invention.

EXAMPLE 1

Cloning and sequencing of HG20

5 A cDNA fragment encoding full-length HG20 can be isolated from a human fetal brain cDNA library by using the polymerase chain reaction (PCR) employing the following primer pair:

HG20.F139 5'-CCGTTCTGAGCCGAGCCG -3' (SEQ.ID.NO.:3)
HG20.R3195 5'-TCCGCAGCCAGAGCCGACAG-3' (SEQ.ID.NO.:4)

10 The above primer pair is meant to be illustrative only. Those skilled in the art would recognize that a large number of primer pairs, based upon SEQ.ID.NO.:1, could also be used.

PCR reactions can be carried out with a variety of thermostable enzymes including but not limited to AmpliTaq, AmpliTaq Gold, Vent polymerase. For AmpliTaq, reactions can be carried out in 10 mM Tris-Cl, pH 8.3, 2.0 mM MgCl₂, 200 µM for each dNTP, 50 mM KCl, 0.2 µM for each primer, 10 ng of DNA template, 0.05 units/µl of AmpliTaq. The reactions are heated at 95°C for 3 minutes and then cycled 35 times using the cycling parameters of 95°C, 20 seconds, 62°C, 20 seconds, 72°C, 3 minutes. In addition to these conditions, a variety of suitable PCR protocols can be found in PCR Primer, A Laboratory Manual, edited by C.W. Dieffenbach and G.S. Dveksler, 1995, Cold Spring Harbor Laboratory Press.

25 A suitable cDNA library from which a clone encoding HG20 can be isolated would be a random primed fetal brain cDNA library consisting of approximately 4.0 million primary clones constructed in the plasmid vector pBluescript (Stratagene, LaJolla, CA). The primary clones of such a library can be subdivided into pools with each pool containing approximately 20,000 clones and each pool can be amplified separately.

30 By this method, a cDNA fragment (SEQ.ID.NO.:1) encoding an open reading frame of 941 amino acids (SEQ.ID.NO.:2) is obtained. This cDNA fragment can be cloned into a suitable cloning vector or

expression vector. For example, the fragment can be cloned into the mammalian expression vector pcDNA3.1 (Invitrogen, San Diego, CA). HG20 protein can then be produced by transferring an expression vector containing SEQ.ID.NO.:1 or portions thereof into a suitable host cell and
 5 growing the host cell under appropriate conditions. HG20 protein can then be isolated by methods well known in the art.

Alternatively, other cDNA libraries made from human tissues that express HG20 RNA can be used with PCR primers HG20.F139 and HG20.R3195 in order to amplify a cDNA fragment
 10 encoding full-length HG20. Suitable cDNA libraries would be those prepared from cortex, cerebellum, testis, ovary, adrenal gland, thyroid, or spinal cord.

As an alternative to the above-described PCR method, a cDNA clone encoding HG20 can be isolated from a cDNA library using as
 15 a probe oligonucleotides specific for HG20 and methods well known in the art for screening cDNA libraries with oligonucleotide probes. Such methods are described in, e.g., Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K., Vol. I, II. Oligonucleotides that
 20 are specific for HG20 and that can be used to screen cDNA libraries are:

	HG20.F46	5'-GGGATGATCATGGCCAGTGC-3' (SEQ.ID.NO.:5)
	HG20.R179	5'-GGATCCATCAAGGCCAAAGA-3' (SEQ.ID.NO.:6)
25	HG21.F43	5'-GCCGCTGTCTCCTTCCTGA-3' (SEQ.ID.NO.:7)
	HG21.R251	5'-TTGGTTCACACTGGTGACCGA-3' (SEQ.ID.NO.:8)
	HG20.R123	5'-TTCACCTCCCTGCTGTCTTG-3' (SEQ.ID.NO.:9)
	HG20.F1100	5'-CAGGCGATTCCAGTTCACTCA-5' (SEQ.ID.NO.:10)
	HG20.F1747	5'-GAACCAAGCCAGCACATCCC-3' (SEQ.ID.NO.:11)
30	HG20.R54	5'-CCTCGCCATACAGAACTCC-3' (SEQ.ID.NO.:12)
	HG20.R75	5'-GTGTCATAGAGCCGCAGGTC-3' (SEQ.ID.NO.:13)
	HG20.F139	5'-CCGTTCTGAGCCGAGCCG-3' (SEQ.ID.NO.:3)
	HG20.R3195	5'-TCCGCAGCCAGAGCCGACAG-3' (SEQ.ID.NO.:4)

Membrane-spanning proteins, such as GABAB receptors, when first translated generally possess an approximately 16 to 40 amino acid segment known as a signal sequence. Signal sequences direct the nascent protein to be transported through the endoplasmic reticulum membrane, following which signal sequences are cleaved from the protein. Signal sequences generally contain from 4 to 12 hydrophobic residues but otherwise possess little sequence homology. The Protein Analysis tool of the GCG program (Genetics Computer Group, Madison, Wisconsin), a computer program capable of identifying likely signal sequences, was used to examine the N terminus of HG20. Several likely candidates for cleavage sites which would generate mature HG20 protein, *i.e.*, protein lacking the signal sequence, were identified. The results are shown in Figure 3.

EXAMPLE 2

Expression of HG20 in normal and diseased adrenal tissue

Northern blots were performed to measure the amount of HG20 RNA in normal and diseased adrenal tissue. The results are shown in Table 2 below. The amount of the approximately 6.5 kb HG20 transcript is shown normalized to the amount of β -actin transcript.

Table 2

<u>Pathology</u>	<u>Profile</u>	<u>HG20</u> <u>RNA</u>	<u>Actin</u> <u>RNA</u>	<u>HG20</u> <u>/actin</u>
Pheochromocytoma	M, 30 yr	0.47	0.74	0.64
Adrenal carcinoma cortex	M, 69 yr	0.61	0.80	0.76
Adrenal adenoma cortex	M, 69 yr	0.62	1.15	0.54
Normal Adrenal	M, 26 yr	1.00	1.00	1.00

The results shown in Table 2 indicate that HG20 expression is decreased in diseased states of the adrenal gland. Thus, increasing the

concentration of HG20 in such diseased states is likely to be pharmacologically useful. Accordingly, one skilled in the art would expect agonists of HG20 to be pharmacologically useful.

5

EXAMPLE 3

Tissue distribution of various HG20 RNA transcripts

Table 3, below, shows the results of experiments to measure the amount of HG20 RNA transcripts of various lengths in various tissues. The results shown were derived from a multiple tissue Northern blot that was hybridized overnight in expressHyb solution (Clontech). Washing conditions were: 0.1X SSC, 0.1% SDS, at 60°C. A ³²P-random primer labelled Eco RI fragment containing the full-length native HG20 DNA was used as a hybridization probe. The greater the number of plus signs in a particular tissue, the greater was the amount of HG20 RNA detected in that tissue.

Table 3

Tissue	6.5 kb	4.5 kb	4.0 kb	1.8 kb
cerebellum	++	+		
cerebral cortex	++++	+		
medulla	+	+		
occipital pole	+	+		
frontal lobe	+++	+		
temporal lobe	+++	+		
putamen	++	+		
spinal cord n=2	++	+		
amygdala	+++			
caudate nucleus	+	+		
corpus callosum	+	+		
hippocampus	++	+		
whole brain	+++	+		
substantia nigra	+	+		
subthalamic nucleus	+	+		
thalamus	++	+		

spleen		+		
thymus n=2		++		
prostate		++		
testis n=2	++	+	+++	
ovary		++	+	+
small intestine n=2		++		
colon (mucosal lining)		++		
peripheral blood leucocytes		++		
stomach n=2	+	+		
thyroid n=2	++	++++		
lymph node		+		
trachea		++		
adrenal gland	+++	+++	+	++++
bone marrow		++		
heart	+	++		
brain	+++++			
placenta		+		
lung		+		
liver		+		
skeletal muscle	+	++		
kidney		+		
pancreas	+	+		
adrenal medulla	+++			+
adrenal cortex	+++++		++	++

The distribution of HG20 RNA shown in Table 3 suggests that HG20 mediates activities of the central and peripheral nervous system.

5

EXAMPLE 4

Distribution of HG20 mRNA in brain

Using in situ hybridisation, the distribution of HG20 mRNA in squirrel monkey brain was studied. Antisense oligonucleotide probes to HG20 were generated on an Applied Biosystems Model 394 DNA synthesiser and purified by preparative polyacrylamide electrophoresis.

10

Probe 1: 5'ATC-TGG-GTT-TGT-TCT-CAG-GGT-GAT-GAG-CTT-CGG-CAC-GAA-TAC-CAG 3' (SEQ.ID.NO.:14);

Probe2: 5' GCT-CTG-TGA-TCT-TCA-TTC-GCA-GGC-GAT-GGT-TTT-CTG-ACT-GTA-GGC 3' (SEQ.ID.NO.:15).

5 Each oligonucleotide was 3'-end labelled with [³⁵S] deoxyadenosine 5'-(thiotriphosphate) in a 30:1 molar ratio of ³⁵S-isotope:oligonucleotide using terminal deoxynucleotidyl transferase for 15 min at 37°C in the reaction buffer supplied (Boehringer). Radiolabelled oligonucleotide was separated from unincorporated nucleotides using Sephadex G50 spin
10 columns. The specific activities of the labelled probes in several labelling reactions varied from 1.2-2.3 x 10⁹ cpm/mg. Squirrel monkey brains were removed and fresh frozen in 1 cm blocks. 12 mm sections were taken and fixed for *in situ* hybridisation. Hybridisation of the sections was carried out according to the method of Sirinathsinghji et al., 1993, Neuroreports
15 4:175-178. Briefly, sections were removed from alcohol, air dried and 5 x10⁵ cpm of each ³⁵S-labelled probe (both oligonucleotides) in 100 ml of hybridisation buffer was applied to each slide. Labelled "antisense" probe was also used in the presence of an excess (100x) concentration of unlabelled antisense probe to define non-specific hybridisation. Parafilm
20 coverslips were placed over the sections which were incubated overnight (about 16 hr) at 37°C. Following hybridisation the sections were washed for 1 hr at 57°C in 1xSSC, then rinsed briefly in 0.1xSSC, dehydrated in a series of alcohols, air dried, and exposed to Amersham Hyperfilm bmax X-ray film. Autoradiographs were analysed using a MCID computerised
25 image analysis system (Image Research Inc., Ontario, Canada).

Highest levels of mRNA for HG20 were found in the hippocampus (dentate gyrus, CA3, CA2, and CA1). High levels were also seen in cortical regions (frontal, cingulate, temporal parietal, entorhinal, and visual) and the cerebellum, although medial septum, thalamic nuclei
30 (medial-dorsal and lateral posterior), lateral geniculates, red nucleus, reticular formation, and griseum pontis all show expression of message. While there are many similarities with the distribution reported for the GABA_B receptor mRNA in rat, one marked difference is that expression of HG20 mRNA in the monkey caudate and putamen is below the level of

detection while cortical levels are high. In the rat, the GABA_B receptor mRNA appears equally expressed in striatum as in cortex. Figure 4 illustrates these results.

5

EXAMPLE 5

Attempted recombinant expression of full-length HG20 protein

Following the cloning of HG20 DNA, attempts were made to express full-length HG20 protein (941 amino acids) using various eukaryotic cell lines and expression vectors. The cell lines that were used were: COS-7 cells, HEK293 cells, and frog melanophores. The expression vectors that were used to attempt to express the full-length HG20 protein were: pCR3.1 and pcDNA3.1 (Invitrogen, San Diego, CA) and pciNEO (promega)

All of the attempts to express full-length HG20 described above were unsuccessful. See, *e.g.*, Figure 7, second bar from the left, marked "HG20." See also Figure 5A, lane 1. Although the reason for these failures is not known, it is possible that the highly GC rich nature of the region of the HG20 mRNA that encodes amino acids 1-51 results in the formation of secondary structure in the mRNA that impedes translation. It was only after the construction of an expression vector that encodes a truncated HG20 protein, lacking the first 51 amino acids, that HG20 was successfully expressed. Figure 5A-B shows the results of the successful expression of an HG20 protein having amino acids 52-941. It is expected that expression of HG20 proteins having amino acids 53-941, 54-941, 55-941, *etc.*, could be accomplished in a similar manner. It is also expected that expression of HG20 proteins having the above-described amino termini but having different carboxyl termini could be accomplished in a similar manner as well. Thus, the expression of an HG20 protein having an amino terminus as listed above and having a truncated carboxyl terminus could be accomplished. Alternatively, the carboxyl terminus could be fused to non-HG20 amino acid sequences, forming a chimeric HG20 protein. It is also possible to express HG20

having an amino terminus listed above as a chimeric protein with non-HG20 sequences fused to the amino terminus.

Figure 5A shows the expression of amino acids 52-941 of HG20 as part of a chimeric or fusion protein with the FLAG epitope fused to the amino terminus of the HG20 sequences in a coupled *in vitro* transcription/translation experiment. Figure 5B shows the expression of amino acids 52-941 of HG20 as part of a chimeric or fusion protein with the FLAG epitope fused to the amino terminus of the HG20 sequences in COS-7 cells and melanophores. The expression vector used in this experiment was pcDNA3.1. The expression constructs used in Figure 5A-B also encoded a cleavable signal sequence from the influenza hemagglutinin gene that has been shown to facilitate the membrane insertion of G-protein coupled receptors (Guan et al., 1992, J. Biol. Chem. 267:21995-21998) and the fusion proteins were detected with anti-FLAG antibody. The expression constructs had also been engineered to contain a Kozak consensus sequence prior to the initiating ATG. The amino acid sequences of the hemagglutinin signal sequence and the FLAG epitope were:

[MKTIALSYIFCLVFA] [DYKDDDDK] SEQ.ID.NO:17
HA signal peptide FLAG epitope

Amino acids 57-941 have been expressed in mammalian cells as part of a chimeric protein. A chimeric construct of HG20 was made that consisted of bases -224 to 99 of the bovine GABA_A α 1 gene, a sequence encoding the c-myc epitope tag (amino acid residues 410-419 of the human oncogene product c-myc), a cloning site encoding the amino acid asparagine, and DNA encoding residues 57-941 of HG20. The resultant chimeric protein has the amino acid sequence shown below, with the construct cloned into pcDNA1.1Amp (Invitrogen, San Diego, CA).

____Bovine alpha 1 signal seq____ _c-myc____ _
MKKSPGLSDYLWAWTLFLSTLTGRSYGQPSLQD EQKLISEEDL N
res. 57-941 HG20

SIMGLMPLT... (SEQ.ID.NO.:18)

The three periods "..." indicate that the chimeric protein sequence extends until amino acid 941 of HG20.

5 The cell surface expression of this construct was verified using a cell surface ELISA technique. Briefly, HEK293 cells were seeded at ~1x10⁵ cells per well in a 24 well tissue culture plate and allowed to adhere for 24 hours. Each well was transfected with a total of 1 µg of DNA. In addition to tagged and un-tagged HG20 constructs, c-myc tagged
10 GABA_A α1 was transfected with GABA_A β1 as a positive control for cell surface expression. Two days after transfection, the cells were assayed for surface expression of the c-myc epitope using the 9E10 monoclonal antibody raised to the c-myc epitope, followed by HRP (horse radish peroxidase) conjugated anti-mouse antibody (Promega) and colormetric
15 development using K-Blue (Bionostics). The results are shown in Figure 7. Figure 7 demonstrates that when HG20 is part of a chimeric protein, it can be expressed well in mammalian cells but that when attempts are made to express full-length HG20 (amino acids 1-941) directly, *i.e.*, not as part of a chimeric protein, essentially no expression is observed.

20

EXAMPLE 6

Construction of Full Length Murine GABA_BR1a Coding Region

Using a combination of TFASTX (Pearson et al., 1997, Genomics 46:24-36) and TBLASTX (Altschul et al., 1997, Nucleic Acids
25 Res. 25:3389-3402) searching programs against dbEST: Database of Expressed Sequence Tags (URL <http://www.ncbi.nlm.nih.gov/dbEST/index.html>), we identified partial cDNA clones in the EST collection which encoded murine GABA_BR1a using the rat GABA_B receptor subunit cDNAs (GenBank Accession Numbers Y10369 and Y10370) as probe
30 sequences (Kaupmann et al., 1997, Nature 386:239-246). Two of these ESTs (IMAGE Consortium clone identification numbers 472408 and 319196) were obtained (Research Genetics, Birmingham, Ala). The DNA

sequences of both cDNA clones were determined using standard methods on an ABI 373a automated sequencer (Perkin-Elmer-Applied Biosystems, Foster City, CA).

The partial cDNAs were assembled by long accurate PCR using the following oligonucleotides: 472408 sense: 5' - GC GAATTC GGTACC ATG CTG CTG CTG CTG CTG GTG CCT - 3' (SEQ.ID.NO.:24), 472408 antisense: 5' - GG GAATTC TGG ATA TAA CGA GCG TGG GAG TTG TAG ATG TTA AA - 3' (SEQ.ID.NO.:25), 319196 sense: 5' - CCA GAATTC CCA GCC CAA CCT GAA CAA TC - 3' (SEQ.ID.NO.:26), 319196 antisense: 5' - CG GCGGCCGC TCA CTT GTA AAG CAA ATG TA - 3' (SEQ.ID.NO.:27) which amplified two fragments corresponding to the 5' 2,100 basepairs and 3' 1,000 basepairs of the murine GABAR1a coding region. The PCR conditions were 200 ng of cDNA template, 2.5 units of Takara LA Taq (PanVera, Madison, WI), 25 mM TAPS (pH 9.3), 50 mM KCl, 2.5 mM MgCl₂, 1 mM 2-mercaptoethanol, 100 mM each dNTP and 1 mM each primer with cycling as follows 94°C 1 min, 9 cycles of 98°C for 20 seconds, 72°C-56°C (decreases 2°C per cycle), 72°C for 30 seconds, followed by 30 cycles of 98°C for 20 seconds, 60°C for 3 minutes. A final extension at 72°C for 10 minutes was performed. PCR products were cloned into the TA-Cloning vector pCRII-TOPO (Invitrogen, San Diego, CA) following the manufacturers directions. Cloned PCR products were confirmed by DNA sequencing. To form full-length cDNA, the pCINeo mammalian expression vector was digested with EcoRI and NotI. The EcoRI fragment from PCR cloning of 472408 and the EcoRI/NotI product from PCR cloning of 319196 were ligated in a three part ligation with digested pCINeo vector. The resulting clones were screened by restriction digestion with SstI which cuts once in the vector and once in the 472408 derived fragment. The resulting expression clone is 2,903 basepairs in length. The overall cDNA length, including untranslated sequences, inferred from the full length of the two ESTs is 4,460 basepairs.

EXAMPLE 7

Preparation of membrane fractions

P2 membrane fractions were prepared at 4°C as follows. Tissues or cells were washed twice with cold PBS, collected by centrifugation at 100xg for 7 min, and resuspended in 10 ml of buffer A: 5 mM Tris-HCl, 2 mM EDTA containing (1X) protease inhibitor cocktail Complete® tablets (Boehringer Mannheim), pH 7.4 at 4°C. Tissues or cells were disrupted by polytron homogenization, centrifuged at 100xg for 7 min to pellet unbroken cells and nuclei, and the supernatant collected. The resulting pellet was homogenized a second time in 10 ml of buffer A, centrifuged as described above and supernatant fractions saved. The pooled S1 supernatant was centrifuged at high speed (27 000xg for 20 min) and the pellet was washed once with buffer A, centrifuged (27 000xg for 20 min) and resuspended in buffer A to make the P2 membrane fraction, and stored at -80°C. Protein content was determined using the Bio-Rad Protein Assay Kit according to manufacturer instructions.

EXAMPLE 8

Receptor filter-binding assays

Competition of [¹²⁵I]CGP71872 binding experiments were performed with ~7 µg P2 membrane protein and increasing concentrations of cold ligand (10⁻¹²-10⁻³ M). The concentration of radioligand used in the competition assays was 1 nM (final). Each concentration was examined in duplicate and incubated for 2 hours at 22°C in the dark in a total volume of 250 µL binding buffer: 50 mM Tris-HCl, 2.5 mM CaCl₂ (pH 7.4) with (1X) protease inhibitor cocktail Complete® tablets. Bound ligand was isolated by rapid filtration through a Brandel 96 well cell harvester using Whatman GF/B filters. Data were analysed by nonlinear least-squares regression using the computer-fitting program GraphPad Prism version 2.01 (San Diego).

EXAMPLE 9

Photoaffinity labelling

P2 membranes were resuspended in binding buffer and
5 incubated in the dark with 1 nM final concentration [125 I]CGP71872
(2200 Ci/mmol) in a final volume of 1 ml for 2 h at 22°C. The membranes
were centrifuged at 27,000xg for 10 min and the pellet was washed in ice-
cold binding buffer, centrifuged at 27,000xg for 20 min, resuspended in 1
10 ml of ice-cold binding buffer, and exposed on ice 2 inches from 360 nm
ultraviolet light for 10 min. Photolabelled membranes were washed,
pelleted by centrifugation, and solubilized in sample buffer (50 mM Tris-
HCl pH 6.5, 10% SDS, 10% glycerol, and 0.003% bromophenol blue with
10% 2-mercaptoethanol). Samples were electrophoresed on precast
15 NOVEX 10% Tris-glycine gels, fixed, dried, and exposed to Kodak XAR
film with an intensifying screen at -70°C.

EXAMPLE 10

Immunoprecipitation and immunoblotting of GABA_B receptors

Digitonin solubilized FLAG-tagged HG20 receptors were
20 immunoprecipitated with a mouse anti-FLAG M2 antibody affinity resin
(Kodak IBI) and immunoblot analysis conducted as previously described
(Ng et al., 1996, Biochem. Biophys. Res. Comm. 227:200-204). Following
washing of the immunoprecipitate, the pellet was resuspended in SDS
sample buffer and subjected to SDS-PAGE and immunoblotted with
25 affinity purified GABA_BR1a-specific antibodies 1713.1 (raised against the
peptide acetyl-DVNSRRDILPDYELKLC-amide (a portion of
SEQ.ID.NO.:20)) and 1713.2 (raised against the peptide acetyl-
CATLHNPTRVKLFK-amide (a portion of SEQ.ID.NO.:20)).

EXAMPLE 11

Melanophore functional assay

Growth of *Xenopus laevis* melanophores and fibroblasts was performed as described previously (Potenza et al., 1992, Anal. Biochem. 206:315-322). The cells (obtained from Dr. M.R. Lerner, Yale University) were collected by centrifugation at 200xg for 5 min at 4°C, and resuspended at 5 x 10⁶ cells per ml in ice cold 70% PBS, pH 7.0. DNA encoding the relevant GPCR was transiently transfected into melanophores by electroporation using a BTX ECM600 electroporator (Genetronics, Inc., San Diego, CA). To monitor the efficiency of transfection, two internal control GPCRs were used independently (pcDNA1amp-cannabinoid 2 and pcDNA3-thromboxane A2; (Lerner, 1994, Trends Neurosci. 17:142-146)). Cells were electroporated using the following settings: capacitance of 325 microfarad, voltage of 450 volts, and resistance of 720 ohms. Following electroporation, cells were mixed with fibroblast-conditioned growth medium and plated onto flat bottom 96 well microtiter plates (NUNC). 24 hrs after the transfection, the media was replaced with fresh fibroblast-conditioned growth media and incubated for an additional day at 27°C prior to assaying for receptor expression. For Gs/Gq-coupling responses (resulting in pigment dispersion), cells were incubated in 100 µl of 70% L-15 media containing 15 mM HEPES, pH 7.3, and melatonin (0.8 nM final concentration) for 1 hr in the dark at room temperature, and then incubated in the presence of melatonin (0.8 nM final concentration) for 1 h in the dark at room temperature to induce pigment aggregation. For Gi-coupled responses (resulting in pigment aggregation), cells were incubated in the presence of 100 µl/well of 70% L-15 media containing 2.5% fibroblast-conditioned growth medium, 2 mM glutamine, 100 µg /ml streptomycin, 100 units/ml penicillin and 15 mM HEPES, pH 7.3, for 30 min in the dark at room temperature to induce pigment dispersion. Absorbance readings at 600 nm were measured using a Bio-Tek Elx800 Microplate reader (ESBE Scientific) before (Ai) and after

(Af) incubation with ligand (GABA; 1.5 hr in the dark at room temperature).

EXAMPLE 12

5 Stable and transient transfections and determination of cAMP response in HEK293 cells

 HG20 and murine GABA_BR1a cDNAs were subcloned into pcDNA3.1 (Invitrogen, San Diego, CA) and used to transfect HEK293 cells. Stably expressing cells were identified after selection in geneticin
10 (0.375 mg/ml) by dot blot analysis. For co-expression experiments, the stable cell lines hgb2-42 (expressing HG20) and rgb1a-50 (expressing murine GABA_BR1a) were transiently transfected with murine GABA_BR1a and HG20, respectively, in pcDNA3.1 and cells were assayed for cAMP responses.

15 Wild-type HEK293 cells, or HEK293 cells stably and transiently expressing HG20 and murine GABA_BR1a receptors were lifted in 1X PBS, 2.5 mM EDTA, counted, pelleted and resuspended at 1.5×10^5 cells per 100 μ l in Krebs-Ringer-Hepes medium (Blakely et al., 1991, Anal. Biochem. 194:302-308), 100 mM Ro 20-1724 (RBI) and incubated at
20 37°C for 20 min. 100 μ l of cells was added to 100 μ l of prewarmed (37°C, 10 min) Krebs-Ringer-Hepes medium, 100 mM Ro 20-1724 without or with agonist and/or 10 μ M forskolin. Incubations with GABA included 100 μ M aminooxyacetic acid (a GABA transaminase inhibitor) to prevent breakdown of GABA and 100 μ M nipecotic acid to block GABA uptake.
25 Following a 20 min incubation at 37°C, the assay was terminated by setting the cells on ice and centrifuging at 2,000 rpm for 5 min at 4°C. 175 ml of assay solution was removed and replaced with 175 ml of 0.1 N hydrochloric acid, 0.1 mM calcium chloride and cells were set on ice for 30
30 min and then stored at -20°C. cAMP determinations were made using a solid phase modification (Maidment et al., 1989, Neurosci. 33:549-557) of the cAMP radioimmunoassay described by Brooker et al. 1979, Adv. Cyclic Nucl. Res. 10:1-33) and previously reported in Clark et al., 1998, Mol.

Endocrinol. 12:193-206). Immulon II removable wells (Dynatech; Chantilly, VA) were coated overnight with 100 μ l of protein G (1mg/ml in 0.1M NaHCO₃, pH 9.0) at 4°C. Prior to use, protein G-coated plates were rinsed with PBS-gelatin-Tween (phosphate buffered saline containing 0.1% gelatin, 0.2% Tween-20) 3 times quickly, and then once for 30 minutes. Following the rinse with PBS-gelatin-Tween, the RIA was set up by adding 100 μ l 50 mM sodium acetate, pH 4.75, cAMP standards or aliquots from treated cells, 5,000-7,000 cpm ¹²⁵I-succinyl cAMP, and 25 μ l of a sheep antibody to cAMP diluted in 50 mM sodium acetate, pH 4.75 (Atto instruments; dilution of stock to 2.5x10⁻⁵, determined empirically) to the plates in a final volume of 175 μ l. Plates were incubated 2 hr at 37°C or overnight at 4°C, rinsed 3 times with sodium acetate buffer, blotted dry, and then individual wells were broken off and bound radioactivity was determined in a gamma counter.

EXAMPLE 13

In situ hybridization for co-localization experiments

Preparation of rat brain sections, prehybridization and hybridization of rat brain slices was performed as described previously (Bradley et al., 1992, J. Neurosci. 12:2288-2302; <http://intramural.nimh.nih.gov/lcmr/snge/Protocol.html>). Adjacent coronal rat brain sections were hybridized with labeled antisense and sense riboprobes directed against HG20 (GenBank accession number AF058795) or murine GABABR1a.

HG20 probes were generated by amplification of HG20 with JC216 (T3 promotor/primer and bases 1172-1191) paired with JC217 (T7 promotor/primer and bases 1609-1626) or with JC218 (T3 promotor/primer and bases 2386-2405) paired with JC219 (T7 promotor/primer and bases 2776-2793):
(JC216: cgcgcaattaaccctcactaaaggACAACAGCAAACGTTTCAGGC (SEQ.ID.NO.:28);

JC217: gcgcgtaatacg actcactatagggCATGCCTATGATGGTGAG
(SEQ.ID.NO.:29);

JC218: cgcgcaattaaccctcactaaagg CTGAGGACAAACCCTGACGC
(SEQ.ID.NO.:30);

5 JC219: gcgcgtaatacgactcactatagggGATGTC TTCTATGGGGTC;
(SEQ.ID.NO.:31)).

Murine GABA_BR1a probes were generated by amplification
of murine GABA_BR1a with JC160 (T3 promotor/primer and bases 631-
648) paired with JC161 (T7 promotor/primer and bases 1024-1041):

10 (JC160: cgcgcaattaaccctcactaaaggAAGCTTATCCACCACGAC
(SEQ.ID.NO.:32);

JC161:gcgcgtaa tacgactcactatagggAGCTGGATCCGAGAAGAA
(SEQ.ID.NO.:33)).

For colocalization experiments, murine GABA_BR1a probes
15 were labeled with digoxigenin-UTP and detected using a peroxidase-
conjugated antibody to digoxigenin and TSA amplification involving
biotinyl tyramide and subsequent detection with streptavidin-conjugated
fluorescein. HG20 probes were radiolabelled
([http://intramural.nimh.nih.gov/lcmr/snge/Protocol.](http://intramural.nimh.nih.gov/lcmr/snge/Protocol.html)
20 [html](http://intramural.nimh.nih.gov/lcmr/snge/Protocol.html)). For individual hybridizations, murine GABA_BR1a and HG20
riboprobes were radiolabeled with ³⁵S-UTP and detected as described
previously (Bradley et al., 1992, J. Neurosci. 12:2288-2302;
<http://intramural.nimh.nih.gov/lcmr/snge/Protocol.html>). Brain slices
were either hybridized with individual radiolabelled probes or, for
25 colocalization studies, simultaneously with probes to both murine
GABA_BR1a and HG20 receptors. Detection of the radiolabeled HG20
probe was performed after detection of the digoxigenin-labeled rgb1 probe
on the same brain slices.

EXAMPLE 14

Construction of N-terminal and C-terminal fragments of murine GABABR1a

The N-terminal fragment of murine GABABR1a, comprising
5 amino acid positions 1-625, was generated by PCR. The coding sequence of
the N-terminal fragment was amplified by using primer pairs: NFP-
CJ7843F139 (5'- ACC ACT GCT AGC ACC GCC ATG CTG CTG CTG
CTG CTT CTG C -3'; SEQ.IS.NO.:34) and NRP-CJ7844 (3'- GG GTG CGA
GCA ATA TAG GTC TTA AGG GTC GGC CGC CGG CGT CAC CA -5'; ;
10 SEQ.IS.NO.:35). Similarly, the C-terminal fragment, amino acid positions
588-942, was generated by PCR using primer pairs: CFP-CJ7845 (5'- ACC
ACT GCT AGC ACC GCC ATG CAG AAA CTC TTT ATC TCC GTC TCA
GTT CTC TCC AGC-3'; ; SEQ.IS.NO.:36) and CRP-CJ7846 (3'- CAG CTC
ATG TAA ACG AAA TGT TCA CTC GCC GGC CGC CGG CGT CAC CA-
15 5'; ; SEQ.IS.NO.:37). PCR reactions were carried out using the
Advantage-HF PCR kit (Clontech, Paolo Alto, CA) with 0.2 ng of murine
GABABR1a DNA as the template, and 10 µM of each primer according to
manufacturer instructions. The PCR conditions were as follows: precycle
denaturation at 94°C for 1 min, and then 35 cycles at 94°C (15 s),
20 annealing and extension at 72°C (3 min), followed by a final extension for
3 min at 72°C. The PCR products, N-gb 1a and C-gb 1a DNA, flanked by
Nhe1 and Not1 sites, were digested and subcloned into the Nhe1/Not1 site
of pcDNA3.1 (Invitrogen, San Diego, Ca).

25

EXAMPLE 15

Cell culture and preparation of membrane fractions for binding experiments using N-terminal and C-terminal GABABR1a fragments

COS-7 cells (ATCC) were cultured in DMEM, 10% bovine
serum, 25 mM HEPES, and antibiotics and transiently transfected with
30 murine gb1a/pcDNA3.1 (encoding full-length GABABR1a), N-gb

1a/pcDNA3.1 (encoding the N-terminal fragment of GABABR1a; see Example 14) or C-gb 1a/pcDNA3.1 (encoding the C-terminal fragment of GABABR1a; see Example 14) using Lipofectamine reagent (Gibco BRL) following the conditions recommended by the manufacturer. At 48 h post-transfection, P2 membrane fractions were prepared at 4°C as follows: Cells were washed twice with cold PBS, collected by centrifugation at 100xg for 7 min, and resuspended in 10 ml of buffer A: 5 mM Tris-HCl, 2 mM EDTA containing (1X) protease inhibitor cocktail Complete® tablets (Boehringer Mannheim), pH 7.4 at 4°C. Cells were disrupted by polytron homogenization, centrifuged at 100xg for 7 min to pellet unbroken cells and nuclei, and the supernatant collected. The resulting pellet was homogenized a second time in 10 ml of buffer A, centrifuged as described above and supernatant fractions saved. The pooled S1 supernatant was centrifuged at high speed (27,000xg for 20 min) and the pellet was washed once with buffer A, centrifuged (27,000xg for 20 min), resuspended in buffer A to make the P2 membrane fraction, and stored at -80°C. Protein content was determined using the Bio-Rad Protein Assay Kit according to manufacturer instructions.

20

EXAMPLE 16

In vitro transcription/translation of GABABR1a and N-terminal and C-terminal fragments

In vitro transcription coupled translation reactions were performed in the presence of [³⁵S]-methionine in the TNT Coupled Reticulocyte Lysate system (Promega, WI) using the pcDNA3.1 plasmid containing the full-length GABABR1a, N-gb1a, and C-gb1a DNAs. Translation products were analysed by electrophoresis on 8-16% Tris-Glycine gradient gels (Novex pre-cast gel system) under denaturing and reducing conditions. Gels were fixed, treated with enlightening fluid (NEN), dried and exposed to Kodak X-AR film at -70°C for 4 to 24 h. Analysis of the results of these *in vitro* transcription coupled translation reactions confirmed that the constructs whose production is described in Example 14 directed the

expression of the appropriate GABABR1a fragments (see Figure 17A).

EXAMPLE 17

5 Immunoblot analysis for experiments with N-terminal and C-terminal
fragments of GABABR1a

The expression of full-length and N-terminal and C-terminal GABABR1a fragments *in vivo* was confirmed by immunoblot analysis. Membranes were solubilized in SDS sample buffer consisting of 50 mM Tris-HCl pH 6.5, 10% SDS, 10% glycerol, and 0.003% bromophenol blue
10 with 10% 2-mercaptoethanol and separated on SDS-PAGE. The full-length receptor and N-terminal fragment were detected using affinity purified rabbit GABABR1a polyclonal antibody 1713.1 (acetyl-DVNSRRDILPDYELKLC-amide; a portion of SEQ.ID.NO.:20) and 1713.2 (acetyl-CATLHNPTRVKLF EK-amide; a portion of SEQ.ID.NO.:20)
15 (Quality Control Biochemicals (Hopkinton, MA). The C-terminal fragment was detected using a GABABR1a antibody raised against the C-terminal tail of the receptor (acetyl-PSEPPDRLSCDGSRVHLLYK-amide; SEQ.ID.NO.:20) (Chemicon Int., Inc., Canada).

20

EXAMPLE 18

Receptor filter-binding assays for experiments with N-terminal and C-terminal fragments of GABABR1a

Competition of [¹²⁵I] CGP71872 binding experiments were performed with ~7 µg P2 membrane protein and increasing
25 concentrations of cold ligand (10⁻¹²-10⁻³ M). The concentration of radioligand used in the competition assays was 1 nM (final). Each concentration was examined in duplicate and incubated for 2 hr at 22°C in the dark in a total volume of 250 µL binding buffer: 50 mM Tris-HCl, 2.5 mM CaCl₂ (pH 7.4) with (1X) protease inhibitor cocktail Complete®
30 tablets. Bound ligand was isolated by rapid filtration through a Brandel

96 well cell harvester using Whatman GF/B filters. Data were analysed by nonlinear least-squares regression using the computer-fitting program GraphPad Prism version 2.01 (San Diego).

5

EXAMPLE 19

Photoaffinity labeling for experiments with N-terminal and C-terminal fragments of GABAR1a

P2 membranes were resuspended in binding buffer, and incubated in the dark with 1 nM final concentration [¹²⁵I]CGP71872 (2200 Ci/mmol) in a final volume of 1 ml for 2 h at 22°C. The membranes were centrifuged at 27,000xg for 10 min and the pellet was washed in ice-cold binding buffer, centrifuged at 27,000xg for 20 min and resuspended in 1 ml of ice-cold binding buffer and exposed on ice 2 inches from 360 nm ultraviolet light for 10 min. Photolabeled membranes were washed and membranes pelleted by centrifugation and solubilized in sample buffer (50 mM Tris-HCl pH 6.5, 10% SDS, 10% glycerol, and 0.003% bromophenol blue with 10% 2-mercaptoethanol). Samples were electrophoresed on precast NOVEX 10% Tris-glycine gels, fixed, dried, and exposed to Kodak XAR film with an intensifying screen at -70°C.

20

EXAMPLE 20

Construction of the FLAG epitope-tagged HG20 and detection of expression in vitro and in COS-1 cells

25

The FLAG epitope-tagged HG20 receptor subunit was constructed by PCR using a sense primer encoding a modified influenza hemagglutinin signal sequence (MKTIIALSYIFCLVFA; a portion of SEQ.ID.NO.:17) (Jou et al., 1980, Cell 19:683-696) followed by an antigenic FLAG epitope (DYKDDDDK; a portion of SEQ.ID.NO.:17) and DNA encoding amino acids 52-63 of HG20 and an antisense primer encoding amino acids 930-941 of the HG20 in a high-fidelity PCR reaction

30

with HG20/pCR 3.1 as a template. HG20/pCR 3.1 is a plasmid that contains full-length HG20 (SEQ.ID.NO.:2) cloned into pCR3.1. The nucleotide sequences of the sense and antisense primers are: sense: 5'-GCC GCT AGC GCC ACC ATG AAG ACG ATC ATC GCC CTG AGC TAC
5 ATC TTC TGC CTG GTA TTC GCC GAC TAC AAG GAC GAT GAT GAC AAG AGC AGC CCG CCG CTC TCC ATC ATG GGC CTC ATG CCG CTC-3', (SEQ.ID.NO.:38); antisense: 5'-GCC TCT AGA TTA CAG GCC CGA GAC CAT GAC TCG GAA GGA GGG TGG CAC-3'. (SEQ.ID.NO.:39). The PCR conditions were: precycle denaturation at 94°C for 1 min, 94°C for 30
10 sec, annealing and extension at 72°C for 4 min for 25 cycles, followed by a 7 min extension at 72°C. The PCR product, SF-HG20 DNA, flanked by *NheI* and *XbaI* sites was subcloned into the *NheI/XbaI* site of pcDNA3.1 (Invitrogen, San Diego, Ca) to give rise to the expression construct SF-HG20/pcDNA3.1. The sequence of this construct was verified on both
15 strands.

The SF-HG20 receptor was expressed in an *in vitro* coupled transcription/translation reaction using the TNT Coupled Reticulocyte Lysate system (Promega, WI) in the presence of [³⁵S]methionine according to the manufacturer instructions. Radiolabeled proteins were
20 analyzed by electrophoresis on 8-16% Tris-Glycine gradient gels (Novex pre-cast gel system) under denaturing and reducing conditions. Gels were fixed and treated with Enlightening fluid (NEN), dried and exposed to Kodak X-AR film at -70°C.

COS-1 cells (ATCC, CRL 1650) were cultured in DMEM, 10%
25 bovine serum, 25 mM HEPES, pH 7.4, and 10 units/mL penicillin- 10 µg/mL streptomycin. Transient transfection of COS-1 cells with SF-HG20/pcDNA 3.1 was carried out using Lipofectamine reagent (Gibco BRL) following the conditions recommended by the manufacturer. At 48 h post-transfection, crude membranes were prepared and receptors were
30 solubilized with digitonin and immunoprecipitated with anti-FLAG M2 affinity gel resin (IBI) under previously described conditions (Ng et al., 1993). The immunoprecipitate was washed and solubilized in SDS sample buffer, sonicated, electrophoresed, and blotted on to nitrocellulose membrane as described (Ng et al., 1993). The FLAG-tagged HG20

receptor was detected using an anti-FLAG antibody (Santa Cruz Biotech., Inc.) by following a chemilumescence protocol of the manufacturer (NEN).

EXAMPLE 21

5 Kir channel activity in *Xenopus* oocytes

With the following modifications, *Xenopus* oocytes were isolated as described (Hébert et al., 1994, Proc. R. Soc. Lond. B 256:253-261) from live frogs supplied by Boreal, Inc. After a brief (10 min) hypertonic shock with 125 mM potassium phosphate pH 6.5, oocytes were
10 allowed to recover in Barth's solution for 1-2 hr. cDNA constructs for human Kir 3.1, Kir 3.2 channel isoforms (generous gifts from Dr. Hubert Van Tol, University of Toronto), and $G\alpha 1$ (a generous gift of Dr. Maureen Linder, Washington University) were linearized by restriction enzymes and purified using GeneClean (Bio 101). Murine GABABR1a or FLAG-HG20 clones were subcloned into pT7TS (a generous gift of Dr. Paul
15 Krieg, University of Texas) before linearization and transcription. Capped cRNA was made using T7 RNA polymerase and the mMessage mMachine (Ambion). Individual oocytes were injected with 5-10 ng (in 25-50 nL) of Kir3.1 and Kir3.2 constructs with mRNAs for murine
20 GABABR1a or FLAG-HG20 and in combination with $G\alpha 1$ as well. Kir currents were also evaluated in oocytes co-injected with Kir3.1, Kir3.2, murine GABABR1a and FLAG-HG20 mRNAs. Currents were recorded after 48 hr. Standard recording solution was KD-98, 98 mM KCl, 1 mM $MgCl_2$, 5 mM K-HEPES, pH 7.5, unless otherwise stated. Microelectrodes
25 were filled with 3 M KCl and had resistances of 1-3 MW and 0.1-0.5 MW for voltage and current electrodes, respectively. In addition, current electrodes were backfilled with 1% agarose (in 3M KCl) to prevent leakage as described (Hébert et al., 1994, Proc. R. Soc. Lond. B 256:253-261). Recordings were made at room temperature using a Geneclamp 500
30 amplifier (Axon Instruments). Oocytes were voltage clamped and perfused continuously with different recording solutions. Currents were evoked by 500 msec voltage commands from a holding potential of -10

mV, delivered in 20 mV increments from -140 to 60 mV to test for inward rectifying potassium currents. Data were recorded at a holding potential of -80 mV and drugs were added to the bath with a fast perfusion system. Data collection and analysis were performed using pCLAMP v6.0 (Axon Instruments) and Origin v4.0 (MicroCal) software. For subtraction of endogenous and leak currents, records were obtained in ND-96, 96 mM NaCl, 2 mM KCl, 1 mM MgCl₂, 5 mM Na-HEPES and these were subtracted from recordings in KD-98 before further analysis.

EXAMPLE 22

Radiation Hybrid mapping of HG20

Radiation hybrid analysis assigned the HG20 gene to chromosome 9, placing it 4.81 cR from the WI-8684 marker on the GeneBridge 4 panel of 93 RH clones of the whole human genome.

Searching of the OMIM database with D9S176 and D9S287 markers proximal to the HG20 gene revealed it to map proximal to the hereditary sensory neuropathy type 1 (HSN-1) locus, a ~8 cM region flanked by D9S176 and 9S318 (Nicholson et al., 1996, Nature Genetics 13, 101-104) (Figure 20). HSN-1 is the most common form of a group of degenerative disorders of sensory neurons characterized by a progressive degeneration of dorsal root ganglion and motor neurons that lead to distal sensory loss, distal muscle wasting and weakness, and neural deafness, among a number of other neuronally related deficits (Nicholson et al., 1996, Nature Genetics 13, 101-104). FCMD (Fukuyama congenital muscular dystrophy) and DYS (dysautonomia, another type of HSN) also map to this area. Candidate gene(s) in these disorders are likely critical to the development, survival, and differentiation of neurons.

A human BAC library was screened using the EcoRI fragment containing the full-length HG20 DNA, and end-sequencing was performed on BAC clones designated 6D18, 168K19, 486B24, and 764N4. The primer pair: ngflt7+ (5'-AAC AGT CAA AAC CCA CCC AG-3'; SEQ.ID.NO.:40) and ngflt7- (5'-AAC AGT TTC CAG CTG TGC CT-3';

SEQ.ID.NO.:41) were identified for radiation hybrid mapping of the HG20 gene on the GENEBRIDGE 4 panel. BAC library screening and radiation hybrid mapping were performed by Research Genetics (Huntsville, AL).

5 The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

10 Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

WHAT IS CLAIMED:

1. An isolated DNA molecule encoding an HG20 polypeptide comprising an amino acid sequence selected from the group consisting of:

5
10
15
SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.

2. The isolated DNA molecule of claim 1 comprising a nucleotide sequence selected from the group consisting of:

20
25
30
SEQ.ID.NO.:1;
Positions 293-3,115 of SEQ.ID.NO.:1;
Positions 317-3,115 of SEQ.ID.NO.:1;
Positions 395-3,115 of SEQ.ID.NO.:1;
Positions 398-3,115 of SEQ.ID.NO.:1;
Positions 404-3,115 of SEQ.ID.NO.:1;
Positions 407-3,115 of SEQ.ID.NO.:1;
Positions 416-3,115 of SEQ.ID.NO.:1;
Positions 422-3,115 of SEQ.ID.NO.:1;
Positions 428-3,115 of SEQ.ID.NO.:1;
Positions 446-3,115 of SEQ.ID.NO.:1; and
Positions 461-3,115 of SEQ.ID.NO.:1.

3. An isolated DNA molecule that hybridizes under stringent conditions to the DNA molecule of claim 2.

4. An expression vector comprising the DNA of claim 1.
5. A recombinant host cell comprising the expression vector of claim 4.
6. The recombinant cell of claim 5 further comprising an expression vector comprising DNA encoding a protein selected from the group consisting of:
7. A protein, substantially free from other proteins, comprising an HG20 protein having an amino acid sequence selected from the group consisting of:
- SEQ.ID.NO.:2;
Positions 9-941 of SEQ.ID.NO.:2;
Positions 35-941 of SEQ.ID.NO.:2;
Positions 36-941 of SEQ.ID.NO.:2;
Positions 38-941 of SEQ.ID.NO.:2;
Positions 39-941 of SEQ.ID.NO.:2;
Positions 42-941 of SEQ.ID.NO.:2;
Positions 44-941 of SEQ.ID.NO.:2;
Positions 46-941 of SEQ.ID.NO.:2;
Positions 52-941 of SEQ.ID.NO.:2; and
Positions 57-941 of SEQ.ID.NO.:2.
8. A heterodimer comprising the protein of claim 7 and a G-protein coupled receptor protein where the heterodimer is substantially free from other proteins.
9. The heterodimer of claim 8 where the heterodimer is held together by N-terminal Sushi repeats, C-terminal alpha-helical

interacting domains, coiled-coil domains, transmembrane interactions, or disulfide bonds.

10. A polypeptide comprising a coiled-coil domain from a
5 first GABA_B receptor subunit and no other contiguous amino acid
sequences longer than 5 amino acids from the first GABA_B receptor
subunit where the coiled-coil domain is present in the C-terminus of the
GABA_B receptor subunit and mediates heterodimerization of the first
GABA_B receptor subunit with a second GABA_B receptor subunit.

10

11. The polypeptide of claim 10 where the coiled-coil
domain is selected from the group consisting of: positions 756-829 of
SEQ.ID.NO.:2; positions 779-814 of SEQ.ID.NO.:2; positions 886-949 of
SEQ.ID.NO.:21; and positions 889-934 of SEQ.ID.NO.:21.

15

12. An isolated DNA molecule encoding a GABA_BR1a
polypeptide comprising the amino acid sequence SEQ.ID.NO.:20.

13. A protein, substantially free from other proteins,
20 comprising a GABA_BR1a protein having the amino acid sequence
SEQ.ID.NO.:20.

14. A method for determining whether a substance binds
GABA_B receptors and is thus a potential agonist or antagonist of the
25 GABA_B receptor that comprises:

(a) providing cells comprising an expression vector
encoding HG20 and an expression vector encoding GABA_BR1a or
GABA_BR1b;

(b) culturing the cells under conditions such that HG20
30 and GABA_BR1a or GABA_BR1b are expressed and heterodimers of HG20
and GABA_BR1a or GABA_BR1b are formed;

(c) exposing the cells to a labeled ligand of GABA_B
receptors in the presence and in the absence of the substance;

(d) measuring the binding of the labeled ligand to the heterodimers of HG20 and GABABR1a or GABABR1b;

where if the amount of binding of the labeled ligand is less in the presence of the substance than in the absence of the substance, then
5 the substance is a potential agonist or antagonist of GABAB receptors.

15. A method of identifying agonists and antagonists of HG20 comprising:

(a) providing test cells by transfecting cells with:
10 (1) an expression vector that directs the expression of HG20 in the cells; and

(2) an expression vector that directs the expression of GABABR1a or GABABR1b in the cells;

(b) exposing the test cells to a substance that is suspected
15 of being an agonist of the GABAB receptor;

(c) measuring the amount of a functional response of the test cells that have been exposed to the substance;

(d) comparing the amount of the functional response exhibited by the test cells with the amount of the functional response
20 exhibited by control cells;

wherein if the amount of the functional response exhibited by the test cells differs from the amount of the functional response exhibited by the control cells, the substance is an agonist or antagonist of the GABAB receptor;

25 where the control cells are cells that have not been transfected with HG20 and GABABR1a or GABABR1b but have been exposed to the substance or are test cells that have not been exposed to the substance.

30 16. A method of producing functional GABAB receptors in cells comprising:

(a) transfecting cells with:
(1) an expression vector that directs the expression of HG20 in the cells; and

(2) an expression vector that directs the expression of GABA β R1a or GABA β R1b in the cells;

(b) culturing the cells under conditions such that heterodimers of HG20 and GABA β R1a or GABA β R1b are formed where the heterodimers constitute functional GABA β receptors.

17. An antibody that binds specifically to HG20 where HG20 has an amino acid sequence selected from the group consisting of:

SEQ.ID.NO.:2;

10

Positions 9-941 of SEQ.ID.NO.:2;

Positions 35-941 of SEQ.ID.NO.:2;

Positions 36-941 of SEQ.ID.NO.:2;

Positions 38-941 of SEQ.ID.NO.:2;

Positions 39-941 of SEQ.ID.NO.:2;

15

Positions 42-941 of SEQ.ID.NO.:2;

Positions 44-941 of SEQ.ID.NO.:2;

Positions 46-941 of SEQ.ID.NO.:2;

Positions 52-941 of SEQ.ID.NO.:2; and

Positions 57-941 of SEQ.ID.NO.:2.

20

18. A method of expressing a truncated version of HG20 protein comprising:

(a) transfecting a host cell with an expression vector that encodes an HG20 protein that has been truncated at the amino terminus;

25

(b) culturing the transfected cells of step (a) under conditions such that the truncated HG20 protein is expressed.

19. A chimeric HG20 protein having an amino acid sequence of HG20 selected from the group consisting of:

30

Positions 51-941 of SEQ.ID.NO.:2;

Positions 52-941 of SEQ.ID.NO.:2;

Positions 53-941 of SEQ.ID.NO.:2;

Positions 54-941 of SEQ.ID.NO.:2;

Positions 55-941 of SEQ.ID.NO.:2;

Positions 56-941 of SEQ.ID.NO.:2;
Positions 57-941 of SEQ.ID.NO.:2; and
Positions 58-941 of SEQ.ID.NO.:2;
covalently linked at the N-terminus with a non-HG20 amino acid
5 sequence.

1/35

1 CCGCCCTCCC CCGGCCGAGC TCCAGGGCTG CCGCCTAGCA GCTCCCGGCG
51 GGAGAGCGGT TCAGAGCTCG CTCCCACCCC TTCCCGGCGT GATTGATCCG
101 TCACGGGCGC CTCCGCTGCC GCCGCCGCCG CCGCGGCGGT TCTGAGCCGA
151 GCCGGAACCC TAGCCCGAGA CGGAGCCGGG GCCCGGGCCG GCGCCATTGC
201 GCGGGCGCCG CGGGAAGACC TTGGCGCGGG GCGGCGGGCC GGGCCAGGCC
251 ATGCGGGCCG AGTGAGCCGG CGCCCGCAGC CCGCGGCGCG GCATGGCTTC
301 CCCGCGGAGC TCCGGGCAGC CCGGGCGGCC GCCGCGCCG CCACCGCCGC
351 CCGCGCGCCT GCTACTGCTA CTGCTGCTGC CGCTGCTGCT GCCTCTGGCG
401 CCCGGGGCCT GGGGCTGGGC GCGGGGCGCC CCCC GGCCGC CGCCAGCAG
451 CCCGCCGCTC TCCATCATGG GCCTCATGCC GCTCACCAAG GAGGTGGCCA
501 AGGGCAGCAT CGGGCGCGGT GTGCTCCCCG CCGTGGAAGT GGCCATCGAG
551 CAGATCCGCA ACGAGTCACT CCTGCGCCCC TACTTCCTCG ACCTGCGGCT
601 CTATGACACG GAGTGCGACA ACGCAAAGG GTTGAAAGCC TTCTACGATG
651 CAATAAAATA CGGGCCGAAC CACTTGATGG TGT TTGGAGG CGTCTGTCCA
701 TCCGTCACAT CCATCATTGC AGAGTCCCTC CAAGGCTGGA ATCTGGTGCA
751 GCTTTCTTTT GCTGCAACCA CGCCTGTTCT AGCCGATAAG AAAAAATACC
801 CTTATTTCTT TCGGACCGTC CCATCAGACA ATGCGGTGAA TCCAGCCATT
851 CTGAAGTTGC TCAAGCACTA CCAGTGGAAG CGCGTGGGCA CGCTGACGCA
901 AGACGTTTCA AGGTTCTCTG AGGTGCGGAA TGACCTGACT GGAGTTCTGT
951 ATGGCGAGGA CATTGAGATT TCAGACACCG AGAGCTTCTC CAACGATCCC
1001 TGTACCAAGT TCAAAAAGCT GAAGGGGAAT GATGTGCGGA TCATCCTTGG
1051 CCAGTTTGAC CAGAATATGG CAGCAAAGT GTTCTGTTGT GCATACGAGG
1101 AGAACATGTA TGGTAGTAAA TATCAGTGGA TCATTCCGGG CTGGTACGAG
1151 CCTTCTTGGT GGGAGCAGGT GCACACGGAA GCCAACTCAT CCCGCTGCCT
1201 CCGGAAGAAT CTGCTTGCTG CCATGGAGGG CTACATTGGC GTGGATTTTCG
1251 AGCCCCTGAG CTCCAAGCAG ATCAAGACCA TCTCAGGAAA GACTCCACAG
1301 CAGTATGAGA GAGAGTACAA CAACAAGCGG TCAGGCGTGG GGCCAGCAA
1351 GTTCCACGGG TACGCTACG ATGGCATCTG GGTCATCGCC AAGACACTGC
1401 AGAGGGCCAT GGAGACACTG CATGCCAGCA GCCGGCACCA GCGGATCCAG
1451 GACTTCAACT ACACGGACCA CACGCTGGGC AGGATCATCC TCAATGCCAT
1501 GAACGAGACC AACTTCTTCG GGGTCACGGG TCAAGTTGTA TTCCGGAATG
1551 GGGAGAGAAT GGGGACCATT AAATTTACTC AATTTCAAGA CAGCAGGGAG
1601 GTGAAGGTGG GAGAGTACAA CGCTGTGGCC GACACACTGG AGATCATCAA
1651 TGACACCATC AGGTTCCAAG GATCCGAACC ACCAAAAGAC AAGACCATCA
1701 TCCTGGAGCA GCTGCGGAAG ATCTCCCTAC CTCTCTACAG CATCCTCTCT
1751 GCCCTACCA TCCTCGGGAT GATCATGGCC AGTGCTTTTC TCTTCTTCAA
1801 CATCAAGAAC CGGAATCAGA AGTCCATAAA GATGTCGAGT CCATACATGA
1851 ACAACCTTAT CATCCTTGGA GGGATGCTCT CCTATGCTTC CATATTTCTC
1901 TTTGGCCTTG ATGGATCCTT TGTCTTGAA AAGACCTTG AAACACTTTG
1951 CACCGTCAGG ACCTGGATTG TCACCGTGGG CTACACGACC GCTTTTGGGG
2001 CCATGTTTGC AAAGACCTGG AGAGTCCACG CCATCTTCAA AAATGTGAAA
2051 ATGAAGAAGA AGATCATCAA GGACCAGAAA CTGCTTGTA TCGTGGGGGG
2101 CATGCTGCTG ATCGACCTGT GTATCCTGAT CTGCTGGCAG GCTGTGGACC
2151 CCCTGCGAAG GACAGTGGAG AAGTACAGCA TGGAGCCGGA CCCAGCAGGA

FIG. 1A

SUBSTITUTE SHEET (RULE 26)

2/35

2201 CGGGATATCT CCATCCGCCC TCTCCTGGAG CACTGTGAGA ACACCCATAT
2251 GACCATCTGG CTTGGCATCG TCTATGCCTA CAAGGGACTT CTCATGTTGT
2301 TCGGTTGTTT CTTAGCTTGG GAGACCCGCA ACGTCAGCAT CCCCAGCACTC
2351 AACGACAGCA AGTACATCGG GATGAGTGTC TACAACGTGG GGATCATGTG
2401 CATCATCGGG GCCGCTGTCT CCTTCCTGAC CCGGGACCAG CCCAATGTGC
2451 AGTTCTGCAT CGTGGCTCTG GTCATCATCT TCTGCAGCAC CATCACCTC
2501 TGCCTGGTAT TCGTGCCGAA GTCATCACC CTGAGAACAA ACCCAGATGC
2551 AGCAACGCAG AACAGGCGAT TCCAGTTCAC TCAGAATCAG AAGAAAGAAG
2601 ATTCTAAAC GTCCACCTCG GTCACCAGTG TGAACCAAGC CAGCACATCC
2651 CGCCTGGAGG GCCTACAGTC AGAAAACCAT CGCCTGCGAA TGAAGATCAC
2701 AGAGCTGGAT AAAGACTTGG AAGAGGTCAC CATGCAGCTG CAGGACACAC
2751 CAGAAAAGAC CACCTACATT AAACAGAACC ACTACCAAGA GCTCAATGAC
2801 ATCCTCAACC TGGGAAACTT CACTGAGAGC ACAGATGGAG GAAAGGCCAT
2851 TTTAAAAAAT CACCTCGATC AAAATCCCCA GCTACAGTGG AACACAACAG
2901 AGCCCTCTCG AACATGCAAA GATCCTATAG AAGATATAAA CTCTCCAGAA
2951 CACATCCAGC GTCGGCTGTC CCTCCAGCTC CCCATCCTCC ACCACGCCTA
3001 CCTCCCATCC ATCGGAGGCG TGGACGCCAG CTGTGTCAGC CCCTGCGTCA
3051 GCCCCACCGC CAGCCCCCGC CACAGACATG TGCCACCCTC CTTCCGAGTC
3101 ATGGTCTCGG GCCTGTAAGG GTGGGGGGCC TGGGCCCGGG GCCTCCCCCG
3151 TGACAGAACC ACACTGGGCA GAGGGGTCTG CTGCAGAAAC ACTGTCGGCT
3201 CTGGCTGCGG AGAAGCTGGG CACCATGGCT GGCCTCTCAG GACCACTCGG
3251 ATGGCACTCA GGTGGACAGG ACGGGGCAGG GGGAGACTTG GCACCTGACC
3301 TCGAGCCTTA TTTGTGAAGT CCTTATTTCT TCACAAAGAA GAGGAACGGA
3351 AATGGGACGT CTTCTTAAC ATCTGCAAAC AAGGAGGCGC TGGGATATCR
3401 AATTCCACCA CACTGGCGGC CCGCGCTTGS TCSTAATCAT GGTCATAACT
3451 GTTTCCTGTG TTGAAATTGT TATCCGCTCC

FIG. 1B

1 MASPRSSGQP GPPPPPPPPP ARLLLLLLLL LLLPLAPGAW GWARGAPRPP
51 PSSPPLSIMG LMPLTKEVAK GSIGRGVLPV VELAIEQIRN ESLLRPYFLD
101 LRLYDTECDN AKGLKAFYDA IKYGNHLMV FGGVCPSVTS IIAESLQGWN
151 LVQLSFAATT PVLADKKKYP YFFRTVPSDN AVNPAILKLL KHYQWKRVGT
201 LTQDVQRFSE VRNDLTGVLY GEDIEISDTE SFSNDPCTSV KKLKGNDVRI
251 ILGQFDQNMA AKVFCCAYEE NMYGSKYQWI IPGWYEPSWW EQVHTEANSS
301 RCLRKNLLAA MEGYIGVDFE PLSSKQIKTI SGKTPQQYER EYNNKRSGVG
351 PSKFHGYAYD GIWVIAKTLQ RAMETLHASS RHQRIQDFNY TDHTLGRIIL
401 NAMNETNFFG VTGQVVFRNG ERMGTIKFTQ FQDSREVKVG EYNAVADTLE
451 IINDTIRFQG SEPPKDKTII LEQLRKISLP LYSILSALT I LGMIMASAFI
501 FFNIKRNQK LIKMSSPYMN NLIILGGMLS YASIFLFGLD GSFVSEKTFE
551 TLCTVRTWIL TVGYTTAFGA MFAKTWRVHA IFKNVKMKKK IIKDQKLLVI
601 VGGMLLIDLC ILICWQAVDP LRRTVEKYSM EPDPAGRDIS IRPLLEHCEN
651 THMTIWLIV YAYKGLLMF GCFLAWETRN VSIPALNSDK YIGMSVYNVG
701 IMCIIGAAS FLTRDQPNVQ FCIVALVIIF CSTITLCLVF VPKLITLRTN
751 PDAATQNRFF QFTQNQKKED SKTSTSVTSV NQASTSRLEG LQSENHRLRM
801 KITELDKDLE EVTMLQDTP EKTYYIKQNH YQELNDILNL GNFTSTDDG
851 KAILKNHLDQ NPQLQWNTTE PSRTCKDPIE DINSPEHIQR RLSLQLPILH
901 HAYLPSIGGV DASCVSPCVS PTASPRHRHV PPSFRVMVSG L

FIG. 2

4/35

Sequence: LPLLLPLAPGAWG-WARGAPRPPSPPLSIMGLMPLTKEVAKGSIGRGVLPVELAIEQIRNE
| (signal) | (mature peptide)
29 42

Other entries above 3.50

Score 11.1 at residue 39

Sequence: LLLLPLLLPLAPG-AWGARGAPRPPSPPLSIMGLMPLTKEVAKGSIGRGVLPVELAIEQI
| (signal) | (mature peptide)
26 39

Score 8.6 at residue 38

Sequence: LLLLPLLLPLAP-GAWGARGAPRPPSPPLSIMGLMPLTKEVAKGSIGRGVLPVELAIEQ
| (signal) | (mature peptide)
25 38

Score 8.1 at residue 35

Sequence: RLILLLLPLLLP-LAPGAWGARGAPRPPSPPLSIMGLMPLTKEVAKGSIGRGVLPVELA
| (signal) | (mature peptide)
22 35

Score 7.9 at residue 36

Sequence: LILLLLPLLLPL-APGAWGARGAPRPPSPPLSIMGLMPLTKEVAKGSIGRGVLPVELAI
| (signal) | (mature peptide)
23 36

Score 6.2 at residue 9

Sequence: -QPGRPPPPPPPARLILLLLPLLLPLAPGAWGARGAPRPPSPPLSI
| (signal) | (mature peptide)
-4 9

Score 5.7 at residue 46

Sequence: LPLAPGAWGARG-APRPPSPPLSIMGLMPLTKEVAKGSIGRGVLPVELAIEQIRNESLLR
| (signal) | (mature peptide)
33 46

Score 5.6 at residue 747

Sequence: ITLCLVFVPKLIT-LRTNPDAATQNRRFQFTQNKKEDSKTSTSVTSVNQASTSRLEGLQSENH
| (signal) | (mature peptide)
734 747

Score 5.0 at residue 44

Sequence LLLPLAPGAWGWA-RGAPRPPSPPLSIMGLMPLTKEVAKGSIGRGVLPVELAIEQIRNESL
| (signal) | (mature peptide)
31 44

Score 4.9 at residue 497

FIG.3A

SUBSTITUTE SHEET (RULE 26)

5/35

Sequence: ILSALTILGMIMA-SAFLFFNIKNRNQKL IKMSSPMNNLI ILGGMLSYASIFLFGLDGSFVSE
|(signal) |(mature peptide)
484 497
Score 4.5 at residue 141

Sequence: LMVFGGVCPSVTS-IIAESLQGWNLVQLSFAATTPVLADKKKYPYFFRTVPSDNAVNPAILKLL
|(signal) |(mature peptide)
128 141
Score 4.4 at residue 734

Sequence: FCIVALVIIFCST-ITLCLVFVPKLITLRTNPDAATQNRRFQFTQNQKKEDSKTSTSVTSVNQA
|(signal) |(mature peptide)
721 734
Score 4.1 at residue 165


Sequence: VQLSFAATTPVLA-DKKKYPYFFRTVPSDNAVNPAILKLLKHYQWKRVGTLTQDVQRFSEVRND
|(signal) |(mature peptide)
152 165
Score 3.6 at residue 158

Sequence: SLQGWNLVQLSFA-ATTPVLADKKKYPYFFRTVPSDNAVNPAILKLLKHYQWKRVGTLTQDVQR
|(signal) |(mature peptide)
145 158

FIG.3B

6/35


Distribution of mRNA for EST z43654 in squirrel monkey brain.




at level of thalamus and hippocampus



example of cold displayed



at level of caudate and putamen



at level of cerebellum and occipital cortex

FIG. 4

7/35




FIG. 5B




FIG. 5A

8/35

PLTKEVAK-GSIGR-GVLPVELAIEQIRNESLLRPYFLDLRLYDTECDNAKGLKAFYDA
... :X: ... :X ...
PVTGPVAQYGDMQRAGAL---MAIEQINKAGGVNGAQLEGVIYDDACDPKQAVAVANKV

IKYGNHLMVFGGVCPSVTSIIAESLQGWNLVQLSFAATTPVLADKKKYPYFFRTVPSDN
... : ... : ... : ... : ... : ... :
VNDGVK--FVVGHVCCSSTQPATDIYEDEGLMITPSATAPEIT-SRGYKLIFRTIGLDN

AVNPAILKLL-KHYQWKRVGTLTQDVQRFSE-VRNDLTGVLYGEDIEISDTESFS---ND
... : ... : ... : ... : ... : ... :
MQGPVAGKFIAERYKVKTIAVL-HDKQQYGEIATEVKKTVEDAGIRVAVFEGLNAGDKD

PCTSVKKLKGNDVRII-LGQFDQNM
... : ... : ... :
FNALISKLLKAGVQFVYFGGYHPEM

FIG.6

9/35




FIG. 7

10/35

GABA - BR1b	69
HG20	75
Consensus	75
<p>MGPGGCTPVGWPLPLLLVMAAGVAPVWASHPHL---PRPHPRVPPHPSSERRAVYIGALFPMGGWP-G--GQ MASPRSSGQGRPPPPPPARLILLLLPLLLPLAPGAWGARGAPRPPSPPLSIMGLMPLTKEVAKGSIGR M.....G.P.P.....A.....L.....R.P.P.....I.L.P.....G.G. Consensus</p>	
GABA - BR1b	143
HG20	149
Consensus	150
<p>ACQPAVEMALEDVNSRRDILPDVELKLIHHSKCDPGQATKYL YELNDPIKIILMPG-CSSVSTLVAEARMW GVLPAVELAIEQIRN-ESLLRPYFLDLRLYDTECDNAKGLKAFYDAIKYGNHLMVFGVCPSVTSIIAESLQGW ...PAVE.A.E.....L.Y.L.L..D..CD.....K.Y.....P.....G.C.SV...AE....W Consensus</p>	
GABA - BR1b	218
HG20	224
Consensus	225
<p>NLIVLSYGSSSPALSNRQRFPTFFRTHPSATLHNPTRVKLFEKWGKKIATIQQTTEVFTSTLDDLEERVKEAGI NLVQLSFAATTPVLADKKKYPYFFRTVPSDNVNPAILKLLKHYQWKRVTLTQDVQRFSEVRNDLTGVL YGEDI NL..LS.....P.L.....P.FFRT.PS....NP..KL...WK...T.Q....F.....DL.....I Consensus</p>	
GABA - BR1b	290
HG20	299
Consensus	300
<p>EITFRQFFSDPAVPVKNLKRQDARIIVGLFYETEARKVFCEVYKERLFGKKYVWFLIGWYADNWF---KTYDPS EISDTEFSNDPCTSVKCLKGNDVRIILGQFDQNMAAKVFCCAYEENMYGSKYQWIIPGWYEPSWMEQVHTEANS EI.....SF..DP...VK.LK...D.RII.G.F...A.KVFC...Y.E...G.KY.W...GWY...W....T...S Consensus</p>	
GABA - BR1b	365
HG20	372
Consensus	375
<p>INCTVEEMTEAVEGHITTEIVMLNPANTRISNMSTSQEFVEKLTKRLKRHPEETGGFQEAPLAYDAIWALALALN SRCLRKNLLAAMEGYIGVDFEPLSSKQIKTISGKTPQQY-EREYNN-KRSGVGPSKFHGYAYDGIWIAKTLQRA ..C.....A.EG.I.....L.....IS..T.Q...E.....KR.....F.....A..L.... Consensus</p>	
GABA - 3R1b	440
HG20	446
Consensus	450
<p>KTSGGGSGRVRLDFNYYNQTITDQIYRAMNSSSFEVSGHVVFDAAGSRMAWTLIEQLQGSYKKIGYVDSTK METLHASSRHQRIDFNFTDHTLGRILNAMNETNFFGTGQVFR-NGERMGTIKFTQFQDSREVKVGEYNAVA R..DFNY...T..I.....AMN..F.GV.G.VVF...G.RM.....Q.Q.....K.G.Y..... Consensus</p>	
GABA - BR1b	512
HG20	519
Consensus	525
<p>DDLWSKTDKWIGGSPADQTLVIKTRFLSQKLFISVSVLSSLGIVLAVVC---LSFNIVNSHVRYIQNSQPNI DTLEIINDTIRFGSEPPKDTII--LEQLRKISLPLYSILSALTILGTMASAFILFFNIKRNQKLIKMSPPYM D.L.....GS.P.....I.....L.....S.LS.L.I.....L.FNI.N.....I..S.P.... Consensus</p>	

FIG.8A

11/35

```

GABA-BR1b  NNL TAVGCSLAAVFLGLDGYHIGRSQFPFVCQARLWLLGLGFSLGYGSMFTKIWWVHTVFTKKEEKEMRKT 587
HG20       NNL IILGGMLSYASIFLFGLDGSFVSEKTFETLCTVRTWILTVGYTTAFGAMFAKTWRVHAIF--KNVKMK-KKI 591
Consensus NNL...G..L..A..F..GLDG.....F...C..R..W..L..G.....G..MF..K..W..VH..F..K..K.....K. 600

GABA-BR1b  LEPWKL YATVGLLVGMDVL TLAIWQIVDPLHRTIETFAKEEPKEDIDVILPQLEHCSSKKNMTWL GIFYGYKGL 662
HG20       IKDQKLLVIVGMLLIDLCLICWQAVDPLRRTVEKYSMEPDAGRDISIRPLEHCENTHMTIWL GIVYAYKGL 666
Consensus ....KL...VG....D...L..WQ.VDPL.RT.E....E.....D.SI.P.LEHC.....M..WLG I..Y.YKGL 675

GABA-BR1b  LLLLGIFLAYETKSVSTEKINDHRAVGMAIYNVAVLCLITAPVTMILSSQDDAAFAFASLAIVFSSYITLVVLFV 737
HG20       LMLFGCFLAWETRNVIPALNDSKYIGMSVYVNGIMCIIGAASVFLTRDQPNVQFCIVALVIIFCSTITLCLV FV 741
Consensus L..L..G.FLA.ET..VS....ND....GM..YNV...C.I.A.V.....Q.....F...L.I.F.S.ITL...FV 750

GABA-BR1b  PKMRLIIRGE-----W-----QSETQDTMKTGSS-TNNNEEKSRL--LEKE-----NRELEKI----- 784
HG20       PKLITLRNPDAAATQNRRFQFTQNKEDSKTSTSVTSVNDASTSRLEGLQSENHRLRMKITELDKDLEEVTMQL 816
Consensus PK...L.T.....Q.....KT..S.T..N.....SRL..L..E.....LE..... 825

GABA-BR1b  --IAEKE-----ERVSE-----LRHQLQSRQQLRRRHPPTPP--DPSGG----- 820
HG20       QDTPEKTTYIKQNHVOELNDILNLGNFTESDGGKAILKNHLDQNPQLQWNTTEPSRTCKDPIEDINSPEHIQRR 891
Consensus ....EK.....L...L...QL.....P.....DP..... 900

GABA-BR1b  -----LPR-GPSEPPDLRLSC-----DGSRVHLL---YK----- 844
HG20       LSLQLPILHHAYLPSIGGVDA SCVSPCVSPTASPRHRHVPPSFRVMVSGL 941
Consensus .....LP..G.....C.....R..... 950

```

FIG.8B

12 / 35




FIG.9

13/35




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E

14/35




FIG. 11A




FIG. 11B

15/35




FIG. 12




FIG. 13A




FIG. 13B

17/35




FIG.14

18/35

1 atgctgctgc tgctgcttct gcttctcttc ctccgcccc tgggcgctgg cggggctcag
61 accccaacg tcacctcgga aggttgccag attatacatc cgccctggga aggtggcatc
121 aggtaccgtg gcttgattcg cgaccagggtg aaggccatca atttcctgcc tgtggactat
181 gagattgaat atgtgtgccg gggcgaacgc gaggtgggtgg ggcccaaggt gcgcaagtgc
241 ctggccaacg gctcctggac ggatatggac acaccagtc gctgtgtccg aatctgtcc
301 aagtcttatt tgaccctgga aaatgggaag gttttcctga cgggtgggga cctcccagct
361 ctggatggag cccgggtgga tttccgatgt gaccctgact tccatctggt gggcagctcc
421 cggagcatct gtagtcaggg ccagtgagac accccaagc cccactgcca ggtgaatcga
481 acgccacact cagaacggcg tgcagtatac atcggggcgc tgtttcccat gagcgggggc
541 tggccggggg gccaggcctg ccagcctgcg gtggagatgg cgctggagga cgtaacagc
601 cgcagagaca tcctgccgga ctacgagctc aagcttatcc accacgacag caagtgcgac
661 ccagggcaag ccaccaagta cttgtatgaa ctactctaca acgaccccat caagatcatc
721 ctcatgcccg gctgcagctc tgtgtccaca ctggtagccg aggtgcccg gatgtggaac
781 cttattgtgc tctcatatgg ctccagctca ccagcctgt caaacgaca gcggtttcca
841 acgttctttc ggacacatcc atccgccaca ctccacaatc ccaccgggt gaaactcttc
901 gaaaagtggg gctggaagaa gattgccacc atccagcaga ctaccgaggt cttcacctca
961 acactggatg acctggagga gcgagtgaag gaggtggga ttgagatcac ttttcgacag
1021 agtttcttct cagatccagc tgtgcctgtt aaaaacctga agcgtcaaga tgctcgaatc
1081 atcgtgggac ttttctatga gaccgaagcc cggaaagtgt tttgtgaggt ctataaggaa
1141 cggctctttg ggaagaagta tgtctgggtt ctcatcgggt ggtatgctga caactggttc
1201 aaaacctatg acccgtaaat caattgtaca gtagaagaga tgactgaggc ggtggagggc
1261 catatcacca cggagattgt catgctgaac cctgccaaca cccgaagcat ttccaacatg
1321 acatcacagg aatttgtgga gaaactaacc aagcggctga aaagacacc tgaggagact
1381 ggaggcttcc aggaggcacc actggcctat gatgctattt gggccttggc tttggccttg
1441 aacaagacct ctggaggagg tggcgttca ggagtgcgc tggaggactt taactacaac
1501 aaccagacca ttacagacca aatctaccgg gccatgaact cctcctcctt tgagggtgtt
1561 tctggccacg tggctcttga tgccagcggc tcccggatgg catggacgct tatcgagcag
1621 ctacagggag gcagctacaa gaagatcggc tactacgaca gcaccaagga tgatctttcc
1681 tgggtccaaaa cagacaagtg gatcggaggg tctccccag ccgaccagac cttggtcatc
1741 aagacattcc gtttctgtc acagaaactc tttatctccg tctcagttct ctccagcctg
1801 ggcattgttc ttgctgttgt ctgtctgtcc tttaacatct acaactccca cgctcgttat
1861 atccagaatt cccagcccaa cctgaacaat ctgactgctg tgggctgctc actggcactg
1921 gctgttgtct tccctctcgg gctggatggt taccacatag ggagaagcca gttcccgttt
1981 gtctgccagg cccgccttg gctcttgggc ttgggcttta gtctgggcta tggctctatg
2041 ttcaccaaga tctggtgggt ccacacagtc ttcacgaaga aggaggagaa gaaggagtgg
2101 aggaagacc tagagccctg gaaactctat gccactgtgg gcctgctggt gggcatggat
2161 gtcctgactc ttgccatctg gcagattgtg gacccttgc accgaaccat tgagactttt
2221 gccaggagg aaccaaagga agacatcgat gtctccattc tgccccagtt ggagcactgc
2281 agtccaaga agatgaatac gtggcttggc attttctatg gttacaagg gctgctgctg
2341 ctgctgggaa tctttcttgc ttacgaaacc aagagcgtgt ccactgaaaa gatcaatgac
2401 cacagggccg tgggcatggc tatctacaat gtcgcggtcc tgtgtctcat cactgctcct
2461 gtgaccatga tcctttccag tcagcaggac gcagccttg cctttgcctc tctggccatc
2521 gtgttctctt cctacatcac tctggttgtg ctctttgtgc ccaagatgcg caggctgatc
2581 acccgagggg aatggcagtc tgaacgcag gacaccatga aaacaggatc atccaccaac
2641 aacaacgagg aagagaagtc ccgactgttg gagaaggaaa accgagaact ggaaaagatc
2701 atcgttgaga aagaggagcg cgtctctgaa ctgcgccatc agctccagtc tcggcagcaa
2761 ctccgctcac ggcgccacc cccaacacc ccagatccct ctgggggcct tcccagggga
2821 ccctctgagc cccctgaccg gcttagctgt gatgggagtc gagtacattt gctttacaag
2881 tga

FIG. 15

SUBSTITUTE SHEET (RULE 26)

MLLLLLLLLLFLRPLGAGGAQTPNVTSEGCQIIHPPWEGGIRYRGLIRDQVKAINFLPVDY
EIEYVCRGEREVVGPKVRKCLANGSWTDMTPSRCVIRCSKSYLTLENGKVFLTGGDLPA
LDGARVDFRCDPDFHLVGSSRSICSQGWSTPKPHCQVNRTPHSERRAVYIGALFPMSSG
WPGGQACQPAVEMALEDVNSRRDILPDYELKLIHHDSCDPGOATKYL YELLYNDPIKII
LMPGCSSVSTLVAEAARMWNLIVLSYGSSSPALSNRQRFPTFFRTHPSATLHNPTRVKLF
EKWGWKKIATIQQTTEVFTSTLDDLEERVKEAGIEITFRQSFFSDPAVPVKNLKRQDARI
IVGLFYETEARKVFCEVYKERLFGKKYVWFLIGWYADNWFKTYDPSINCTVEEMTEAVEG
HITTEIVMLNPANTRISNMTSQEFVEKLTkRLKRHPEETGGFQEAPLAYDAIWALALAL
NKTSGGGGRSGVRLEDfNYNNQTI TDQIYRAMNSSSFEGVSGHVVF DASGSRMAWTLIEQ
LQGGSYKKIGYYDSTKDDL SWSKTDKWIGGSPPADQTLVIKTRFLSQKLFISVSVLSSL
GIVLAVVCLSFNIYN SHARYIQNSQPNLNNLTAVGCSLALAVVFPLGLDGYHIGRSQFPF
VCQARLWLLGLGFSLGYGSMFTKIWWVHTVFTKKEEKEWRKTLEPWKLYATVGLLVGMD
VLTLAIWQIVDPLHRTIETFAKEEPKEDIDVSILPQLEHCSSKKMNTWLGI FYGYKGLLL
LLGIFLAYETKSVSTEKINDHRAVGMAIYNVAVLCLITAPVTMILSSQQDAAFASLAI
VFSSYITLVVLFVPKMRLITRGEWQSETQDTMKTGSSTNNNEEEKSRLL EKENRELEKI
IAEKEERVSEL RHQLQSRQQLRSRRHPPTPPDPSSGGLPRGPSEPPDRLSCDGSRVHLLYK

FIG. 16

20 / 35




FIG.17A

FIG.17B

21/35

MLLLLLLAPLFLRPPGAGGAHTPNATSEGCQIIHPPWEGGIRYRGLTRDQV
KAINFLPVDYEIEYVCRGEREVVGPKVRKCLANGSWTMDTPSRCVRICS
KSYLTLENGKVFLTGGDLPALD GARADFRCDPDFHLVGSSRSICSQGQWST
PKPHCQVNRTPHSERRAVYIGALFMSGGWPGGQACQPAVEMAEDEVNS
RRDILPDYELKLIHHD SKCDPGQATKYL YELLYNDPIKII LMPGCSSVSTLV
AEAARMWNLIVLSYGSSSPALSNRQRFPTFFRTHPSATLHNPTRVKLFEKW
GWKKIATIQQTTEVFTSTLDDLEERVKEAGIEITFRQSFFSDPAVPVKNLKRQ
DARIIVGLFYETEARKVFCEVYKERLFGKKYVWFLIGWYADNWFKJYDPS
INCTVDEMTEAVEGHITTEIVMLNPANTRISNMTSQEFVEKLT KRLKRHPE
ETGGFQEAPLAYDAI WALALALNKTSGGGGRSGVRLEDFNYYNNQTITDQI
YRAMNSSSFEGVSGHVFDASGSRMAWTLIEQLQGGSYKKIGYYDSTKDD
LSWSKTDKWIGGSPPADQTLVIKTRFLSQKLFISVSVLSSLGIVLAVVCLSF
NIYN SHVRYIQNSQPNLNNLTAVGCSLALAAVFPLGLDGYHIGRNQFPFV
CQARLWLLGLGFSLGYGSMFTKIWWVHTVFTKKEEKKEWKRTLEPWKLY
ATVGLLVGMDVLT LAIWQIVDPLHRTIETFAKEE PKEDIDVSILPQLEHCSS
RKMNTWLGIFYGYKGLLLLLGIFLAYETKSVSTEKINDHRAVGMAIYNVA
VLCLITAPVTMILSSQQDAAFASLAIVFSSYITLVVLFVPMRRLITRGE
WQSEAQDTMKTGSSTNNNEEEKSRLL EKENRELEKIIAEKEERVSEL RHQLQ
SRQQLRSRRHPPTPPEPSGGLPRGPPEPPDRLSCDGSRVHLLYK

FIG. 18A

22/35

```

1 atgttgctgc tgctgctact ggcgccactc ttcttcgcc ccccgggcgc gggcggggcg
61 catacccca acgccacctc agaaggttgc cagatcatac acccgccctg ggaagggggc
121 atcaggtacc ggggcctgac tcgggaccag gtgaaggcta tcaacttcct gccagtggac
181 tatgagattg agtatgtgtg ccggggggag cgcgaggtgg tggggcccaa ggtccgcaag
241 tgcctggcca acggctcctg gacagatatg gacacacca gccgctgtgt ccgaatctgc
301 tccaagtctt atttgaccct ggaaaatggg aaggttttcc tgacgggtgg ggacctcca
361 gctctggacg gagcccgggc ggatttccgg tgtgaccccg acttccatct ggtgggcagc
421 tcccggagca tctgtagtca gggccagtgg agcaccacca agccccactg ccaggtgaat
481 cgaacgccac actcagaacg gcgcgcagtg tacatcgggg cactgtttcc catgagcggg
541 ggctggccag ggggccaggc ctgccagccc gcggtggaga tggcgctgga ggacgtgaat
601 agccgcaggg acatcctgcc ggactatgag ctcaagctca tccaccacga cagcaagtgt
661 gatccaggcc aagccacca gtacctatat gagctgctct acaacgacct tatcaagatc
721 atccttatgc ctggctgcag ctctgtctcc acgctggtgg ctgaggctgc taggatgtgg
781 aacctcattg tgctttccta tggctccagc tcaccagccc tgtcaaaccg gcagcgtttc
841 ccacttttct tccgaacgca cccatcagcc acactccaca accctaccgg cgtgaaactc
901 tttgaaaagt ggggctggaa gaagattgct accatccagc agaccactga ggtcttccact
961 tcgactctgg acgacctgga ggaacgagtg aaggaggctg gaattgagat tactttccgc
1021 cagagtttct tctcagatcc agctgtgccc gtcaaaaacc tgaagcgcca ggatgcccga
1081 atcatcgtgg gacttttcta tgagactgaa gcccgaaag ttttttgtga ggtgtacaag
1141 gagcgtctct ttgggaagaa gtacgtctgg ttcttcattg ggtggtatgc tgacaattgg
1201 ttcaagatct acgacccttc tatcaactgc acagtggatg agatgactga ggcggtggag
1261 ggccacatca caactgagat tgtcatgctg aatcctgcc aatcccgcag catttccaac
1321 atgacatccc aggaatttgt ggagaaacta accaagcgac tgaaaagaca ccctgaggag
1381 acaggaggct tccaggaggc accgctggcc tatgatgcca tctgggcctt ggcactggcc
1441 ctgaacaaga catctggagg aggcggccgt tctggtgtgc gcctggagga cttcaactac
1501 aacaaccaga ccattaccga ccaaacttac cgggcaatga actcttcgtc ctttgagggg
1561 gtctctggcc atgtggtgtt tgatgccagc ggctctcgga tggcatggac gcttatcgag
1621 cagcttcagg gtggcagcta caagaagatt ggctactatg acagaccaa ggatgatctt
1681 tcctggtcca aaacagataa atggattgga ggggtcccc cagctgacca gacctggtc
1741 atcaagacat tccgcttctc gtcacagaaa ctctttatct ccgtctcagt tctctccagc
1801 ctgggcattg tcctagctgt tgtctgtctg tcctttaaca tctacaactc acatgtccgt
1861 tatatccaga actcacagcc caacctgaac aacctgactg ctgtgggctg ctactggct
1921 ttagctgctg tcttccccct ggggctcgat ggttaccaca ttgggaggaa ccagtttctt
1981 ttgctctgcc aggccgcct ctggctcctg ggcctgggct ttagtctggg ctacggttcc
2041 atgttcacca agatttggtg ggtccacacg gtcttcacaa agaaggaa gaagaaggag
2101 tggaggaaga ctctggaacc ctggaagctg tatgccacag tgggcctgct ggtgggcatg
2161 gatgtcctca ctctcgccat ctggcagatc gtggaccctc tgaccggac cattgagaca
2221 tttgccaagg aggaacctaa ggaagatatt gacgtctcta ttctgcccc gctggagcat
2281 tgcagctcca ggaagatgaa tacatggctt ggcattttct atggttacia ggggctgctg
2341 ctgctgctgg gaatcttctt tgcttatgag accaagagtg tgtccactga gaagatcaat
2401 gatcaccggg ctgtgggcat ggctatctac aatgtggcag tcctgtgcct catcactgct
2461 cctgtcacca tgattctgtc cagccagcag gatgcagcct ttgcctttgc ctctcttgcc
2521 atagttttct cctctatat cactcttgtt gtgctctttg tgcccaagat gcgcaggctg
2581 atcacccgag gggaatggca gtcggaggcg caggacacca tgaagacagg gtcacgcacc
2641 aacaacaacg aggaggagaa gtcccggctg ttggagaagg agaaccgtga actggaaaag
2701 atcattgctg agaaagagga gcgtgtctct gaactgcgcc atcaactcca gtctcggcag
2761 cagctccgct cccggcgcca cccaccgaca ccccagaac cctctggggg cctgcccagg
2821 ggacccccct agccccccga ccggcttagc tgtgatggga gtcgagtga tttgctttat
2881 aagtga

```

FIG. 18B

23/35

```
1 atgctgctgc tgctgctggc gccactcttc ctccgcccc cgggcgcggg cggggcgcag
61 accccaacg ccacctcaga aggttgccag atcatacacc cgccctggga agggggcatc
121 aggtaccggg gcctgactcg ggaccagggt aaggctatca acttctctgc agtggactat
181 gagattgagt atgtgtgccg gggggagcgc gaggtggtgg ggcccaagggt ccgcaagtgc
241 ctggccaacg gctcctggac agatatggac acaccagcc gctgtgtccg aatctgctcc
301 aagtcttatt tgacctgga aaatgggaag gttttcctga cgggtgggga cctcccagct
361 ctggacggag cccgggtgga tttccggtgt gaccccgact tccatctggt gggcagctcc
421 cggagcatct gtagtcaggg ccagtggagc accccaagc cccactgcca ggtgaatcga
481 acgccacact cagaacggcg cgcagtgtac atcggggcac tgtttcccat gagcgggggc
541 tggccagggg gccaggcctg ccagcccgcg gtggagatgg cgctggagga cgtgaatagc
601 cgcagggaca tcttgccgga ctatgagctc aagctcatcc accacgacag caagtgtgat
661 ccaggccaag ccaccaagta cctatatgag ctgctctaca acgacctat caagatcatc
721 cttatgcctg gctgcagctc tgtctccacg ctggtggctg aggtgctag gatgtggaac
781 ctcatgtgctc tttcctatgg ctccagctca ccagccctgt caaacggca gcgtttcccc
841 actttcttcc gaacgcacc atcagccaca ctccacaacc ctaccgcgt gaaactcttt
901 gaaaagtggg gctggaagaa gattgctacc atccagcaga ccaactgagg cttcacttcg
961 actctggacg acctggagga acgagtgaag gaggtggaa ttgagattac tttccgccag
1021 agtttcttct cagatccagc tgtgcccgtc aaaaacctga agcgccagga tgcccgaatc
1081 atcgtgggac ttttctatga gactgaagcc cggaaagttt tttgtgaggt gtacaaggag
1141 cgtctctttg ggaagaagta cgtctggttc ctcatgggt ggtatgctga caattggttc
1201 aagatctacg acccttctat caactgcaca gtggatgaga tgactgaggc ggtggagggc
1261 cacatcacia ctgagattgt catgctgaat cctgccaata cccgcagcat ttccaacatg
1321 acatcccagg aatttgtgga gaaactaacc aagcgactga aaagacacc tgaggagaca
1381 ggaggcttcc aggaggcacc gctggcctat gatgccatct gggccttggc actggccctg
1441 aacaagacat ctggaggagg cggcgttct ggtgtgcgcc tggaggactt caactacaac
1501 aaccagacca ttaccgacca aatctaccgg gcaatgaact cttcgtcctt tgaggggtgc
1561 tctggccatg tgggtgttga tgccagcggc tctcgatgg catggacgt tatcgagcag
1621 cctcagggtg gcagctacaa gaagattggc tactatgaca gcaccaagga tgatctttcc
1681 tgggtccaaa cagataaatg gattggaggg tccccccag ctgaccagac cctggtcatc
1741 aagacattcc gcttctctgc acagaaactc tttatctccg tctcagttct ctccagcctg
1801 ggcattgtcc tagctgttgt ctgtctgtcc tttaacatct acaactcaca tgtccgttat
1861 atccagaact cacagcccaa cctgaacaac ctgactgctg tgggtgctc actggcttta
1921 gctgctgtct tccccctggg gctcgatggt taccacattg ggaggaacca gtttcctttc
1981 gtctgccagg cncgcctctg gctcctgggc ctgggcttta gtctgggcta cggttccatg
2041 ttcaccaaga tttggtgggt ccacacgggc ttcacaaaga aggaagaaaa gaaggagtgg
2101 aggaagactc tggaaacctg gaagctgtat gccacagtgg gcctgctggt gggcatggat
2161 gtcctcactc tcgccatctg gcagatcgtg gaccctctgc accggaccat tgagacattt
2221 gccaaaggagg aacctaaagg agatattgac gtctctatc tgccccagct ggagcattgc
2281 agctccagga agatgaatac atggcttggc attttctatg gttacaagg gctgctgctg
2341 ctgctgggaa tcttcttgc ttatgagacc aagagtgtgt ccactgagaa gatcaatgat
2401 caccgggctg tgggcatggc tatctacaat gtggcagtc tgtgcctcat cactgctcct
2461 gtcaccatga ttctgtccag ccagcaggat gcagccttg cctttgcctc tcttgccata
2521 gttttctcct cctatatcac tctgttgtg ctctttgtgc ccaagatgcg caggctgatc
2581 acccgagggg aatggcagtc ggaggcgag gacaccatga agacagggc atcgaccaac
2641 aacaacgagg aggagaagtc ccggctgttg gagaaggaga accgtgaact ggaaaagatc
2701 attgctgaga aagaggagcg tgtctctgaa ctgcgccatc aactccagtc tcggcagcag
2761 ctccgctccc ggcgccacc accgacacc ccagaaccct ctgggggcct gccagggga
2821 cccctgagc ccccgaccg gcttagctgt gatggagtc gagtgcattt gctttataag
2881 tgagggtagg gtgaggagg acaggccagt agggggagg aaaggagag gggaagggca
2941 ggggactcag gaagcaggg gtcccatcc ccagctggga agaacatgct atccaatctc
3001 atctcttgta aatacatgtc cccctgtgag ttctgggctg atttgggtct ctcatacctc
3061 tgggaaacag accttttct ctctactgc ttcagttaat tttgtatcac ctcttcacaa
```

FIG. 19A

SUBSTITUTE SHEET (RULE 26)

24/35

3121 tttagttcgt acctggcttg aagctgctca ctgctcacac gctgcctcct cagcagcctc
3181 actgcatctt tctcttccca tgcaacaccc tcttctagtt accacggcaa cccctgcagc
3241 tcctctgect ttgtgctctg ttctgtcca gcaggggtct cccaacaagt gctctttcca
3301 ccccaaaggg gcctctcctt ttctccactg tcataatctc tttccatctt acttgccctt
3361 ctatactttc tcacatgttg cttccccctga attttgcttc ctttgggagc tcattctttt
3421 cgccaagget cacatgctcc ttgcctctgc tctgtgcaact cacgctcagc acacatgcat
3481 cctccccctc cctgcgtgtg cccactgaac atgctcatgt gtacacacgc ttttcccgtc
3541 tgcttttctc atgttcagtc acatgtgctc tcgggtgccc tgcattcaca gctacgtgtg
3601 cccctctcat ggtcatgggt ctgcccttga gcgtgtttgg gtaggcattg gcaatttgtc
3661 tagcatgctg agtcatgtct ttctatttg cacacgtcca tgtttatcca tgtactttcc
3721 ctgtgtaccc tccatgtacc ttgtgtactt tcttccctta aatcatggta ttcttctgac
3781 agagccatat gtaccctacc ctgcacattg ttatgcactt ttccccaatt catgtttggt
3841 ggggccatcc acaccctctc ctgtgcacag aatctccatt tctgctcaga ttccccccat
3901 ctccattgca ttcatgtact accctcagtc tacactcaca atcatcttct cccaagactg
3961 ctcccccttg ttttgtgttt ttttgagggg aattaaggaa aaataagtgg gggcaggttt
4021 ggagagctgc ttccagtga tagttgatga gaatcctgac caaaggaagg cacccttgac
4081 tggtgggata gacagatgga cctatggggg gggaggtggt gtccctttca cactgtgggtg
4141 tctcttgggg aaggatctcc ccgaatctca ataaaccagt gaacagtgtg actcggaaaa
4201 aaaaaaaaaa aaaaaaaaaa

FIG. 19B

25/35

PROXIMAL TO HSN-1. FCMD, DYS LOCI ON CHROMOSOME 9




FIG. 20

26/35




FIG. 21

27/35




FIG. 22

28/35

COILED-COIL DOMAIN IN C-TERMINUS OF gb1 α AND HG20
MEDIATING HETERODIMERIZATION

gb1 WQSEA.QDTMKTGSSNNNEEK...SRLEK..ENRELEKIIAEKEERVSELRHQLQSRQQLRSRRHPP
hg20 QNRRFQ TQNQKKEDSKTSTSVT SVNQASTSRLEGLQSENHRLRMKI TELDKDLEEVMTQLODTPEKTTYIKQN

FIG.23

[illegible]

110 120 130 140 150 160 170 180 190 200 210 220
 ENCKVFL TGGDLPALDQARVDFRCDPDLHLVQSSRSIQSQWSTPKPHCQNRTPHSERRAVYIGALFPMSCGWPPGGQACQPAVEMALDQVNSRDILDPVE[KL]IHDSQDPGQ
 ---MFVRSSWLLDMGTIOWASAEVTLHIGGTFPMES[Q]-----SCGWAGGGLQPAVEMALQVNSRDILDPGMNMTINSCQGPGL
 ---MNIFRRHGGIPLPLGVFTVQK-----ECFPDALPAIRIALSHVSRSCILGGYRLEMIVKDT[HK]TSQ
 RLILLLLPLLLPLAPGANGWACAPRPPSSPPLSIMG-----LMPLTKEVAKGSIGRCVLPAVELATEQIRNES-LURPVFLDLRLYDIECDNAK

230 240 250 260 270 280 290 300 310 320 330 340

QATKYLYELLYNDQIKIILMFCQSSVSDIAEAAARMNQLIVLSYGSSPALSNRQREFTERTHPSATLHNPIRWKLFEKMGWKKIATIQOTTIEVFTSTLDLEEFVRVKEAGIEITFR

IAQQLYDFLYKPPDKMLITQCSPTITVIAEAAPIVQLMWSYGSSPALSNRQREFTERTHPSANMQNPITRIHMEKFKWKRFTILMSVEEVFVITAKVDLEVSERKKGIKVDRI

GMKALFDLIAASRPBPVAILIGQQOTEVNEPTAMALKYMQIVQLSVAEITHAMNGQLQLFTTFRWVPGSRNITIMAKCKFVNFEGWKRVGIVKQNDQ-----

CLIKAFDAIKYGPENHLWFGVGPSPMTSIIAESLQGMNVLVQLSEFAITITPVLADKKKYPYEFRTIPSDNAVNPAILKLLKHYGMKRVGILITQDVQKRFSEVRNDLTGVLGYGDIETSDT

QSFSDPAPVVKQLKQDARIIVGLFYEIEARKVLEMYKVERLFGKKYVWFLIGWYADWFKIYDP--SINCTVDEMTAEV⁴³⁰EGHITTEI⁴⁴⁰WMLNPAN⁴⁵⁰-----TRLSN⁴⁶⁰WTSQEEVEK⁴⁷⁰
QSFYGDPTDAMKTLIQDARIIVGLFYVITEARKVLQQA⁴⁸⁰YHGLYGRPRYVWFLIGWYADWFKIYDP--EEHLNCTIAEQMTAEV⁴⁹⁰HTTIESVWMLSRDN⁵⁰⁰-----IPALSEMT⁵¹⁰IGMQEQQR⁵²⁰
-----PRYALVRG⁵³⁰VRTILVDVDEEMAATMLQAGYHRCMYGD⁵⁴⁰NMTLPGYHSDRM⁵⁵⁰NQ-----THDNCTVEEMREAKNHF⁵⁶⁰SV⁵⁷⁰E⁵⁸⁰FAL⁵⁹⁰TRRDVDTK⁶⁰⁰IVGN⁶¹⁰TS⁶²⁰PYVTLN⁶³⁰LFQR⁶⁴⁰
EFSNDPCTSVKILKGN⁶⁵⁰DVRIILGCOFDONAAK⁶⁶⁰NVFOCCAFEE⁶⁷⁰NMGSKYQW⁶⁸⁰ILPGWYEP⁶⁹⁰SMWEEQV⁷⁰⁰HTEANS⁷¹⁰SRL⁷²⁰RKNLL⁷³⁰AAMEGYIG⁷⁴⁰DFEPLSSKQ⁷⁵⁰-----IK⁷⁶⁰TSKTPQ⁷⁷⁰QYERE⁷⁸⁰

450 460 470 480 490 500 510 520 530 540 550 560
 [KRLKRHPETGGTCEAPLAYDAI]WALALANITSGGGFS--GRIEDENANQITDQIYRAMNSSFEVSGHMFDAAGSRMAMLTIEQLGGGSKIKICYDSTKODISMSK
 [IQYQKDTANVGGPEEAPLAYDAI]WALALANQITRN--LPS--HRIENETIDNKKVIAQTILFCQVKNTSFRVSGCKMVSQGDRIARITQIEQMGCKKIKICYDITSCDLEMYN
 ACDVWNEITQLDPNNTWRCYLIDGIMTLALAEISHSGD-----NAEFSHHKMMETIDNSSFCGLTCKKAFANN-ERLGLVDIKQWSDGQMPFAMVG--ADDEFKI
 YNNKR----SGVGPS-KFHCYAYDGIWYIAKTLORAME TLHASSRHQRIQDFNYTDHTLGRILILNAMNE TNIEFGITGQWMERG--ERMGITKF IQFQDSPEMKVGEYNAVADTLEIIN

FIG. 24A

570 TMS-3
 580 TMS-2
 590 TMS-1
 600 TMS-4
 610 TMS-5
 620 TMS-6
 630 TMS-7
 640 TMS-8
 650 TMS-9
 660 TMS-10
 670 TMS-11
 680 TMS-12
 690 TMS-13
 700 TMS-14
 710 TMS-15
 720 TMS-16
 730 TMS-17
 740 TMS-18
 750 TMS-19
 760 TMS-20
 770 TMS-21
 780 TMS-22
 790 TMS-23
 800 TMS-24
 810 TMS-25
 820 TMS-26
 830 TMS-27
 840 TMS-28
 850 TMS-29
 860 TMS-30
 870 TMS-31
 880 TMS-32
 890 TMS-33
 900 TMS-34
 910 TMS-35
 920 TMS-36
 930 TMS-37
 940 TMS-38
 950 TMS-39
 960 TMS-40
 970 TMS-41
 980 TMS-42
 990 TMS-43
 1000 TMS-44
 1010 TMS-45
 1020 TMS-46
 1030 TMS-47
 1040 TMS-48
 1050 TMS-49
 1060 TMS-50
 1070 TMS-51
 1080 TMS-52
 1090 TMS-53
 1100 TMS-54
 1110 TMS-55
 1120 TMS-56
 1130 TMS-57
 1140 TMS-58
 1150 TMS-59
 1160 TMS-60
 1170 TMS-61
 1180 TMS-62
 1190 TMS-63
 1200 TMS-64
 1210 TMS-65
 1220 TMS-66
 1230 TMS-67
 1240 TMS-68
 1250 TMS-69
 1260 TMS-70
 1270 TMS-71
 1280 TMS-72
 1290 TMS-73
 1300 TMS-74
 1310 TMS-75
 1320 TMS-76
 1330 TMS-77
 1340 TMS-78
 1350 TMS-79
 1360 TMS-80
 1370 TMS-81
 1380 TMS-82
 1390 TMS-83
 1400 TMS-84
 1410 TMS-85
 1420 TMS-86
 1430 TMS-87
 1440 TMS-88
 1450 TMS-89
 1460 TMS-90
 1470 TMS-91
 1480 TMS-92
 1490 TMS-93
 1500 TMS-94
 1510 TMS-95
 1520 TMS-96
 1530 TMS-97
 1540 TMS-98
 1550 TMS-99
 1560 TMS-100
 1570 TMS-101
 1580 TMS-102
 1590 TMS-103
 1600 TMS-104
 1610 TMS-105
 1620 TMS-106
 1630 TMS-107
 1640 TMS-108
 1650 TMS-109
 1660 TMS-110
 1670 TMS-111
 1680 TMS-112
 1690 TMS-113
 1700 TMS-114
 1710 TMS-115
 1720 TMS-116
 1730 TMS-117
 1740 TMS-118
 1750 TMS-119
 1760 TMS-120
 1770 TMS-121
 1780 TMS-122
 1790 TMS-123
 1800 TMS-124
 1810 TMS-125
 1820 TMS-126
 1830 TMS-127
 1840 TMS-128
 1850 TMS-129
 1860 TMS-130
 1870 TMS-131
 1880 TMS-132
 1890 TMS-133
 1900 TMS-134
 1910 TMS-135
 1920 TMS-136
 1930 TMS-137
 1940 TMS-138
 1950 TMS-139
 1960 TMS-140
 1970 TMS-141
 1980 TMS-142
 1990 TMS-143
 2000 TMS-144
 2010 TMS-145
 2020 TMS-146
 2030 TMS-147
 2040 TMS-148
 2050 TMS-149
 2060 TMS-150
 2070 TMS-151
 2080 TMS-152
 2090 TMS-153
 2100 TMS-154
 2110 TMS-155
 2120 TMS-156
 2130 TMS-157
 2140 TMS-158
 2150 TMS-159
 2160 TMS-160
 2170 TMS-161
 2180 TMS-162
 2190 TMS-163
 2200 TMS-164
 2210 TMS-165
 2220 TMS-166
 2230 TMS-167
 2240 TMS-168
 2250 TMS-169
 2260 TMS-170
 2270 TMS-171
 2280 TMS-172
 2290 TMS-173
 2300 TMS-174
 2310 TMS-175
 2320 TMS-176
 2330 TMS-177
 2340 TMS-178
 2350 TMS-179
 2360 TMS-180
 2370 TMS-181
 2380 TMS-182
 2390 TMS-183
 2400 TMS-184
 2410 TMS-185
 2420 TMS-186
 2430 TMS-187
 2440 TMS-188
 2450 TMS-189
 2460 TMS-190
 2470 TMS-191
 2480 TMS-192
 2490 TMS-193
 2500 TMS-194
 2510 TMS-195
 2520 TMS-196
 2530 TMS-197
 2540 TMS-198
 2550 TMS-199
 2560 TMS-200
 2570 TMS-201
 2580 TMS-202
 2590 TMS-203
 2600 TMS-204
 2610 TMS-205
 2620 TMS-206
 2630 TMS-207
 2640 TMS-208
 2650 TMS-209
 2660 TMS-210
 2670 TMS-211
 2680 TMS-212
 2690 TMS-213
 2700 TMS-214
 2710 TMS-215
 2720 TMS-216
 2730 TMS-217
 2740 TMS-218
 2750 TMS-219
 2760 TMS-220
 2770 TMS-221
 2780 TMS-222
 2790 TMS-223
 2800 TMS-224
 2810 TMS-225
 2820 TMS-226
 2830 TMS-227
 2840 TMS-228
 2850 TMS-229
 2860 TMS-230
 2870 TMS-231
 2880 TMS-232
 2890 TMS-233
 2900 TMS-234
 2910 TMS-235
 2920 TMS-236
 2930 TMS-237
 2940 TMS-238
 2950 TMS-239
 2960 TMS-240
 2970 TMS-241
 2980 TMS-242
 2990 TMS-243
 3000 TMS-244
 3010 TMS-245
 3020 TMS-246
 3030 TMS-247
 3040 TMS-248
 3050 TMS-249
 3060 TMS-250
 3070 TMS-251
 3080 TMS-252
 3090 TMS-253
 3100 TMS-254
 3110 TMS-255
 3120 TMS-256
 3130 TMS-257
 3140 TMS-258
 3150 TMS-259
 3160 TMS-260
 3170 TMS-261
 3180 TMS-262
 3190 TMS-263
 3200 TMS-264
 3210 TMS-265
 3220 TMS-266
 3230 TMS-267
 3240 TMS-268
 3250 TMS-269
 3260 TMS-270
 3270 TMS-271
 3280 TMS-272
 3290 TMS-273
 3300 TMS-274
 3310 TMS-275
 3320 TMS-276
 3330 TMS-277
 3340 TMS-278
 3350 TMS-279
 3360 TMS-280
 3370 TMS-281
 3380 TMS-282
 3390 TMS-283
 3400 TMS-284
 3410 TMS-285
 3420 TMS-286
 3430 TMS-287
 3440 TMS-288
 3450 TMS-289
 3460 TMS-290
 3470 TMS-291
 3480 TMS-292
 3490 TMS-293
 3500 TMS-294
 3510 TMS-295
 3520 TMS-296
 3530 TMS-297
 3540 TMS-298
 3550 TMS-299
 3560 TMS-300
 3570 TMS-301
 3580 TMS-302
 3590 TMS-303
 3600 TMS-304
 3610 TMS-305
 3620 TMS-306
 3630 TMS-307
 3640 TMS-308
 3650 TMS-309
 3660 TMS-310
 3670 TMS-311
 3680 TMS-312
 3690 TMS-313
 3700 TMS-314
 3710 TMS-315
 3720 TMS-316
 3730 TMS-317
 3740 TMS-318
 3750 TMS-319
 3760 TMS-320
 3770 TMS-321
 3780 TMS-322
 3790 TMS-323
 3800 TMS-324
 3810 TMS-325
 3820 TMS-326
 3830 TMS-327
 3840 TMS-328
 3850 TMS-329
 3860 TMS-330
 3870 TMS-331
 3880 TMS-332
 3890 TMS-333
 3900 TMS-334
 3910 TMS-335
 3920 TMS-336
 3930 TMS-337
 3940 TMS-338
 3950 TMS-339
 3960 TMS-340
 3970 TMS-341
 3980 TMS-342
 3990 TMS-343
 4000 TMS-344
 4010 TMS-345
 4020 TMS-346
 4030 TMS-347
 4040 TMS-348
 4050 TMS-349
 4060 TMS-350
 4070 TMS-351
 4080 TMS-352
 4090 TMS-353
 4100 TMS-354
 4110 TMS-355
 4120 TMS-356
 4130 TMS-357
 4140 TMS-358
 4150 TMS-359
 4160 TMS-360
 4170 TMS-361
 4180 TMS-362
 4190 TMS-363
 4200 TMS-364
 4210 TMS-365
 4220 TMS-366
 4230 TMS-367
 4240 TMS-368
 4250 TMS-369
 4260 TMS-370
 4270 TMS-371
 4280 TMS-372
 4290 TMS-373
 4300 TMS-374
 4310 TMS-375
 4320 TMS-376
 4330 TMS-377
 4340 TMS-378
 4350 TMS-379
 4360 TMS-380
 4370 TMS-381
 4380 TMS-382
 4390 TMS-383
 4400 TMS-384
 4410 TMS-385
 4420 TMS-386
 4430 TMS-387
 4440 TMS-388
 4450 TMS-389
 4460 TMS-390
 4470 TMS-391
 4480 TMS-392
 4490 TMS-393
 4500 TMS-394
 4510 TMS-395
 4520 TMS-396
 4530 TMS-397
 4540 TMS-398
 4550 TMS-399
 4560 TMS-400
 4570 TMS-401
 4580 TMS-402
 4590 TMS-403
 4600 TMS-404
 4610 TMS-405
 4620 TMS-406
 4630 TMS-407
 4640 TMS-408
 4650 TMS-409
 4660 TMS-410
 4670 TMS-411
 4680 TMS-412
 4690 TMS-413
 4700 TMS-414
 4710 TMS-415
 4720 TMS-416
 4730 TMS-417
 4740 TMS-418
 4750 TMS-419
 4760 TMS-420
 4770 TMS-421
 4780 TMS-422
 4790 TMS-423
 4800 TMS-424
 4810 TMS-425
 4820 TMS-426
 4830 TMS-427
 4840 TMS-428
 4850 TMS-429
 4860 TMS-430
 4870 TMS-431
 4880 TMS-432
 4890 TMS-433
 4900 TMS-434
 4910 TMS-435
 4920 TMS-436
 4930 TMS-437
 4940 TMS-438
 4950 TMS-439
 4960 TMS-440
 4970 TMS-441
 4980 TMS-442
 4990 TMS-443
 5000 TMS-444
 5010 TMS-445
 5020 TMS-446
 5030 TMS-447
 5040 TMS-448
 5050 TMS-449
 5060 TMS-450
 5070 TMS-451
 5080 TMS-452
 5090 TMS-453
 5100 TMS-454
 5110 TMS-455
 5120 TMS-456
 5130 TMS-457
 5140 TMS-458
 5150 TMS-459
 5160 TMS-460
 5170 TMS-461
 5180 TMS-462
 5190 TMS-463
 5200 TMS-464
 5210 TMS-465
 5220 TMS-466
 5230 TMS-467
 5240 TMS-468
 5250 TMS-469
 5260 TMS-470
 5270 TMS-471
 5280 TMS-472
 5290 TMS-473
 5300 TMS-474
 5310 TMS-475
 5320 TMS-476
 5330 TMS-477
 5340 TMS-478
 5350 TMS-479
 5360 TMS-480
 5370 TMS-481
 5380 TMS-482
 5390 TMS-483
 5400 TMS-484
 5410 TMS-485
 5420 TMS-486
 5430 TMS-487
 5440 TMS-488
 5450 TMS-489
 5460 TMS-490
 5470 TMS-491
 5480 TMS-492
 5490 TMS-493
 5500 TMS-494
 5510 TMS-495
 5520 TMS-496
 5530 TMS-497
 5540 TMS-498
 5550 TMS-499
 5560 TMS-500
 5570 TMS-501
 5580 TMS-502
 5590 TMS-503
 5600 TMS-504
 5610 TMS-505
 5620 TMS-506
 5630 TMS-507
 5640 TMS-508
 5650 TMS-509
 5660 TMS-510
 5670 TMS-511
 5680 TMS-512
 5690 TMS-513
 5700 TMS-514
 5710 TMS-515
 5720 TMS-516
 5730 TMS-517
 5740 TMS-518
 5750 TMS-519
 5760 TMS-520
 5770 TMS-521
 5780 TMS-522
 5790 TMS-523
 5800 TMS-524
 5810 TMS-525
 5820 TMS-526
 5830 TMS-527
 5840 TMS-528
 5850 TMS-529
 5860 TMS-530
 5870 TMS-531
 5880 TMS-532
 5890 TMS-533
 5900 TMS-534
 5910 TMS-535
 5920 TMS-536
 5930 TMS-537
 5940 TMS-538
 5950 TMS-539
 5960 TMS-540
 5970 TMS-541
 5980 TMS-542
 5990 TMS-543
 6000 TMS-544
 6010 TMS-545
 6020 TMS-546
 6030 TMS-547
 6040 TMS-548
 6050 TMS-549
 6060 TMS-550
 6070 TMS-551
 6080 TMS-552
 6090 TMS-553
 6100 TMS-554
 6110 TMS-555
 6120 TMS-556
 6130 TMS-557
 6140 TMS-558
 6150 TMS-559
 6160 TMS-560
 6170 TMS-561
 6180 TMS-562
 6190 TMS-563
 6200 TMS-564
 6210 TMS-565
 6220 TMS-566
 6230 TMS-567
 6240 TMS-568
 6250 TMS-569
 6260 TMS-570
 6270 TMS-571
 6280 TMS-572
 6290 TMS-573
 6300 TMS-574
 6310 TMS-575
 6320 TMS-576
 6330 TMS-577
 6340 TMS-578
 6350 TMS-579
 6360 TMS-580
 6370 TMS-581
 6380 TMS-582
 6390 TMS-583
 6400 TMS-584
 6410 TMS-585
 6420 TMS-586
 6430 TMS-587
 6440 TMS-588
 6450 TMS-589
 6460 TMS-590
 6470 TMS-591
 6480 TMS-592
 6490 TMS-593
 6500 TMS-594
 6510 TMS-595
 6520 TMS-596
 6530 TMS-597
 6540 TMS-598
 6550 TMS-599
 6560 TMS-600
 6570 TMS-601
 6580 TMS-602
 6590 TMS-603
 6600 TMS-604
 6610 TMS-605
 6620 TMS-606
 6630 TMS-607
 6640 TMS-608
 6650 TMS-609
 6660 TMS-610
 6670 TMS-611
 6680 TMS-612
 6690 TMS-613
 6700 TMS-614
 6710 TMS-615
 6720 TMS-616
 6730 TMS-617
 6740 TMS-618
 6750 TMS-619
 6760 TMS-620
 6770 TMS-621
 6780 TMS-622
 6790 TMS-623
 6800 TMS-624
 6810 TMS-625
 6820 TMS-626
 6830 TMS-627
 6840 TMS-628
 6850 TMS-629
 6860 TMS-630
 6870 TMS-631
 6880 TMS-632
 6890 TMS-633
 6900 TMS-634
 6910 TMS-635
 6920 TMS-636
 6930 TMS-637
 6940 TMS-638
 6950 TMS-639
 6960 TMS-640
 6970 TMS-641
 6980 TMS-642
 6990 TMS-643
 7000 TMS-644
 7010 TMS-645
 7020 TMS-646
 7030 TMS-647
 7040 TMS-648
 7050 TMS-649
 7060 TMS-650
 7070 TMS-651
 7080 TMS-652
 7090 TMS-653
 7100 TMS-654
 7110 TMS-655
 7120 TMS-656
 7130 TMS-657
 7140 TMS-658
 7150 TMS-659
 7160 TMS-660
 7170 TMS-661
 7180 TMS-662
 7190 TMS-663
 7200 TMS-664
 7210 TMS-665
 7220 TMS-666
 7230 TMS-667
 7240 TMS-668
 7250 TMS-669
 7260 TMS-670
 7270 TMS-671
 7280 TMS-672
 7290 TMS-673
 7300 TMS-674
 7310 TMS-675
 7320 TMS-676
 7330 TMS-677
 7340 TMS-678
 7350 TMS-679
 7360 TMS-680
 7370 TMS-681
 7380 TMS-682
 7390 TMS-683
 7400 TMS-684
 7410 TMS-685
 7420 TMS-686
 7430 TMS-687
 7440 TMS-688
 7450 TMS-689
 7460 TMS-690
 7470 TMS-691
 7480 TMS-692
 7490 TMS-693
 7500 TMS-694
 7510 TMS-695
 7520 TMS-696
 7530 TMS-697
 7540 TMS-698
 7550 TMS-699
 7560 TMS-700
 7570 TMS-701
 7580 TMS-702
 7590 TMS-703
 7600 TMS-704
 7610 TMS-705
 7620 TMS-706
 7630 TMS-707
 7640 TMS-708
 7650 TMS-709
 7660 TMS-710
 7670 TMS-711
 7680 TMS-712
 7690 TMS-713
 7700 TMS-714
 7710 TMS-715
 7720 TMS-716
 7730 TMS-717
 7740 TMS-718
 7750 TMS-719
 7760 TMS-720
 7770 TMS-721
 7780 TMS-722
 7790 TMS-723
 7800 TMS-724
 7810 TMS-725
 7820 TMS-726
 7830 TMS-727
 7840 TMS-728
 7850 TMS-729
 7860 TMS-730
 7870 TMS-731
 7880 TMS-732
 7890 TMS-733
 7900 TMS-734
 7910 TMS-735
 7920 TMS-736
 7930 TMS-737
 7940 TMS-738
 7950 TMS-739
 7960 TMS-740
 7970 TMS-741
 7980 TMS-742
 7990 TMS-743
 8000 TMS-744
 8010 TMS-745
 8020 TMS-746
 8030 TMS-747
 8040 TMS-748
 8050 TMS-749
 8060 TMS-750
 8070 TMS-751
 8080 TMS-752
 8090 TMS-753
 8100 TMS-754
 8110 TMS-755
 8120 TMS-756
 8130 TMS-757
 8140 TMS-758
 8150 TMS-759
 8160 TMS-760
 8170 TMS-761
 8180 TMS-762
 8190 TMS-763
 8200 TMS-764
 8210 TMS-765
 8220 TMS-766
 8230 TMS-767
 8240 TMS-768
 8250 TMS-769
 8260 TMS-770
 8270 TMS-771
 8280 TMS-772
 8290 TMS-773
 8300 TMS-774
 8310 TMS-775
 8320 TMS-776
 8330 TMS-777
 8340 TMS-778
 8350 TMS-779
 8360 TMS-780
 8370 TMS-781
 8380 TMS-782
 8390 TMS-783
 8400 TMS-784
 8410 TMS-785
 8420 TMS-786
 8430 TMS-787
 8440 TMS-788
 8450 TMS-789
 8460 TMS-790
 8470 TMS-791
 8480 TMS-792
 8490 TMS-793
 8500 TMS-794
 8510 TMS-795
 8520 TMS-796
 8530 TMS-797
 8540 TMS-798
 8550 TMS-799
 8560 TMS-800
 8570 TMS-801
 8580 TMS-802
 8590 TMS-803
 8600 TMS-804
 8610 TMS-805
 8620 TMS-806
 8630 TMS-807
 8640 TMS-808
 8650 TMS-809
 8660 TMS-810
 8670 TMS-811
 8680 TMS-812
 8690 TMS-813
 8700 TMS-814
 8710 TMS-815
 8720 TMS-816
 8730 TMS-817
 8740 TMS-818
 8750 TMS-819
 8760 TMS-820
 8770 TMS-821
 8780 TMS-822
 8790 TMS-823
 8800 TMS-824
 8810 TMS-825
 8820 TMS-826

31/35




FIG. 25B




FIG. 25D

FIG. 25C

mGABAb1a
 hGABAb1a
 hGABAb2
 mG1uR1
 LivK
 LivBP

M L L L L L L L L L F L R P L G A G G A Q T P N V T S E G C Q I I H P M E G G I R Y R G L I R D Q V K A I N F L P V D Y E I E Y V C R G E R E V G P K V R K C L A N G S W T D M D I P S R C V R I C S V S I T L E N G K V F L T G G D L P : 119
 M L L L L L L L L L F L R P P G A G G A Q T P N A T S E G C C Q I I H P M E G G I R Y R G L I R D Q V K A I N F L P V D Y E I E Y V C R G E R E V G P K V R K C L A N G S W T D M D I P S R C V R I C S V S I T L E N G K V F L T G G D L P : 120
 M L L L L L L L L L F L R P P G A G G A Q T P N A T S E G C C Q I I H P M E G G I R Y R G L I R D Q V K A I N F L P V D Y E I E Y V C R G E R E V G P K V R K C L A N G S W T D M D I P S R C V R I C S V S I T L E N G K V F L T G G D L P : 30
 M L L L L L L L L L F L R P P G A G G A Q T P N A T S E G C C Q I I H P M E G G I R Y R G L I R D Q V K A I N F L P V D Y E I E Y V C R G E R E V G P K V R K C L A N G S W T D M D I P S R C V R I C S V S I T L E N G K V F L T G G D L P : 44
 M L L L L L L L L L F L R P P G A G G A Q T P N A T S E G C C Q I I H P M E G G I R Y R G L I R D Q V K A I N F L P V D Y E I E Y V C R G E R E V G P K V R K C L A N G S W T D M D I P S R C V R I C S V S I T L E N G K V F L T G G D L P : 29
 M L L L L L L L L L F L R P P G A G G A Q T P N A T S E G C C Q I I H P M E G G I R Y R G L I R D Q V K A I N F L P V D Y E I E Y V C R G E R E V G P K V R K C L A N G S W T D M D I P S R C V R I C S V S I T L E N G K V F L T G G D L P : 6

mGABAb1a
 hGABAb1a
 hGABAb2
 mG1uR1
 LivK
 LivBP

A L D C A R V D F R C D P D F H L V G S S R S I C S C Q Q V S T P K P H C Q V N R T P H S E R R A V Y I G A L F P M S . G G W P G I G Q A C O P A V E M A L E D V N S R R D . I L P D Y E L K L I H H D . S K D P F Q Q A I T K Y L Y E L L Y : 233
 A L D C A R V D F R C D P D F H L V G S S R S I C S C Q Q V S T P K P H C Q V N R T P H S E R R A V Y I G A L F P M S . G G W P G I G Q A C O P A V E M A L E D V N S R R D . I L P D Y E L K L I H H D . S K D P F Q Q A I T K Y L Y E L L Y : 234
 L L L P L A P G A G W A R Q A P R P P P S S P . P L S I M G L M P L T K E V A K G S I G R G V L P A V E L A T E Q I . R N E S L L R P Y F L D R L R Y D . T E C N A K G L K A F Y D A I K : 122
 V I I G A L F S W H Q P P A E K V P E R K C G E I R E Q V G I Q R V E A M F H T L D K I N A D P V L L P N I T L G S E . I R D . S C W H S S V A L E Q S I E F I R D S L I S I R D E K G I N R C L P : 142
 . W G A M S G P I . A Q N G I M E F N G A E Q A I K D I N A K G S I K G D K L V G M E . Y D D . A C D P K Q A V A V A N K I V N : 90
 . W G A M S G P V . A Q V G D Q E F T G A E Q A V A D I N A K G S I K G N K L Q I A K . Y D D . A C D P K Q A V A V A N K V V N : 67

mGABAb1a ND
 hGABAb1a ND
 hGABAb2 YQ
 mG1uR1 DQSLPPGRTKMP
 LivK DQ
 LivBP DQ

P I K I I L M P G . C S S V S T I L V A E A A R M N L I V L S V G S S P A L S I N R F P T F F R I T P S A T L H N P T R V K L F E K W G A K K I A T I Q Q T T E V F T S . T D D L E E R V K E A G I : 334
 P I K I I L M P G . C S S V S T I L V A E A A R M N L I V I S T G S S P A L S I N R F P T F F R I T P S A T L H N P T R V K L F E K W G A K K I A T I Q Q T T E V F T S . T D D L E E R V K E A G I : 335
 P I H L M F G V Q D S V S T I L V A E S L G G W N L V Q L S F A A T I P V A D K K K P Y F F R I M P S D N A V N P A I L K L I K H Y Q A K R V G T L T Q D V Q R F S E . V R N D L I G V L Y G E D I : 224
 D Q S L P P G R T K M P I A G V I . G P G S S V A I Q V N L L Q L F D I P Q I A Y S A I S I D L S O K T U N K Y F I R V P S O T L Q A R A M D I V K R Y N I T Y V S A V . H T E G N Y G E S G M D A F K E L A A Q E Q L : 253
 I T K V I . C H I L C S S I S T O P A S D I Y E D E G I L M I S P G A T A P E L I T A R G . M Q H I M R T A G L D S S Q Q P T A A K Y I L E I T V K P . Q R I A I I I . H D K Q Q Y G E . Q L A R S V Q D Q L : 185
 I T K V I . C H I L C S S I S T O P A S D I Y E D E G I L M I T P A A T A P E L I T A R G . Y Q L I U R I T G L D S D Q Q P T A A K Y I L E I K V K P . Q R I A I V . H D K Q Q Y G E . Q L A R A V Q D Q L : 162

FIG. 26A-1

mGABab1a	EIIITFRSFFSDPAPVKN.....	[KRODARI]	[INGLFYET]	[EARKVCEVYKERLFGKYYWFLIGYADNMFK]	TYDPSINCTVEEM.TEAMEGHITTE	IVMLNP:431
hGABab1a	EIIITFRSFFSDPAPVKN.....	[KRODARI]	[INGLFYET]	[EARKVCEVYKERLFGKYYWFLIGYADNMFK]	TYDPSINCTVDEM.TEAMEGHITTE	IVMLNP:432
hGABab2	EIISDIESFSDPCTSVK.....	[KGNURRI]	[ILGQFDON]	MAAKVFCACAYEENMYSYQWITPCWYEPSWMEQ	VHTEANSSRCLRKNL.LAAWEGYIGVD	FEPLSS:324
mGluR1	CIJAHSDKIYSN...AGEASFDRLLPKLRELPKARVVVCECEM	[TVRGLLSAM]	[RRLGVGEFSLIG]	SDGMADRDDEVIEGYEVEANGGIT	IKLOSPEVRSFDDYFLKRLDTN	:362
Li vK	KAANANVVFDDGITAGEOF SALT.....	[ARLKKENIDFVYGGYPPHMQMLROA]	[RSVGLKITOF]	MG.PEG	V.GNASLSNIAGDAEG	M.LVTM:271
Li vBP	KKGNANVVFDDGITAGEOFSTLV.....	[ARLKKENIDFVYGGYPPHMQILROA]	[BAAGKITOF]	MG.PEG	V.ANVSLSNIAGESAEG	L.LVTK:248
mGABab1a	ANTRISNMITSOEFEVTKLTKRLKRP	[EAPLAYD]	[ETGGF]	TSGGGGRCVRLDFNYYNQITTDQIYRAMSSS	FEVSGHWM	FDASGSRMA:534
hGABab1a	ANTRISNMITSOEFEVTKLTKRLKRP	[EAPLAYD]	[ETGGF]	TSGGGGRCVRLDFNYYNQITTDQIYRAMSSS	FEVSGHWM	FDASGSRMA:535
hGABab2	KQIKTISGKTPOQYEREYNN..KRSGV	[HG.YAYD]	[GIMVIAKTILQAMETLHASSRHQ]	RIOQDFNYDHTLGRITILNAME	TNFCGVITQWMI	FR.NGERMG:424
mGluR1	TRNPWFPEFWQHRFOCRLLPGHLEN	[NFKRICTONESLEENYQDSKMGFVINALIYMAHGLQ]	[NMHHALCPGHVGL]	CDAMKPID	..GSKLLDFLLIKSS	ICVSGEEMWDEKCDAPG:477
Li vK	PK.....RYD.....	[QDPANOGIV]	[DALKAD.KKOPSGFIV]	WITYMAVQSIALALETGSDPLAL	[VQDLKANG]	..ANTVIGPLN
Li vBP	PK.....NYD.....	[QVPANKPIV]	[DAIKAK.KQDPSGAFV]	WITYMAVQSIALALETGSDPLAL	[VQDLKANG]	..ANTVIGPLN
mGABab1a	WTL.IE.....	[QLGGSYKKIGYYD]	[STKDDLS.WSKTDKWIQGS]	[PPAD]	:575
hGABab1a	WTL.IE.....	[QLGGSYKKIGYYD]	[STKDDLS.WSKTDKWIQGS]	[PPA]	:575
hGABab2	TIKFT.....	[QFQDSREVKVCEYN]	[AVADTLEIINDTIRFQGS]	[PPKORTIILEQLR]	:475
mGluR1	RYDIMNLQYTEANRYDYHVGTHWEGVLNIDDYKIQMKNKSGVVRVCSGPC	[KGQIKVIRKGEVSCWICTACKENYVQDEFTCKACDLGWPPNADL	TGCEPIPVRY	:585		
Li vK	FDF.....	[GVFQ]	[WHADGS]	[STAAK]	:369
Li vBP	FEF.....	[GVFD]	[WHANGT]	[ATDAK]	:344

33/35

FIG.26A-2

34/35




FIG. 26B

SUBSTITUTE SHEET (RULE 26)

35/35




FIG.27